ACR Convergence 2020 Abstract Presenting Author Disclosures

The following types of relationships may be deemed relevant include: 1. Stockholder 2. Grant/Research Support 3. Employee 4. Ownership Interest 5. Consulting Fees (e.g., advisory boards) 6. Officer or Board Member 7. Royalties 8. Speaker/Honoraria includes speakers bureau, symposia, and expert witness 9. Other Financial or Material Support

Abbas, Laila, BA Aboulenain, Samar, MD 1560. Measuring Asymmetry in Facial Morphea 1737. What Influences Fatigue Improvement in via 3D Stereophotogrammetry Rheumatoid ? A Prospective Cohort Disclosure: Nothing to disclose Study Disclosure: Nothing to disclose Abe, Kazuya, MD 1835. Evaluation of Low Dose Glucocorticoid Acosta, Maria Elisa, MD Effects on Infection Occurrence in Systemic 0340. Neuropathic Pain Relationship with Erythematosus Patients Comorbidity in Psoriatic Arthritis Patients and Its Disclosure: Nothing to disclose Influence on Disease Activity Disclosure: Nothing to disclose Abe, Nobuya, MD 0835. Pathogenic Effect of Chronic Stress- Adami, Giovanni, MD induced interleukin-12/23p40 on 0120. Risk of Fracture in Patients with Different Neuropsychiatric System in Lupus-prone Mouse Glucocorticoid Requiring Diseases Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Aboulenain, Samar, MD Adami, Giovanni, MD 1735. Effect of Aerobic Land-based Exercise 0940. In Patients with Inflammatory Arthritides Intervention on Fatigue in : Central Pain Sensitization Is Strictly Associated A Systematic Review and Meta-analysis with Functional Disability Disclosure: Nothing to disclose Disclosure: Nothing to disclose

1

Adler, Brittany, MD 0077. Mimickers of Immunoglobulin G4-Related 2039. Short Telomeres and Disease Targeting Telomere-Associated Proteins in Disclosure: Nothing to disclose Disclosure: Nothing to disclose Ahmad, Nadia, MRCP 0404. Isolated Aortitis: Single Centre Experience Afinogenova, Yuliya, MD of Clinical Spectrum and Management 1894. Use of Facebook and Electronic Patient Disclosure: Nothing to disclose Portal to Identify Axial Spondyloarthritis in Patients with Chronic Back Pain Ahmed, Fiza, MBBS, BSc Disclosure: Nothing to disclose 0916. Validating Associations and Clinical Impact of Severe Gastrointestinal Afroz, Sana, MD Involvement in Systemic Sclerosis 0275. Paradoxical Relationship Between Disease Disclosure: Nothing to disclose Activity and Satisfaction with Care in Lupus Disclosure: Nothing to disclose Ai, Rizi, PhD 0030. Distinct DNA Methylation Patterns of Agarwal, Sandeep, MD, PhD Rheumatoid Arthritis Peripheral Blood and 1702. RA-Related Knowledge and Skills of Synovial Tissue T Cells Fellows Among 20 US Academic Disclosure: Nothing to disclose Institutions Disclosure: Nothing to disclose Akram, Bushra, MD 1569. Immune Related Adverse Events Related Aggarwal, Rohit, MD to Check Point Inhibitors Among Outpatients in 0955. Efficacy and Safety of IVIg (Octagam 10%) an Academic Center in Patients with Active . Results Disclosure: Nothing to disclose of a Randomized, Double-Blind, Placebo- Controlled Phase III Trial (ProDERM Study) Al Birdisi, Majed, MBBS Disclosure: Abbvie (5); Bristol Myers Squibb (2, 0242. Autoantibody Profile and Ethnicity: Risk 5); Csl Behring (5); Kezar (5); Mallinckrodt (2, 5); Factors for Accelerated Development of Lupus Octapharma (5); Pfizer (2) Nephritis Disclosure: Nothing to disclose Aggarwal, Rohit, MD 0958. Tocilizumab in : Results of a Phase Alba, Marco A, MD, PhD IIb Double-Blind Randomized Controlled Trial 0510. Expression and Functional Activity of the Disclosure: Abbvie (5); Bristol Myers Squibb (2, Angiotensin II System in Temporal Artery Lesions 5); Csl Behring (5); Kezar (5); Mallinckrodt (2, 5); from Patients with Octapharma (5); Pfizer (2) Disclosure: Nothing to disclose

AGUIRRE, ALFREDO, MD AlDuraibi, Fatima, MD 0587. Barriers to Rheumatologic Care and 0289. Endogenous Interferon-β and Low IL-4R on Antimalarial Refills Among a Cohort of Patients Transitional B Cells Promotes Lupus Nephritis with Systemic Lupus Erythematosus During the Disclosure: Nothing to disclose COVID-19 Pandemic Disclosure: Nothing to disclose AlDuraibi, Fatima, MD 0682. Role of Inflammatory and Oxidative Stress Ahmad, Madiha, MD Pathway Biomarkers in Renal Disease in Gout Disclosure: Nothing to disclose

2

Osteoarthritis Alehashemi, Sara, MD, MPH Disclosure: Nothing to disclose 1157. Health and Socioeconomic Outcomes in a Neonatal-Onset Multisystem Inflammatory Ali, Hiba, MD Disease (NOMID) Cohort Followed for a Median 1799. High Fat-Diet as a Catalyst to Lupus of Fifteen Years Development and Autoimmunity in MRL/lpr Disclosure: Nothing to disclose Mice Disclosure: Nothing to disclose Alesaeidi, Samira, MD 1418. Clinical Presentations and Follow-up Aljaberi, Najla, MBBS Results of Granulomatosis with Polyangiitis: An 1672. Renal Activity Index for Lupus Nephritis Analysis of 8 Years Clinical Experience with 220 Distinguishes Active Renal Disease Among Patients from a National Referral Center Childhood Systemic Lupus Erythematosus Disclosure: Nothing to disclose Patients Disclosure: Nothing to disclose Aletaha, Daniel, MD, MS, MBA 1749. Efficacy of Filgotinib in Patients with Alkanhal, Abdulrahman, MBBS, MPH Rheumatoid Arthritis with Poor Prognostic 1689. Unexpectedly High Incidence of Kawasaki Factors: Post Hoc Analysis Disease in a Well-Characterized Population in Disclosure: AbbVie (2, 5, 8); Amgen (5, 8); Bristol- Atlantic Canada Myers Squibb (8); Celgene (5, 8); Eli Lilly (5, 8); Disclosure: Nothing to disclose Gilead Sciences, Inc. (2, 5); Janssen (5); Medac (5, 8); Merck Sharp & Dohme (2, 5, 8); Novartis (2, 5, Alkilany, Reem, MD 8); Pfizer (5, 8); Roc 1584. Telemedicine Visits During COVID-19 Improved Clinic Show Rates Alexander, Alexander, BA Disclosure: Nothing to disclose 1612. Assessing Patient Self-Reported Transition Readiness in a Large Pediatric Rheumatology Allanore, Yannick, MD, PhD Center 2040. Continued Treatment with Nintedanib in Disclosure: Nothing to disclose Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim ALhammadi, Nouf, MBBS Analysis of SENSCIS-ON 0264. Prevalence and Risk Factors Associated Disclosure: Bayer (5); Boehringer Ingelheim (5, with Isolated Neutropenia in Outpatients with 8); Curzion (5); Medsenic (5); Roche (8); Sandoz Systemic Lupus Erythematosus (2); Sanofi (5, 8) Disclosure: Nothing to disclose Allen, Kelli, PhD Ali, Ali, MD 1146. Pilot Study of an Internet-Based Pain 1724. A Feasible and Efficient Approach to Coping Skills Training Program for Patients with Implementing Rheumatoid Arthritis Disease Systemic Lupus Erythematosus Activity Measure in a Busy Rheumatology Clinic: Disclosure: Nothing to disclose A Quality Improvement Project Disclosure: Nothing to disclose Allison, Matt 0167. Rheumatoid Arthritis Patient Phenotypes Ali, Amanda, PhD from a Digital Health Coaching Engagement 0701. miRNome Sequencing Identifies a Unique Program Profile of Circulating MicroRNAs in Early Knee Disclosure: Nothing to disclose

3

Almeida, Gustavo, PhD, PT 0614. Impact of COVID-19 Pandemic on the 0693. Effect of Physical Activity on Cartilage Rheumatology Practice in Mexico: Mexican Degradation and Inflammation in Individuals College of Rheumatology Survey with Lumbar Spinal Stenosis Disclosure: Nothing to disclose Disclosure: Nothing to disclose Alsaleem, Alhanouf, MD, MBBS Almeida de Jesus, Adriana, MD, PhD 1156. Comparison of Immunological Biomarkers 0471. Splice Site Variants in IKBKG, Encoding and Lung Histology in Patients with Elevated IL18 NEMO, Detected by a Customized Analysis of - Pulmonary Alveolar Proteinosis and Recurrent Next-Generation Sequencing Data Cause an Macrophage Activation Syndrome (IL-18PAP- Early-onset Autoinflammatory Syndrome of MAS) and Other Inflammatory Lung Diseases Panniculitis and Cytopenias in Male and Female Disclosure: Nothing to disclose Patients Disclosure: Nothing to disclose Alten, Rieke, MD, PhD, Professor of 1216. Filgotinib Provided Rapid and Sustained Almutairi, Khalid, BS, MSc Improvements in Functional Status, Pain, and 1012. The Global Prevalence of Rheumatoid Health Related Quality of Life, and Reduced Arthritis: A Meta-Analysis Fatigue over Time in Patients with Rheumatoid Disclosure: Nothing to disclose Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study Almutairi, Khalid, BS, MSc Disclosure: AbbVie (2, 5); Bristol-Myers Squibb (2, 1609. The Accuracy of Administrative Health 5); Gilead Sciences, Inc. (2); Lilly (2, 5); Novartis Data for Identifying Patients with Rheumatoid (2); Pfizer (2, 8); UCB (2, 5) Arthritis: A Validation Study Using Medical Records in Western Australia Alten, Rieke, MD, PhD, Professor of Medicine Disclosure: Nothing to disclose 1745. A Novel Method for Predicting 1-Year Retention of Abatacept Using Machine Learning Alongi, Alessandra, MD Techniques 1494. Patient-Reported Adverse Events, Quality Disclosure: AbbVie (2, 5); Bristol-Myers Squibb (2, of Life and Treatment Adherence in Juvenile 5); Gilead Sciences, Inc. (2); Lilly (2, 5); Novartis Idiopathic Arthritis: Analysis of Two Large (2) International Cohorts ; Pfizer (2, 8); UCB (2, 5) Disclosure: Nothing to disclose Amarilyo, Gil, MD Aloush, Valerie, MD 0720. Long Term Efficacy and Safety of 0026. A Modified Version of the 2016 ACR Triamcinolone Hexacetonide versus Fibromyalgia Criteria Cognitive Items Results in Triamcinolone Acetonide Intraarticular Injection Stronger Correlation Between Subjective and for Juvenile Idiopathic Arthritis Objective Measures of Cognitive Impairment Disclosure: Nothing to disclose Disclosure: Nothing to disclose Amissah-Arthur, Maame-Boatemaa, MD Aloush, Valerie, MD 0054. "Is It Spiritual?" Complexities of 0028. Pain in the Time of Corona: Impact of Understanding Health-Seeking Behaviour in COVID 19 Outbreak on Fibromyalgia Patients Patients with Chronic Autoimmune Rheumatic Disclosure: Nothing to disclose Diseases in Sub-Saharan Africa Disclosure: Nothing to disclose Alpizar-Rodriguez, Deshire, MD, PhD Amoura, Zahir, MD

4

1836. Alternative Renal Response Definitions in a A Prospective Cohort Study Randomized, Controlled Trial of Obinutuzumab Disclosure: Nothing to disclose for Proliferative Lupus Nephritis Disclosure: Roche (2) ANDRES, MARIANO, PhD 0671. Structured Cardiovascular Assessment in Anandarajah, Allen, MD, MS Gout Incorporating Carotid Ultrasound: Analysis 0052. Loneliness and Social Isolation Are of Subsequent Events in the Follow-Up Important Social Determinants Among Patients Disclosure: Grünenthal (2, 8); Horizon (8); from Minority Communities with Rheumatic Menarini (8) Diseases Disclosure: Nothing to disclose Angarola, Ernestina, MD 0416. IgG4-related Retroperitoneal . Anastasiou, Christine, MD Retrospective Cohort 0582. Mortality and Cost of Hospitalization: Do Disclosure: Nothing to disclose Hospitals Caring for More SLE Patients Perform Better? Ani, Nizar, MD Disclosure: Nothing to disclose 0218. Clinical Outcomes of Earlier versus Delayed Treatment of Iraqi Patients with Rheumatoid Anastasiou, Christine, MD Arthritis with Etanercept 1773. Worse Maternal and Fetal Outcomes Disclosure: Nothing to disclose Among Hospitalized U.S. Pregnant Women with Systemic Lupus Erythematosus (SLE) and Antonelli, Maria, MD Rheumatoid Arthritis (RA) 0442. Disparities in CoronaViridae Infection Are Disclosure: Nothing to disclose Readily Apparent in Rheumatology Patients Despite Use of Hydroxychloquine And/or Anderson, Erik, MD, PhD Methotrexate 1804. Impact of the Kynurenine/Tryptophan Disclosure: Nothing to disclose Pathway on Cognitive Dysfunction and Depression in Systemic Lupus Erythematosus Aouad, Krystel, MD Disclosure: Nothing to disclose 0321. Outcome Measures in Psoriatic Arthritis Registries Are Very Heterogeneous: A Systematic Anderson, Erik, MD, PhD Literature Review of 27 Registries, or 16183 1806. The Association of Interferon-α with Patients Kynurenine/Tryptophan Pathway Activation in Disclosure: Nothing to disclose Systemic Lupus Erythematosus Disclosure: Nothing to disclose Aoyagi, Kosaku, PhD, PT 0961. Development of a Pain Sensitivity Index to Andonian, Brian, MD Examine the Transition from Intermittent to 1757. High-Intensity Interval Training Increases Constant Pain in Knee Osteoarthritis: The Rheumatoid Arthritis Cardiorespiratory Fitness in Multicenter Osteoarthritis Study Association with Improvements in CD4+ Disclosure: Nothing to disclose and Skeletal Muscle Mitochondrial Metabolism Disclosure: Nothing to disclose Aoyagi, Kosaku, PhD, PT 1662. Do Weight-bearing versus Non-weight- Andreasen, Rikke Asmussen, MD, PhD bearing Pain Reflect Different Pain Mechanisms 1901. Clinical Characteristics of Importance to in Knee Osteoarthritis?: The Multicenter Outcome in Patients with Axial Spondyloarthritis: Osteoarthritis Study Disclosure: Nothing to disclose

5

Susceptible to Citrullination of Self-Proteins Apostolopoulos, Diane, MBBS Disclosure: Nothing to disclose 1296. Associations of Metabolic Syndrome and Adipokines in SLE Arnold, Erin Disclosure: Nothing to disclose 1725. An Investigation of the Relationship Between Patient Reported Outcomes and Appenzeller, Simone, MD, PhD Biomarkers in a Community Rheumatology 1675. Microstructural Damage Is Associated with Practice Age at Disease-onset and Cognitive Impairment 1726. Assessment of the Components of RAPID3 in Systemic Lupus Erythematosus Patient Reported Outcomes in an Community Disclosure: Nothing to disclose Rheumatology Practice Disclosure: Nothing to disclose Appenzeller, Simone, MD, PhD 1992. Longitudinal Evaluation of Axonal Arora, Shilpa, MD, MBBS Dysfunction, Neuronal Markers and Serum 0259. Guillain-Barré Syndrome in Systemic Lupus Cytokines in Childhood-onset Systemic Lupus Erythematosus - Results of a Nationwide Analysis Erythematosus Disclosure: Nothing to disclose Disclosure: Nothing to disclose Arora, Shilpa, MD, MBBS Ardalan, Kaveh, MD, MS 0260. Does Higher Quality of Care in SLE Improve 1138. Estimation of Clinically Important Quality of Life? Differences in Patient-Reported Outcomes Disclosure: Nothing to disclose Measurement Information System (PROMIS) Measures in Juvenile Myositis Ashouri-Sinha, Judith, MD Disclosure: Nothing to disclose 0774. Nr4a1-high Arthritogenic T Cells from SKG Mice Are Associated with Markers of Recent and Arevalo, Ana B, MD Chronic Antigen-stimulation and an Altered T 0664. Uric Acid Level Is Associated with Severity Cell Receptor Repertoire of Heart Failure with Preserved Ejection Fraction Disclosure: Nothing to disclose Disclosure: Nothing to disclose Askanase, Anca, MD, MPH Aringer, Martin, MD 1842. Repository Corticotropin Injection (Acthar® 1940. In Newly Diagnosed Giant Cell Arteritis in a Gel) for Persistently Active Systemic Lupus Real Life Setting Relapses Are Seen in More Than Erythematosus: Post Hoc Analyses of Patient- a Third of Patients – and Despite Faster Early Reported Outcomes from a Phase 4, Multicenter, Reduction High Cumulative Glucocorticoid Doses Randomized, Double-blind, Placebo-Controlled Are Reached Trial Disclosure: AbbVie (5, 8); AstraZeneca (5, 8); Disclosure: AbbVie (5); AstraZeneca (2, 5); Bristol Boehringer Ingelheim (5, 8); Bristol Myers Squibb Myers Squibb (5); Eli Lilly (2); GlaxoSmithKline (2, (5, 8); Chugai (5, 8); Lilly (5, 8); MSD (5, 8); 5); Janssen (2); LuCIN (2); Mallinckrodt Novartis (5); Pfizer (8); Roche (5, 8); Sanofi (5, 8); Pharmaceuticals (2); Pfizer (2) UCB (8) Assassi, Shervin, MD, MS Aripova, Nozima, BS 1378. Understanding Diagnostic Pathways in 0772. Modification of THP-1 Cells with Systemic Sclerosis and Systemic Sclerosis- Malondialdehyde-Acetaldehyde Increases Associated Interstitial Lung Disease (SSc-ILD) Cellular Calcium Load Rendering Cells Disclosure: Boehringer Ingelheim (2, 5, 8); corbus

6

(5); Integrity Continuing Education (8); Momenta by the Fibrosis-4 Index (2) Disclosure: Bristol Myers Squibb (2, 5, 8)

Astakhova, Kira, PhD Aydin, Sibel Zehra, MD 1453. A First in Class Therapeutic Nanoparticle 0311. The Link Between Joints and Entheses in for Specific Targeting of Anti-citrullinated Protein Psoriatic Arthritis: An Ultrasound Study Antibody Ameliorates Serum Transfer and Supporting the Synovio-entheseal Complex Collagen Induced Arthritis Theory Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Atagunduz, Pamir, MD Aydin, Sibel Zehra, MD 1882. Are There Any Clues to Predict Bamboo 0314. Accuracy of Physical Examination to Detect Spine in Axial Spondyloarthritis? Synovial and Extra-synovial in Disclosure: Nothing to disclose Psoriatic Arthritis in Comparison to Ultrasonography Atienza-Mateo, Belén Disclosure: Nothing to disclose 1050. in the Treatment of Interstitial Lung Disease Associated with Autoimmune Ayesha, Bibi, MD Diseases: Experience from a Single Referral 0458. Rapid Implementation of a Center Multidisciplinary COVID-19 Cytokine Storm Disclosure: Nothing to disclose Syndrome Task Force Disclosure: Nothing to disclose Atsumi, Tatsuya, MD 0203. Safety of Baricitinib in Patients with Ayub, Shazeen, MBChB, MRCP Rheumatoid Arthritis: Interim Report from All- 1651. Efficacy and Safety of Multiple Intra- Case Post‑Marketing Study in Clinical Use articular Corticosteroid Injections for Disclosure: AbbVie Inc. (5, 8, 9); Astellas Pharma Osteoarthritis – a Systematic Review and Meta- Inc. (8, 9); Bristol Myers Squibb Co. (2, 8); Chugai analysis of Randomised Controlled Trials and Pharmaceutical Co., Ltd. (2, 8, 9); Daiichi Sankyo Observational Studies Company, Limited (5, 8, 9); Eisai Co., Ltd. (8); Eli Disclosure: Nothing to disclose Lilly Japan K.K. (2, 5, 8); Gilead Baalbaki, Hussein, MD AUROUX, Maxime, MD 1945. Characterization of Visual Manifestations 1104. The Disability Associated with Hand and Identification of Risk Factors for Permanent Osteoarthritis Is Substantial in a Cohort of Post- Vision Loss in Patients with Giant Cell Arteritis menopausal Women : The QUALYOR Study Disclosure: Nothing to disclose Disclosure: Nothing to disclose Bacalao, Maria, MD Avouac, Jerome 0604. Increasing the Rate of Pneumococcal 0192. Influence of Inflammatory and Non- Vaccination in an Academic Rheumatology inflammatory Rheumatic Disorders on the Outpatient Clinic Clinical and Biological Profile of Adult-onset Disclosure: Nothing to disclose Diabetes Disclosure: Bristol Myers Squibb (2, 5, 8) Bacalao, Maria, MD 0607. The Evolution of Rheumatologist's Practice Avouac, Jerome in Response to the COVID19 Pandemic 0205. Methotrexate Is Not Associated Disclosure: Nothing to disclose with an Increased Risk of Liver Fibrosis Assessed

7

Badley, Elizabeth, PhD 0561. Risk Factors for Falls Among Individuals Baker, Rahaf, MD, MPH with Knee OA: A Longitudinal Community-based 0042. Racial and Ethnic Differences in a Multiple Study Biochemical Measure of Rheumatoid Arthritis Disclosure: Nothing to disclose Disease Activity Disclosure: Nothing to disclose Bae, Sangmee, MD 0959. Altered Gut Microbiome in Baker Frost, DeAnna, MD, PhD Dermatomyositis 1913. Investigation of the Cellular Mechanism Disclosure: Nothing to disclose for Estradiol-Induced Dermal Fibrosis Disclosure: Nothing to disclose Bae, Sangmee, MD 1090. Abnormal HDL Antioxidant Function Is Balbi, Verena, MD Associated with Longitudinal Change in Lung 1678. Hydroxychloroquine Blood Levels Predicts Physiology in Dermatomyositis/ 6-Months Disease Activity in Juvenile Lupus Associated Lung Disease Nephritis Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Bae, Sangmee, MD Baldini, Chiara, MD, PhD 1091. A Computer-Aided Diagnostic System for 1253. Re-evaluation of the Extent of Lymphocytic Quantitative Scoring of Extent of Interstitial Lung Infiltration May Improve the Diagnostic Accuracy Disease (ILD) in Dermatomyositis/Polymyositis of Lip Biopsy in Primary Sjögren’s Syndrome Associated ILD (pSS) Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Baert, Charlotte Baldini, Chiara, MD, PhD 1375. Remission in Axial Spondyloarthritis: Is 1503. Ultra High‐resolution Ultrasound (UHFUS) There a Difference Between NSAIDs and of Labial Salivary Glands Might Help to Avoid Biologics in the Real Life? Unnecessary Lip Biopsy in Patients with Sicca Disclosure: Nothing to disclose Syndrome Disclosure: Nothing to disclose Bagrova, Anastasiya, MD 1708. Itching to Learn: Infusion Reactions Baldock, Denise, BSc, MSc Curriculum for Medicine Trainees 0708. Differences in Treating Knee Osteoarthritis Disclosure: Nothing to disclose by Clinician Specialty Disclosure: Nothing to disclose Baker, Joshua, MD, MS 1650. A Double-Blind Randomized Trial to Ballal, Priyanka, MD Evaluate the Efficacy of Corticosteroid Injections 0934. Warfarin Use and Risk of Knee and Hip for Osteoarthritis of the Knee Using Mobile Replacements Devices Disclosure: Nothing to disclose Disclosure: Nothing to disclose Balmuri, Nayimisha, MD Baker, Matthew, MD, MS 0723. Social Determinants of Health and Time to 1995. Non-invasive Vagus Nerve Stimulation First Pediatric Rheumatology Appointment in Improves Signs and Symptoms of Rheumatoid Polyarticular Juvenile Idiopathic Arthritis Arthritis: Results of a Pilot Study Disclosure: Nothing to disclose Disclosure: Vorso Corp (1, 5)

8

Balmuri, Nayimisha, MD 0726. Who Ordered the Stiff One? Baraliakos, Xenofon, MD Characteristics of Polyarticular Juvenile 0505. Secukinumab Provides Sustained Idiopathic Arthritis Patients Associated with the Improvements in Clinical and Imaging Outcomes Presence and Increased Duration of Joint in Patients with Psoriatic Arthritis and Axial Stiffness Manifestations: Results from the MAXIMISE Trial Disclosure: Nothing to disclose Disclosure: AbbVie (2, 5); Bristol-Myers Squibb (2, 5); Celgene (2, 5); Chugai (2, 5); Eli Lilly (2, 5); Balmuri, Nayimisha, MD Galapagos (2, 5); Hexal (2, 5); Janssen (2, 5); 1174. HEADSS and Shoulders, Knees and Toes: MSD (2, 5); Novartis (2, 5); Pfizer (2, 5); Sandoz Improving Sexual Orientation and Gender (2, 5); UCB (2, 5) Identity Screening in the Pediatric Rheumatology Clinic Baraliakos, Xenofon, MD Disclosure: Nothing to disclose 0897. Temporal Achievement of Clinical Response and Inactive Disease Status in Patients Banbury, Brittany, MD with Axial Spondyloarthritis Treated with 0047. Administrative Barriers to Enrollment of Etanercept Ethnic Minorities in Clinical Research of Disclosure: AbbVie (2, 5); Bristol-Myers Squibb (2, Rheumatic/Immune-Mediated Diseases 5); Celgene (2, 5); Chugai (2, 5); Eli Lilly (2, 5); Disclosure: Nothing to disclose Galapagos (2, 5); Hexal (2, 5); Janssen (2, 5); MSD (2, 5); Novartis (2, 5); Pfizer (2, 5); Sandoz Banerjee, Shubhasree, MD, MBBS (2, 5) 1416. Effects of the COVID-19 Pandemic on ; UCB (2, 5) Patients Living with Vasculitis Disclosure: Nothing to disclose Baraliakos, Xenofon, MD 1364. Bimekizumab Long-Term Efficacy and Bankert, Jason, DO Safety over 96 Weeks in Patients with Ankylosing 1966. Improving Value Concordant Care Through Spondylitis: Interim Results from a Phase 2b Increased Use of Subcutaneous Methotrexate in Open-Label Extension Study Rheumatoid Arthritis Disclosure: AbbVie (2, 5); Bristol-Myers Squibb (2, Disclosure: Nothing to disclose 5); Celgene (2, 5); Chugai (2, 5); Eli Lilly (2, 5); Galapagos (2, 5); Hexal (2, 5); Janssen (2, 5); Bannerman, Heather, MD MSD (2, 5); Novartis (2, 5); Pfizer (2, 5); Sandoz 1616. Systematic Review of Effectiveness (2, 5); UCB (2, 5) Outcomes Reported in Rheumatology Transition Literature Baraliakos, Xenofon, MD Disclosure: Nothing to disclose 1904. Clinical Features of Patients with Active Ankylosing Spondylitis Who Did Not Respond to Baraliakos, Xenofon, MD Adalimumab but Responded to Ixekizumab: A 0447. Magnetic Resonance Imaging Post-hoc Analysis Characteristics in Patients with Spondyloarthritis Disclosure: AbbVie (2, 5); Bristol-Myers Squibb (2, and Clinical Diagnosis of Heel Enthesitis: 5); Celgene (2, 5); Chugai (2, 5); Eli Lilly (2, 5); Screening Data from a Phase 3 Trial Galapagos (2, 5); Hexal (2, 5); Janssen (2, 5); Disclosure: AbbVie (2, 5); Bristol-Myers Squibb (2, MSD (2, 5); Novartis (2, 5); Pfizer (2, 5); Sandoz 5); Celgene (2, 5); Chugai (2, 5); Eli Lilly (2, 5); (2, 5); UCB (2, 5) Galapagos (2, 5); Hexal (2, 5); Janssen (2, 5); MSD (2, 5); Novartis (2, 5); Pfizer (2, 5); Sandoz Baraliakos, Xenofon, MD (2, 5); UCB (2, 5)

9

2022. Effects of Anti-TNF-therapy on Barbhaiya, Medha, MD, MPH Osteoblastic Activity in Ankylosing Spondylitis – 0523. Characterization of Antiphospholipid Results from a Prospective Study Using PET-MRI Antibody-Associated Nephropathy: An of SIJ and Spine International Survey of Renal Society Disclosure: AbbVie (2, 5); Bristol-Myers Squibb (2, Members 5); Celgene (2, 5); Chugai (2, 5); Eli Lilly (2, 5); Disclosure: Nothing to disclose Galapagos (2, 5); Hexal (2, 5); Janssen (2, 5); MSD (2, 5); Novartis (2, 5); Pfizer (2, 5); Sandoz Bardin, Thomas, MD (2, 5) 0684. The Shrinking Toe: A Sign of Crystal ; UCB (2, 5) Dissolution During Urate Lowering Treatment of Severe Gouty Arthropathy Barbacki, Ariane, MD, FRCP Disclosure: Nothing to disclose 2036. Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling Barnado, April, MD, MSCI Disclosure: Nothing to disclose 0245. Systemic Lupus Erythematosus Phenotype Risk Score Identifies Undiagnosed Cases in a Barbarroja, Nuria, PhD Large Electronic Health Record 1856. Abnormal DNA Methylation in CD4+T Cells Disclosure: Nashville Biosciences (5) Is Associated with Cardiovascular Risk in Psoriatic Arthritis Barnado, April, MD, MSCI Disclosure: Nothing to disclose 1766. Trends of Pregnancy Outcomes in a Large Electronic Health Record Cohort of Systemic Barbar-Smiley, Fatima, MD, MPH Lupus Erythematosus Patients 1670. Low Copy Number of Long C4 Genes Is a Disclosure: Nashville Biosciences (5) Genetic Risk Factor for Childhood Onset SLE (cSLE) but Is Associated with Higher Age of Barnas, Jennifer Disease Onset 0990. Interferon Lambda Promotes Human Disclosure: Nothing to disclose Plasma Cell Differentiation in Lupus and Healthy Donors Barbhaiya, Medha, MD, MPH Disclosure: Nothing to disclose 0020. Characteristics of Rheumatology Outpatients with Suspected or Confirmed Baronaite Hansen, Renata, MD COVID-19 During the Pandemic in New York City 1287. Prevalence of Morbidity Prior to Diagnosis Disclosure: Nothing to disclose of Incident Systemic Lupus Erythematosus in the Danish Population Barbhaiya, Medha, MD, MPH Disclosure: Nothing to disclose 0466. Dosage Modification of Immunomodulatory Medications by Barr, Ann Cameron, MD Rheumatology Patients in New York City During 0439. Hurried Communication and Low Patient the Peak of the COVID-19 Pandemic Self-Efficacy Are Associated with Persistent Non- Disclosure: Nothing to disclose Adherence to SLE Medications Disclosure: Nothing to disclose Barbhaiya, Medha, MD, MPH 0522. Development of New International Barraclough, Michelle, PhD Classification Criteria for Antiphospholipid 1819. Altered Brain Functional Connectivity in Syndrome: Phase III Case Collection Results Systemic Lupus Erythematosus Disclosure: Nothing to disclose Disclosure: Sanofi Genzyme (2)

10

Barreira, Sofia 1918. Efficacy and Safety of Methotrexate in Bautista-Molano, Wilson, MD, PhD Giant Cell Arteritis: Results from a Bicentric 0771. Factors Associated to Clinical and Portuguese Cohort Study Radiographic Disease Progression in Patients Disclosure: Nothing to disclose with Early RA and First-degree Relatives: A 1-year Follow-up Barry, Austin Disclosure: Nothing to disclose 0785. Identification of Recruited CCR2+ Inflammatory Monocytes in a Mouse Model of Bax, Christina, BA RA-associated Lung Disease with Potential Role 1063. Spirulina Stimulates Inflammatory for resolvin-D1 in Reducing Monocyte Cytokine Production Through the STING and TLR Inflammatory Responses Pathways in Dermatomyositis in Vitro Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Bartels, Christie, MD, MS Baxendell, Haylee, BS 0603. Multisite Study of the Impact of COVID-19 1454. B Cell-specific TLR7 Regulates Lupus in Era Telemedicine Expansion on Reduction in No- TLR9 Deficient Mice Show Rates Disclosure: Nothing to disclose Disclosure: Independent Grants for Learning and Change (Pfizer) (2) Baxter, Sarah, MD, PhD 0463. Molecular Diagnosis of Childhood Bartels, Christie, MD, MS Immunodysregulation, Endocrinopathy and 1281. Opioid-Related Encounters as a Predictor Enteropathy X-linked (IPEX)-Like Syndrome and of 30-Day Readmissions in Lupus Implications for Clinical Management Disclosure: Independent Grants for Learning and Disclosure: Nothing to disclose Change (Pfizer) (2) Bayat, Sara, MD Bass, Anne, MD 0820. High Remission Rates in RA – Real Life Data 0960. The Risk of Venous Thromboembolism from Bariticinib After Septic Total Knee Replacement (TKR) Disclosure: Novartis (8) Revision Is Double the Risk After Aseptic TKR Revision: An Analysis of Administrative Discharge Baysac, Kathleen, PhD Data 1455. Functional Characterization of PLCG2 Disclosure: Nothing to disclose Mutations Found in Subjects with Autoinflammation and PLCG2-Associated Bass, Ronald Antibody Deficiency and Immune Dysregulation 0401. Prevalence and Characteristics of Systemic (APLAID) Reveals Both Hypermorphic and Sclerosis Patients Fulfilling the 2019 EULAR/ACR Hypomorphic Mutants Classification Criteria for Systemic Lupus Disclosure: Nothing to disclose Erythematosus Disclosure: Nothing to disclose Beck, David, MD, PhD 1953. Somatic Mutations in a Single Residue of Basta, Fabio, MD UBA1 Cause VEXAS, a Severe Adult-Onset 0718. Obesity Impairs Achievement of Clinical Rheumatic Disease Presenting as Relapsing Inactive Disease (CID) in Patients with Juvenile Polychondritis, Polyarteritis Nodosa, or Giant Cell Idiopathic Arthritis (JIA) Treated with TNF Arteritis Inhibitors Disclosure: Nothing to disclose Disclosure: Nothing to disclose

11

Beckers, Esther, MSc Lupus Patients Using a Mobile Application 0879. Application of Treat-to-Target in Axial Disclosure: Nothing to disclose Spondyloarthritis in Daily Practice Disclosure: Nothing to disclose Benard, Valerie, MD 2048. Comparison of Two Rituximab Regimens Beg, Shazia, MD for Induction of Remission in Antineutrophil 0189. Determining the Relationship Between Cytoplasm Antibody-associated Vasculitis: Mycobacterium Avium Subspecies Systematic Review and Meta-analysis Paratuberculosis Serostatus, Dietary Habits, Disclosure: Nothing to disclose Medication Regimen, and Joint Pain in Patients with Rheumatoid Arthritis Bender, Stephen, BS Disclosure: Nothing to disclose 1696. Measuring Quality Improvement from CME Participants: Results from the RAPID® CME Behrens, Frank, MD Initiative 0882. Efficacy and Safety of Secukinumab in Disclosure: Nothing to disclose Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Berenbaum, Francis, MD, PhD Randomized, Placebo-controlled Phase 3b Trial 0703. Liraglutide as a Potential Intra-Articular Disclosure: AbbVie (2, 5, 8); Biotest (5, 8); BMS Treatment for Cartilage Regeneration in (5, 8); Boehringer (5, 8); Celgene (5, 8); Chugai (2, Osteoarthritis: In Vitro and In Vivo Studies 5, 8) Supporting a Pro-Chondrogenic Effect ; Galapagos (5, 8); Genzyme (5, 8); Janssen (2, 5, Disclosure: Nordic, (9, travel support); Pfizer (5, 8); Lilly (5, 8); MSD (5, 8); Novartis (2, 5, 8); Pfizer 8); Roche (8); Sandoz (8); Sanofi (5); UCB (5) (2, 5, 8) Bergman, Martin, MD Behrens, Frank, MD 1728. Patient-Reported Outcomes of 1011. Effectiveness, Safety and Quality of Life Upadacitinib versus Abatacept in Patients with with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis and an Inadequate Rheumatoid Arthritis Under Routine Clinical Response to Biologic Disease-Modifying Care: First Interim Results from a German Non- Antirheumatic Drugs: 12-Week Results of a Interventional, Prospective, Multi-Center Study Phase 3 Study Disclosure: AbbVie (2, 5, 8); Biotest (5, 8); BMS Disclosure: AbbVie (5, 8); Amgen (5, 8); Bristol- (5, 8); Boehringer (5, 8); Celgene (5, 8); Chugai (2, Myers Squibb (5, 8); Genentech/Roche (5, 8); 5, 8); Galapagos (5, 8); Genzyme (5, 8); Janssen Gilead (5, 8); Janssen (5, 8); JNJ (parent of (2, 5, 8); Lilly (5, 8); MSD (5, 8); Novartis (2, 5, 8); Janssen) (1); Merck (5, 8); Novartis (5, 8); Pfizer Pfizer (2, 5, 8); Roche (2, 5, 8); Sanofi (2, 8); UCB (5, 8); Regeneron (5, 8); Sandoz (5, 8); Sanofi (5, (5, 8) 8)

Belanger, Matthew, MD Bergot, Anne-Sophie, PhD 0654. The Effects of Dietary Macronutrients on 1859. Curdlan-induced Villous Permeability, Serum Urate: A Secondary Analysis of the Luminal Pathobiont Translocation to the Ileal OmniHeart Trial Crypts, Ileitis and Arthritis Are Mitigated by Disclosure: Nothing to disclose Clostridia in Colonised Germ-free SKG Mice Disclosure: Nothing to disclose Bell, Kristy 0280. Compliance and Validation of Patient Berlinberg, Adam, MD Reported Outcome Information Collected from 1517. Metabolic Regulation of Type 3 Innate Lymphoid Cells by Intestinal Bacteria-Derived

12

Indoles in Ankylosing Spondylitis 0398. Chest CT Ordering Practices at Expert Disclosure: Nothing to disclose Scleroderma Centers in the United States Disclosure: Boehringer Ingelheim (Individual(s) Berman, Mark, MD Involved: Self): 2, 5 0527. Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicenter Berti, Alvise, MD Israeli Experience 1439. Proteinase 3-Reactive B Cell Pool Disclosure: Nothing to disclose Restructuring After Rituximab and Risk of Relapse in Severe PR3-ANCA-Associated Bermas, Bonnie, MD Vasculitis 1497. COVID-19 in Pregnant Patients with Disclosure: Nothing to disclose Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance Betts, Marissa, MSc Disclosure: Nothing to disclose 0883. Network Meta-Analysis of Long-Term Efficacy (ASAS40) of Biologic Disease-Modifying Bernatsky, Sasha, MD, PhD Anti-Rheumatic Drugs (bDMARDs) in bDMARD- 0002. Hydroxychloroquine and Chloroquine and Naïve Patients with Non-Radiographic Axial Hospitalizations for Viral Infection in the Pre- Spondyloarthritis COVID-19 Era Disclosure: UCB Pharma (2, UCB Pharma funded Disclosure: Nothing to disclose this study, which was conducted by Evidera)

Bernatsky, Sasha, MD, PhD Bhatty, Osman, MD 0556. Recent Use, Missed Doses and 1598. Efficacy of Universal Depression Screening Discontinuation of Infliximab in New-users: in a Rheumatology Clinic Comparisons of Biosimilar and Originator Disclosure: Nothing to disclose Exposures Disclosure: Nothing to disclose BHUYAN, FARZANA, PhD 1531. Characterization of Cytokine/chemokine Bernatsky, Sasha, MD, PhD Profile in Patient-derived M1/ M2 Macrophages 0757. Sunlight Exposure, Sun-protective to Identify Biomarkers for Genetically-defined Behaviour, and Anti-citrullinated Protein Systemic Autoinflammatory Diseases Antibody Positivity: A General Population-based Disclosure: Nothing to disclose Study in Quebec, Canada Disclosure: Nothing to disclose Bigley, Tarin, MD, PhD 1415. Murine Roseolovirus Induces Autoimmune Bernatsky, Sasha, MD, PhD Disease and Development of Autoreactive T Cells 0869. Retinal Toxicity in a Multinational and Autoantibodies Inception Cohort of Systemic Lupus Patients on Disclosure: Nothing to disclose Hydroxychloroquine Disclosure: Nothing to disclose Bilgin, Emre, MD 1313. Prevalence of Extra-Articular Bernatsky, Sasha, MD, PhD Manifestations in Early Ankylosing Spondylitis 1841. Outcomes After Hydroxychloroquine versus Non-Radiographic Axial Spondyloarthritis: Reduction or Discontinuation in a Multinational A Systematic Literature Review and Meta- Inception Cohort of Systemic Lupus Analysis of 1504 Patients Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Bernstein, Elana, MD Bingham, Clifton, MD

13

0136. Filgotinib Significantly Improved Patient- Antigen Presentation by B Cells reported Health-related Quality of Life for Disclosure: Nothing to disclose Patients with Active Rheumatoid Arthritis: A Post Hoc Analysis of SF-36 and HAQ-DI from Phase 3 Blanco, Luz, PhD Studies 0287. RNA Externalized by Neutrophil 1210. Patient-Reported Outcomes Measurement Extracellular Traps Promotes Inflammatory Information System (PROMIS) Assessment of Pathways in Endothelial Cells Response to Treatment with Golimumab IV or Disclosure: Nothing to disclose Infliximab in Rheumatoid Arthritis Patients: Results from a Phase 4 Study Blanken, Annelies 1228. Baricitinib 2-mg Provides Greater 1548. Blood Pressure, BMI and Sex Affect Optical Improvements in Patient-Reported Outcomes Spectral Transmission Imaging Measurements of Across All Disease Activity Levels Compared to the Hands Placebo: Post-hoc Analyses of RA-BEACON and Disclosure: Nothing to disclose RA-BUILD Trials Disclosure: AbbVie (5); Bristol-Myers Squibb (2, 5, Blazer, Ashira, MD 8); Eli Lilly (5); Genetech (5, 8); Gilead Sciences, 0984. Neighborhood Deprivation and Inc. (5); Pfizer (5); Regeneron (5); Sanofi (5, 8) Race/Ethnicity Affects COVID-19 Risk and Severity in SLE Bingham, Kathleen, MD, PhD Disclosure: Nothing to disclose 1260. Longitudinal Relationships Between Depression, Anxiety and Cognition in Lupus Boel, Anne, MSc Disclosure: Nothing to disclose 1867. Two-Year Diagnostic Consistency in Patients with Chronic Back Pain Suspected of Birru Talabi, Mehret, MD, PhD Axial Spondyloarthritis in Protocolised Follow-up: 1621. Cervical Cancer Screening Among Women Data from the Spondyloarthritis Caught Early with Systemic Lupus Erythematosus or Cohort Prescribed Tumor Necrosis Alpha-inhibitors Who 1868. Comparison of Quality of Life Between Receive Outpatient Rheumatology Care Chronic Back Pain Patients with and Without a Disclosure: Nothing to disclose Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-up: Data from the Bitencourt, Nicole, MD Spondyloarthritis Caught Early Cohort 1987. Predictors of Adverse Outcomes in 1871. Comparison of Work Productivity Patients with Childhood-Onset Systemic Lupus Outcomes Between Chronic Back Pain Patients Erythematosus Transitioning to Adult Care with and Without a Diagnosis of Axial Disclosure: Nothing to disclose Spondyloarthritis After 2-Year Protocolised Follow-Up: Data from the Spondyloarthritis Black, Samantha, BS Caught Early Cohort 1397. Clinical and Demographic Features of Disclosure: Nothing to disclose Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Bolko, Lois, MD, MB Morphea of Adults and Children Cohort 1076. Anti-Jo1 Antibody Quantification Serve as Disclosure: Nothing to disclose a Prognostic Factor in Anti-synthetase Syndrom Disclosure: Nothing to disclose Blake, Joseph 0286. An SLE-linked ITGAM Gene Variant Bombardier, Claire, MD, FRCPC Changes Mac-1 Structure, Signaling, and Surface 1714. Disease Activity Trajectories for Early and Expression and Enhances IFNg Production and Established Rheumatoid Arthritis: Real World

14

Results from a Rheumatoid Arthritis Cohort Boutsicaris, Christina, MD Disclosure: Abbvie (2); Amgen (2); CIHR (2); 1566. Onset and Disease Course of Inflammatory Janssen (2); Medexus (2); Merck (2, 5); MOHLTC Arthritis in Patients Receiving Immune (2); Novartis (2); Pfizer (2) Checkpoint Inhibitor Therapy at a Single Institution Bosch, Philipp, MD Disclosure: Nothing to disclose 0518. The Impact of Large Vessel Vasculitis of the Axillary Artery on Cumulative Glucocorticoid Bouzit, Lilia, MS Dose and Relapse Rate in Giant Cell Arteritis 1008. Assessing Improved Risk Prediction of Disclosure: Nothing to disclose Seropositive Rheumatoid Arthritis by Environmental, Genetic, and Preclinical Plasma Boteanu, Alina, MD Metabolite Factors 0710. Early Start of Biological Treatment in Disclosure: Nothing to disclose Juvenile Idiopathic Arthritis: Does a Therapeutic Window Exist in Real Life? Bracaglia, Claudia, MD Disclosure: AbbVie (8); Novartis (8); Roche (8) 1149. Risk Score of Macrophage Activation Syndrome (MAS) in Patients with Systemic Botson, John, MD, RPh Juvenile Idiopathic Arthritis (sJIA) 0665. Trends in Immunomodulation/pegloticase 1150. Traditional Laboratory Parameters and Co-therapy from 2015-2019: A Claims Database New Biomarkers in Macrophage Activation Study Syndrome and Secondary Hemophagocytic 0677. A Multicenter, Efficacy and Safety Study of Lymphohistiocytosis Methotrexate to Increase Response Rates in Disclosure: SOBI (8) Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Brandl, Carolin, PhD Open-Label Study 0492. Microbiota-induced Intestinal Barrier Disclosure: Abbvie (5, 8); Celgene (5, 8); Horizon Dysfunction Initiates the Shuttling of Immune Therapeutics plc (2, 5, 8); Novartis (5, 8); Radius Cells from the Gut to the Joints Health (2) Disclosure: Nothing to disclose

Boucher, Alexandra, BS Brandt, Jennifer, MD, MPH 0925. Early Hydroxychloroquine Use May Reduce 0059. EHR-Supported Staff Protocol Improves Risk for SSc-Associated Pulmonary Hypertension Smoking Cessation in a Diverse Rheumatology Disclosure: Nothing to disclose Clinic: Results of Quit Connect Dissemination Project Boulougoura, Afroditi, MD Disclosure: Nothing to disclose 0929. The Effect of Mycophenolate Mofetil on Pulmonary Function Tests in Patients with Braun, Juergen, MD Systemic Sclerosis-associated Interstitial Lung 1366. Secukinumab Improved Signs and Disease, and the Difference Between the African Symptoms in Patients with Non-radiographic Americans versus Non-African Americans Axial Spondyloarthritis: Results from a Disclosure: Nothing to disclose Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation Bourji, Khalil, MD, PhD Disclosure: AbbVie (2, 5, 8); Amgen (2, 5, 8); BMS 1095. Avascular Necrosis in the Hopkins Myositis (2, 5, 8); Boehringer (2, 5, 8); Celgene (2, 5, 8); Cohort: A Single Center Experience Celltrion (2, 5, 8); Centocor (2, 5, 8); Chugai (2, 5, Disclosure: Nothing to disclose 8); EBEWE Pharma (5, 8); Medac (2, 5, 8); MSD (2, 5, 8); Mundipharma (2, 5, 8); Novartis (2, 5,

15

8); Pfizer (2, 5, 8); Roche (2, 5, 8); Sanofi-Aventis 1310. Gut Microbiome Changes Are Different (2, 5, 8); UCB (2, 5, 8) Between Ankylosing Spondylitis and Inflammatory Bowel Disease, and Correlate with Braverman, Genna Disease Activity in Both Diseases 1178. Associations of Walking Endurance and Disclosure: Nothing to disclose Speed with Multiple Measures of Subclinical Cardiovascular Disease in Rheumatoid Arthritis Brunner, Hermine, MD, MSc, MBA Disclosure: Nothing to disclose 1495. Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Bray, Monica, MD Analysis of Data up to 5.5 Years from an Open- 1687. Kawasaki Disease Shock Syndrome in the label, Long-term Extension Study Intensive Care Unit: A Single Center Cohort Disclosure: AbbVie (5); AstraZeneca-MedImmune Disclosure: Nothing to disclose (5); Bayer (5); Biocon (5); Boehringer Ingelheim (5); Bristol-Myers Squibb (2, 5); Cincinnati Breitman, Maya, PhD Children’s Hospital Medical Center (3); Eli Lilly 0745. Development of Functional Assays to Pre- (5); GlaxoSmithKline (8); Janssen (5); qualify Human Mesenchymal Stem Cells for MedImmune (2); Novartis (2, 8); Pfizer Inc (2, 5); Rheumatoid Arthritis Treatment Roche (5, 8); R-Pharm (5) Disclosure: Nothing to disclose Bucci, Justin, MD Brevet, Pauline, MD 1652. Progression of Knee OA with Use of Intra- 0773. The Anti-carbamylated Fibrinogen articular Corticosteroids (CS) vs Hyaluronic Acid Response in Rheumatoid Arthritis Targets a (HA) Specific Epitope on the γ-chain and Is Associated Disclosure: Nothing to disclose with a More Active Disease Disclosure: Nothing to disclose Buch, Maya H., MD, PhD 2012. A Phase IIb, Randomized, Double-blind Bridges, John, MD Study in Patients with Rheumatoid Arthritis 1509. Leukocyte Telomere Length and Childhood Evaluating the Safety and Efficacy of Evobrutinib Onset of Systemic Lupus Erythematosus in the Compared with Placebo in Patients with an Black Women’s Experiences Living with Lupus Inadequate Response to Methotrexate (BeWELL) Study Disclosure: AbbVie (5); Eli Lilly and Company (5); Disclosure: Nothing to disclose Gilead Sciences, Inc. (5); Merck-Serono (5); Pfizer (2) Briones Figueroa, Andrea, MD ; Roche (2); Sandoz (5); Sanofi (5); UCB (2) 1279. Clinical Characteristics and Impact of the COVID-19 Pandemic in Systemic Lupus Buehring, Bjoern, MD Erythematosus Patients in a Spanish Tertiary 0536. Systematic Geriatric Assessment in Older Hospital Patients with Rheumatic Diseases - The Disclosure: Nothing to disclose RheuMAGIC Pilot Study Disclosure: AbbVie (8, 9, Travel reimbursement); Brittan, Kaitlyn, MD Amgen (5, 8); GE/Lunar (2, 5); Gilead (5); Janssen 1002. Prostate Cancer Risk Is Not Increased in (9, Travel reimbursement); Kinemed (2); Lilly (9, Rheumatoid Arthritis After Accounting for Travel reimbursement); MSD (8); UCB (5, 8, 9, Retention in a Health Care System Travel reimbursement) Disclosure: Nothing to disclose Bugdayli, Kubra, MD Brown, Matthew

16

1929. Visual Ischemia During Relapse and Lupus Erythematosus (SLE) Follow-up of Giant Cell Arteritis: A Systematic Disclosure: Nothing to disclose Review Disclosure: Nothing to disclose Bykerk, Vivian, MD, FRCPC 0483. Can a Clinical Disease Activity Index Based Bulbin, David, DO on Patient-Reported Joint Counts (PT-CDAI) Be 1712. Implementation of a Musculoskeletal Used to Inform Target-Based Care in Ultrasound (MSUS) Curriculum in an Academic Telemedicine? An Analysis of 2 Early RA Cohort Rheumatology Fellowship Within an Integrated Studies Health System: A Four-Year Experience Disclosure: Amgen (5); BMS (5); Gilead (5); NIH Disclosure: Alexion (8); Novartis (5, 8) (2); Pfizer (5); Sanofi-Genzyme/Regeneron (5); Scipher (5) Bull Haaversen, Anne, MD ; UCB (5) 1938. Risk for Vision Loss and Relapse in Patients with Giant Cell Arteritis Byun, John, MD Disclosure: Nothing to disclose 0139. Routine Assessment of Patient Index Data (RAPID) 3 as a Predictor of Weight Reduction in Burmester, Gerd, MD Rheumatology Patients Undergoing Bariatric 0226. Similar Efficacy of Sarilumab Monotherapy (MONARCH) vs Sarilumab and Methotrexate Disclosure: Nothing to disclose Combination Therapy (MOBILITY B) in Patients with Rheumatoid Arthritis Cabrera, Diego, MD Disclosure: AbbVie (5, 8); Celgene (5); Eli Lilly (5, 0624. Association of Regional Body Composition 8); Gilead Sciences, Inc. (5, 8); Novartis (5); Pfizer and Physical Function Using the Short Physical (5, 8) Performance Battery Among Peruvian Women with HIV Burmester, Gerd, MD Disclosure: Nothing to disclose 1238. Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported Cai, Ken, MBBS, FRACP, MSc Outcomes in Sarilumab Clinical Trials 0950. The Association Between Gout and 1350. Safety Profile of Upadacitinib in Psoriatic Cardiovascular Disease Outcomes: Assessment Arthritis: Integrated Analysis from Two Phase 3 and Recalibration of Individual-level Primary Trials Prevention Risk Prediction Equations in Disclosure: AbbVie (5, 8); Celgene (5); Eli Lilly (5, Approximately 450,000 New Zealanders 8); Gilead Sciences, Inc. (5, 8); Novartis (5); Pfizer Disclosure: Nothing to disclose (5, 8) Calabrese, Cassandra, DO Burnham, Jon, MD, MS 1697. Immune Related Adverse Events from 1986. Determinants of Variation in Pediatric Checkpoint Inhibitor Therapy: Survey of Systemic Lupus Erythematosus Care Delivery Hospitalists’ Awareness and Experiences Disclosure: Nothing to disclose Disclosure: Abbvie (5); Regeneron (8)

Buyon, Jill, MD Calabrese, Leonard, DO 1808. Erythrocyte Complement Receptor 1 1730. Comparison of MBDA Score, Patient Global (ECR1) and Erythrocyte Bound C4d (EC4d) Assessment and Evaluator Global Assessment for Associate with Adverse Pregnancy Outcomes and Predicting Risk of Radiographic Progression Preeclampsia in Pregnant Women with Systemic Disclosure: AbbVie (5, 8); Bristol-Myers Squibb (5); Crescendo (5); Genentech (5, 8); Gilead (5)

17

; GlaxoSmithKline (5); Horizon (5); Janssen (5, 8); 1289. Sex Differences in Mental Health and Novartis (5, 8); Sanofi (5) Quality of Life and Their Impact in the Treatment of Patients with Systemic Lupus Erythematosus Calabuig, Irene, MD Disclosure: Nothing to disclose 0650. Risk of Vertebral Fractures at Lateral Chest Radiographies in Patients with Gout Cao, Shu, MD 0686. Renal Evolution During the First Year of 1930. Thirty-Day Readmission Rate in Patients Urate-lowering Therapy According to Who Were Initially Admitted for Active Giant Cell Sonographic Joint Deposition: Data from the Arteritis Lille-Alicante Inception Cohort 1941. Outcome of Giant Cell Arteritis Patients Disclosure: Nothing to disclose Who Were Primarily Admitted for Venous Thromboembolism Events Calixto, Omar-Javier, MD Disclosure: Nothing to disclose 0559. Low Frequency of ANA/DFS70 Pattern Positive Result in a Large Cohort of Cao, Ye, PhD Autoimmune/autoinflammatory Diseases 2046. Alterations in Circulating CD4+ T Cell Compared with First Degree Relatives and Phenotypes in CCP+ Early RA and CCP+ At-risk Healthy Controls Evaluated in a Single Hospital Individuals by Mass Cytometry from Colombia Disclosure: Nothing to disclose Disclosure: Nothing to disclose Carbo, Marlies, MD Campbell, Mark, MD 1320. Are Coping Strategies, Anxiety and 1116. Magnetic Resonance Imaging Structural Depression Associated with Daily Physical Changes Correlated with Knee Extension: Data Activity in Patient with Axial SpA? from the Osteoarthritis Initiative 1886. Measuring Physical Activity in Disclosure: Nothing to disclose AxSpA:Content Validity and Measurement Properties of the New AxSpA-SQUASH Canavan, Mary, PhD Disclosure: Nothing to disclose 0067. Functionally Mature CD1c+ Dendritic Cells Contribute to Synovial Inflammation in Cardwell, Francesca, PhD Rheumatoid Arthritis via STAT3 1301. Characterizing How SLE Patients Access Disclosure: Nothing to disclose Health Information Pre and During COVID-19 Disclosure: Nothing to disclose Canning, Jordan, BSc, MSc 0487. Association Between an Extended Lifestyle Carlomagno, Raffaella, MD Score and Adverse Health-related Outcomes in 1669. Genetics of Age at Diagnosis in Systemic People with Rheumatoid Arthritis: A Study of Lupus Erythematosus 5295 UK Biobank Participants Disclosure: Nothing to disclose Disclosure: Nothing to disclose Carlsson, Emil, PhD Cannon, Laura, MD 1796. A Panel of Urinary Proteins Predicts Active 1666. Elucidating Research Priorities in Lupus Nephritis and Response to Rituximab Childhood-Onset Systemic Lupus Erythematosus: Treatment A Qualitative Study Disclosure: Nothing to disclose Disclosure: Nothing to disclose Carlucci, Philip, BS Cano Cruz, Lilian Guadalupe, MD 1515. Renal Responder Status and Associated Clinical Variables in the Lupus Accelerating

18

Medicines Partnership Cohort Disclosure: Nothing to disclose Case, Siobhan, MD, BA, MHS 1271. Post-Traumatic Stress Disorder (PTSD) and Carlucci, Philip, BS Risk of Systemic Lupus Erythematosus (SLE) 1516. The Value of Renal Biopsy at Lower Levels Among Medicaid Recipients of Proteinuria in Patients Enrolled in the Lupus Disclosure: Nothing to disclose Accelerating Partnership Disclosure: Nothing to disclose Castelino, Flavia, MD 0390. Baseline Characteristics of Systemic Carluzzo, Kathleen, MS Sclerosis (SSc) Patients with Restrictive Lung 0144. Age, Income, Education, and Health Disease in a Multi-Center United States Based Conditions Are Associated with Patient Longitudinal Registry Empowerment Among US Adults with Arthritis, Disclosure: Boehringer Ingelheim (5, 8) but Race and Geography Are Not Disclosure: Nothing to disclose Castillo-Bustamante, Melissa, MD Carneiro, Chantelle, MD, MS 1759. Rheumatoid Arthritis Affects the Ossicular 0547. Transgender Patients in the Rheumatology Joints: A Human Otopathologic Study Setting Disclosure: Nothing to disclose Disclosure: Nothing to disclose Castro, Adela, MD Carr, Hayley, BSc 0797. Comparison of the Efficacy and Safety of 0796. Development of a Tool to Assess Synovial Janus Kinase Inhibitors and DMARDs in Patients Tissue Infiltrates and Derive Histological with Active Rheumatoid Arthritis: A Bayesian Pathotype in Inflammatory Arthritis: Relationship Network Meta-Analysis to Clinical and Ultrasound Variables 1357. Comparative Efficacy of Janus Kinase Disclosure: Nothing to disclose Inhibitors and TNF Inhibitors in Ankylosing Spondylitis: A Network Meta-Analysis Carrino, John, MD, M.P.H. Disclosure: Novartis (Individual(s) Involved: 1482. Joint Safety with Tanezumab: Integrated Spouse/Partner): 3 Analyses from Randomized Controlled Phase 3 Studies in Patients with Osteoarthritis Cetin, Cigdem, MD Disclosure: Arthritis and Rheumatology journal 0266. The Correlation Between Pregnancy, (9, Associate Editor (Imaging)); Covera Health Disease Activity and Adverse Pregnancy (5); Image Analysis Group (5); Image Biopsy Lab Outcomesin Patients with Systemic Lupus (5); Osteoarthritis Imaging journal (9, Associate Erythematosus Editor (CT & CBCT)); Pfizer (5); Simplify Medical Disclosure: Nothing to disclose (5) Cetin Gedik, Kader, MD Carson, Joseph, MSc 0453. Monitoring of BK Reactivation and Long- 1586. Rheum Service: Comprehensive Virtual term Safety on JAK1/2 Inhibition with Baricitinib Care During COVID-19 Disclosure: Nothing to disclose Disclosure: Nothing to disclose Chakravarty, Eliza, MD Case, Aaron, MD 0989. Withdrawal of MMF Is Safe in Quiescent 1037. Relationship Between Air Quality and Renal and Non-Renal SLE: Results from a Multi- Sarcoidosis Inflammatory Activity Center Randomized Trial Disclosure: Nothing to disclose Disclosure: Nothing to disclose

19

Chalhoub, Nathalie, MD, MSc Charles-Schoeman, Christina, MD 1679. Developing a Standardized Corticosteroid 0239. Adjudicated MACE and VTE in the Dosing Regimen in Pediatric Proliferative Lupus Filgotinib RA Program: Integrated Analysis from Nephritis Phase 2 and 3 Clinical Trials Disclosure: Nothing to disclose 0484. Relationship Between Paraoxonase-1 Genotype, Activity, and Major Adverse Challener, Gregory, MD Cardiovascular Events in Patients with 1755. Body Mass Index Trajectory and Variability Rheumatoid Arthritis Receiving Tofacitinib in Rheumatoid Arthritis 1211. Relationship Between Changes in Lipid Disclosure: Nothing to disclose Levels and Improvement in Disease Activity Outcomes in Patients with Rheumatoid Arthritis Chalmers, Samantha, PhD Receiving Upadacitinib Treatment: Pooled 0840. Amelioration of - Analysis of Data from Two Phase 3 Studies Mediated Glomerulonephritis via CD6 Disclosure: AbbVie (2, 5); Bristol-Myers Squibb Modulation (2); Gilead (5); Pfizer Inc (2, 5); Regeneron-Sanofi 0841. CD6 Modulation Ameliorates Kidney and (5) Skin Disease in a Spontaneous Murine Lupus Model Chatterjee, Rudrarpan, MD Disclosure: Nothing to disclose 1099. High Burden of Infections in Indian Patients with Idiopathic Inflammatory Myopathy: Chandra, Tanya, MBBS Validation of Observations from the MyoCite 1058. The Relationship of Different Muscle Dataset Enzymes in Adult Myositis Patients Disclosure: Nothing to disclose Disclosure: Nothing to disclose Chauhan, Krati, MD, MPH CHANG, Juliana, MD 0055. Racial and Sex-based Disparities in Health 1607. Effectiveness of Dietary Counseling on Care Utilization: Eye Inflammation as a Paradigm Gout Management and Risk Factors for Disclosure: Nothing to disclose Metabolic Syndrome in Gout Patients Disclosure: Gilead (1) Cheah, Jenice, BS 1388. A Systematic Assessment of Chang, Margaret, MD, PhD Demographics, Clinical and Serological Features 2045. Resident Memory T Cells in Synovial Tissue Associated with Colonic Hypomotility in Systemic Mediate Arthritis Flares Sclerosis Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Chao, Yusuf, MD Chen, Eugenia, MD 1592. Improving Documentation of Smoking 0338. Increased Risk of Lymphoproliferative Cessation Counseling Among Disorders in Psoriatic Arthritis Spondyloarthropathy Smokers Disclosure: Nothing to disclose Disclosure: Nothing to disclose Chen, Jia (Sijia), MD, PhD Chapman, Marquis, BSc 1519. Interleukin-17D, a Cytokine Derived from 1838. Aerobic Exercise Improves Fatigue and Stromal Cells, Attenuates Joint Inflammation Quality of Life in Women with Systemic Lupus Disclosure: Nothing to disclose Erythematosus (Preliminary Analysis) Disclosure: Nothing to disclose Chen, Jianmeng

20

0868. Impact of Proteinuria on the Clearance of 0251. Dynamics of Anti-Nuclear Antibodies in a Monoclonal Antibodies: Potential Clinical Longitudinal Study of a Large Systemic Lupus Implications Erythematosus Cohort Disclosure: Nothing to disclose 1286. Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Chen, Shang-Yang, BSc Erythematosus by Global Assessment 0072. Characterizing Heterogeneity of Synovial of Disease Activity Macrophages in Rheumatoid Arthritis Patients 1473. A Combination of Healthy Lifestyle Disclosure: Nothing to disclose Behaviors Reduce Risk of Incident Systemic Lupus Erythematosus in the Nurses’ Health Chen, Tommy Studies 0595. High Satisfaction with Tele-medicine in a 1507. Longitudinal Analysis of ANA Assay New York City Clinic Performance in SLE from the SLICC Inception Disclosure: Nothing to disclose Cohort Disclosure: Nothing to disclose Chen, Yuling, MD 1408. Metabolic Reprogramming in Memory Choi, Yunjung, MD, PhD CD4+ T Cells Is Associated with Immune Cell 0181. Methotrexate Use Does Not Increase the Dysfunction During Aging Prevalence of Hepatic Steatosis: A Real-World Disclosure: Nothing to disclose Retrospective Nested Case-Control Study Disclosure: Nothing to disclose Cherny, Dmitriy, MD 1082. The Presence of Anti-Jo1, anti-PL7, And/or Choquette, Denis, MD, FRCPC anti-MDA5 Antibodies in Idiopathic Inflammatory 0333. Comparative Effectiveness of Myopathy Confers an Increased Risk of a Secukinumab, Adalimumab and Other Tumor Significant Restrictive Pulmonary Defect Necrosis Factor Inhibitors Used with or Without Disclosure: Nothing to disclose Methotrexate in the Treatment of Psoriatic Arthritis Chiruvolu, Neha, DO Disclosure: AbbVie Canada (5, 8); Amgen Canada 0623. Cytokine Storm: Outcomes in SARS-CoV-2 (5, 8); Bristol-Myers-Squibb Canada (5, 8); Eli Lilly Patients Treated with Biologics in a Canada (5, 8); Janssen Canada (5); Merk Canada Rheumatology Cohort (5, 8); Novartis Canada (5, 8); Pfizer Canada (5, Disclosure: Nothing to disclose 8); Roche Canada (5); Sandoz Canada (5

Chiu, Cindy, DO Choquette Sauvageau, Loïc, BSc 0568. Clinical Timelines and Management Delays 1898. Comparative Effectiveness of in Suspected Giant Cell Arteritis Secukinumab, Adalimumab and Other Tumor Disclosure: Nothing to disclose Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis Chohan, Saima, MD Disclosure: Nothing to disclose 1369. Efficacy of Tildrakizumab in PsA: DAPSA Remission and Low Disease Activity in PASDAS Chowdhury, Samira, MD Through Week 52 1248. Patients Seropositive for La/SSB Without Disclosure: Arizona Arthritis and Rheumatology Ro/SSA Differ from Those Displaying La/SSB with Associates (9, Partner/Physician) Ro/SSA in a Single Center Sjogren's Cohort Disclosure: Nothing to disclose Choi, May, MD, FRCPC Choy, Ernest, MD, FRCP

21

0215. Incidence and Risk of Venous Setting Thromboembolic Events Among Patients with Disclosure: Nothing to disclose Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program Chua, Choon-Guan, MRCP 1226. Outcomes and Efficacy of Selective versus 1071. Characteristics of Anti-Transcription Automatic Switching from Etanercept to a Intermediary Factor 1-gamma Autoantibody Biosimilar in Inflammatory Arthritis Using Positive Dermatomyositis Patients in Singapore Electronic Health Records from UK Disclosure: Nothing to disclose 1234. Noninflammatory Pain Is a Frequent Phenomenon in Rheumatoid Arthritis and Chung, Cecilia, MD, MPH Responds Well to Treatment with Sarilumab 0027. CYP2D6 Genotype and Reduced Codeine 2006. Identification of a Rule to Predict Response Analgesic Effect in Real-World Clinical Practice to Sarilumab in Patients with Rheumatoid Disclosure: Nothing to disclose Arthritis Using Machine Learning and Clinical Trial Data Chung, Melody, MD, MS Disclosure: Abbvie (2, 8); Amgen (2, 8); 0382. Increased Rates of Obstetric Complications AstraZeneca (2, 8); Bio-Cancer (2, 8); Biogen (2, Prior to Systemic Sclerosis Diagnosis 8); Boehringer Ingelheim (2, 8); Bristol-Myers 0385. A Pilot Study to Evaluate the Safety and Squibb (2, 8); Celgene (2, 8); Chugai Pharma (2, Efficacy of Treprostinil in the Treatment of 8); Eli Lilly (2, 8); Ferring Pharmaceuticals Calcinosis in Patients with Systemic Sclerosis Disclosure: Nothing to disclose Christ, Lisa, MD 0515. A Proof of Concept Study to Assess the Ciciriello, Sabina, MD Efficacy of Tocilizumab in Combination with 0903. Changing Patterns of Use of Ultra-Short Glucocorticoid Administration to Biologic/Targeted Synthetic DMARDs in Psoriatic Treat Newly Diagnosed Giant Cell Arteritis – a 24 Arthritis: An Analysis of the OPAL Dataset Week Analysis Disclosure: Gilead (8) Disclosure: Nothing to disclose Cid, Maria C., MD Christiansen, Sara Nysom, MD L06. Mavrilimumab (anti GM-CSF Receptor α 0445. Dual-Energy CT in Gout Patients: Do All Monoclonal Antibody) Reduces Time to Flare and Color-Coded Lesions Actually Represent Increases Sustained Remission in a Phase 2 Trial Monosodium Urate Crystals? of Patients with Giant Cell Arteritis Disclosure: Bristol Myers Squibb (BMS) (8); Disclosure: Kiniksa (2) General Electric (GE) (8) Clancy, Robert, PhD Chriswell, Meagan, BS 0293. Contraction of the Stool Taxa Clostridia Is 0778. Bacterial Families Associated with the Development of Clinical Lachnospiraceae/Ruminococcaceae Are Disease Among Anti-Ro+ Mothers of Children Immunologically Targeted in Individuals At-risk with Neonatal Lupus for RA and a Specific Strain Is Arthritogenic in Disclosure: Nothing to disclose Monocultured Gnotobiotic Mice Disclosure: Nothing to disclose Clark, Kristina, MD, MRCP 1909. High-density Proteomic Analysis of Skin Chu, Jun, CRNP Blister Fluid and Plasma in Systemic Sclerosis 0437. Integrating Reproductive Health in Identifies Local and Systemic Differences for Key Systemic Lupus Erythematosus in a Tertiary Care Proteins 1910. Integrated Molecular Analysis of Systemic

22

Sclerosis Skin and Blood Highlights Significant of Exposure in Patients with Rheumatoid Differences Between Major Autoantibody Arthritis Subgroups 0828. Clinical and Functional Response to Disclosure: Nothing to disclose Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase Clowse, Megan, MD, MPH 3b/4 Methotrexate Withdrawal Study 1499. The Frequency of Contraception 0894. Efficacy and Safety of Neihulizumab Documentation in Women with Lupus and (AbGn-168H) in Patients with Active Psoriatic Rheumatoid Arthritis Within the RISE Registry Arthritis: 24-week Results from a Phase II Open 1782. Use of a Patient-reported Survey to Label Study Document Contraceptive Use and Interest in Disclosure: AbbVie (2, 5); Amgen Inc (2, 5); Pregnancy to Identify Patients with Unmet Boehringer Ingelheim (2, 9, Personal Fees); Eli Pregnancy Prevention and Planning Needs Lilly (2, 5); Gilead (2, 5); Pfizer (2, 5); Sandoz (2, 9, Disclosure: Astra Zeneca (5); GSK (2, 5); Pfizer (2); Personal Fees) UCB (5) Coit, Patrick, MPH Coates, Laura, PhD, MBChB 0494. Genetic-epigenetic Interaction and the 0353. Achievement of Sustained Remission and Relationship Between DNA Methylation Patterns Low Disease Activity with Secukinumab Improves and Disease Activity in a Longitudinal Cohort of Quality of Life and Physical Function in Patients Lupus Patients with Psoriatic Arthritis: Results from a Disclosure: Nothing to disclose Randomized Phase 3 Study 0907. Long-term Outcomes with Filgotinib, an Colaco, Keith, MSc Oral Selective Janus Kinase 1 Inhibitor: 100-week 0503. Targeted Metabolomic Profiling and Data from an Open-label Extension (OLE) Study Prediction of Cardiovascular Events: A in Patients with Active Psoriatic Arthritis (PsA) Prospective Study of Patients with Psoriatic 1349. Guselkumab Provides Domain-Specific and Arthritis and Psoriasis Comprehensive Efficacy as Assessed Using 1328. Cardiac Biomarkers Are Associated with Composite Endpoints in Patients with Active the Development of Cardiovascular Events in Psoriatic Arthritis Patients with Psoriatic Arthritis and Psoriasis 1353. Achievement of Remission Is Associated 1476. Trends in Mortality and Cause-specific with Improvement in Functionality in Mortality Among Patients with Psoriasis and Certolizumab Pegol-Treated Patients with Psoriatic Arthritis in Ontario, Canada Psoriatic Arthritis, Irrespective of Pre-Existing Disclosure: Nothing to disclose Radiographic Structural Damage Disclosure: AbbVie (2, 5, 8); Amgen Inc. (5, 8); Colloca, Luana, MD, PhD, MS Biogen (8); Boehringer Ingelheim (5); Celgene (2, 1645. Placebo Group Responses in Clinical Trials 5, 8); Eli Lilly (2, 5, 8); Gilead (5, 8); Janssen (5, 8); of Patients with Osteoarthritis: Data from the Medac (8); MSD (5); Novartis (2, 5, 8); Pfizer (2, Tanezumab Development Program 5, 8); UCB Pharma Disclosure: Nothing to disclose

Cohen, Stanley, MD Colmegna, Ines, MD 0235. Safety and Biological Activity of Rozibafusp 0632. Systems Approach to Understanding Alfa in Subjects with Rheumatoid Arthritis: Final Reasons for Influenza Vaccine Hesitancy in Results of a Phase 1b Randomized, Double-blind, Rheumatic Diseases Placebo-Controlled, Multiple Ascending Dose Disclosure: Nothing to disclose Study 0237. Safety Profile of Upadacitinib up to 3 Years Combe, Bernard, MD, PhD

23

0208. Efficacy and Safety of Filgotinib for Constantin, Arnaud, MD, PhD Patients with Rheumatoid Arthritis with 0380. Efficacy and Safety of Ixekizumab in Inadequate Response to Methotrexate: 52-Week Patients with Psoriatic Arthritis and Inadequate Results Response to TNF Inhibitors: 3 Year Results from a 0220. Impact of Concomitant Glucocorticoids on Phase 3 Study the Clinical Efficacy and Safety of Upadacitinib in Disclosure: AbbVie Inc. (5, 8); Amgen (5, 8); Patients with Rheumatoid Arthritis: An Ad Hoc Celltrion (5); Eli Lilly and Company (5, 8); Gilead Analysis of Data from Three Phase 3 Studies (5, 8); Janssen (8); Novartis (5, 8); Pfizer Inc. (5, 1998. Ten-year Analysis of the Risk of Severe 8); UCB (5, 8) Outcomes Related to Very Low-dose Glucocorticoids in Early Rheumatoid Arthritis Cooley, Helen, MD Disclosure: AbbVie (5, 8); Bristol-Myers Squibb 0231. Treatment Patterns of Biologic/Targeted (8); Eli Lilly (2, 5, 8); Gilead Sciences, Inc. (5, 8); Synthetic DMARDs for the Management of Janssen (5); MSD (8); Novartis (2); Pfizer (2, 8); Rheumatoid Arthritis in Australia: An Analysis of Roche-Chugai (5, 8); Sanofi (5) the OPAL Dataset Disclosure: Janssen (9, Conference sponsorship); Compán Fernández, Olga, MD Novartis (5); UCB (8) 1337. Relationship of the Pro12Ala Polymorphism of the PPARg Gene with Coras, Roxana, MD Inflammatory Activity, Osteoporosis and Obesity 0318. Oxylipin Profile Is Associated with Skin in Patients with Psoriatic Arthritis Disease and Enthesitis in Psoriatic Disease Disclosure: Nothing to disclose 0970. Oxylipins Profiles During the Earliest Phases of Rheumatoid Arthritis: Associations Conaghan, Philip, MD, PhD with Clinical Stage and Treatment Outcomes 0140. Meaningful Within-Patient Change in 1994. Rheumatoid Arthritis Improvement After WOMAC Domains in Patients with Moderate-To- Exposure to an Anti-Inflammatory “ITIS” Diet Is Severe Osteoarthritis Associated with Changes of Gut Microbiome and 1713. Exploring Novel Tenosynovitis and Systemic Metabolome Combined Inflammation Imaging Outcomes: Disclosure: Nothing to disclose Results from a Randomized Controlled Trial in Early Rheumatoid Arthritis Corbitt, Kelly Disclosure: AbbVie (5, 8); Bristol-Myers Squibb 1246. Sjogren’s Syndrome and Its Risk of Cervical (2); Eli Lilly (5); EMD Serono (5); Flexion Lesions Therapeutics (5, 8); Galapagos (5); Gilead (5); Disclosure: Nothing to disclose GlaxoSmithKline (5); Janssen (5); Novartis (5, 8); Pfizer Inc (5); Regeneron (5); Samum Cordisco, Anthony, MA 0806. Identification and Adjustment for Factors Concha, Josef, MD Associated with Clinical Response in Rheumatoid 1982. Quality of Life of Patients with Facial Arthritis Clinical Trials to Improve Comparisons Cutaneous Lupus Erythematosus of Treatment Efficacy Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Consolaro, Alessandro, MD, PhD Coronel, Luis, MD 1985. Validity and Reliability of Four 1543. Prevalence of Ultrasound Findings Parent/Patient Reported Outcome Measures for Suggestive of Inflammatory Arthritis in Children Juvenile Idiopathic Arthritis with Skin Psoriasis (ChildEchoPso) Disclosure: Nothing to disclose Disclosure: Nothing to disclose

24

Correia Marques, Mariana, MD 1163. Predictors of Colchicine Response in Craig, Gary, MD Patients with Undefined Systemic 1046. Risk Factors Associated with Interstitial Autoinflammatory Diseases Lung Disease in Patients with RA: Findings from a Disclosure: This work was supported by a Fred Retrospective Healthcare Database Analysis Lovejoy Resident Research and Education Award. Disclosure: AbbVie (2); Amgen/Celgene (8); (2) Arthritis Northwest (9, Partner); Bristol-Myers Squibb (2, 5, 8); Discus Analytics (1); Eli Lilly (8); Correll, Colleen, MD Genentech (2, 8); Gilead (5); MR (5); Novartis (5, 0711. Alternative Dosing of Biologic Is 8); Pfizer (5); Sanofi (8); UCB (8) Frequent Among Children with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Cramarossa, Gemma, MD Rheumatology Research Alliance Registry 1825. Risk Factors for Antimalarial-Induced Disclosure: Nothing to disclose Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases Corrigan, Patrick, PhD, DPT Disclosure: Nothing to disclose 0563. Relation of Pain Sensitization to Isokinetic Knee Extension Torque: The MOST Study Crisafulli, Francesca 0565. In Those with Unilateral Frequent Knee 0262. SLE Pregnancies: C4 as Predictor of Flares Pain, Between-Limb Differences in Stance Time and Adverse Pregnancy Outcomes During Walking Increase the Risk of Frequent Disclosure: Nothing to disclose Pain in the Other Knee: The MOST Study Disclosure: Nothing to disclose Cron, Randy, MD, PhD 0473. Characterization of DOCK8 as a Novel Cosman, Felicia, MD Gene Associated with Cytokine Storm Syndrome 1973. Treatment Sequences with Romosozumab Disclosure: Novartis (5); Pfizer (5); Sobi (2, 5, 8) Before or After Antiresorptive Medication Disclosure: Amgen Inc. (2, 5, 8); Radius Health (5, Crosley, Erica, MD, MPH 8) 1980. Understanding the Relationship Between Illness Perceptions and Self-Efficacy Among Latin Costenbader, Karen, MD, MPH Americans with SLE Through the Hablemos De 0244. What Are the Early versus Late Predictors Lupus Facebook Page for Systemic Lupus Erythematosus (SLE) Disclosure: Lupus Foundation of America (2) Diagnosis? 0252. Corticosteroid and Opioid Use Remain Cruz-Machado, Ana Rita, MD High in Systemic Lupus Erythematosus Patients 1324. Risk Factors for Adverse Pregnancy Receiving Biologic Therapy: A Retrospective Outcomes in Women with Spondyloarthritis: An Claims Database Analysis Observational Study from Two European Disclosure: Glaxo Smith Kline (5); Lupus Multidisciplinary Pregnancy Clinics Foundation of America (6); Neutrolis Inc (5); 1944. Predictors of Visual Loss and UpToDate (7) Cerebrovascular Accidents in Giant Cell Arteritis Disclosure: Nothing to disclose Courties, Alice, MD, PhD 1101. Effect of Transcutaneous Vagal Nerve Cudrici, Cornelia, MD Stimulation in Erosive Hand Osteoarthritis: 0687. Musculoskeletal Manifestations in Patients Results from an Open-label Non-randomized with CD73 Deficiency Pilot Trial Disclosure: Nothing to disclose Disclosure: Nothing to disclose

25

Culebro Bermejo, Hector Alejandro, PhD 1180. External Validation of a Multi-biomarker- 1097. Immunophenotypic Characterization of Based Cardiovascular Disease Risk Prediction Myeloid Derived Supressor Cells (MDSCs) and Score for Rheumatoid Arthritis Patients Their Relationship to the Clinical Characteristics 1185. Performance of the MBDA-based CVD Risk of Patients with Inflammatory Myopathies Score in RA Patient Groups of Clinical Interest Disclosure: Nothing to disclose 1732. Machine Learning Coupled with Patient Reported Outcome Data to Classify & Predict RA Cunningham, Clare, PhD Disease Activity 1520. Characterisation of Rheumatoid and 1978. Prevalence and Factors Associated with Psoriatic Arthritis Synovial Fibroblasts Patient-Physician Discordance Among RA Disclosure: Nothing to disclose Patients Initiating Advanced Therapy Disclosure: AbbVie (2, 5); Amgen (2, 5); Bristol- Cunningham, Michael, MD Myers Squibb (2, 5); Corrona (2, 5); Gilead 1581. Neutrophil to Lymphocyte Ratio as a Sciences, Inc. (5); Janssen (2, 5); Lilly (2, 5); Predictor of Immune-Related Adverse Events in Myriad (2, 5); Pfizer (2, 5); Regeneron (2, 5); CTLA-4 Treated Patients: A Retrospective Review Roche (2, 5); Sanofi (5); UCB (2, 5) Disclosure: Nothing to disclose Dabit, Jesse Cunningham-Bussel, Amy, MD, PhD 0540. Risk of Hydroxychloroquine Retinopathy in 1570. Immune Checkpoint Inhibitor Treatment in the Community Cancer: Immunomodulator Use and Evaluation Disclosure: Nothing to disclose by Rheumatology Disclosure: Nothing to disclose D'Agostino, Maria-Antonietta, MD, PhD, MSc 1361. Secukinumab Significantly Decreased Joint Curran, Ashley, BSc Synovitis Measured by Power Doppler 0770. Effect of Citrullination on the Processing Ultrasonography in Biologic-naïve Patients with and Presentation of Rheumatoid Arthritis Active Psoriatic Arthritis: Primary (12-Week) Autoantigens Results from a Randomized, Placebo-Controlled Disclosure: Nothing to disclose Phase III Study Disclosure: AbbVie (5, 8); Bristol Myers Squibb (5, Curtis, Jeffrey R, MD, MS, MPH 8); Novartis (5, 8); Roche (5, 8) 0332. Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Dalal, Deepan, MD, MPH Arthritis: Results from a Phase 3 Trial 0815. Initial Pharmaceutical Management in a 0533. Characterization of Older Male Patients National Cohort of Elderly-Onset Rheumatoid with a Fragility Fracture Arthritis Patients 0549. Developing an Algorithm for Identifying 1582. Average Follow-up Time After Mortality in MarketScan Claims Data Using Telemedicine Visit Is Longer Than Conventional Machine Learning Face-to-Face Visit in Outpatient Rheumatology 0834. Is Disease Severity Greater Among Patients Practice During COVID-19 Pandemic with Rheumatoid Arthritis Who Receive a Newly Disclosure: Nothing to disclose Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry Dalbeth, Nicola, MD 0939. Maintenance of Remission After 0110. Does Urate Directly Influence Bone Withdrawal of Etanercept or Methotrexate in Turnover? Randomized Controlled Trial of Patients with Rheumatoid Arthritis in Sustained Inosine Supplementation Remission on Combination Therapy: Results from 0440. Representation of Women as Authors of a Randomized, Double-blind, Controlled Trial Rheumatology Research Articles

26

Disclosure: Abbvie (9, Podcast fees); Arthrosi (5); 1614. Use of a Best Practice Alert to Encourage AstraZeneca (2, 5); Dyve BioSciences (5); Janssen Transition Planning and Readiness (8) Disclosure: Nothing to disclose ; Selecta (5) D'Anna, Kathleena, DO Dalén, Johan, MSc 0596. Clinical Academic Rheumatology: A Boon 0163. Cost of Non-Persistence in the Treatment for Health Systems with Subcutaneous Tumor Necrosis Factor-Alpha Disclosure: Nothing to disclose Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach Das, Priyam, PhD Disclosure: Merck & Co., Inc. (9, Consultant to 1223. Characterizing Rheumatoid Arthritis Merck & Co., Inc in conjunction of the Patients by Their Biologic DMARD Prescription development of this abstract) History Disclosure: Nothing to disclose Damerau, Alexandra 1970. Mimicking Cytokine-driven Key Features of Davergne, Thomas, PhD, PT Arthritis Using a Human in Vitro 3D Joint Model 1981. Patients with Inflammatory Arthritis Who Disclosure: Nothing to disclose Are More Adherent to Treatment Do Not Perform More Physical Activity Collected by Damjanovska, Sofi, MD Smartphone Apps: A Cross-sectional Study of 101 1186. Red Cell Distribution Width and Absolute Patients, the ImBAIA Study Lymphocyte Count Associate with Biomarkers of Disclosure: Nothing to disclose Inflammation and Subsequent Mortality in Rheumatoid Arthritis De Cock, Diederik, PhD Disclosure: Nothing to disclose 0222. tsDMARD Therapy Is Associated with More Initial Therapy Prolongations Compared to Dan, Diana Camelia, MD bDMARDs Both in Bionaive and Bioexperienced 0102. Bone Health in Patients with Psoriatic Patients with Rheumatoid Arthritis Arthritis in the National Swiss Cohort: A Cross- 0589. The Ideal Mhealth Application for sectional Study Rheumatoid Arthritis: Qualitative Findings from Disclosure: Nothing to disclose Stakeholder Focus Groups 1734. The Challenge of Assessing Wellbeing from Danguecan, Ashley, PhD the Patients` Perspective in Early Rheumatoid 1175. Using a Patient-Engaged Approach to Arthritis Identify Cross-Cutting Disease Factors Impacting Disclosure: Nothing to disclose Mental Health in Youth with Rheumatologic Disease de Diego Sola, Andrea, MD Disclosure: Nothing to disclose 0833. Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Dankers, Wendy Survival Study and Analysis of Patient 0304. Type I Interferon Inhibits Glucocorticoid- Characteristics Induced Leucine Zipper (GILZ) Expression and Disclosure: Nothing to disclose Upregulation by Glucocorticoids Disclosure: Nothing to disclose de Montjoye, Stéphanie 0753. Synovial Tissue Histopathology Findings in Danna, Bernard, MD Early RA. Is It Useful? Analysis of the Belgian CAP48 Cohort Disclosure: Nothing to disclose

27

DeMizio, Daniel, MD de Wolff, Liseth, MSc 0600. Gout Increases Length of Stay in Patients 1502. Composite of Relevant Endpoints for Hospitalized for Heart Failure Exacerbation Sjögren’s Syndrome (CRESS) Disclosure: Nothing to disclose Disclosure: Nothing to disclose Dempster, David W, PhD Deane, Kevin, MD, PhD 0107. Effects of Abaloparatide on Modeling and 1720. Factors Associated with an Increased Risk Remodeling Based Bone Formation of Imminent Rheumatoid Arthritis in ACPA+ Disclosure: Radius Health, Inc. (2, 5, 8) Individuals 1721. Increasing Autoantibody Positivity During Dennis, Natalie Pre-RA Is Associated with the Imminent 0331. Work Absenteeism and Disability Development of Classifiable RA Associated with Psoriatic Arthritis and Psoriasis Disclosure: Nothing to disclose in the United States – A Retrospective Study of Claims Data from 2009 to 2020 Decarriere, Guillaume, MD Disclosure: Nothing to disclose 0994. Does Tofacitinib Impact B Cell Functions? Disclosure: Nothing to disclose Deodhar, Atul, MD 0350. The Impact of Age and Time Since del Rio Oliva, Marta, MD Diagnosis on Response to Treatment with 1916. KZR-616, a First-in-class Selective Inhibitor Secukinumab in Pooled Week 52 Data from 4 of the Immunoproteasome, Ameliorates Phase 3 Studies in Patients with Ankylosing Polymyositis in a Murine Model Spondylitis Disclosure: Nothing to disclose 0369. Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and DElia, Helena, MD Inadequate Response to Nonsteroidal Anti- 1858. Increased Proportion of TH17, TH22 and inflammatory Drugs TC17 Cells and the Correlation to IL-22 and 0885. Impact of HLA-B27 Status on Clinical Clinical Parameters in Patients with Ankylosing Outcomes in Patients with Ankylosing Spondylitis Spondylitis from Northern Sweden Treated with Secukinumab Disclosure: Nothing to disclose 0886. Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated Patients Dellaripa, Paul, MD with Ankylosing Spondylitis 1049. Effects of Nintedanib in Patients with 0906. Bimekizumab Treatment Is Associated with Progressive Fibrosing - Improvements in Back Pain and Fatigue in related Interstitial Lung Diseases (ILDs) in the Patients with Active Psoriatic Arthritis: 48-Week INBUILD Trial: Subgroups by HRCT Pattern Results from a Phase 2b Study Disclosure: Bristol Myers Squibb (9, Principal 0908. Guselkumab Efficacy in Adult Patients with Investigator Clinical Trial); Genentech (9, Active Psoriatic Arthritis by Baseline Principal Investigator Clinical Trial) Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo- Delle Sedie, Andrea, MD Controlled Studies 1334. Does Interstitial Lung Disease Represent a 1342. Efficacy Outcomes Following Etanercept Real Comorbidity in Spondyloarthritis Patients? Withdrawal by Sustained Remission Status in Results from an Ultrasound, Monocentric, Pilot Patients with Nr-axSpA: Results from RE- Study EMBARK Disclosure: Nothing to disclose 1358. Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis

28

Stratified by Baseline MRI and C-Reactive Protein Associated with Osteoporosis at the Hip Status Disclosure: Nothing to disclose 1367. Impact of Ixekizumab on Work Productivity in Non-Radiographic Axial Dhillon, Sandeep, MD, BSc, MSc Spondyloarthritis Patients: Results from the 0927. Care Gap in Patients with Systemic COAST-X Trial at 52 Weeks Sclerosis with CXR Findings Suggestive of Fibrosis 1372. Efficacy and Safety of Upadacitinib in Disclosure: Nothing to disclose Patients with Psoriatic Arthritis and Axial Involvement Dhital, Rashmi, MD 2023. Efficacy and Safety of Upadacitinib in 0121. Association of Low Bone Density with Patients with Active Ankylosing Spondylitis: 1- Need for Early Revision After Elective Joint Year Results from a Randomized, Double-Blind, Replacement for Osteoarthritis in Placebo-Controlled Study with Open-Label Postmenopausal Women Extension 1293. Factors Associated with Early Hospital L11. Tofacitinib for the Treatment of Adult Readmission in Systemic Lupus Erythematosus: Patients with Ankylosing Spondylitis: Primary Data from National Readmission Database Analysis of a Phase 3, Randomized, Double-blind, Disclosure: Nothing to disclose Placebo-controlled Study Disclosure: AbbVie, Amgen, BMS, Boheringer Diaz, Talia, MD Ingelheim, Celgene, Gilead, Glapagos, Janssen, 1668. Long-Term Outcomes in Children Born to Lilly, Novartis, Pfizer, UCB (Self) : 5, 2, 8 Anti-Ro and/or Anti-La Positive Mothers Disclosure: Pfizer (2) Deonaraine, Kristina, MS 1793. Safety of Obtaining Research Tissue During Diaz Martinez, Juan Pablo, PhD Clinically Indicated Kidney Biopsies: Data from 1300. Identifying Cognitive Impairment in the Lupus Accelerating Medicines Partnership Patients with Systemic Lupus Erythematosus Disclosure: Nothing to disclose Using Hidden Markov Models: A Bayesian Approach Desai, Ruhani, MD Disclosure: Nothing to disclose 1698. Polyarthritis Workup in Primary Care Setting : How Are We Doing? Diaz-Angulo, Jazzia Emily, MD Disclosure: Nothing to disclose 1785. Use of Contraceptive Methods in Mexican Women with Rheumatic Diseases Deshauer, Siobhan, MD Disclosure: Nothing to disclose 0928. Systemic Sclerosis Progression and Pregnancy: A Hopeful Message from the Dill, Sarah, MD Canadian Scleroderma Registry Database 0594. Mechanical and Temperature Stress Disclosure: Nothing to disclose During Biologic Shipments to Rheumatology Patients Dey, Abhishikta, MD Disclosure: Nothing to disclose 1130. Patient Perspectives on Biobanking and Data-linkage for Rheumatic Disease Research DiRenzo, Dana, MD, MHS Disclosure: Nothing to disclose 1126. A Mobile Mindfulness Meditation Program May Improve Health-Related Quality of Life for Dey, Mrinalini, MRCP, MA, MBBCH Patients with Rheumatic Disease, a Pilot Study 0544. Risk Factors for Lumbar Vertebral Disclosure: Nothing to disclose Osteoporosis Do Not Reflect Factors Traditionally Dizon, Brian, MD, PhD

29

0462. Lupus-like Autoimmunity and Increased 0667. Gout Management Beyond Prescription Interferon Response in Patients with STAT3- Writing: The Role of the Pharmacist deficient Hyper-IgE Syndrome Disclosure: Nothing to disclose Disclosure: Nothing to disclose Dourado, Eduardo, MD Domsic, Robyn, MD, MPH 1935. Predictors of Early Mortality for Giant Cell 0391. Defining the Optimal Disease Duration of Arteritis at the Time of Diagnosis Early Diffuse Systemic Sclerosis for Clinical Trial Disclosure: Nothing to disclose Design Disclosure: Corbus Pharmaceutical Holdings (5); Drenkard, Cristina, MD, PhD Eicos Sciences, Inc (5); Formation Biologics (5) 1020. Relationship Between Skin-related Quality of Life, Psychosocial Stress, and Race in Domsic, Robyn, MD, MPH Cutaneous Lupus Erythematosus 1379. Clinical Outcomes Among Participants with Disclosure: Nothing to disclose Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Driban, Jeffrey, PhD Series 0539. Sports with a Bat or Racket Are Not 2035. Exploring Stratification Strategies for Early Associated with Thumb-base Osteoarthritis: Data Diffuse Systemic Sclerosis Clinical Trial Design from the Osteoarthritis Initiative Disclosure: Corbus Pharmaceutical Holdings (5); 1113. Intrameniscal Signal Alterations Strongly Eicos Sciences, Inc (5); Formation Biologics (5) Predict Destabilizing Meniscal Tears and Accelerated Knee Osteoarthritis: Data from the Dore, Robin, MD Osteoarthritis Initiative 1758. Prevalence and Incidence of Infection and Disclosure: Eli Lilly and Company (5); Pfizer, Inc. Venous Thromboembolism in Rheumatoid (5, 8) Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012– Drobinski, Patryk, MSc 2016 US Medicare Data 1220. Increased Serum Levels of Circulating Disclosure: AbbVie (2, 5); Amgen (2, 5); Biogen Vimentin and Citrullinated Vimentin Are (2, 5); Bristol-Myers Squibb (2, 5); Eli Lilly and Co Differently Regulated by Tocilizumab and (2, 5); Exagen (8); Gilead Sciences, Inc. (2, 5); Methotrexate Monotherapies in Rheumatoid GlaxoSmithKline (2, 5); Myriad (2, 5); Novartis (2, Arthritis 5); Pfizer (2, 5); Radius (2, 5); Regeneron (2, 5); Disclosure: Nothing to disclose Sanofi (2, 5); UCB (2, 5) D'Silva, Kristin, MD Dörner, Thomas, MD 0430. Outcomes of Coronavirus Disease 2019 0848. Delineation of a Proinflammatory Cytokine Infection Among Patients Living with Rheumatic Profile Targeted by Janus Kinase 1/2 Inhibition Diseases: A Matched Cohort Study from a US Using Baricitinib in a Phase 2 Systemic Lupus Multi-Center Research Network Erythematosus Trial 1051. Rituximab for Interstitial Pneumonia with 1831. Biomarkers Linked to Anti-IFN-I and Autoimmune Features at Two Academic Medical Ustekinumab Suggest Distinct Mechanism of Centers Action in Systemic Lupus Erythematosus Disclosure: Nothing to disclose Disclosure: Abbvie (2, 5); Celgene (5); Eli Lilly and Company (2, 5); Novartis (2, 5); Pfizer Duarte-Garcia, Ali, MD Corporation (2); Roche (2, 5); Sanofi (2, 5) 0277. Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Dorris, Emma, PhD Different Classification Criteria

30

1024. Time Trends in the Incidence of Systemic at 5 Years from the ERA Louvain Brussels Cohort Lupus Erythematosus: A 40-Year Study Disclosure: Nothing to disclose 1025. Prevalence Estimates for Systemic Lupus Erythematosus over Four Decades Duruöz, Mehmet Tuncay, MD Disclosure: Nothing to disclose 1900. The Clinical and the Functional Impact of Central Sensitization on Patients with Axial Dubash, Sayam, FRCP, MBChB Spondyloarthritis 0312. Dactylitis Is Associated with Greater Disclosure: Nothing to disclose Disease Severity, Ultrasound Synovitis, and Erosive Damage, in Very Early DMARD Naïve Dutz, Jan, MD Psoriatic Arthritis 0362. Patients with Psoriatic Arthritis Treated 0313. Swollen Joints but Not Tender Joints Are with Guselkumab Achieved Psoriasis-Related Associated with Ultrasound Power Doppler Symptom-Free State and Had No Skin Condition Synovitis in Very Early DMARD Naive Psoriatic Impact on Their Health Related Quality of Life Arthritis 0891. Four-Year Efficacy and Safety of Disclosure: Nothing to disclose Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis Duca, Lindsey, PhD from VOYAGE 1 and VOYAGE 2 1458. Slower Current Walking Speed Is Disclosure: Janssen Research & Development, LLC Associated with Progression in Radiographic (2) Knee Osteoarthritis: The Johnston County Osteoarthritis Project Duvvuri, Bhargavi, PhD Disclosure: Nothing to disclose 0957. Mitochondrial ROS as a Regulator of Calcinosis in Juvenile Dermatomyositis Dunford, Paul, PhD Disclosure: Nothing to disclose 0860. PREVAIL 1: A Multiple Ascending Dose Study in Normal Healthy Volunteers of PRV- Dyball, Sarah, MBBS 3279, a Novel Bispecific DART Molecule 0421. Polymyalgia Rheumatica Is Associated with Targeting CD32B and CD79B on B Cells, with Later Menopause: An Observational Study Potential for Treatment of SLE Disclosure: Nothing to disclose Disclosure: Nothing to disclose Dyke, Bernard, MB, MRCP Dunga, Saikumar, MD 1608. Survey of Minimally-Invasive Ultrasound- 1457. Two Minute Walking Distance and Other Guided Synovial Biopsy Performed at Timed Function Tests Are Superior to MMT-8 in Rheumatology Centres Assessing Outcomes in Polymyositis and Disclosure: Nothing to disclose Dermatomyositis Disclosure: Nothing to disclose Eberhard, Anna, MD 1716. Predictors of Unacceptable Pain and Dupont, Julia Unacceptable Pain with Low Inflammation in 0480. Impact of Targeting Remission or Low Early Rheumatoid Arthritis Disease Activity on 10-year Severity in Disclosure: Nothing to disclose Rheumatoid Arthritis : Data from ESPOIR Cohort Disclosure: Nothing to disclose Edens, Cuoghi, MD 0636. Rheumatology Patient Experience and Durez, Patrick, MD Trends During the SARS-COV-2 Pandemic 0221. Should We Use BioDMARDS in First Disclosure: Nothing to disclose Intention in Early Rheumatoid Arthritis? : Results

31

Eder, Lena, MD is a military service member. This work was 1619. Subclass Ordering prepared as part of his official duties.) Patterns for IgG4-Related Disease at an Academic Medical Center Egan, Allyson, MD 1839. Medication Adherence Barriers and 1427. Anti-IL5 Therapy for Eosinophilic Opportunities to Overcome Them Among Granulomatosis with Polyangiitis (EGPA) - An 18 Patients with SLE Month Follow-up Study as a Steroid Sparing 0310. The Prediction of Psoriatic Arthritis Tool Therapeutic Approach (PRESTO) Study – Interim Report Disclosure: Nothing to disclose 0377. Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Egües Dubuc, César Antonio, MD, MSc Active Psoriatic Arthritis: A Post Hoc Analysis of 0087. Hemophagocytic Syndrome. Clinical Two Phase 3 Randomized Controlled Trials Characteristics and Prognostic Factors of a Series 1850. The Association Between Imaging Sub- of 30 Clinical Cases phenotypes of Psoriatic Arthritis and Gene Disclosure: Nothing to disclose Expression Profiles 2021. The Reliability of Scoring Sonographic Ehlers, Lisa Entheseal Abnormalities – the Diagnostic 0066. AMP Deaminase 2 Is Expressed on the Ultrasound Enthesitis Tool (DUET) Study Surface of Human Immune Cells as a Novel Disclosure: AbbVie (2, 5, 8); Celgene (5); Eli Lilly Regulator of Extracellular Adenosine Metabolism (2, 5); Novartis (5); Pfizer Inc (2, 5); UCB (2, 5, 8) Disclosure: Nothing to disclose

Edgerton, Colin, MD El Ouali, Zakaria, MD 0365. Experience with Apremilast in Treatment 0009. Prevalence of Hydroxychloroquine and of Psoriatic Arthritis in US Clinical Practice; Chloroquine Side Effects in Rheumatology Assessments from Trio Health and the American Patients: A Retrospective Survey of 115 Cases Rheumatology Network (ARN) Disclosure: Nothing to disclose Disclosure: Sandoz (5) Elam, Rachel, MD Edigin, Ehizogie 0103. The Association of Methotrexate, 0269. Systemic Lupus Erythematosus with Sulfasalazine and Hydroxychloroquine Use with Libman-Sacks Endocarditis Increases Inpatient Incident Fractures in Postmenopausal Women Mortality with Rheumatoid Arthritis: Findings from the 0400. Outcomes of Systemic Sclerosis Women’s Health Initiative Hospitalizations by Hospital Teaching Status: Disclosure: Nothing to disclose Analysis of the National Inpatient Sample 1278. Does Co-existing Systemic Lupus Elefante, Elena, MD Erythematosus Affect Outcomes of 0265. Evaluation of the Lupus Foundation of Hospitalizations for Ischemic Stroke? America-Rapid Evaluation of Activity in Lupus as 1761. Rheumatoid Arthritis Inpatient Mortality: a Measure of Systemic Lupus Erythematosus An Analysis of the National Inpatient Sample (SLE) Disease Activity from the Clinician and the Disclosure: Nothing to disclose Patient Perspective: Experience from an Italian Cohort Edison, Jess, MD Disclosure: Nothing to disclose 1635. Profile of Topical Diclofenac Sodium Gel 1% (Voltaren®) Users in a United States Elemam, Noha, PhD, BSc, MSc Longitudinal Electronic Health Records Database 1529. Differentially Expressed Chemokines and Disclosure: Department of Defense (9, Jess Edison Cytokines in Peripheral Blood Mononuclear Cells

32

(PBMCs) of Rheumatoid Arthritis (RA) Patients Learning Collaborative to Promote Shared Disclosure: Nothing to disclose Decision-Making Disclosure: Nothing to disclose Elkiran, Burak, MD 1062. Dermatomyositis: A - Eshak, Nouran, MD Rheumatology Clinic Retrospective Analysis 0944. Obstructive Sleep Apnea in Fibromyalgia Disclosure: Nothing to disclose Patients: A Meta-analysis Disclosure: Nothing to disclose Elliott, Sabrina, MS 1398. The Isolated Nucleolar Pattern ANA Espigol-Frigole, Georgina, MD Antibody in a Systemic Sclerosis Patient Cohort 1933. Small Vessel Vasculitis Surrounding a Disclosure: Nothing to disclose Preserved Temporal Artery: Search for Tissue Biomarkers with Potential Diagnostic Value Emery, Paul, MD, FRCP, MA, FMedSci Disclosure: Nothing to disclose 0826. Clinical Responses and Patient Flow over 2 Years of Treatment with Abatacept, Including Espinosa, Gerard, MD Dose De-Escalation, in Patients with Early, MTX- 1817. Changes in Macular Capillary Network Naïve, ACPA+ RA: Results from a Phase IIIb Study Measured with Optical Coherence Tomography- Disclosure: AbbVie (2, 8); Bristol-Myers Squibb angiography in Patients with Systemic Lupus Company (2, 8); Celltrion (8); Eli Lilly (8); Gilead Erythematosus (8); Novartis (2, 8); Pfizer (8); Roche (2, 8); Disclosure: Nothing to disclose Samsung (8) Eudy, Amanda, PhD England, Bryant, MD, PhD 0256. Patient Perspective of the Type 1 and 2 SLE 0178. Associations of Multimorbidity with Model: A Qualitative Study DMARD Initiation and Achieving Target Disease 0258. Using Patient-Reported Outcomes Activity Thresholds in Active Rheumatoid Measures to Classify Patients with Systemic Arthritis: A Cohort Study Using the Lupus Erythematous Rheumatology Informatics System for Disclosure: NIH NCATS Award Number Effectiveness (RISE) Registry 1KL2R002554 (2); Pfizer (2) 0179. Identification of Multimorbidity Patterns in Rheumatoid Arthritis Through Machine Learning Exarchou, Sofia, MD, PhD 1466. Multimorbidity in Rheumatoid Arthritis, 1027. The National Prevalence of Clinically Psoriatic Arthritis, Gout, and Osteoarthritis Diagnosed Psoriatic Arthritis in Sweden 2017 Within the Rheumatology Informatics System for Disclosure: Novartis (5) Effectiveness (RISE) Registry Disclosure: Nothing to disclose Fadel, Kristen, BS 1711. Musculoskeletal Sarcoidosis Learning Englund, Martin, MD, PhD Module for Trainees: 0964. Is Meniscal Status in the Anterior Cruciate Developing a Rheumatology Curriculum Ligament Injured Knee Associated with Change in Disclosure: Nothing to disclose Bone Surface Area? An Exploratory Analysis of Data from the KANON Trial Fair, Danielle, MD Disclosure: Pfizer (5) 0724. Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) Correlate with Eseddi, Joad, MD Pain and Stress Using Patient-Reported 1595. Using Rheumatoid Arthritis Outcomes Measurement Information System Communication Tool Developed by the RISE

33

(PROMIS®) Early Rheumatoid Arthritis Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Falls, Anna, DO Fava, Andrea, MD 0153. Counseling on Safe Driving Strategies in 0250. Lupus Nephritis and Renal Outcomes in Patients with Osteoarthritis and Rheumatoid African-Americans: The Accelerating Medicines Arthritis Partnership Cohort Experience 1587. Improving Cardiovascular Risk Assessment 0936. Urine Proteomics and Single Cell in Patients with Rheumatoid Arthritis and Transcriptomics Identify IL-16 as a Biomarker for Systemic Lupus Erythematosus in an Internal Lupus Nephritis Medicine Resident Clinic: A Quality Improvement 1512. Trajectory Analysis of Repeat Renal Initiative Biopsies Identified Previous Endocapillary Disclosure: Nothing to disclose Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Faludi, Tamas, PhD Nephritis 0842. mTOR Signaling Pathway Blockade and Disclosure: Nothing to disclose Rab4 Expression Affects Metabolism of Lupus T Cells Fechtner, Sabrina, PhD Disclosure: Nothing to disclose 0779. Antibody Responses to Epstein-Barr Virus Are Altered in the Pre-Clinical Period of Famenini, Sina, MPH Rheumatoid Arthritis 0926. Risk Factors for Fractures and Disclosure: Nothing to disclose Osteoporosis Among Patients with Systemic Sclerosis in a United States Cohort Feist, Eugen, MD Disclosure: Nothing to disclose 0832. PROSARA - A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety Farouk, Mai, MD and Effectiveness of Sarilumab for the Treatment 1329. Subclinical Atherosclerosis Risk in Psoriatic of Active Rheumatoid Arthritis in Regular Care in Arthritis: Could It Be Prevented? Germany Disclosure: Nothing to disclose Disclosure: AbbVie (5, 8); BMS (5, 8); Lilly (5, 8); MSD (5, 8); Novartis (5, 8); Pfizer (5, 8); Roche (5, Farran, Yvette, MD 8); Sanofi (5, 8); Sobi (5, 8) 1889. Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients Feldman, Debbie, PhD, PT Disclosure: Nothing to disclose 0571. Improving Care for Patients with Inflammatory Arthritis by Enabling Physical Farrell, Jessica, PharmD Therapists to Directly Refer to Rheumatologists: 0438. Pharmacist-Led Multidisciplinary Approach A Qualitative Study to Opioid Tapering in a Large Private 0620. Do Physical Therapists Follow Evidence- Rheumatology Practice Based Practice Recommendations for Treatment Disclosure: Abbvie (8); Gilead (5); Janssen (9, of Inflammatory Arthritides? Fellowship salary support for my trainee); Pfizer Disclosure: Nothing to disclose (8) Fennell, Patricia, MSW Fatima, Safoora, MD 1128. The Diagnosis of Systemic Sclerosis as a 1736. Health Assessment Questionnaire Predicts Traumatic Experience: Patients’ Reactions to the All-Cause Mortality at One Year in Patients with Diagnostic Process 1394. Pathway to Systemic Sclerosis: Concerning

34

Patients’ Experiences During the Diagnostic 0768. Dynamics of Follicular Helper T Cells Process Subsets in Rheumatoid Arthritis Patients Before Disclosure: Nothing to disclose and After Treatment Disclosure: Nothing to disclose Ferm, Julie, PharmD 0133. Pharmacist-Driven Clinic Development for Feterman Jimenez, Dominique, MD Patients with Incidental Vertebral or Hip 1481. A Systematic Review to Quantify the Fractures Extent of Pharmaceutical Company Involvement Disclosure: Nothing to disclose in Rheumatology Consensus-Based Recommendations Fernandes, Ana, MSc Disclosure: Nothing to disclose 0038. Protein Biomarkers May Differentiate Responders and Non-Responders to Figueroa Sierra, Marielys, MD, MS Adalimumab, a Tumour Necrosis Factor Inhibitor, 0113. Improving Glucocorticoid-Induced in Ankylosing Spondylitis Patients - The Osteoporosis Screening and Management in Bioefficacy SpA Study Patients with Rheumatic Diseases Using the 2017 Disclosure: Nothing to disclose ACR Guidelines Disclosure: Nothing to disclose Fernandes, Maria, PhD 0777. CLEC12A Expression as a Potential Fike, Alice, MSN, NP Predictor of Disease Activity in Early Rheumatoid 0057. Increased Susceptibility to Measles in Arthritis Patients from Central America and Mexico in a Disclosure: Nothing to disclose U.S. Rheumatology Clinic Disclosure: Nothing to disclose Fernandez Ruiz, Ruth, MD 1274. COVID-19 in Patients with Systemic Lupus Finckh, Axel, MD Erythematosus 0467. Incidence of COVID-19 in Patients Treated Disclosure: Nothing to disclose with Infliximab Compared to Patients Treated with Rituximab Fernández-Ávila, Daniel, MD, PhD, MSc 1464. Multi-Variate Approach Including Serology 0605. How Did SARS-CoV2/COVID-19 Pandemic and Genetics for an Improved Identification of Affected Rheumatology Practice in Latin Patients at Risk of Developing Rheumatoid America? A Regional Survey from PANLAR Arthritis 1140. How Did SARS-CoV2/COVID-19 Pandemic Disclosure: AB2Bio (8); AbbVie (8); Bristol-Myers Affected Patients with Rheumatic Diseases in Squibb Company (2, 8); Eli Lilly (2, 8); Pfizer (2, 8); Latin America? A Regional Survey from PANLAR Sandoz (8); Sanofi (8) Disclosure: Nothing to disclose Firestein, Gary, MD Ferrada, Marcela, MD 0749. Locating Cellular Subsets in Rheumatoid 0423. Defining Ear Chondritis: Data from 685 Arthritis Synovium Using CO-Detection by Patients with Relapsing Polychondritis IndEXing (CODEX) 0509. Classification of Patients with Relapsing Disclosure: Eli Lilly (2) Polychondritis Based on Somatic Mutations in UBA1 Fitzcharles, Mary-Ann, MD Disclosure: Nothing to disclose 0373. Medical Cannabis in Ankylosing Spondylitis Following Recreational Legalization: A Ferrero, Paola Virginia, MSc Prospective Cross-sectional Study 0942. Use of Medical Cannabis by Patients with

35

Fibromyalgia: A Prospective Cross-sectional Reduced Hospitalisation Following Community Study COVID-19 Infection; Results of the Trinity Disclosure: Nothing to disclose Rheumatology and Covid-19 Registry - TRACR Disclosure: Nothing to disclose Fitzgerald, Gillian, MBBCH 1312. Time-dependent Analysis of Incident Extra- Florez-Pollack, Stephanie, MD articular Manifestations and Comorbidities in 0263. Factors Associated with Disease Activity Axial Spondyloarthritis Remission and Recurrence in Cutaneous Lupus Disclosure: Nothing to disclose Erythematosus Disclosure: Nothing to disclose Fleischmann, Roy, MD 0210. Long-term Safety and Efficacy of Sarilumab Floudas, Achilleas, PhD over 5 Years in Patients with Rheumatoid 0991. Pathogenic, Glycolytic PD-1+ B Cells Arthritis Refractory to Tumor Necrosis Factor Accumulate in the Hypoxic RA Joint Inhibitors 1414. Highly Polyfunctional Metabolically 0212. Long-Term Safety and Effectiveness of Altered Pathogenic T Cells Accumulate in the Upadacitinib or Adalimumab in Patients with Synovial Tissue of RA Patients and Arthralgia Rheumatoid Arthritis: Results at 72 Weeks Subject but Not Healthy Control Synovial Tissue 0240. Long-term Safety and Efficacy of Sarilumab Disclosure: Nothing to disclose over 5 Years in Patients with Rheumatoid Arthritis with 1 or >1 Prior Tumor Necrosis Factor Foeldvari, Ivan, MD Inhibitor Failures 0733. Practice Patterns for Tapering Medications 0798. A Randomized, Double-blind Phase 3 Study in the Treatment of JIA-associated Uveitis Comparing the Efficacy, Safety and 1171. Under Detection of Interstitial Lung Immunogenicity of PF-06410293 (Abrilada™), an Disease in Juvenile Systemic Sclerosis (jSSc) Adalimumab (ADL) Biosimilar, and Reference Utilizing Pulmonary Function Tests. Results from ADL (Humira®) in Patients with Moderate to the Juvenile Scleroderma Inception Cohort Severe Active RA: Results from Weeks 52-92 1173. No Disease Progression After 36 Months 1213. Discrepancy Between the Multi-biomarker Follow up in the Juvenile Disease Activity Score and Clinical Disease Inception Cohort Activity Scores in a 2‑Part, Multicenter Study of Disclosure: Abbvie (5); Amgen (5); BMS (5); Repository Corticotropin Injection (Acthar® Gel) Chugai (5); gilead (5); GSK (5); Lilly (5); Novartis for Patients with Persistently Active Rheumatoid (5); Sanofi (5) Arthritis Disclosure: Pfizer (2, 5) Fong, Warren, MBBS, MRCP 1315. Exploring the Prevalence and Factors Flipo, Rene-Marc Associated with Fatigue in Axial Spondyloarthritis 0348. Biologics History and Sex Are Linked to in a Multiethnic Asian Cohort in Singapore Golimumab Discontinuation in Axial Disclosure: Nothing to disclose Spondyloarthritis: A Sub-Analysis of the Post- Registration GO-Practice Study Foucher, Kharma, MD, PhD Disclosure: Abbvie (2, 8); Biogen (8); BMS (8); 1664. Walking Energetics, Fatigue, and Physical Janssen (2, 8); MSD (8); Nordic (8); Novartis (2, Activity in People with Knee Osteoarthritis 8); Pfizer (2, 8); Roche-Chugai (2, 8); Sanofi (8) Disclosure: Nothing to disclose

Flood, Rachael, MD Franco, Karen, MD 0454. Anticytokine Therapies for Inflammatory 0893. Is It Feasible to Achieve Recommended Rheumatic Disease (IRD) Are Associated with Therapeutic Target Objective in Patients with

36

Axial Spondyloarthritis in Clinical Practice? Data 0541. Suboptimal Vaccination Coverage with from the SpA-paz Cohort Influenza, Pneumococcal and Herpes Zoster Disclosure: Nothing to disclose Vaccines Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases Franco-Trepat, Eloi, MS, BSc in a Nationwide Health Care Plan 0063. Novel Repurposed Drugs Against Joint 1562. Subclinical Joint Inflammation of Hands by Inflammation Reveal Potential Use for Gout Magnetic Resonance Imaging in Patients with Treatment: An In Silico, In Vitro and Clinical Psoriatic Arthritis in Clinical Remission Compared Study to Active Disease Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Frausto Lerma, Paola Fernanda, MS Furie, Richard, MD 1331. Carotid Ultrasound Findings in Psoriatic 0850. What Does It Mean to Be a BICLA (BILAG- Arthritis: A Case-control Study Based Composite Lupus Assessment) Responder? Disclosure: Nothing to disclose Post Hoc Analysis of the Phase 3 TULIP-1 and TULIP-2 Trials Frech, Tracy, MD 0855. Treatment of SLE with or Without 0915. Clinical Bedside Tools to Assess Systemic Nephritis with the Immunoproteasome Inhibitor Sclerosis Vasculopathy: Can Digital Thermal KZR-616: Updated Results of the MISSION Study Monitoring and Sublingual Microscopy Identify 0935. Efficacy and Safety Results from a Phase 2, Patients with Current or past Digital Ulcers? Randomized, Double-Blind Trial of BIIB059, an 1377. Raynaud's Phenomenon and Systemic Anti-Blood Dendritic Cell Antigen 2 Antibody, in Sclerosis in Post-9/11 Deployed Veterans SLE Receiving Care Veterans Health Administration 0988. Two-Year Results from a Randomized, Care Controlled Study of Obinutuzumab for Disclosure: Nothing to disclose Proliferative Lupus Nephritis 1441. Effects of Belimumab on Renal Outcomes, Friedman, Deborah, MD Overall SLE Control and Biomarkers: Findings 1500. Electrocardiographic QT Intervals in from a Phase 3, Randomized, Placebo-controlled Infants Exposed to Hydroxychloroquine 104-week Study in Patients with Active Lupus Throughout Gestation Nephritis Disclosure: Nothing to disclose 1822. Serum Proteomics from a Phase III, Randomized, Placebo-Controlled Study of Friedman, Marcia, MD Patients with Active Lupus Nephritis: Correlation 1038. STAT1 and JAK2 Are the Most Appropriate with Baseline Disease Characteristics and Targets of JAK-inhibitor Therapy for Sarcoidosis: Response to Therapy An In-silico Meta-nalysis 1824. Selective Expansion of Regulatory T Cells in 1039. Tofacitinib as a Steroid-sparing Therapy in Patients with Systemic Lupus Erythematosus by a Pulmonary Sarcoidosis: Two Prospective Cases Novel IL-2 Conjugate, NKTR-358 and Molecular Analysis 1827. Flare Reduction and Oral Corticosteroid Disclosure: Nothing to disclose Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials Fujita, Yuya, MD 1829. Lupus Disease Activity After Cessation of 1217. Effects of JAK Inhibitors Against JAK2- Anifrolumab Treatment During the Phase 2b mediated Signaling in Innate Immune Cells MUSE Trial Follow-up Period Disclosure: Nothing to disclose Disclosure: GSK (2, 5)

Furer, Victoria, MD Furst, Daniel, MD

37

0199. A Phase 1, Randomized, Open-label, Psychometric and Factor Analysis in a Parallel Group, Single-dose Study to Compare Monocentric Cohort the Pharmacokinetics and Safety of the Auto- Disclosure: Nothing to disclose injector and Pre-filled Syringe of CT-P17, a Proposed, Higher Concentration Biosimilar (100 Garcia, Sayra, MS, BS mg/mL) Adalimumab, in Healthy Subjects 0498. Exploring the Role of Lipocalin-2 in Disclosure: AbbVie (5); Actelion (2, 5); Amgen (2, Neuropsychiatric SLE Pathogenesis 5); BMS (2); CMC Connect (McCann Health Disclosure: Nothing to disclose Company) (8); Corbus (2, 5); Cytori (5); Galapagos (2, 5); Gilead (2); GSK (2); Horizon (2, García Escudero, Paula, MD 5); Kadmon (2); NIH (2); Norvatis (2, 5) 0016. Differential Characteristics in Inflammatory Rheumatologic Patients with Gabbeta, Avinash, MD Severe and Mild COVID-19 Infection 0721. Validation of New Antirheumatic Drug Use Disclosure: Nothing to disclose as a Proxy for Increased JIA Disease Activity Disclosure: Nothing to disclose Garcia Fernandez, Antia, MD 0641. Cohort of Rheumatic Patients Treated with Gaber, Timo, PhD, MSc Rituximab and COVID-19: Does Rituximab 0065. The Energy-dependent Hierarchy of Treatment Increases the Severity of SARS-COV2 Immune Functions in Human Monocytes Infection? 0117. Development of an In Vitro Trabecular 0722. Evaluation of Flare Rate and Tapering Human Bone Model to Recapitulate Features of Strategies in Juvenile Idiopathic Arthritis Glucocorticoid-induced Osteoporosis Disclosure: Nothing to disclose Disclosure: Nothing to disclose Garcia Salinas, Rodrigo, MD Gad, Ibtissam, MD 0317. Axial Involvement in Psoriatic Arthritis in a 1187. Red Cell Distribution Width Is Associated Comprehensive Rapid Diagnosis Program with ASCVD Risk Score and CVD in RA After (Reuma-check PsA). Analysis of Its Characteristics Initiation of Methotrexate 0766. ACPA and Cholesterol Titers as Predictors Disclosure: Nothing to disclose of Good Clinical Response at One Year in an Argentine Cohort Gaffo, Angelo, MD, FACP. 1876. The Role of HLA B27 in Axial 0691. Denosumab Did Not Improve Spondyloarthritis: Prevalence and Performance Computerized Tomography Erosion Scores When as a Marker in an Argentinian Cohort Added to Intensive Urate-Lowering Therapy in Disclosure: Nothing to disclose Gout: Results from a Pilot Study Disclosure: Amgen (2) Garcia-Hernandez, Maria de la luz, PhD 0343. Co-expression of DC-STAMP and CX3CR1: Biomarkers for Tissue Resident Osteoclasts in Gao, Kevin, BS Psoriatic Arthritis 0947. STING Gain-of-Function in Radio-resistant Disclosure: Nothing to disclose Cells Supports a Lymphocyte Dependent Auto- inflammatory Lung Disease Garg, Ria, BSc Disclosure: Nothing to disclose 1784. Roles and Perspectives of Partners of Women with Rheumatoid Arthritis on Garaiman, Alexandru, MD Reproductive Decision Making: A Constructivist 0921. The Hospital Anxiety and Depression Scale Grounded Theory Study in Patients with Systemic Sclerosis - A Disclosure: Nothing to disclose

38

Gaujoux-Viala, Cécile, MD, PhD Garg, Shivani, MD, MS 1318. Catastrophizing in Patients with Axial 0433. Racial Disparities and New SLE-Specific Spondyloarthritis and Psoriatic Arthritis Predictors of Stroke and Ischemic Heart Disease Disclosure: AbbVie (5); Amgen (5, 8); Bristol- in Patients with Lupus Myers Squibb (5); Celgene (5, 8); Eli Lilly (5); 0598. Impact of a Dedicated Lupus Nephritis Gilead Sciences, Inc. (5); Janssen (5, 8); Medac Clinic to Improve Time to Biopsy and Care (5); Merck-Serono (5); Mylan (5, 8); Nordic Quality Pharma (5); Novartis (5, 8); Pfizer (5); Roche (5); 0867. Hydroxychloroquine Use Predicts Sandoz (5, 8); Sanofi (5); UCB (5) Significantly Higher Patient and Graft Survival in Post-Renal Transplant Lupus Nephritis Patients Gaurav, Rohit, PhD Disclosure: Nothing to disclose 0461. High-Throughput Single-Cell Analysis Reveals Unique Lung Cellular Subsets in a Murine Garlapati, Priyatha, MD Model of Rheumatoid Arthritis-Inflammatory 1143. The Influence of YouTube on Spreading Lung Disease Awareness and Patient Education Regarding Disclosure: Nothing to disclose Systemic Lupus Erythematosus Disclosure: Nothing to disclose Gauto-Mariotti, Estefania, MD 1026. The Incidence, Mortality, and Economic Garrido-Cumbrera, Marco, PhD Burden of Potentially Preventable Infections in 0464. Assessment of the COVID-19 Pandemic Systemic Lupus Erythematosus Patients from the Perspective of People with Rheumatic Disclosure: Nothing to disclose Musculoskeletal Diseases in Europe. Preliminary Results from the REUMAVID Study Gavigan, Kelly, MPH 1322. Prevalence and Associated Factors of Sleep 1316. Patient Perceptions of Fibromyalgia Disorders in Patients with Axial Symptoms and the Overlap with Axial Spondyloarthritis. Results from the European Spondyloarthritis Map of Axial Spondyloarthritis (EMAS) Disclosure: Nothing to disclose 1866. Patient-reported Impact of Axial Spondyloarthritis on Working Life. Results from Gavin, Joshua, DO the Spanish Atlas 2017 0676. Surveying Practicing Rheumatologists Disclosure: Nothing to disclose Regarding Gout Management and Barriers in Gout Care Gartshteyn, Yevgeniya, MD 1709. Teaching Clinical Application of Bayesian 1510. Platelet-bound C4d Is Associated with Reasoning in Rheumatology to Internal Medicine Platelet Activation and Arterial Thrombotic Residents and Medical Students Events Disclosure: Nothing to disclose 1792. Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Gazitt, Tal, MD, MSc Thromboses in SLE 0320. Assessment of Implementation of Treat to Disclosure: Nothing to disclose Target Concept Using Validated Composite Scores in Psoriatic Arthritis Patients Garvey, Thomas, MD Disclosure: Nothing to disclose 0517. Trends in the Incidence and Use of Diagnostic Modalities for Giant Cell Arteritis over Geier, Christian, MD Seven Decades: A Population-based Study 0786. A Combination of Dimensionality Disclosure: Nothing to disclose Reduction Techniques Reveals Novel HLA-DR+ ‘Candidate’ Antigen-Presenting Cell Subsets

39

(cAPC) in Patients with Rheumatoid Arthritis (RA) Gharaee-Kermani, Mehrnaz, PhD, MPH, DVM Disclosure: Nothing to disclose 0076. The Role of Interferon Kappa in Psoriasis Disclosure: Nothing to disclose George, Michael, MD 0044. Characterization of Racial Disparities in Ghosh, Biswadip, MD Rheumatoid Arthritis Treatment Choice and 1648. Comparison of Methotrexate and Location of Care Glucosamine in Primary Knee Osteoarthritis with 0468. Concerns and Health-Related Behaviors Inflammation During the COVID-19 Pandemic in Patients with Disclosure: Nothing to disclose or Without Autoimmune Rheumatic Disease in a Large Physician Network Ghosh, Nilasha, MD 1144. Concerns and Behaviors of Patients with 1568. Impact of the SARS-CoV-2 Pandemic on a Common Autoimmune Rheumatic Diseases in Cohort of Patients with Rheumatic Complications the United States Early in the COVID-19 of Immune Checkpoint Inhibitors: A Registry Pandemic Survey Study 1751. Forecasting Healthcare Utilization in 1574. Over Half of Patients with Immune Rheumatoid Arthritis: A Machine Learning Checkpoint Inhibitor-related Myositis, Predictive Model of Emergency Department and/or Myocarditis Have Visits and Prednisone Initiation in a Single Autoantibodies: Results from a Systematic Tertiary Academic Center Literature Review Disclosure: Bristol-Myers Squibb (2) Disclosure: Nothing to disclose

Germano, Giuseppe Giancane, Gabriella, MD, PhD 1551. Rapid Effect of Tofacitinib in Reducing US 1155. Long-term Safety Profile of Anakinra in Joint and Tendon Inflammatory Lesions of RA Patients with Systemic Juvenile Idiopathic Patients: Data from a 24 Weeks Longitudinal Arthritis Study Disclosure: Nothing to disclose Disclosure: Nothing to disclose Gianfrancesco, Milena, PhD, MPH Gernaat, Sofia, PhD 0006. Race/ethnicity Is Associated with Poor 1257. Gestational Diabetes Mellitus in Pregnant Health Outcomes Amongst Rheumatic Disease Women with Systemic Lupus Erythematosus Patients Diagnosed with COVID-19 in the US: Disclosure: Nothing to disclose Data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry Gertel, Smadar, PhD 0257. Application of Text Mining Methods to 1406. LAG-3+ T Cells Are Diminished in Active Identify Lupus Nephritis from Electronic Health Psoriatic Arthritis Patients and Their Restoration Records in Vitro Is Mediated by TNF Inhibitors 0981. Mortality Among Minority Populations Disclosure: Nothing to disclose with Systemic Lupus Erythematosus, Including Asian and Hispanic Status: The California Lupus Gessl, Irina Surveillance Project, 2007-2017 1549. Joint Damage and Malalignment Disclosure: Nothing to disclose Determine Articular Tenderness More Than Inflammation in Rheumatoid Arthritis, Psoriatic Gibson, Kathryn Arthritis or Osteoarthritis in Established Disease 0137. PROMIS-29 Scores Are Significantly Higher Disclosure: Sobi (9, EULAR congress fee) in Patients with Rheumatoid Arthritis Who Meet Criteria for Co-morbid Fibromyalgia (FM) Than in Those with Rheumatoid Arthritis and No FM

40

Disclosure: Abbvie (8); Janssen (5); Novartis (2); Glick, Lauren, MD UCB (8) 1764. Disease Modifying Anti-rheumatic Drug and Biologic Therapy in Pregnancy: A Single- Gill, Rabia, MD center Mixed Methods Study 1034. Trend of Treatment Plans, and Outcomes Disclosure: Nothing to disclose of Therapy in Cardiac Sarcoidosis via Analysis of Standardized Uptake Values Score and Ejection Gmuca, Sabrina, MD, MSc Fraction Using a Cardiac PET-CT 0736. Identification of Salient Resilience Disclosure: Nothing to disclose Domains Among Adolescents with Chronic Musculoskeletal Pain and Their Parents Gilvaz, Vinit, MD Disclosure: Nothing to disclose 0625. Machine Learning Model to Predict Culture Positivity in Suspected Septic Arthritis Goglin, Sarah, MD Disclosure: Nothing to disclose 0476. Using Consensus Building to Guide Rheumatology Curriculum Development for Ginzler, Ellen, MD, MPH Internal Medicine Residents 1843. Integrated Efficacy of the AURORA 1 and Disclosure: Nothing to disclose AURA-LV Trials Confirms Voclosporin Rapid Proteinurea Reduction in the Presence of Low- Goh, Y. Ingrid, PhD Dose Steroids 0597. Telemedicine in Pediatric Rheumatology Disclosure: Aurinia Pharmaceuticals, Inc. (2) During COVID-19: The PR-COIN Experience Disclosure: Nothing to disclose Giorgiutti, Stéphane 1426. Prevalence of ANCA-associated Vasculitis Gohir, Sameer, BSc, PT, MSc and Spatial Association with Quarries in a French 1483. A Randomised Controlled Trial Evaluating Northeast Region: A Capture-recapture and the Efficacy of Internet-based Exercises Aimed at Geospatial Analysis Treating Knee Osteoarthritis (iBEAT-OA) Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Gisslander, Karl, MSc Gokaraju, Sirisha, MD 1434. The Role of Sural Nerve Biopsy in the 0478. Increasing Awareness of Advocacy During Diagnosis of Systemic Vasculitis – a Retrospective Early Career – a Web-Based Educational Program Study from Two Specialized Centres Disclosure: Nothing to disclose Disclosure: Nothing to disclose Gokaraju, Sriya Glaser, Daniel, MD 0015. COVID -19 Lung Inflammation – What Have 1169. Three-Dimensional Analysis of Facial We Learnt so Far ? Asymmetry in Craniofacial Scleroderma Disclosure: Nothing to disclose Disclosure: Nothing to disclose Golder, Vera, PhD, MBBS, FRACP Glasser, Jillian, BA 0255. Effect of Removing Haemolytic and 0963. Chronic Obstructive Pulmonary Disease Gastrointestinal Activity from the Operational Associated with Prolonged Opiate Use, Increased Definition of the Lupus Low Disease Activity Short-Term Complications and the Need for State – Implications for Use as a Trial Endpoint Revision Surgery Following Total Knee Disclosure: Nothing to disclose Arthroplasty Disclosure: Nothing to disclose Goldhahn, Jörg, MD

41

1485. LNA043, a Novel Cartilage Regenerative 0448. Disease-related factors associated to Treatment for Osteoarthritis: Results from a atherosclerotic disease in axial spondyloarthritis. First-In-Human Trial in Patients with Knee A mutlicenter study with 806 patients. Osteoarthritis 1035. Study of Ocular Sarcoidosis and Clusters of Disclosure: Nothing to disclose Clinical Associations in a Series of 383 Patients with Systemic Sarcoidosis from a Single Hospital Golightly, Yvonne, PhD, MS, PT 1045. Biological therapy in atypical optic neuritis 0564. Incidence and Progression of Foot refractory to conventional treatment. A Osteoarthritis multicenter study with 19 patients. Disclosure: Nothing to disclose 1330. Subclinical atherosclertoic disease in ankylosing spondylitis and non-radiographic axial Goncalves Marangoni, Roberta, MD, PhD spondyloarthritis. A multicenter study with 806 1912. Novel Role of Thy-1 (CD90) in the patients. Pathogenesis of Skin Fibrosis Disclosure: Nothing to disclose 1915. Leptin Plays a Critical Role in Modulating Dermal Adipose Tissue, Inflammation and Skin González-Meléndez, Ariana, MD Fibrosis 1254. Lack of Efficacy of Early Treatment with Disclosure: Nothing to disclose Hydroxychloroquine in a Group of Hispanics with Primary Sjögren’s Syndrome Gono, Takahisa, MD Disclosure: Nothing to disclose 1067. Anti-Viral Proinflammatory Phenotype in Circulating Monocytes from Patients with Anti- Good, Samuel, MD Melanoma Differentiation-Associated Gene 5 0088. The Spectrum of Hemophagocytic Antibody-Associated Interstitial Lung Disease Lymphohistiocytosis: Autoimmunity vs. Disclosure: Boehringer Ingelheim (8); Bristol Malignancy Myers Squibb (8); Chugai pharmaceutical (8); Disclosure: Nothing to disclose Janssen (8); Ono pharmaceutical (8) Goodman, Susan, MD Gonzalez, Carlos M, MD, PhD 1743. Perioperative Steroids in Rheumatoid 0643. Use of Biologic Treatment and Risk to Be Arthritis Patients Having Total Joint Admitted for COVID-19 Infection Replacements: Help or Harm? Disclosure: Abbvie (8); Celgene (8); Gilead (5, 8); Disclosure: Horizon (2); Novartis (2); Pfizer (2); Janssen (5, 8); Merck (5); Novartis (5, 8); Pfizer regenosine (4, 6); UCB (5) (8); Roche (8) Goonesekera, Sunali, MS González Fernández, Marta, MD 0531. The Prevalence of Systemic Sclerosis, 0642. COVID-19 Infection in Rheumatologic Dermatomyositis/Polymyositis, and Giant Cell Patients on Treatment with Targeted Therapies Arteritis in the United States by Race and Disclosure: Nothing to disclose Ethnicity: An Analysis Using Electronic Health Records Gonzalez Hombrado, Laura, MD Disclosure: Nothing to disclose 0238. Gestational Desire and Certolizumab Pegol in Patients with Chronic Inflammatory Rheumatic Gossec, Laure, MD, PhD Disease. Preliminary Results of the GESTAMAD 0336. Anxiety and Depression in Psoriatic Cohort Arthritis (PsA) - Prevalence and Impact on Disclosure: Nothing to disclose Patient Reported Outcomes: Real-World Survey in the US and Europe Gonzalez-Mazon, Inigo, MD 0351. Ustekinumab-Treated Patients with

42

Psoriatic Arthritis in a Real-world Study: Similar Review Clinical Responses and Treatment Persistence Disclosure: Nothing to disclose over One Year in Elderly and Younger Patients 0356. Bimekizumab Improves Patient-Reported Greco, Jessica, MD Outcomes in Psoriatic Arthritis: 48-Week Results 1684. Increase in Emergency Department Visits from a Phase 2b Study and Association Between and Hospitalizations, Decrease in Outpatient Patient-Reported Outcomes and Disease Activity Visits Following Transition to Adult Disclosure: AbbVie (5, 8); Amgen Inc. (5, 8); Rheumatologic Care Biogen (5, 8); Celgene (5, 8); Eli Lilly (1, 5, 8); Disclosure: Nothing to disclose Janssen (5, 8); Novartis (5, 8); Pfizer (1, 5, 8); Sandoz (1); Sanofi (5, 8); UCB Pharma (5, 8) Greenblatt, Heinrich-Karl 1611. Documentation of Pregnancy Counseling Gottenberg, Jacques-Eric, MD, PhD in SSA-Positive Patients of Childbearing 0216. A Subgroup Analysis of Low Disease Potential: A Cross-Sectional Study Activity and Remission from Phase 3 Study of Disclosure: Nothing to disclose Filgotinib in Patients with Inadequate Response to Biologic DMARDs Greenwald, Morgan, BA Disclosure: AbbVie (2, 8); Bristol-Myers Squibb (2, 1741. Does Preventive Care Matter? (in RA) 8); Eli Lilly (2, 8); Pfizer (2, 5); Roche (2, 8); Sanofi- Disclosure: Nothing to disclose Genzyme (5, 8); UCB (5, 8) Gribbons, Bates, BS Gould, Patrick, BA 1922. Association of Leukocyte Populations in 0744. Circulating Fibroblast Growth Factor-21 Peripheral Blood and Arterial Wall Inflammation Levels in Rheumatoid Arthritis: Associations with Assessed by FDG-PET in Takayasu’s Arteritis and Disease Characteristics, Body Composition, and Giant Cell Arteritis Physical Functioning Disclosure: Nothing to disclose Disclosure: Nothing to disclose Grieshaber-Bouyer, Ricardo, MD Gowda, Prateek, BS 0948. Mass Cytometry Reveals Activation 1556. Assessing Calcinosis in Dermatomyositis Heterogeneity of Circulating Neutrophils in with Computed Tomography and Calcium Systemic Lupus Erythematosus Scoring Disclosure: Nothing to disclose Disclosure: Nothing to disclose Groen, Solveig S., BSc, MSc Grabner, Michael, PhD 0374. Neo-epitopes of Type I Collagen Can Be 0371. Identifying Inadequate Response Among Utilized as Translational Biomarkers for Skin and Ankylosing Spondylitis Patients Prescribed Joint Turnover in Patients with Psoriasis and Biologics in a Real-world Commercially Insured Psoriatic Arthritis Adult Population in the United States Disclosure: Nothing to disclose 0898. Inadequate Response Among Psoriatic Arthritis Patients Prescribed Advanced Therapy Grönwall, Caroline, PhD in a Real-world US Commercially Insured 1456. Exploring the RA Bone Marrow Niche by Population Single-cell Technology to Identify Long Lived Disclosure: Nothing to disclose ACPA+ Plasma Cells Disclosure: Nothing to disclose Graham, Jove, PhD 1122. Osteoarthritis in a Large Integrated Health Grosso, Giorgia, MD System Population: 18-Year Retrospective

43

0528. The Complex Relationship Between C4b 1413. An Imbalance Between Regulatory and Binding Protein, Warfarin and Antiphospholipid Inflammatory T Cell Subsets Distinguishes Antibodies Systemic Autoimmune Rheumatic Disease Disclosure: Nothing to disclose Patients from Asymptomatic ANA+ Individuals 0814. “I Want to Switch Back”: Real-world Guan, Steven Experience of Switching Intravenous Abatacept 0750. Nuclei Detection in Rheumatoid Arthritis and Tocilizumab to Subcutaneous Injection Synovial Tissue Using Artificial Intelligence During the COVID-19 Pandemic Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Guermazi, Ali, MD Gupta, Sandeepkumar, MD 1644. Radiographic Exclusionary Findings During 1075. Diagnostic Utility of Myositis Antibodies in Screening for Three Phase III Trials of HyperCKemia: A University Affiliated Single Subcutaneous Tanezumab in Patients with Center Retrospective Study Moderate to Severe Hip or Knee Osteoarthritis Disclosure: Nothing to disclose Disclosure: AstraZeneca (5); Boston Imaging Core Lab (1); Galapagos (5); MerckSerono (5); Pfizer Gupta, Vinod K., PhD (5); Roche (5); TissueGene (5) 0795. Minimum Clinically Important Improvement in Patients with Rheumatoid Guglielmo, Dana, MPH Arthritis Associates with Gut Microbiome 0532. State-Specific Percentage of Adults with Disclosure: Nothing to disclose Arthritis Who Report Both Severe Joint Pain and Physical Inactivity and Their Characteristics, Gur, Chamutal, MD, PhD United States, Behavioral Risk Factor Surveillance 1526. Single Cell Analysis of Skin and Blood of System, 2017 Scleroderma Patients Towards Identification of Disclosure: Nothing to disclose New Disease Mechanisms, Prognostic Biomarkers and Potential Therapeutic Targets Guma, Monica, MD, PhD Disclosure: Nothing to disclose 0680. Sustained Treat to Target Uric Acid Lowering Therapy Markedly Lowers Fatty Acids Gurrea Rubio, Mikel, PhD Levels in Gout Patients 1575. CD6 Is a Target for Cancer Immunotherapy Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Gupta, Akash, MD Guthridge, Joel, PhD 0062. The Role of PGLYRP1 in the Pathogenesis 1840. A Novel Biomarker Identifies Systemic of Lyme Disease Lupus Erythematous (SLE) Patients Who Benefit Disclosure: Nothing to disclose from Obexelimab (XmAb®5871) Treatment Disclosure: Nothing to disclose Gupta, Angela, MD 0878. Absolute Lymphocyte Count Is Negatively Guzman, Jaime, MD, MSc Correlated with Atherosclerotic Cardiovascular 1984. Causal Pathways to Health-Related Quality Disease Risk Score and Red Cell Distribution of Life in Children with Juvenile Idiopathic Width in Psoriatic Arthritis and Increases with Arthritis: Results from the ReACCh-Out Cohort TNF-Inhibitor Therapy Disclosure: Nothing to disclose Disclosure: Nothing to disclose Haase, Isabell, MD Gupta, Rashi, MBBS, BSc 1776. Safety and Beneficial Effects of Hydroxychloroquine on Pregnancy Outcomes in

44

Women with Systemic Lupus Erythematosus 1777. Low Dose Aspirin to Prevent Pre-eclampsia Hamitouche, Faten, MD in SLE Pregnancies – Counselling Helps to Realize 1317. A Large Agreement Between the Pain Our Full Potential Points of the ACR 1990 Fibromyalgia Criteria and Disclosure: Nothing to disclose the MASES Enthesitis Score Is Observed in Patients with Axial Spondylitis, Including in Haberman, Rebecca, MD Patients Without Concomitant Fibromyalgia 0305. A Delphi Consensus Study to Standardize Disclosure: Nothing to disclose Terminology for the Pre-clinical Phase of Psoriatic Arthritis Hammam, Nevin, MD, PhD 1339. COVID-19 in Patients with Inflammatory 0408. Epidemiology and Treatment of Behçet’s Arthritis: A Prospective Study on the Effects of Disease Insights from the Rheumatology Comorbidities and DMARDs on Clinical Informatics System for Effectiveness (RISE) Outcomes Registry Disclosure: Janssen (5) 1600. Relationship Between Electronic Health Record Vendor and Performance on Patient- Hadi, Mohanad, MD reported Outcome Quality Measures in the 0668. Outcomes and Resource Utilization After ACR’s Rheumatology Informatics System for Total Knee Arthroplasty in Calcium Effectiveness (RISE) Registry Pyrophosphate Crystal Deposition Disease Disclosure: Nothing to disclose Patients: Insights from the National Inpatient Sample Database Hamroun, Sabrina Disclosure: Nothing to disclose 1771. Fertility and Pregnancy Outcomes in Women with Spondyloarthritis: A Systematic Hahn, Jill, MS, DSc Review and Meta-analysis 1471. Healthy Lifestyle and Risk of Rheumatoid Disclosure: Nothing to disclose Arthritis in Women: A Prospective Cohort Study Disclosure: Nothing to disclose Hanberg, Jennifer, MD 0195. Epidemiology and Characteristics of Haj-Ali, Mayce, MD Incident Rheumatoid Arthritis in Persons with 1844. Hydroxychloroquine and QTc Prolongation and Without HIV in a Cohort of SLE Patients Disclosure: Nothing to disclose Disclosure: Nothing to disclose Hang-Korng, Ea Hajj-ali, Rula, MD 0669. Calcium Pyrophosphate Crystal Deposition 0409. Clinical Characteristics, Brain MRI Findings, in Gouty Tophi and Diagnostic Approach of the Central Nervous Disclosure: Nothing to disclose System Vasculitis by Affected Vessel Size 0411. Serial Vessel Wall Enhancement Change on Hanlon, Megan, PhD, BSc High-Resolution MRI Vessel Wall Imaging in 0071. Significant Enrichment of Transcriptionally Primary Central Nervous System Vasculitis Distinct CD206+CD163+ Macrophage Population Disclosure: ABBVIE (8); Rockpoint (8) in Rheumatoid Arthritis Synovial Tissue Disclosure: Nothing to disclose Haj-Mirzaian, Arya, MD, MPH 1547. Role of Artificial Intelligence in Assessment Hanly, John, MD of Peripheral Joint MRI in Inflammatory Arthritis: 1014. Disease Modifying Anti-rheumatic Drugs, A Systematic Review and Meta-analysis Biologics and Corticosteroid Use in Older Disclosure: Nothing to disclose Patients with Rheumatoid Arthritis over 20 Years

45

1508. Blood-Brain Barrier Leakage in Systemic 0801. The Comparative Effectiveness of Lupus Erythematosus Is Associated with Gray Abatacept versus TNF Inhibitors in Patients Who Matter Loss and Cognitive Impairment Are ACPA Positive and Have the Shared Epitope: Disclosure: Nothing to disclose Results from a US National Observational Study 0824. The Comparative Effectiveness of Hardy, Courtney, BSc Abatacept versus Tofacitinib After 6 Months of 1832. Barriers to Medication Adherence and Treatment in Patients with RA Who Were Anti- Degree of Nonadherence in a Systemic Lupus citrullinated Protein Antibody Positive at Erythematosus Outpatient Population Baseline: Results from a US National Disclosure: Nothing to disclose Observational Study Disclosure: Bristol-Myers Squibb Company (5) Harkey, Matthew, PhD 0696. Femoral Cartilage Ultrasound Echo- Harry, Onengiya, MD, MSc, MPH Intensity Associates with Arthroscopic Cartilage 0048. Determinants of Participation in Clinical Damage in People Following Anterior Cruciate Trials Among Patients with Lupus in the United Ligament Reconstruction States Disclosure: Pfizer, Inc. (8) Disclosure: Nothing to disclose

Harley, Isaac, MD, PhD Hartman, Julia, BS 1452. Transcriptomic Meta-analysis Reveals a 0395. African Ancestry-Specific Variants Regulate Core Transcriptional Program in Murine B Cell TGFB3 Expression in Systemic Sclerosis Anergy and Implicates Immunometabolic Disclosure: Nothing to disclose Regulation as a Central Pathway in Maintaining Non-responsiveness of Autoreactive B-cells in Hartman, Linda, MSc Both Mouse and Man 2009. Treat-to Target for Early RA Patients in Disclosure: Selected Does Disclose, but no Usual Clinical Practice, a Randomized Study with financial relationship listed. a Favorable Effect of a Second Oral Pulse of Prednisolone. the Amsterdam COBRA Treat-to- Harmon, Alexis, BS target Study 1693. Evaluation of B-cell Depletion with Disclosure: Nothing to disclose Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease Hassan, Neelam, MBBCH Disclosure: Nothing to disclose 1703. Gender Equity in Academic Rheumatology – Is There a Gender Gap at European Harris, Julia, MD Rheumatology Congresses? 0457. Improving Pneumococcal Vaccination Disclosure: Nothing to disclose Rates in Immunosuppressed Rheumatology Patients Hassen, Nejat, MSc 0634. Influenza Knowledge and Barriers to 1013. National Burden of RA in Canada 1990- Vaccination in Immunosuppressed Patients in 2017: Findings from the Global Burden of the Pediatric Rheumatology Clinic Disease Study 2017 1617. New Juvenile Idiopathic Arthritis Quality Disclosure: Nothing to disclose Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network Hatemi, Gülen Disclosure: Nothing to disclose 0405. Disease Activity and Quality-of-Life Outcomes in Patients with Behçet’s Syndrome Harrold, Leslie, MD, MPH Who Achieved and Maintained Oral Ulcer Complete Response with Apremilast Treatment

46

0407. Achievement of Early and Sustained 2000. Risk of Venous Thromboembolism in Complete Response of Oral Ulcers with Rheumatoid Arthritis Patients Treated with Apremilast Compared with Placebo in Patients Methotrexate versus Hydroxychloroquine with Active Behçet’s Syndrome Disclosure: Nothing to disclose 0512. Efficacy of Apremilast for the Treatment of Manifestations of Behçet’s Syndrome Other Hebing, Renske, MSc Than Oral Ulcers, Including Skin Lesions and 0799. Effectiveness of Electronic Drug Arthritis Monitoring Feedback in Order to Increase Disclosure: AbbVie (8); Bayer (5); BMS (2); Adherence in RA Patients Starting with a Celgene Corporation (2); Eli Lilly (5); Mustafa Biological DMARD Nevzat (8); Novartis (8); Silk Road Therapeutics Disclosure: Nothing to disclose (2); UCB (8) Hecquet, Sophie Hausmann, Jonathan, MD 1535. Frequency and Anatomic Distribution of 1469. Characteristics of Adult Patients with Magnetic Resonance Imaging Lesions in the Rheumatic Diseases During the COVID-19 Sacro-iliac Joints of Healthy Subjects and Patients Pandemic: Data from an International Patient with Spondyloarthritis Survey 1852. Intestinal Permeability in the Adjuvant 1685. Impact of the COVID-19 Pandemic Among Induced Arthritis Model: Preliminary Study and Children with Rheumatic Diseases from Around Impact of NSAIDs the Globe Disclosure: Nothing to disclose 1769. Patient-reported COVID-19 Infection in Pregnant Women with Rheumatic Disease: Data Hedrich, Christian, MD, PhD from the COVID-19 Global Rheumatology 1400. cAMP Response Element Modulator Alliance Patient Experience Survey (CREM)α Promotes PD-1- effector CD4+ T Cells in Disclosure: Novartis (5) Psoriasis and Psoriatic Arthritis Disclosure: Nothing to disclose Hawker, Gillian, MD, MSc 1654. The Relationship Between Patient- Heisler, Andrew, MD Reported Readiness for Total Knee Arthroplasty 0022. Association Between Changes in Pain and the Likelihood of a Good Outcome at One Sensitization and Changes in Disease Activity Year After 12 Weeks of Disease Modifying Anti- Disclosure: University of Toronto (2) Rheumatic Drug Therapy in Rheumatoid Arthritis Disclosure: Nothing to disclose Hayashi, Yutaro, MD 1435. Prognostic Factors for Mononeuritis Helfgott, Simon, MD Multiplex Associated with ANCA-associated 0812. Real-World Utilization of Infliximab (IFX) Vasculitis and Its Biosimilars in Patients (Pts) with Disclosure: Nothing to disclose Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US Hayward, Kristen, MD 0887. Increasing Use of Biologics in Treatment of 1710. Remote Rheumapalooza: Reboot of a Systemic Lupus Erythematosus Patients in US Foundational Rheumatology Curriculum for Pre- Clinical Practice: Real-World Observations from Clinical Medical Students in the Era of Virtual Trio Health and the American Rheumatology Learning Network Disclosure: Nothing to disclose Disclosure: Abbvie (5)

He, Mengdong, MHS Helget, Lindsay, MD

47

0662. Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Herrmann, Matthew, MD, MS Matched Cohort Study 0397. Assessing Adherence to Screening of Disclosure: Nothing to disclose Systemic Sclerosis-Related Lung Disease Disclosure: Nothing to disclose Helliwell, Philip, PhD, DM, FRCP, MA 1348. What Influence Do Clinical Domains Other Hetland, Merete Lund, MD, PhD Than Arthritis Have on Composite Clinical 1010. Infection and Malignancy Outcomes in Outcomes in Psoriatic Arthritis?: Comparison of Patients with RA Treated with Abatacept: Results Treatment Effects in the SEAM-PsA Trial from a Multinational Surveillance Study Disclosure: AbbVie (2, 8); Amgen (8); Celgene (8); Disclosure: AbbVie (2); Biogen (2, 5); Bristol- Galapagos (8); Janssen (2); Novartis (2); Pfizer Inc Myers Squibb Company (2); Celltrion (5); Eli Lilly (8); UCB (8) (5); Merck (2, 5); Novartis (2); Orion Pharma (5); Pfizer (2, 5); Roche (2); Samsung Bioepis (5) Henderson, Lauren, MD, MSc 1496. Outcomes of an Evidence Based Guideline Hidalgo, Cristina, MD for the Treatment of Hemophagocytic 1389. Clinical Characteristics and Treatment Lymphohistiocytosis and Macrophage Activation Outcome of a Cohort of Patients with Joint and Syndrome Fascial Involvement in the Context of Chronic Disclosure: Adaptive Biotechnologies (5); CARRA Graft versus Host Disease (9, salary support); Sobi (5) Disclosure: Nothing to disclose

Henes, Jorg, MD Higashida-Konishi, Misako 1632. Long-Term Efficacy and Safety of 0197. The Clinical and Laboratory Features of Canakinumab in Patients with Autoinflammatory Seronegative Rheumatoid Arthritis with and Periodic Fever Syndromes – First Interim Analysis Without Malignancy of the FMF-TRAPS-HIDS/MKD Subgroup of the Disclosure: Nothing to disclose RELIANCE Registry Disclosure: Novartis (2, 5); Roche-Chugai (2, 5) Highland, Kristin, MD 0918. Decline in Forced Vital Capacity in Patients Henrotin, Yves, PhD with Systemic Sclerosis-Associated Interstitial 1647. An Oleuropein-based Dietary Supplement Lung Disease (SSc-ILD) with and Without Improves Joint Function in Older People with Gastroesophageal Reflux Disease: Further High Knee Joint Pain Analyses of the SENSCIS Trial Disclosure: Artialis SA (1) Disclosure: Actelion Pharmaceuticals (2, 5, 8); Bayer (2, 8); Boehringer Ingelheim (2, 5, 8); Eiger Heřmánková, Barbora, MS BioPharmaceuticals (2); Genentech (2); Gilead 0930. Sexual Health Impairment in 90 Female Sciences (8); Gossamer Bio (2); Reata Patients with Systemic Sclerosis Pharmaceuticals (2) 1072. Sexual Health Impairment in 62 Female ; United Therapeutics (2, 5, 8) Patients with Idiopathic Inflammatory Myopathies Hile, Grace, MD 1227. Reduction in Peripheral CD19+ CD27- 0283. Genome-wide DNA Methylation Analysis in Naïve B Cells Is Associated with Clinical Lupus Keratinocytes Identifies Differential Remission in Patients with Rheumatoid Arthritis Methylation of Genes That Regulate Apoptosis Receiving Combined Treatment with Disclosure: Nothing to disclose Methotrexate and TNF Inhibitors Disclosure: Nothing to disclose Hiramatsu Asano, Sumie, MD, PhD

48

0837. Deletion of miR-223 Exacerbates Lupus Osteoarthritis: Results from the 5-Year Forward Nephritis by Targeting S1pr1 in Faslpr/lpr Mice Study Disclosure: Nothing to disclose Disclosure: ACI Clinical (5); Bone Therapeutics (5); BriOri Biotech (1); Bristol Myers Squibb (5); Hirano, Fumio, MD, PhD Covance Inc. (5); Eli Lilly (5); Elsevier (7); EMD 1902. Determinants of Physician Global Serono (5); Galapagos (5); Gilead (5); Assessment and Influence of Contextual Factors GlaxoSmithKline (5); IBSA Institut Biochi; ICON plc in Early Axial Spondyloarthritis (5); IQVIA (5); Novartis Pharma AG (5); Noven Disclosure: Nothing to disclose Pharmaceuticals Inc. (5); Pfizer Inc. (5); Regenosine (5); Rheumcon, Inc. (6); Samumed Hitchon, Carol, MD LLC (5); Theralogix LLC (5); Theralogix LLC. (1); 0223. Safety of Low Dose Methotrexate (MTX) Vizuri Health Sciences (5); Wolters Kluwer (7) and Tuberculosis (TB) Disclosure: Pfizer (2); UCB Canada (2) Homann, Sarah, MD 1624. Improving Pneumococcal Vaccination in Hmamouchi, Ihsane, MD, PhD Veterans with Rheumatic Diseases 0962. Efficacy of Clomipramine for Chronic Disclosure: Pfizer (2) Lumbar Radicular Pain a Randomized Clinical Trial Honer, Katelin R. Disclosure: Nothing to disclose 1164. Frequency of Genetic Diagnosis in an Autoinflammatory Disease Natural History Ho, I-Cheng, MD, PhD Protocol Cohort of Patients 1399. Differential Impacts of TNFa Inhibitors on Disclosure: Nothing to disclose the Expression of Th Cytokines Disclosure: Nothing to disclose Honick, Brian, PT 0697. Inferior Tendon Structure and Function Hocaoglu, Mehmet, MD Seen in Patients with Achilles Tendinopathy and 0274. The Rising Incidence of Lupus Nephritis: A Neovascularization of the Achilles Tendon Population-Based Study of Four Decades Disclosure: Nothing to disclose 0278. Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population- Hoover, Paul, MD, PhD Based Study 0839. Single-Cell Transcriptomics of Mouse and Disclosure: Nothing to disclose Human Lupus Nephritis Identifies Conserved Myeloid Populations Across Species Hocevar, Alojzija, MD 0979. The Identification of Shared and Unique 0415. Characteristics of Arthritis in Adult IgA Myeloid Cell States in Pre- and Post-nephritic Vasculitis Lupus Mouse Models, Sle.Yaa1 and NZBW 1431. Interstitial Lung Disease in Patients with Disclosure: Nothing to disclose ANCA Associated Vasculitis – a Prospective Single Centre Study Horomanski, Audra, MD 1932. Giant Cell Arteritis – the Relationship 1135. Barriers to Influenza Vaccination in Between the Extensiveness of Vasculitis and the Patients at a Tertiary Care Rheumatology Clinic Clinical Presentation Disclosure: Nothing to disclose Disclosure: Nothing to disclose Hosoya, Tadashi, MD, PhD Hochberg, Marc, MD, MPH 1948. Identification of Small Molecules with 1486. Long-term Efficacy and Safety of Intra- Efficacy as Steroid Sparing Suppression of articular Sprifermin in Patients with Knee Chemokine and Cytokine Production by

49

Rheumatoid Arthritis Fibroblast-like Synoviocytes 1307. Detecting Subtle Changes in Fundoscopic Disclosure: GlaxoSmithKline Pharmaceuticals Ltd. Retinal Images in Patients with Axial (2) Spondyloarthritis with Deep Learning Disclosure: Nothing to disclose Howlett, Natalie, MD 2042. A Low FODMAP Diet Is Not Associated with Huang, Yun-Ju Decreased GI Symptoms or Changes in GI 0493. Automatic Joint Space Assessment in Hand Microbial Composition in Patients with Systemic Radiographs with Deep Learning Among Patients Sclerosis with Rheumatoid Arthritis Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Hsieh, Chen-I, MD Huang, Zhengping, MD 1975. Predicting Bone Mineral Density of Lumbar 0173. mTORC1 Signaling Promotes Monocytosis Vertebrae by Assessing Plain Film with Deep and Arthritis Development in IL-1 Receptor Learning Antagonist-deficient Mice Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Huang, Frank Huizinga, Thomas, MD, PhD 0070. Neutrophils Transiting Through 0827. Comparative Clinical Efficacy of Sarilumab Megakaryocytes During Emperipolesis Exhibit versus Upadacitinib over 12 Weeks: Matching- Distinct Fates and Acquire the Capacity to Guide Adjusted Indirect Comparison Analysis Other Neutrophils via MK Trails Disclosure: GSK (2) Disclosure: Nothing to disclose Humbel, Morgane, MS Huang, Michelle, MS 0291. SLAMF7 and CD38 on NK Cells Represent 0285. CXCL13 Neutralization Reduces Potential New Therapeutic Targets for Systemic Neuropsychiatric Manifestations in MRL/lpr Mice Lupus Erythematosus Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Huang, Shirley, PharmD Hunter, David, PhD, MBBS 0566. Healthcare Utilization and Costs Prior to 1641. Clinically Important Improvements in Diagnosis of ANCA Vasculitis in Medicare Patients with Osteoarthritis Treated with Beneficiaries Subcutaneous Tanezumab: Results from a 56- Disclosure: GlaxoSmithKline (9, Postdoctoral Week Randomized NSAID-Controlled Study fellowship funded by GSK) Disclosure: Merck Serono (5); Pfizer, Lilly (5)

Huang, Sicong, MD, MS Huse, Sarah, DO 1183. Factors Associated with Incident Heart 1297. Lupus Antibodies in Relation to Failure Subtypes in Patients with Rheumatoid Malignancy Arthritis Using Electronic Health Record Data Disclosure: Nothing to disclose Disclosure: Nothing to disclose Husni, M. Elaine, MD, MPH Huang, Xuechan 1189. Serum High-sensitive Cardiac Troponin at 0792. LY294002 Improves the Collagen-induced Baseline Predict Cardiovascular Events in Arthritis by Inducing Neutrophil Apoptosis Rheumatoid Arthritis and Osteoarthritis Disclosure: Nothing to disclose Disclosure: Abbvie (5); BMS (5); Janssen (5); Lilly (5); National Psoriasis Foundation (6); Novartis Huang, Yun Ju

50

(5); PASE questionnaire (7); Pfizer (5); Pfizer (2); Regeneron (5) Injean, Patil, DO 0023. Hypophosphatasia May Be Misdiagnosed Huston, Kent Kwas, MD as Fibromyalgia: A Single Center Experience 0601. The “Why” of Drug Discontinuation; Disclosure: Nothing to disclose Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases Injean, Patil, DO Disclosure: Nothing to disclose 0639. Immunological Abnormalities in a SARS- CoV-2-Cytokine Release Syndrome Huston, Kent Kwas, MD Rheumatology Cohort 0610. Change in Utilization of Outpatient Disclosure: Nothing to disclose Services at US Community Rheumatology Practices During COVID-19 Outbreak Injean, Patil, DO Disclosure: Nothing to disclose 1132. Reliability of Virtual Sources of Education for Patients with Vasculitis Hwang, Mark, MD Disclosure: Nothing to disclose 1874. Differences Between Men and Women in the Patient Pathways to Diagnosis of Ankylosing Isozaki, Takeo, MD, PhD Spondylitis 1528. Filgotinib Inhibits Monocyte Disclosure: Nothing to disclose Differentiation and Pro Inflammatoly Cytokine Production in Osteoblasts Hwang, Yong Gil, MD Disclosure: Nothing to disclose 0751. Serum Interferon-Alpha Levels Could Help Identify a Subgroup of Rheumatoid Arthritis with Ito, Takanori, MD Poorer Physical Function and Higher Physician 0912. Effectiveness of DETECT Algorithm in Global Assessment Japanese Systemic Sclerosis Patients with Old or Disclosure: Nothing to disclose New Hemodynamic Definition of Pulmonary Arterial Hypertension Ikari, Yuzo, MD, PhD Disclosure: Nothing to disclose 0791. Peficitinib Inhibits Angiogenesis via Suppression of VEGF Production in Rheumatoid Iudici, Michele, MD, PhD Arthritis Fibroblast-like Synoviocytes 2051. Localized versus Systemic Granulomatosis Disclosure: Nothing to disclose with Polyangiitis: Data from the French Vasculitis Study Group Database Inanc, Nevsun, MD Disclosure: Nothing to disclose 1251. Assessing the Construct Validity of the Novel OMERACT Ultrasound Scoring System for Ivanova, Mariana, MD, PhD Salivary Glands Target Lesions by Comparison 2011. Olokizumab Improves Patient Reported with MRI in Patients with Sjögren's Syndrome - Outcomes in Patients with Moderately to An OMERACT Ultrasound Working Group Severely Active Rheumatoid Arthritis Exercise Inadequately Controlled by Methotrexate: Disclosure: Nothing to disclose Results from the Double-Blind, Randomized Controlled Phase III Study Inanc, Nevsun, MD Disclosure: JSC “R-Pharm” (2) 1252. Ultrasound-guided Parotid Gland Biopsy in Cadavers Performed by Rheumatologists – an Iversen, Lars, MD OMERACT Ultrasound Working Group Study 1630. Long-term Safety of Tildrakizumab in Disclosure: Nothing to disclose Patients with Moderate to Severe Plaque

51

Psoriasis: Incidence of Confirmed Major Adverse James, Alanna, MD, BS Cardiovascular Events Through 3 Years (148 0588. Feast or Famine? An Institutional Weeks) from Two Phase 3 Trials Assessment of Hydroxychloroquine Screening Disclosure: AbbVie (2, 5, 8); Almirall (2, 5, 8); Practices Amgen (2, 5, 8); AstraZeneca (2, 5, 8); Boehringer Disclosure: Nothing to disclose Ingelheim (2, 5, 8); Bristol Meyers Squibb (2, 5, 8); Celgene (2, 5, 8); Centocor (2, 5, 8); Eli Lilly (2, James, Eddie, PhD 5, 8); Janssen-Cilag (2, 5, 2044. Complex, Dynamic Attributes of Antigen- specific T Cells in Rheumatoid Arthritis Izadi, Zara, PharmD Disclosure: Janssen (2); Novartis (2); Pfizer (2); 1963. Variation in Quality of Care Among Patient Sanofi (2) Sociodemographic Groups in RISE Practices Disclosure: Nothing to disclose Jani, Meghna, PhD 0534. National Variation and Factors Associated Izuka, Shinji, MD with Long-term Opioid Use for Non-cancer Pain 1830. Adverse Drug Reactions to Trimethoprim- in the First Year of Use sulfamethoxazole as a Prophylactic Agent Disclosure: Nothing to disclose Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Janow, Ginger, MD, MPH Antibody as a Possible Risk Factor 1153. Trends in Timing of Biologic Use for Disclosure: Nothing to disclose Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry Jafarzadeh, S. Reza, PhD Disclosure: Nothing to disclose 1470. Machine Learning-Based Prediction of Knee Replacement in Persons with and Without Jansen, Tim, MD PhD Radiographic Osteoarthritis Using Clinical and 0368. Comparable Impact and Burden of Disease Imaging Features of Osteoarthritis: The of Psoriatic Arthritis Patients with Limited Joint Multicenter Osteoarthritis Study Involvement vs. Those with More Extensive Joint Disclosure: Nothing to disclose Involvement: Interim Results from a Prospective, Multicenter, Real-World Study in Patients Jakibchuk, Kalyna, MD Treated with Apremilast 1105. RANK-L Activity: Understanding the Disclosure: AbbVie (5); Celgene Corporation (5); Pathogenesis of Erosive Osteoarthritis Grunenthal (2, 8); Olatec (2); Sobi (8) Disclosure: Nothing to disclose Jeffries, Matlock, MD, FACP, FACR Jakiela, Jason, MS 0702. Distinct Murine Cartilage Microbial DNA 1459. The Association of Frequent Knee Bending Signatures Are Seen in High Fat Diet-Induced with Trajectories of Pain and Physical Function Obesity and Aging over 8 Years in Knee Osteoarthritis 0704. The Murine Ear Wound Cartilage Disclosure: Nothing to disclose Superhealer Trait, Mediated by the Gut Microbiome, Is Transgenerationally Heritable Jamaludin, Amir, PhD Following Cecal Transplantation 1365. Machine Learning-based Berlin Scoring of 1971. Gut Microbiome Transplantation from Magnetic Resonance Images of the Spine in MRL/MpJ Mice Prevents Post-Traumatic Patients with Ankylosing Spondylitis: Analysis of Osteoarthritis in C57BL6/J Mice Data from a Phase 3 Trial with Secukinumab Disclosure: Nothing to disclose Disclosure: Nothing to disclose Jensen, Kasper Yde, MSc

52

1093. Impact of Blood Flow Restricted Strength Training on Myogenic Stem Cells and Myofiber Jonsson, Anna Helena, MD, PhD Hypertrophy in Sporadic Inclusion Body Myositis 2047. Synovial CD8 T Cells in Rheumatoid Patients Arthritis Exhibit High Antigen-independent Disclosure: Nothing to disclose Cytokine Production and Low Cytotoxic Potential Disclosure: Nothing to disclose Jeucken, Kim 0998. Differential Roles of TNFRI and TNFRII in Jorge, April, MD the Morphology of Secondary Lymphoid Organs 0871. Hydroxychloroquine Dose Reduction and 1952. Activated Memory T Cells Produce Ligands SLE Flares That Cause NF-κB-dependent Inflammatory 1302. Exploration of Machine Learning Methods Activation of the Endothelium: Identification of in Predicting Systemic Lupus Erythematosus Novel Therapeutic Targets Hospitalizations Disclosure: Nothing to disclose 1514. The Impact of Renal Transplantation on Cardiovascular Events Among Patients with End- Jiang, Wei, MD State Kidney Disease Due to Lupus Nephritis: A 0788. Rigorous Plasma Microbiome Analysis Nationwide Cohort Study Method Enables Disease Association Discovery Disclosure: Nothing to disclose Disclosure: Nothing to disclose Jose, Donna, MD Joerns, Elena, MD 0119. Fracture Liaison Service at an Academic 1623. Improving Pneumococcal Vaccination Center with an Open Health System: 30-month Rates Among Immunosuppressed Adults in an Outcomes Academic Rheumatology Clinic Utilizing a Nurse Disclosure: Nothing to disclose Driven Protocol Disclosure: Pfizer (2) Joshua, Vijay, PhD 1445. Citrulline Reactive B Cells Are Present in Jolly, Meenakshi, MD, MS the Lungs of Risk RA and Early Untreated RA 1181. Gains in Cardiovascular Risk Knowledge Disclosure: Nothing to disclose Through Web Based Educational Intervention for Rheumatoid Arthritis Patients Juge, Pierre Antoine Disclosure: AURINIA (7); BI (7); BMS (7); CELGENE 1194. MUC5B Promoter Variant rs35705950 and (7); EVIDERA (7); LUCIN (5); PFIZER (2) Risk Stratification for Rheumatoid Arthritis - Interstitial Lung Disease Jones, Jordan, MS, DO 1195. MUC5B rs35705950 and Rheumatoid 0734. Differences and Similarities Between down Arthritis Associated Interstitial Lung Disease Syndrome-associated Arthritis and Juvenile Progression Idiopathic Arthritis in the New Childhood 1199. Prevalence of Subclinical Interstitial Lung Arthritis and Rheumatology Research Alliance Disease After a Mean Rheumatoid Arthritis (CARRA) Registry Duration of 13 Years: Results from the French Disclosure: Nothing to disclose ESPOIR Cohort Disclosure: Bristol-Myers Squibb Company (5) Jones, Niall, MD, FRCP 0825. Sex Differences in the Efficacy and Safety Jule, Amelie, PhD of Tofacitinib in Rheumatoid Arthritis Patients: A 0470. Th1 Polarization Defines the T Cell Post Hoc Analysis of Phase 3 and Long-Term Compartment in the Joints of Oligoarticular Extension Trials Juvenile Idiopathic Arthritis Patients Disclosure: Nothing to disclose Disclosure: Nothing to disclose

53

1021. Organ Damage in Systemic Lupus Jung, Ju-Yang Erythematosus Is Attributable More to 0098. CCL2 and CCR2 in Adult Onset Still's Comorbidity (Hypertension) and Less to Disease Socioeconomic Status Disclosure: Nothing to disclose 1258. Trajectory of Damage Accrual in African- American vs. Caucasian Systemic Lupus Jurkowski, Mali, MD Erythematosus 0627. Complications of COVID-19 Infection in Disclosure: Nothing to disclose Patients with Rheumatic Disease: A Case Series Disclosure: Nothing to disclose Kambhatla, Soumyasri, MD 1004. The Incidence, Mortality, and Economic Kaellmark, Hanna, MD Burden of Potentially Preventable Infections in 1997. Immunogenicity of Adjuvanted Herpes Rheumatoid Arthritis Patients Zoster Subunit Vaccine in Rheumatoid Arthritis Disclosure: Nothing to disclose Patients Treated with Janus Kinase Inhibitors and Controls: Preliminary Results Kameda, Tomohiro, MD Disclosure: Nothing to disclose 1572. Clinical Characteristics of Methotrexate Associated Lymphoproliferative Disorders and Kahle, Dana, BS RA Treatment After Lymphoproliferative Onset in 1159. Novel STING1 Mutations Including in the 92 Cases Transmembrane Linker Region Cause STING- Disclosure: Nothing to disclose associated Vasculopathy with Onset in Infancy (SAVI) Kamen, Diane, MD, MSCR Disclosure: Nothing to disclose 0863. Residual Treatment Burden, Desired Improvement, and Prioritized Treatment Goals in Kahlenberg, J. Michelle, MD, PhD Systemic Lupus Erythematosus (SLE): Results 0956. An IL-18-Containing Five-Gene Signature from the SLE-UPDATE (Understanding Distinguishes Histologically Identical Preferences, Disease Activity and Treatment Dermatomyositis and Lupus Erythematosus Skin Expectations) Survey in the United States Lesions Disclosure: Nothing to disclose Disclosure: AstraZeneca (5); Avion Pharma (5); Bristol Myers Squibb (2, 5); Celgene (2); Eli Lilly Kamiya, Mari, MD, PhD (5) 1077. Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Inflammation and Muscle Kaieda, Shinjiro, MD, PhD Fiber Death, and Ameliorates Muscle Weakness 1256. Mast Cells Contribute to the Development in Experimental Polymyositis of Sialadenitis Associated with Sjögren's Disclosure: Nothing to disclose Syndrome via Inducing Tissue Fibrosis by TGFβ Production Kampylafka, Eleni Disclosure: Nothing to disclose 0335. Interleukin-17 Blockade Leads to Shifts from Stage-based Towards Response-based Kaler, Jaspreet, MD Disease Clusters- Comparative Data from Very 1606. Mortality with Idiopathic Inflammatory Early and Established Psoriatic Arthritis Myositis in an Academic Hospital Setting: A Five- Disclosure: Bristol-Myers-Squibb (8); Janssen (8); year Retrospective Study Novartis (8) Disclosure: Nothing to disclose Kaneko, Kaichi, MD, PhD Kallas, Romy, MD

54

0126. Immunophenotyping of Peripheral Blood 1192. Subclinical Coronary Calcification Highlights an Association of Dysregulated Associated with Long-term Cardiovascular Lymphocytes with Patients with Glucocorticoid- Outcomes in Rheumatoid Arthritis induced Osteonecrosis Disclosure: Pfizer (Individual(s) Involved: Self): 2 Disclosure: Nothing to disclose Kassamali, Bina, BA Kannuthurai, Vijay, MD 0086. Geographic Distribution of Eosinophilic 0045. Healthcare Practitioner Confidence Fasciitis Cases in Massachusetts and Associated Assessing Rashes in Patients of Skin of Color with Environmental Triggers Lupus 2037. Geographic Distribution and Disclosure: Nothing to disclose Environmental Triggers of Systemic Sclerosis in Massachusetts Karim, Muntarin, DO Disclosure: Nothing to disclose 0050. Demographic Disparities in the Medically Underserved Populations of Southern California: Kasturi, Shanthini, MD, MS A Rheumatology Cohort of Cytokine Release 1145. Implementation of Web-Based Patient- Syndrome Patients Due to COVID-19 Reported Outcome Measures (PROMs) in SLE Disclosure: Nothing to disclose Clinical Care: A Multi-Center Prospective Cohort Study Karkache, Wassim, MD Disclosure: Nothing to disclose 1136. Survey of Medical Cannabis Use in Lupus and Scleroderma Katz, Alexis, DO Disclosure: Nothing to disclose 1066. Prevalence of Cervical Dysplasia in Women with Karmacharya, Paras, MBBS Disclosure: Nothing to disclose 0308. Delay in Transition from Psoriasis to Psoriatic Arthritis: A Population Based Study Katz, Patricia, PhD 0309. Diagnostic Delay in Psoriatic Arthritis: A 0434. Changes in Mental Health During the Population Based Study COVID-19 Pandemic Among Individuals with 0342. Multimorbidity Clusters in Psoriatic Rheumatic Disease Arthritis: A Population-Based Study 1288. Predictors of Frailty Identified by the Short Disclosure: National Center for Advancing Physical Performance Battery and Associations Translational Science (2, Dr. Karmacharya’s work with Patient-reported Outcomes was supported by National Center for Advancing Disclosure: Nothing to disclose Translational Science grant UL1-TR-002377.) ; SPARTAN (Spondyloarthritis Research and Kaundal, Urvashi, PhD Treatment Network) (2, SPARTAN Fellow 1525. Intergenic HLA Variants in African American Patients with Systemic Sclerosis Karpouzas, George, MD Regulate Expression of HLA-DRB1 0485. Non-obese Rheumatoid Arthritis Patients Disclosure: Nothing to disclose with Low Low-density Lipoprotein Have Higher Coronary Atherosclerosis Burden, Greater Plaque Kavanaugh, Arthur, MD Progression and Cardiovascular Event Risk 0213. Sustainability of Response to Upadacitinib 0486. Differences in Low-density Lipoprotein as Monotherapy or in Combination Among (LDL) Particle Composition and Oxidation May Patients with Rheumatoid Arthritis and Prior Underlie the Paradoxical Association of Low LDL Inadequate Response to Conventional Synthetic with Higher Coronary Atherosclerosis Burden in DMARDs Rheumatoid Arthritis Disclosure: Eli Lilly and Company (5)

55

1291. Depressed Symptomatology Persists over Kay, Jonathan, MD Time in the Majority of Systemic Lupus 0800. A Randomized, Double-Blind, Phase 3 Erythematosus Patients and Is Independent of Study to Compare the Efficacy and Safety of a Disease Activity Proposed High Concentration (100 mg/mL) Disclosure: Nothing to disclose Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to- Kennedy, Kevin, MA Severe Active Rheumatoid Arthritis 0613. Modeling the Effects of Covid-19 1204. Use of Multi-Biomarker Disease Activity Protective Behaviors and Healthcare Delivery on Scores to Assess Biosimilarity in a Phase 3 the Health of Patients with Rheumatic Disease Randomized Controlled Trial Comparing Disclosure: Lyceum Health (5) Biosimilar Infliximab-qbtx (PF‑06438179/GP1111) with EU-Sourced Kenney, H. Mark Reference Infliximab in Patients with Active RA 0969. Investigating Murine Joint-Draining 1233. Use of Multi-Biomarker Disease Activity Lymphatics: Lineage Tracing and Single Cell RNA Scores to Compare Biosimilar Adalimumab-afzb Sequencing Reveal Evidence That Popliteal (PF-06410293) with EU-Sourced Reference Lymphatic Muscle Cells and Their Progenitors Adalimumab in a Phase 3, Randomized, Double- Represent Distinct Cell Types Divergent from Blind Trial in Patients with Active RA Striated and Vascular Muscle Cells Disclosure: Alvotech Suisse AG (5); Arena 1557. Lymphatics as a Biomarker of Joint Pharmaceuticals, Inc. (5); Boehringer Ingelheim Physiology: Near-Infrared Imaging of GmbH (5); Celltrion Healthcare Co. Ltd. (5); Indocyanine Green Identifies Novel Routes of Gilead Sciences, Inc. (9, Has received research Lymphatic Drainage from Metacarpophalangeal support, paid to his institution); Mylan Inc. (5); Joints in Healthy Human Hands Novartis AG Disclosure: Nothing to disclose

Kedra, Joanna, MD, MSc Kenninger, Hannah, MD 0184. Lymphomas Complicating Rheumatoid 1622. Determining the Zoster Vaccination Rate Arthritis: Results of a French Multi-Centre Case- Among Veterans on Chronic Immunosuppressive Control Study Therapy at the Southeast Louisiana Veterans 1717. Impact of Treatments on Favorable Healthcare System – a Quality Indicator Outcome over the First 10 Years of Disease in Disclosure: Nothing to disclose Early Rheumatoid Arthritis: Results from a WCE Model in the ESPOIR Cohort Kermani, Tanaz, MD 1718. Impact of Treatments on Radiographic 0418. Prevalence of Thyroid Disease Among Progression over the First 10 Years of Disease in Patients with Vasculitis Early Rheumatoid Arthritis: Results from the 1432. Thyroid Disease in Patients with ANCA- ESPOIR Cohort Associated Vasculitis Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Keegan Strosser, Julie, MMS, PA-C Kerr, Gail, MD, FRCP 0435. Low Incidence of Coronavirus Disease 0043. Geographical Disparity in Rheumatoid 2019 (COVID-19) Infection in Patients on Biologic Arthritis Disease Burden Independent of Infusion Therapies at a Community Race/Ethnicity Rheumatology Practice Disclosure: BMS (2, 5); Gilead (2); Janssen (5); Disclosure: Nothing to disclose Novartis (2); Regeneron (5)

Kellahan, Sara, NP Kerschbaumer, Andreas, MD

56

0748. Joint Space Narrowing Precedes Erosive Mycophenolate Mofetil in Patients with Radiographic Damage in Patients with Refractory Gout—a Phase II Double Blind Rheumatoid Arthritis Randomized Controlled Trial Disclosure: Bristol-Myers Squibb, Celgene, Eli- Disclosure: Dyve (5); Selecta (5) Lilly, Merck Sharp and Dohme, Novartis, Pfizer (8); Gilead (9) Kharouf, Fadi, MD 0085. Classifications of Inflammatory Khalili, Leila, FNP Myopathies: Differentially Expressed Membrane- 1280. COVID-19 Infections May Increase the Risk Bound Complement Regulators Allow Specific of SLE Flares Patterns of Membrane Attack Complex Disclosure: Nothing to disclose Deposition Disclosure: Nothing to disclose Khan, Muhammad Asim, MD, FRCP 1862. Genetic Influences on Occurrence of Axial Khawaja, Sehris, DO Spondyloarthritis (axSpA) in First-degree 1420. Characterization of ANCA-Associated Relatives During a Prospective Study Lasting 35 Vasculitis Among African American Patients Years Disclosure: Nothing to disclose Disclosure: Nothing to disclose Khullar, Nitasha, MD Khanna, Aakanksha, MD 0122. Osteoporosis Medication Utilization 0477. Rheumatology Fellowship Program Patterns over Time in the ACR RISE Registry Directors in the United States: Analysis of Disclosure: Nothing to disclose Demographics, Educational and Scholarly Achievements Kidwell, Kyle, MD Disclosure: Nothing to disclose 0389. Organ Specific Treatment Patterns of a Real-World, Electronic Health Record Cohort of Khanna, Dinesh, MD, MSc Patients with Systemic Sclerosis 0396. Safety and Efficacy of Subcutaneous Disclosure: Nothing to disclose Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase 3 Trial Kiefer, David, MD L09. A Phase 2a Randomized, Double-blind, 1888. Successful Evaluation of Spinal Mobility Placebo-controlled Study of Ziritaxestat in Early Measurements with the Epionics SPINE Device in Diffuse Cutaneous Systemic Sclerosis (NOVESA) Patients with Axial Spondyloarthritis Compared Disclosure: Abbvie, (5); Acceleron, (5); Actelion, to Controls (5); Amgen, (5); Bayer (2); Bayer, (5); BMS (2); Disclosure: Nothing to disclose Boehringer Ingelheim (5); CiviBioPharma/Eicos Sciences Inc (6); Corbus, (5); CSL Behring (5); Kieskamp, Stan, MD Eicos Sciences Inc (4); Galapagos, (5); 1321. Central Sensitization, Disease Perception Genentech/Roche (5); GSK (5); Horizon (5); and Obesity Should Be Taken into Account When Horizon (2); Immune Tolerance Network (2); Interpreting Disease Activity in Patients with Impact PH (9, CME programs); Merck, (5); Axial Spondyloarthritis Mitsubishi Tanabe Pharma (5); NIH (2); Pfizer (2); Disclosure: Novartis (2) Sanofi-Aventis (5); Scleroderma Development (6); United Therapeutics (5) Kilian, Adam, MD 1576. Acute Respiratory Viral Adverse Events Khanna, Puja, MD, MPH During Use of Antirheumatic Disease Therapies: 0952. Reducing Immunogenicity of Pegloticase A Scoping Review (RECIPE) with Concomitant Use of Disclosure: Nothing to disclose

57

Kim, Seoyoung, MD, ScD Kiltz, Uta, MD 1005. Risk of Non-vertebral Fractures Among 0354. How Do TNF-alpha-Inhibitors in Medical Rheumatoid Arthritis Patients Treated with History Affect Patient Reported Outcomes and Biologic or Targeted-Synthetic DMARDs: A Multi- Retention in Ankylosing Spondylitis Patients Database Comparative Safety Study Treated with Secukinumab in Real World? – 1993. Cardiovascular Risk in Rheumatoid German Observational Study Arthritis Patients Treated with Methotrexate 0358. Does Smoking Affect Secukinumab versus Hydroxychloroquine Treatment Outcomes and Safety in Patients with Disclosure: AbbVie (2); Bristol-Myers Squibb (2); Ankylosing Spondylitis? – Real World Data from Pfizer (2); Roche (2) German Observational Study 0360. Does Smoking Affect Secukinumab Kim, Woo Jin Treatment Outcomes and Safety in Patients with 0728. Clinical Outcomes of Juvenile Arthritis in Psoriatic Arthritis? – Real World Data from Adulthood: A Systematic Review German Observational Study Disclosure: Nothing to disclose 0573. Effects of Successive Switches of Two Different Biosimilars of Etanercept on Outcomes Kimura, Yukiko, MD in Inflammatory Rheumatic Diseases in Daily 1492. The Childhood Arthritis and Rheumatology Practice Research Alliance Start Time Optimization of 0877. Improvements in Global Functioning and Biologic Therapy in Polyarticular JIA Study: Health-related Quality of Life and Their Report of Primary Study Outcomes Association with Disease Activity and Functional Disclosure: CARRA (9, Salary support); Genentech Improvement in Patients with Active Ankylosing (2); Up to Date (7) Spondylitis Treated with Upadacitinib 1890. Daily Management of Patients with Axial King, Lauren, MD Spondyloarthritis: Self-monitoring of Disease 1657. Do Comorbidities Limit Improvement in Activity with a Smartphone App Is Feasible – a Pain and Physical Function After Total Knee Proof of Concept Study Arthroplasty in Patients with Knee Disclosure: Abbvie (2, 5); Biocad (2, 5); Biogen (2, Osteoarthritis? 5); Chugai (2, 5); Eli Lilly (2, 5); Grünenthal (2, 5); Disclosure: Nothing to disclose Janssen (2, 5); MSD (2, 5); Novartis (2, 5); Pfizer (2, 5); Roche (2, 5); UCB (2, 5) Kinnett-Hopkins, Dominique, PhD 0021. Prioritizing Patient Safety While Kim, Alfred, MD, PhD Maintaining Study Integrity During COVID-19: 0064. Neutrophil Extracellular Traps Are Lupus Intervention Fatigue Trial Modifications Sufficient to Activate the Alternative Pathway of and Lessons Learned Complement Disclosure: Nothing to disclose Disclosure: Alexion Pharmaceuticals (5); Annexon Biosciences (5); Exagen Diagnostics, Inc. (5, 8); Kirkham, Bruce, MD GlaxoSmithKline (2, 5, 8); JPMorgan Chase & Co. 1374. Secukinumab in the Treatment of (5) Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Kim, Hanna, MD, MS Trial 1990. Janus Kinase (JAK) Inhibition with Disclosure: AbbVie (9, Personal fees); Eli Lilly & Baricitinib in Refractory Juvenile Co (2, 9, Personal fees); Gilead (9, Personal fees); Dermatomyositis Janssen (9, Personal fees); Novartis (2, 9, Disclosure: Eli Lilly and Company (9, Drug) Personal fees); UCB (2, 9, Personal fees)

58 kishimoto, mitsumasa, MD 0803. Real-World DMARD Experience and Kiwalkar, Sonam, MD Outcomes for Rheumatoid Arthritis Patients in 1869. “Rheum to Diagnosis”: Uncovering Japan: Safety Impediments to Accurate Diagnosis of Non- Disclosure: AbbVie (5, 8); Amgen-Astellas Pharm radiographic Axial Spondylarthritis (nr-axSpA) (5, 8); Asahi-Kasei Pharm (5, 8); Ayumi Pharm (5, Disclosure: Nothing to disclose 8); BMS (5, 8); Chugai (5, 8); Daiichi Sankyo (5, 8); Eisai (5, 8); Eli Lilly (5, 8); Gilead (5, 8); Janssen Klapa, Sebastian, MD (5, 8); Kyowa Kirin (5, 8); Novartis (5, 8); Pfizer (5, 2050. Autoantibodies Targeting Complement 8); Tanabe Mitsubishi (5, 8); Teijin (5, 8); UCB (5, Receptors C3aR and C5aR1 Are Decreased in 8) ANCA-associated Vasculitis and Correlate with a Higher Relapse Rate Kissel, Theresa, PhD Disclosure: Nothing to disclose 0993. N-linked Glycosylation of the Immunoglobulin Variable Domain Affects Kleinert, Stefan, MD Antigen Binding and Autoreactive B Cell 0182. Chronic Kidney Disease Is Underestimated Activation in Patients with Rheumatoid Arthritis – Real Disclosure: Nothing to disclose World Data Gathered from a Network of Rheumatologists Kisten, Yogan, BSc, MMed Disclosure: Abbvie (8); Novartis (2, 5) 0759. Presence of Ultrasound Imaging Biomarkers Are Good Predictors of Arthritis Knight-Zhang, Erin, PhD Development in a Population at Risk for 1602. Assessing the Psychometric Properties of a Rheumatoid Arthritis Measure of Patient Empowerment with Patients Disclosure: Nothing to disclose with Arthritis Disclosure: Nothing to disclose Kitakule, Moses, BS 0095. Systematic Evaluation of Nine Monogenic Koh, Li Wearn, FRCP Autoinflammatory Diseases Reveals Common 0058. Drug Retention and Discontinuation of and Disease-Specific Correlations with - Biological DMARDs and Novel Small Molecules: Associated Features Data from the Singapore National Biologics Disclosure: Nothing to disclose Registry Disclosure: Astellas Pharma (8); DKSH (9, Kivitz, Alan, MD Conference Sponsorship) 1218. Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, Health- Koo, Bon San, MD related Quality of Life, and Fatigue in Patients 0357. Suppressing Inflammation Rather Than with Rheumatoid Arthritis and Inadequate Lowering the Disease Activity Score Should Be Response to Methotrexate Targeted During TNF Inhibitor Treatment to Slow 1544. Tc99m Tilmanocept Imaging Is an Early Radiographic Changes in Patients with Predictor of Clinical Response in Rheumatoid Ankylosing Spondylitis Arthritis Patients Beginning New Anti-TNFα Disclosure: Nothing to disclose Therapy Disclosure: AbbVie (5); Amgen (1); Boehringer Korsunsky, ilya, PhD Ingelheim (5); Celgene (8); Flexion (8); Genzyme 1957. A Single Cell Stromal Atlas Identifies (5, 8); Gilead (1); Horizon (8); Janssen (5); Merck Conserved Fibroblast Phenotypes Expanded in (8); Novartis (8); Pfizer (1, 5, 8); Regeneron (5, 8); the Inflamed Synovium, Lung, Intestine, and ; Sanofi (1, 5, 8); Sun Pharma (5); UCB (5)

59

Salivary Gland 0742. Effect of IA OnabotulinumtoxinA and Disclosure: Brilyant LLC (5) Vanilloids on Substance P and Neurokinin 1 Receptor Expression in the Dorsal Root Ganglia Kostadinova, Lenche, MD of Mice with Monoarthritis 0558. Statin Use Pattern in Patients with Disclosure: Nothing to disclose Inflammatory Joint Disease in a Single Site VA Medical Center Kudo, Yuki, MMed Disclosure: Nothing to disclose 1908. Establishment of iPSc and Differentiated Endothelial Cells of Systemic Sclerosis Associated Koster, Matthew, MD Pulmonary Arterial Hypertension ; Functional 1428. The Efficacy and Safety of Tocilizumab in and Molecular Analysis Patients with Giant Cell Arteritis: A Systematic Disclosure: Nothing to disclose Review and Meta-Analysis Disclosure: Nothing to disclose Kuemmerle-Deschner, Jasmin, MD 1479. Long-Term Effectiveness of Canakinumab Kouki, Inès in Autoinflammatory Diseases – Interim Analysis 1103. Metacarpo-phalangeal Osteoarthritis Is of the CAPS Subgroup from the RELIANCE Not Rare and Is Associated with Mechanical Registry Rather Than Systemic Factors in Hand Disclosure: AbbVie (2, 5); Novartis (2, 5); SOBI (2, Osteoarthritis: An Observational Study from a 5) Large Hospital-based Cohort Disclosure: Nothing to disclose Kumar, Ravi, PhD 2043. Identification and Validation of Citrulline Koyama, Yoshinobu, MD, PhD Specific TCRs in CD4+T Cells in Rheumatoid 1225. Targeting to IL-6 or Specific JAKs for RA Arthritis Treatment: Seeking a Rationale for Switching Disclosure: Nothing to disclose Each Other If One of These Treatments Resulted in Lack of Efficacy Kumari, Pooja, MD Disclosure: Abbvie (8); Ayumi (8); BMS (8); 0243. The Role of Anti-dsDNA Antibodies in Chugai (8); Eisai (8); Eli-Lilly (2); Mitsubishi Predicting Incident Lupus Nephritis in Newly Tanabe (8); Mochida (2); Ono (8) Diagnosed Lupus Disclosure: Nothing to disclose Kröber, Georg, MD 2014. The Relative Diagnostic Utility of Kundakci, Burak, MSc Inflammatory Back Pain Criteria in an Inception 0024. An International Delphi Consensus on Non- Cohort of Patients with Psoriasis, Iritis, and pharmacological Interventions for Fibromyalgia Colitis Presenting with Undiagnosed Back Pain Disclosure: Nothing to disclose Disclosure: Nothing to disclose Küppers, Dennis Michael, MD Kronzer, Vanessa, MD 0705. lncRNA H19 and Micro RNA 675-3p Are 1198. Lifestyle and Clinical Risk Factors for Altered by Visfatin During Osteogenesis Incident Rheumatoid Arthritis-Associated Disclosure: Nothing to disclose Interstitial Lung Disease Among Patients with Rheumatoid Arthritis Kuwana, Masataka, MD, PhD Disclosure: Nothing to disclose 0388. Factors Prognostic of Greater Decline in Forced Vital Capacity in Patients with Systemic Krug, Hollis, MD Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the Placebo Group of the

60

SENSCIS Trial Disclosure: AbbVie Inc. (8); Astellas (8); Chugai Lanata, Cristina, MD (2, 8); Eisai Co., Ltd. (8); Mitsubishi Tanabe 1812. Longitudinal Blood DNA Methylation in a Pharma Corporation (2, 8); Ono Pharmaceutical Multi-ethnic Cohort of SLE Patients (2, 8) Disclosure: Nothing to disclose

Kwan, Andrew Landewé, Robert B.M., MD 1788. Assessment of the Impact of Interferon 1763. Blending Hierarchical Cluster Analysis and Levels on Cognitive Dysfunction in Patients with Cluster-Specific Regressions to Predict Clinical SLE Outcome to Tofacitinib Treatment in Patients Disclosure: Nothing to disclose with Rheumatoid Arthritis Disclosure: AbbVie (2, 5, 8); Ablynx (5); Amgen (2, Kwoh, C. Kent, MD 5, 8); AstraZeneca (5); Bristol-Myers Squibb (5, 1114. Longitudinally Assessed Structural 8); Celgene (5); Eli Lilly (5); Galapagos (5); Gilead Abnormalities on MRI and Relative Contributions (5); GlaxoSmithKline (5); Janssen (2, 5, 8); Merck to Risk of Incident Radiographic Knee (5, 8); Novartis (5); Novo Nordisk (5); Pfizer Inc Osteoarthritis over 10 Years of Follow-up (2, 5, 8); Rheumatology Consultancy BV (1); Disclosure: Abbvie (2); Eli Lilly (2); EMD Serono Roche (2, 5, 8); Schering (2, 5, 8); TiGenix (5); (5); Express Scripts (5); Fidia (5); GSK (2); Kolon UCB (2, 5, 8) Tissue Gene (5); Merck KGaA (2, 5); Novartis (2); Pfizer (2); Regeneron (5); Regulus (5); Taiwan Landon-Cardinal, Océane, MD Liposome (5); Thusane Astellas (5); UCB (2) 1060. B-cell-rich Inflammatory Myopathies in Adults: Striking Association with Connective Kwok, Timothy, MD Tissue Diseases 0330. Musculoskeletal Surgery in Psoriatic 1069. Scleromyositis Is Associated with Nailfold Arthritis: Prevalence and Risk Factors Capillary Abnormalities Compared to Immune- Disclosure: Nothing to disclose Mediated Necrotizing Myopathy 1070. Scleromyositis Is Associated with Distinct Lahiry, Piya, MD, PhD Muscle Vasculopathic Features 1681. Hemophagocytic Lymphohistiocytosis Disclosure: Nothing to disclose (HLH) Gene Variants in Childhood-onset SLE (cSLE) with Macrophage Activation Syndrome Lanzoni, Gloria, MD (MAS) 1172. Cardiovascular involvement as a clue for Disclosure: Nothing to disclose diagnosis of Juvenile Systemic Sclerosis sine scleroderma Lally, Brianna, BS Disclosure: Nothing to disclose 1816. Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis Larid, Guillaume, MSc Disclosure: Nothing to disclose 1857. KIR3DL2 Is Not Overexpressed on CD4+ T Cells and NK Cells in Patients with Axial Lammi, Matthew, MD Spondyloarthritis csDMARD and bDMARD Naive 1381. Real-World Mono-, Double and Triple Disclosure: Nothing to disclose Combination Treatment Patterns with Macitentan in Patients with Pulmonary Arterial Larosa, Maddalena, MD Hypertension Associated with Connective Tissue 1501. Obstetrical Outcome and Thromboses in a Disease (PAH-CTD): Evidence from the Combined Multicentric Cohort of Antiphospholipid OPUS/OrPHeUS Dataset Syndrome (APS) Patients with Severe Disclosure: Nothing to disclose Preeclampsia: An Analysis of APS Classification

61

Criteria Lebwohl, Mark, MD Disclosure: Nothing to disclose 1631. No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Laurynenka, Viktoryia, PhD Analyses of the Tildrakizumab Psoriasis Clinical 0495. Epstein Barr Virus (EBV), an Etiologic Program Factor for Systemic Lupus Erythematosus (SLE), Disclosure: AbbVie (2); Aditum Bio (5); Allergan Interacts with SLE Risk Loci Through EBV- (5); Almirall (5); Amgen (2); Arcutis (2, 5); Avotres encoded Transcription Co-factors (co-TFs) Therapeutics (5); BirchBioMed Inc. (5); BMD Disclosure: Nothing to disclose skincare (5); Boehringer Ingelheim (2, 5); Bristol- Myers Squibb (5); Castle Biosciences (5); Corrona Lavery, Criswell (5); Dermavant (2, 5); Eli Lilly (2); Evelo (5); 1605. Knowledge of Biosimilars and Perceptions Facilitate International Dermatologic Education of Biosimilar Naming Conventions in Clinical (5); Foundation for Research and Education in Practice Dermatology (5); Incyte (2); Inozyme Pharma (5); Disclosure: Nothing to disclose Janssen Research & Development, LLC (2); Kyowa Kirin (5); LEO Pharmaceuticals (2, 5); Meiji Seika Law, Jammie, MD Pharma (5); Menlo (5); Mitsubishi (5); Mount 1096. Assessing Interstitial Lung Disease in a Sinai (3); Neuroderm (5); Ortho Dermatologics Racially Diverse Population with Idiopathic (2); Pfizer (2, 5); Promius/Dr. Reddy’s Inflammatory Myositis Laboratories (5); Serono (5); Theravance (5); Disclosure: Nothing to disclose UCB, Inc. (2); Verrica (5)

Lazizi, Selma, MD Leclair, Valérie, MD 1391. Associations Between Autoantibodies in 1081. Patient-reported Outcomes in Early Systemic Sclerosis and Cancer in a National Autoimmune Inflammatory Myopathies Registry Disclosure: Nothing to disclose Disclosure: Nothing to disclose Lee, Eunyoung, MD Le Joncour, Alexandre, MD, MSc 0295. CCL3L3–null Status May Predispose to 0520. Antiphospholipid Antibodies and Systemic Lupus Erythematosus and Non-scarring Thrombotic Events in COVID-19 Patients Alopecia Hospitalized in Medicine Ward Disclosure: Nothing to disclose Disclosure: Nothing to disclose Lee, Hemin, MD Le Pluart, Adrien, MBBS 1001. Risk of Malignant Melanoma and 0630. “No Benefit from a Strict Immobilization in Nonmelanoma Skin Cancer in Rheumatoid Vertebral Osteomyelitis” Vertebral Arthritis Patients Initiating Methotrexate versus Immobilization and Neurological Complication in Hydroxychloroquine Acute Pyogenic Vertebral Osteomyelitis: Disclosure: Nothing to disclose SPONDIMMO, a Prospective Cohort of 250 Patients Lee, Jun, MD Disclosure: Nothing to disclose 0190. Hepatic Steatosis in Rheumatoid Arthritis: Frequency and Disease-Related Contributors Leask, Megan, PhD Disclosure: Nothing to disclose 0659. Polynesian-Specific Gout-Associated Frameshift Variant in PRPSAP1 Lee, Kevin, MD, BSc Disclosure: Nothing to disclose 0114. Incidence of Follow-Up Dual-Energy X-Ray Absorptiometry Scanner Error: A Contributor to

62

Precision Error 1851. Different Disease Activity Trajectories in 1573. Gout as an Immune-Related Adverse Event Early Axial Spondyloarthritis Lead to Significantly from Immune Checkpoint Inhibitors Different Long-term Outcomes : A Cluster-based Disclosure: Nothing to disclose Analysis of the DESIR Cohort Disclosure: Nothing to disclose Lee, Sandy, DO 0060. ANCA-associated Vasculitis in Caucasian Lessard, Christopher, PhD and Hispanics of the Inland Empire of Southern 1954. Genome-wide Association Study of California Sjögren’s Syndrome Identifies Ten New Risk Loci 0592. A Rheumatology-Driven Protocol and 1956. Dysregulated Expression of the Long Non- Treatment Algorithm of SARS-CoV-2 Cytokine coding RNA, LINC01871, Implicated in Sjögren’s Release Syndrome and Its Associated Outcomes Syndrome Pathogenesis Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Lefferts, Adam, BSc Letarouilly, Jean-Guillaume, FCPS 1521. A Novel Gut-joint Migratory TCRab+ Cell 1360. New-Onset Inflammatory Bowel Diseases Subset Relies on sphingosine-1-phosphate for Among IL-17 Inhibitors-Treated Patients: Results Tissue Localization from the Case-Control MISSIL Study Disclosure: Nothing to disclose Disclosure: Pfizer (2)

Legge, Alexandra, MD Leung, Aretina, BA 0271. External Validation of the Systemic Lupus 0150. The Preparation Experience for Total Knee International Collaborating Clinics Frailty Index Arthroplasty of Patients with Osteoarthritis: A (SLICC-FI) as a Predictor of Mortality and Organ Cross-Sectional Survey Damage Accrual in Systemic Lupus Disclosure: Nothing to disclose Erythematosus Disclosure: Nothing to disclose Leung, Jerik, BA 1147. Development of a Digital Toolkit to Leifer, Valia, BA Improve Quality of Life of Patients with Systemic 1960. Cost-effectiveness of Surgical and Non- Lupus Erythematosus: A Pilot Study Surgical Weight Loss Programs for Morbidly Disclosure: Nothing to disclose Obese Patients with Knee Osteoarthritis Disclosure: Nothing to disclose Leverenz, David, MD 1588. A Quality Improvement Project to Improve Lenert, Aleksander, MD, MS, FRCPC Bone Densitometry Ordering in Adult Patients on 1160. Treatment Intensity and Impact on Bone Chronic Glucocorticoids Lesion Evolution and Distribution Patterns in 1591. A Quality Improvement Project to Increase Severe Chronic Recurrent Multifocal Vitamin D Prescribing for Pediatric Patients on Osteomyelitis Glucocorticoids Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Lenfant, Tiphaine, MD Levescot, Anais, PhD 0452. Recombinant Zoster Vaccine in Patients 1410. Resident Memory T Cells Persist in Joints with Rheumatic Diseases: A Retrospective Study of Anakinra-Treated Mice in Spontaneous of 622 Patients Arthritis Model Disclosure: Astellus (8) Disclosure: Nothing to disclose

Leslie, Benattar, MD Levin, Robert, MD

63

0138. Alignment and Discordances in Treatment Disclosure: Arthritis Foundation (2); CARRA (9, Perceptions and Shared Decision-Making Among Chair of SVARD Research Committee - 10% salary RA Patients and Rheumatology Care Teams support for administrative duties)); Merck (3); Disclosure: Abbvie (2, 8); Exagen (5, 8); Janssen Scleroderma Foundation (2); UpToDate (7, (5); Lilly (2); Myriad (2, 5); Pfizer (2); Sanofi (8); UpToDate Section Editor) Takeda (2) Li, Yan, MD Levinson, Justin, MD, MBA 1047. Prospective Analysis of a Cohort of 0094. Validation Study of Proposed Diagnostic Patients with Interstitial Lung Disease Associated Criteria for Sympathetic Joint Effusion with Connective Tissue Disease and Their Disclosure: Nothing to disclose Response to Immunosuppression with Mycophenolate Mofetil and Rituximab Lévy, Dan Disclosure: Nothing to disclose 1917. In Myositis Patients, Sjögren’s Syndrome Is Associated with Inclusion Body Myositis and with Li, Yubin, PhD anti-cN1A Antibody Independently of the 1087. Plasma-derived Extracellular Vesicles Myositis Subgroups Induced STING-mediated Proinflammatory Disclosure: Nothing to disclose Effects in Dermatomyositis Disclosure: Nothing to disclose Lew, Daphne, PhD, MPH 1299. Longitudinal Patterns of Anxiety Li, Zhixiu, PhD Symptomology Among Patients with Systemic 1875. Heterogeneity Amongst Men and Women Lupus Erythematosus (SLE) Remain Stable over with Ankylosing Spondylitis and Non- Time and Do Not Associate with SLE Disease Radiographic Axial Spondyloarthritis Activity 1899. Life Expectancy a Swiss Cohort of Patients Disclosure: Nothing to disclose with Ankylosing Spondylitis: A 35-Year Follow-up Study Lewis, Cara, PhD Disclosure: Nothing to disclose 0537. Hip Abductor Strength and Its Association with New or Worsening Knee Pain: The MOST Lieber, Sarah, MD, MS Study 1269. Evaluation of a Patient-reported Frailty Disclosure: Nothing to disclose Tool in Women with Systemic Lupus Erythematosus Li, Jing, MPH 1284. Application of a Novel Method for 0046. Socioeconomic Disparities in Functional Determination of Muscle Mass Relative to Fat Status Among RA Patients: A Longitudinal Mass in Women with Systemic Lupus Analysis Using RISE Data Erythematosus and Association with Disability Disclosure: Nothing to disclose 1285. Association of Frailty with Disability Is Not Attenuated by Lean Body Mass in Women with Li, Suzanne, MD, PhD SLE 1167. Capturing the Range of Disease Disclosure: Nothing to disclose Involvement in Localized Scleroderma: The Total Morbidity Score Liem, Sophie, MD 1168. Reliability and Validity of a New Skin 1384. Usage, Needs and Preferences Regarding Activity Measure for Localized Scleroderma in Patients with Systemic 1991. Abatacept Treatment Reduces Cutaneous Sclerosis and Joint Activity in Juvenile Localized 1385. Physical Therapy in Patients with Systemic Scleroderma Sclerosis: The Perspective of Physical Therapists

64

on Current Delivery and Educational Needs Lima, Kaitlin, MD Disclosure: Nothing to disclose 1263. Association of the Systemic Lupus International Collaborating Clinics Frailty Index Liew, David, MBBS, FRACP (SLICC-FI) and Damage Accrual in Long Standing 1580. Generalized Immune Activation in Systemic Lupus Erythematosus Structures Related to PMR or GCA on PET/CT 1790. Association of Telomere Length and the Assessment Does Not Occur in Immune Systemic Lupus International Collaborating Checkpoint Inhibitor-Treated Patients Who Do Clinics Frailty Index (SLICC-FI) in Long Standing Not Go on to Develop Rheumatic Immune- Systemic Lupus Erythematosus Related Adverse Events Disclosure: Nothing to disclose Disclosure: Nothing to disclose Liphardt, Anna-Maria, PhD Liew, Jean, MD 0337. Similar Impact of Psoriatic Arthritis and 1112. Relationship of Depth-Specific Rheumatoid Arthritis on Objective and Subchondral Bone Mineral Density and Pain in Subjective Parameters of Hand Function Knee Osteoarthritis: The Multicenter Disclosure: Abbvie Deutschland GmbH & Co KG Osteoarthritis Study (8); Meda Pharma GmbH & Co KG (5); Novartis 1883. Exercise Partially Explains the Impact of Pharma GmbH (2) Body Mass Index on Disease Activity in Ankylosing Spondylitis Lipsky, Peter, MD 1884. Disease Activity in an Axial 0685. The Impact of Azathioprine on the Spondyloarthritis Cohort During the COVID-19 Frequency of Persistent Responsiveness to Pandemic Pegloticase in Patients with Chronic Refractory Disclosure: Nothing to disclose Gout 0851. Iberdomide Decreases B Cells and Lillegraven, Siri, MD, PhD, MPH Plasmacytoid Dendritic Cells, Increases 2010. Stable versus Tapered and Withdrawn Regulatory T Cells and IL-2, and Has Enhanced Treatment with Tumor Necrosis Factor Inhibitor Clinical Efficacy in Active Systemic Lupus in Rheumatoid Arthritis Remission: A Erythematosus Patients with High Aiolos or the Randomized, Open-Label, Phase 4, Non- IFN Gene Expression Signature Inferiority Trial 1847. Delayed and Immediate Release Disclosure: Nothing to disclose Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus Lim, Chong Seng Edwin, MD Disclosure: Horizon Therapeutics (3) 1309. Prevalence of Undiagnosed Axial Spondyloarthritis Among Patients with Littlejohn, Geoffrey, MBBS Inflammatory Bowel Disease: A Secondary Care 0817. Uptake of Janus Kinase Inhibitors for Cross-Sectional Study Management of Rheumatoid Arthritis in Disclosure: Nothing to disclose Australia Disclosure: AbbVie (5); BMS (5); Janssen (5); MSD Lim, S. Sam, MD, MPH (5); Pfizer (5); Roche (5); Seqirus (5) 1275. Unexpected Changes in Physical and Psychological Measures Among Georgia Lupus Liu, Bonnia, MD, BSc Patients During the Early Weeks of the COVID-19 0635. Hydroxychloroquine Is Not Associated with Pandemic in the United States, March 30–April Reduced Influenza Admissions in Rheumatoid 21, 2020 Arthritis Patients Disclosure: Nothing to disclose Disclosure: Nothing to disclose

65

Liu, Ming-Lin, MD, PhD Arterial Stiffness, and Subclinical Atherosclerosis 0845. Hematopoietic Specific Deficiency of Rho Disclosure: Nothing to disclose Kinase Attenuates Neutrophil NETosis and UVB- induced Skin Inflammation Loeser, Richard, MD Disclosure: Nothing to disclose 1491. Association of a Leaky Gut but Not Microbial Dysbiosis with Obesity-related OA: A Liu, Tian, MD Translational Study 0025. Clinical and Psychological Assessment of Disclosure: Bioventus (2); Unity Biotechnology (5) Rheumatoid Arthritis Patients with Fibromyalgia: A Real World Study Loeuille, Damien Disclosure: Nothing to disclose 1108. Cartilage Biomarkers s-Coll2-1 and s-Coll2- 1NO2 Are Associated with Knee Osteoarthritis Llop Vilaltella, María, MD MRI Features and Predict Disease Worsening 1895. Radiographic Progression in Patients with Disclosure: Nothing to disclose Axial Spondyloarthritis Under Treatment with TNF Inhibitors. Data from REGISPONSERBIO Lomzenski, Hannah, MD (Spanish Register of Biological Therapy in 1188. Serum Anti-malondialdehyde- Spondyloarthritides) acetaldehyde IgA Antibody Concentration Disclosure: Nothing to disclose Improves Prediction of Coronary Atherosclerosis Beyond Traditional Risk Factors in Patients with Lo, Grace, MD, MSc Rheumatoid Arthritis 1663. Walking for Exercise May Be Symptom and Disclosure: Nothing to disclose Structure Modifying for Those with Established OA and with Varus Alignment - Data from the Longobardi, Sherri, BS Osteoarthritis Initiative 0997. Novel Shared Antibody Specificities in Ro Disclosure: Takeda Pharmaceuticals (1); Taro Antibody Negative Sjögren’s Syndrome Pharmaceuticals (1); Teva Pharmaceuticals (1); Disclosure: Nothing to disclose XBI Biotech Co (1) López-Gutierrez, Fernando, PhD Loarce Martos, Jesús, MD 0014. Does the Type of Rheumatic Disease or 0629. COVID-19 Among Patients with Immune- Biologic Treatment Increase the Risk of mediated Inflammatory Diseases: A Descriptive Developing Severe COVID-19? Study Disclosure: Nothing to disclose Disclosure: Nothing to disclose Lopez-Hoyos, Marcos Lobo, Gitanjali, MD 0762. Anti-Protein-Arginine Deiminase (PAD) 1 0586. Performance Characteristics of ANA by IgG Is a Promising Novel Autoantigen in Elisa and Immunofluorescence Rheumatoid Arthritis (RA) and Increases Disclosure: Nothing to disclose Diagnostic Performance in Combination with Anti-PAD4 IgG Using a Composite Biomarker Loef, Marieke, MD Score 1488. Application of the Knee Injury and Disclosure: Nothing to disclose Osteoarthritis Outcome Score Percentile Curves on Preoperative and up to 2 Years Postoperative Lopez-Medina, Clementina, PhD Data of Patients Undergoing Total Knee 1028. Probabilistic Linkage of a Cohort of Arthroplasty Individuals with Symptoms Suggestive of Early 1658. Mediation of the Association Between Spondyloarthritis and the French National Obesity and Osteoarthritis by Blood Pressure, Healthcare Database

66

1311. Identification of Clinical Phenotypes in Patients with Axial Spondyloarthritis, Peripheral Lovy, Michael, MD Spondyloarthritis and Psoriatic Arthritis 0090. 110 Patients with Monoclonal According to Peripheral Musculoskeletal Gammopathy of Undetermined Significance Manifestations: A Cluster Analysis in the (MGUS) in a Rheumatology Disease Unit: International ASAS-PerSpA Study Fracture, Neuropathy, and Pernicious Anemia 1879. Development of a Deep Learning Are Clues to Recognition Algorithm to Predict Positive MRI of the 0091. Helicobacter Pylori Infection, Autoimmune Sacroiliac Joints According to the ASAS Definition Disease and Paraproteinemia Influence the in Patients with Recent Axial Spondyloarthritis Presentation of a Cohort of 150 Pernicious 2015. Prevalence and Distribution of Peripheral Anemia Patients Diagnosed in a Rheumatology Musculoskeletal Manifestations in Axial Clinic Spondyloarthritis, Peripheral Spondyloarthritis Disclosure: Nothing to disclose and Psoriatic Arthritis: Results of the International, Cross-sectional ASAS-PerSpA Study Lugo, Salvador, MD Disclosure: Nothing to disclose 1540. Association Between Disease Activity and Left Ventricular Systolic Function in Patients with Lopez-Pedrera, Chary, PhD Rheumatoid Arthritis: A Case-Control Study 1449. Altered Splicing in Leukocytes from Disclosure: Nothing to disclose Patients with Antiphospholipid Syndrome, Systemic Lupus Erythematosus and Luo, Yiming, MD Antiphospholipid Syndrome with Lupus: Clinical 0425. MAGIC Syndrome in a Cohort of Patients Involvement with Relapsing Polychondritis 1811. Distinctive Molecular Signatures Among Disclosure: Nothing to disclose Monocytes from Childhood- and Adult-onset Systemic Lupus Erythematosus: Clinical Luque-Tevar, Maria, MSc Involvement and Relevance of Sustained Anti- 1193. Unsupervised Molecular Profile Clustering dsDNA Positivity in the Serum of Rheumatoid Arthritis Patients Disclosure: Nothing to disclose Identifies Groups with Differential CV-risk SCORE: Modulation by Biological Therapies Louis-sidney, Fabienne 2004. Circulating Biomolecules as Potential 0699. Lumbar Spine Stenosis Treatment : Is Biomarkers of Early and Establishedresponse to Surgery Better Than Medical Treatment in Afro- TNFi Therapy in Rheumatoid Arthritis Patients Descendant Populations ? Disclosure: Nothing to disclose Disclosure: Nothing to disclose Luquini Pereira, Andre Luiz, MD Lovell, Daniel J., MD, MPH 1467. Effectiveness of the Making It Work™ 0713. Longitudinal Effectiveness of Abatacept in Program at Improving Presenteeism and Work JIA: Results from an Ongoing JIA Registry Cessation in Workers with Inflammatory Arthritis 0714. Response to Abatacept in JIA Categories: – Results of a Randomized Controlled Trial Results from the PRCSG/PRINTO JIA Abatacept Disclosure: Nothing to disclose Phase IV Registry Disclosure: Abbott (5); AbbVie (2); Amgen (5); Luttrell-Williams, Elliot AstraZeneca (5); Boehringer Ingelheim (5); 0870. Hydroxychloroquine Is Associated with Bristol-Myers Squibb (2); Celgene (5); Forest Lower Platelet Activity and Improved Vascular Research (5); GlaxoSmithKline (5); Janssen (2); Health in Systemic Lupus Erythematosus Novartis (2, 5); Pfizer Inc (2, 5); Roche (2, 5); Disclosure: Nothing to disclose Takeda (5); UBC (2, 5); Wyeth (5)

67

Ma, Zechen 0530. Pediatric APS: Clinical Features, 1719. Prevalence and Trajectory of Erosions, Therapeutic Interventions, and Damage in a Synovitis, and Bone Marrow Edema in Feet of Series of 22 Cases Patients with Early Rheumatoid Arthritis Disclosure: Nothing to disclose Disclosure: Nothing to disclose Magder, Laurence, PhD MacDonald, Thomas, MD, FRCP 0847. Impact of Hydroxychloroquine Treatment L08. Long Term Cardiovascular Safety of on Immunologic Markers in SLE Depends on Febuxostat and Allopurinol in Patients with Ethnicity Chronic Gout: The Febuxostat versus Allopurinol Disclosure: Nothing to disclose Streamlined Trial (on Behalf of the FAST Investigators) Magrey, Marina, MD Disclosure: Amgen (2) 0056. Role of Socioeconomic and Cultural Factors in Racial Disparities in Disease Severity MacFarlane, Lindsey, MD, MPH and Health Status of Patients with Axial 1655. Pain Reduction Post Total Knee Spondyloarthritis Replacement in Opioid Users and Non-users 0361. Response to Treatment with Ixekizumab in Disclosure: Amgen (2); Flexion (2, 5); Samumed Patients with Active Non-Radiographic Axial (2) Spondyloarthritis Based on HLA-B27 Status and Disease Duration Mackay, Kirsten, MD 0876. Gender Differences in Baseline Clinical 0578. Going Digital Due to COVID 19 Crisis: A Characteristics Among Patients with Ankylosing Rapid Reorganisation of Medication Clinics Spondylitis and Non-radiographic Axial 0615. Rheumatology Going Digital: Developing a Spondyloarthritis: Data from 3 Randomized Rheumatology App for Use by All Patients Ixekizumab Controlled Trials Attending Our Department to Aid Remote Disclosure: AbbVie (2); Amgen (2); Eli Lilly (5); Working and Self-management Janssen (5); Novartis (5); Pfizer (5); UCB (2) Disclosure: Nothing to disclose Maguire, Sinead, MD MacLauchlan, Susan, PhD 1323. Pregnancy in Axial Spondyloarthropathy: A 0074. The Intracellular DNA Sensor STING Systematic Review & Meta-Analysis Protects Against Bone Loss Through Regulation 1887. Spinal Mobility and Function: How Closely of Type I Interferons Do They Associate in Axial Spondyloarthropathy? Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Maddukuri, Spandana, BS Maheswaranathan, Mithu, MD 1949. CB2 Receptor Distribution and Effects of 0248. Assessment of Lupus Knowledge Through LenabasumTM in Dermatomyositis In Vitro Creation of the Lupus Knowledge Assessment Disclosure: Nothing to disclose Test (LKAT) 1127. Association of Health Literacy and Madenidou, Anastasia- Vasiliki, MD, MSc Numeracy with Patient Reported Psychological 0108. The Relationship Between Body Fat Outcomes Percentage and Bone Mineral Density in 1131. Patient Perspective of Helpfulness of Rheumatoid Arthritis Patients Lupus Medications: A Qualitative Study of Disclosure: Nothing to disclose Medication Use Within the Type 1 and 2 SLE Model Madison, Jacqueline, MD 1583. Impact of Telehealth Implementation on Practice Patterns and Electronic Health Record

68

Utilization During COVID19 Axial Spondyloarthritis Disclosure: Nothing to disclose 2020. Preliminary Definition of a Positive MRI for Structural Lesions in the Sacroiliac Joints in Axial Mahmood, Shereen, MD Spondyloarthritis 0051. COVID-Related Distress and Mental Health 2024. Effects of Filgotinib on Spinal Lesions in in Adult Rheumatology Patients During the Patients with Ankylosing Spondylitis: Magnetic COVID-19 Pandemic Resonance Imaging Data from the Placebo- Disclosure: Nothing to disclose Controlled, Double‑Blind, Randomized TORTUGA Trial Mahmud, Reshad, MD Disclosure: AbbVie (2, 5); Boehringer Ingelheim 0932. Skeletal Muscle Involvement in Systemic (5); Galapagos (5); Gilead (5); Janssen (5); Lilly Sclerosis Predisposes to Severe Gastrointestinal (5); Novartis (2, 5); Pfizer (2, 5); UCB Pharma (5) Tract and Cardiac Muscle Disease Disclosure: Nothing to disclose Manion, Kieran, PhD 0302. Longitudinal Study of Acute SLE Flare Makowska, Joanna Reveals Dynamic Changes in Multiple Immune 1559. Fully Automatic Assessment of Nail Fold Cell Subsets Capillaroscopy Software - Early Results 0303. SLE Patients Stratify into Distinct Clusters Disclosure: Nothing to disclose Based on Their Peripheral Blood Immunologic Phenotype During Acute Flare Maksymowych, Walter, MD, FRCPC Disclosure: Nothing to disclose 0341. Metabolomics Profiling of Human Serum for Discovering Biomarkers to Diagnose Psoriatic Mar, Diane, MD Arthritis and Ankylosing Spondylitis with High 0394. Prevalence of a Diagnosis of Specificity Osteopenia/Osteoporosis Amongst Patients with 0363. Efficacy of Ixekizumab on Disease Activity Systemic Sclerosis and Identification of and Quality of Life in Patients with Active Associated Clinical Factors Nonradiographic Axial Spondyloarthritis and Disclosure: Nothing to disclose Objective Signs of Inflammation, Stratified by Baseline CRP/Sacroiliac Joint MRI Status Marchand, Nathalie, ScD 0911. Impact of Filgotinib on Structural Lesions 1003. Long-term Weight Changes and Risk of in the Sacroiliac Joints at 12 Weeks in Patients Rheumatoid Arthritis Among Women in a with Active Ankylosing Spondylitis: Correlation Prospective Cohort: A Marginal Structural Model with Clinical Endpoints Approach 1347. Predictors of Response in Patients with 1463. Threshold Level for Long-term Healthy Diet Non-Radiographic Axial Spondyloarthritis Adherence to Reduce the Risk of Rheumatoid Receiving Certolizumab Pegol in the C-axSpAnd Arthritis Among Women in a Prospective Cohort Study Using a Marginal Structural Model Approach 1877. Diagnosis of Axial Spondyloarthritis: A Disclosure: Pritikin Longevity Center (9, Nutrition Primary Unmet Educational Need for Consulting) Rheumatologists Is Interpretation of MRI 1878. Consensus Definitions for MRI Lesions in Marco, Joanna, MD the Spine of Patients with Axial 1052. Connective Tissue Disease-Related Spondyloarthritis: First Analysis from the Interstitial Lung Disease in American Assessments in SpondyloArthritis International Indian/Alaska Native People in Alaska Society Classification Cohort 1244. Clinical Characteristics and Outcomes in 2019. Preliminary Definition of a Positive MRI for Patients with Primary Sjögren’s Syndrome- Active Lesions in the Sacroiliac Joints Typical of

69

Associated Interstitial Lung Disease 383 Patients from a Single University Hospital Disclosure: Nothing to disclose 1638. Systemic Treatment in Behçet’s Disease According to Clinical Phenotypes. Study of 111 Marino, Achille, MD Patients 1247. Features of Childhood Sjogren’s Disclosure: Lilly (2) Syndrome: A Literature Review Based Cohort Disclosure: Nothing to disclose Martinho, Joana, MD 1943. The Prevalence of Anxiety and Depression Markiewicz, Margaret, MD in Patients with Giant Cell Arteritis 1820. Serum α-Klotho Is Decreased in Older 1947. Risk Factors for Anxiety and Depression in Systemic Lupus Erythematosus Patients and Patients with Giant Cell Arteritis Correlate with Markers of Disease Activity Disclosure: Nothing to disclose Disclosure: Nothing to disclose Martin-Nares, Eduardo, MD, MSc Marques, Mary Lucy, MD 0417. Different Immunophenotypes 1896. No Relationship Between Lumbar Bone Characterized IgG4-Related Disease Clinical Mineral Density and Syndesmophyte Formation Phenotypes at the Same Level - A Multilevel Analysis in Disclosure: Nothing to disclose Patients with Radiographic Axial Spondyloarthritis Martín-Varillas, Jose Luis, MD Disclosure: Nothing to disclose 0406. Infliximab in Refractory Uveitis Due to Behçet’s Disease: Long Term Follow-up and Martin, Richard, MD, MA Therapy Optimization. Multicenter Study of 103 1707. Development and Delivery of Continuing Caucasian Patients Education Interventions Promoting Shared 1054. Treatment with Certolizumab Pegol in Decision Making in Rheumatoid Arthritis Refractory Uveitis Secondary to Inmune- Disclosure: Abbvie (9, Clinical Trial Contracts); Mediated Inflammatory Diseases. Multicenter Amgen (9, Clinical Trial Contracts); Eli Lilly (9, Study of 39 Patients Clinical Trial Contracts) Disclosure: Nothing to disclose

Martín López, María, PhD Marzaioli, Viviana, PhD 0902. Impact of Dose Escalation of Secukinumab 0075. CD209+/CD14+ Dendritic Cells in Patients with Psoriatic Arthritis in Real-World Characterization in Rheumatoid versus Psoriasis Setting Arthritis Patients Disclosure: Nothing to disclose 1133. Patient Perceptions of Diagnosis, Tests, Treatments, Adherence and the Impact on Their Martinez-Lopez, David Disease Understanding and Participation in 0092. Diagnosis of Behçet’s Disease: Comparison Research Studies of Two Sets of Classification Criteria. Application Disclosure: Nothing to disclose in 111 Patients of a Well-defined Population Disclosure: Lilly (2) Marzo-Ortega, Helena, PhD 0364. Subcutaneous Secukinumab 150 Mg Provides Sustained Relief in Total and Nocturnal Martinez-Lopez, David Back Pain, Morning Stiffness, Fatigue, and Low 1033. Systemic Treatment in Sarcoidosis. Study Disease Activity in Patients with Active of 377 Patients from a Single University Hospital Ankylosing Spondylitis: End-of-study (5-year) 1036. Ocular Involvement and Treatment in Data from the MEASURE 2 Trial Sarcodosis. Study of 41 Patients of a Series of 1340. Secukinumab Improves Pain, Morning

70

Stiffness, Fatigue and Physical Function in Tumor on Pain in Rheumatic Diseases: A Systematic Necrosis Factor Inhibitor-Naïve Patients with Review and Meta-analysis Non-Radiographic Axial Spondyloarthritis: Disclosure: Abbvie (8); Bristol Myers Squibb (8); Results from a Randomized Controlled Phase III Merck Sharp and Dohme (8); Novartis (8); Pfizer Study (8); Roche and Chugai (8) Disclosure: AbbVie Inc. (5, 8); Celgene (5, 8); Eli Lilly (5, 8); Janssen (2, 5, 8); Novartis (2, 5, 8); Matsui, Toshihiro, MD, PhD Pfizer (5, 8); Takeda Pharmaceutical Company (5, 0183. Incidence of Malignancies in Japanese 8); UCB (5, 8) Patients with Rheumatoid Arthritis: Data from a Large Japanese National Registry Mashayekhi Sardoo, Atlas Disclosure: Astellas (8); Ayumi (8); Chugai (2, 8); 1338. Identification of Muscle Associated Key Daiichi-Sankyo (8); Eli Lilly (8); Ono (8); Pfizer Inc Genes to Support Axial Spondyloarthritis (5, 8); Takeda (8); Tanabe-Mitsubishi (8) Diagnosis by Transcriptomic Approach, the MyoSpA Study Matsumoto, Rachel, MS Disclosure: Nothing to disclose 1704. Identifying Primary Care Clinician Knowledge Gaps and Needs in Rheumatologic Master, Hiral, PhD, PT, MPH, MPT Care for Rural Veterans 1468. The Association of Walking Speed from Disclosure: Nothing to disclose Short- and Standard-Distance Tests with Mortality Risk Among Adults with Radiographic Matteson, Eric, MD, MPH Knee Osteoarthritis: Data from Johnston County 1048. Reduced Decline in Forced Vital Capacity in Osteoarthritis Project, Osteoarthritis Initiative Patients with Progressive Fibrosing Autoimmune and Multicenter Osteoarthritis Stu Disease-Related Interstitial Lung Diseases (ILDs) Disclosure: Nothing to disclose Treated with Nintedanib Disclosure: Arena Pharmaceuticals (5); Mathew, Ashish, MD Boehringer Ingelheim (5); Gilead (5); Simply 0375. Efficacy of Disease Modifying Anti- Speaking (8); TympoBio (5); Up-to-date (7) Rheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort Matthijssen, Xanthe, MD Disclosure: Nothing to disclose 0444. Chronological Order of Decrease of Synovitis, Osteitis and Tenosynovitis in Early Mathew, Stephanie, DO Arthritis Patients Receiving First DMARD- 1601. Pilot Testing Supports Utility of a Point-of- treatment Care Dashboard to Enhance Patient and Clinician Disclosure: Nothing to disclose Partnerships in the Management of RA Disclosure: Nothing to disclose Matza, Mark, MD, MBA 1480. Abatacept for the Treatment of IgG4- Mathias, Lauren, MD Related Disease 0525. Epidemiology of Thromboembolic 1946. Fast-Track Giant Cell Arteritis Clinic Complications Among Hospitalized Patients with Experience in the United States Antiphospholipid Syndrome in the United States Disclosure: Nothing to disclose Disclosure: Nothing to disclose Mayer, Adam, MD Mathieu, Sylvain 0403. Comparison of Immediate Post-Operative 0185. Prevalence of Migraine and Neuropathic and Long-Term Outcomes in Aortitis and Non- Pain in Rheumatic Disease Inflammatory Thoracic Aortic Aneurysms 1202. Cannabis Use Assessment and Its Impact

71

Undergoing Open Surgical Repair Disclosure: Nothing to disclose McFalls, Caya, BS 1911. IL-11 Expression in Systemic Sclerosis McAlindon, Timothy, MD, MRCP, MPH Pulmonary Fibroblasts Is Mediated by Caspase-1 0593. Patient Characteristics and Factors Disclosure: Nothing to disclose Affecting Decision-Making Regarding Total Knee Replacement by Different Types of McGonagle, Dennis, PhD, MB, FRCPI Treating Patients with Knee OA 0895. Effects of Guselkumab, a Monoclonal 1123. The Patient Journey in Knee OA: Variations Antibody That Specifically Binds to the p19- in Patient Characteristics and Treatment by Subunit of Interleukin-23, on Dactylitis and Physician Specialty Enthesitis in Patients with Active Psoriatic Disclosure: Anika Therapeutics (5); Kiniksa Arthritis: Pooled Results Through Week 24 from Pharmaceuticals (5); Kolon Tissuegene (5); Pfizer Two Phase 3 Studies (5); Samumed (5); Sanofi Aventis US (5); 1359. Targeted Serum Proteomic Analysis Seikagaku (5) Following Upadacitinib Treatment in Ankylosing Spondylitis Shows Robust Suppression of Innate McClung, Michael, MD and Adaptive Immune Pathways with Tissue 0101. Romosozumab After Denosumab Improves Repair Modulation Lumbar Spine and Maintains Total Hip Bone Disclosure: AbbVie Inc. (2, 8); Janssen Research & Mineral Density in Postmenopausal Women with Development, LLC (2) Low Bone Mass Disclosure: Amgen Inc. (5, 8); Myovant (5) McInnes, Iain, FRCP 0506. Efficacy and Safety of Guselkumab, a McColl, Jeanine, MD Monoclonal Antibody Specific to the p19-Subunit 1683. Ready or Not? Measuring Readiness for of Interleukin-23, Through Week 52 of a Phase 3, Transition to Adult Care in Adolescents with JIA Randomized, Double-blind, Placebo-controlled & jSLE Study Conducted in Biologic-naïve Patients with Disclosure: Nothing to disclose Active Psoriatic Arthritis 0875. Secukinumab Provides Sustained McCormick, Natalie, PhD, MSc Improvements in Subgroup Analyses of Joint 0672. Prospective Study of the Patterns of Joint Tenderness and Swelling in Patients with Involvement for Sequential Gout Flares Psoriatic Arthritis: 5‑Year Results from the Phase 1472. Assessing Causal Associations of Urate 3 FUTURE 2 Study Levels with Type 2 Diabetes and Related 0896. Impact of Upadacitinib on Reducing Pain in Glycemic Traits Using Bidirectional Mendelian Patients with Active Psoriatic Arthritis: Results Randomization from Two Phase 3 Trials in Patients with Disclosure: Nothing to disclose Inadequate Response to Non-biologic or Biologic DMARDs McCoy, Sara, MD, MS 0909. Residual Disease Activity in Psoriatic 1245. Smoking Might Reduce Odds of Sjӧgren’s Arthritis Patients Treated with Secukinumab and Syndrome Among Rheumatoid Arthritis Patients Adalimumab Who Achieved Remission or Low 1255. Sjӧgren’s Syndrome Minor Salivary Gland Disease Activity: Results from a Phase 3b, Mesenchymal Stromal Cells Derived Deploy Randomized, Double-blinded, Active-controlled, Intact Immune Plasticity and Display Head-to-head Study Myofibroblast-Like Properties 2026. Efficacy and Safety of Upadacitinib versus 1504. Four Distinct Symptom-Based Clusters Placebo and Adalimumab in Patients with Active Identified from the Sjӧgren’s Foundation Survey Psoriatic Arthritis and Inadequate Response to Disclosure: Bristol-Myers Squibb (5); Novartis (2) Non-Biologic Disease-Modifying Anti-Rheumatic

72

Drugs: A Double-Blind, Randomized Controlled Randomized, Open-Label Phase 4 Study Phase 3 Trial 0873. Impact of Skin Involvement on Disease Disclosure: AbbVie (9, Personal fees); Burden Among Patients with Psoriatic Arthritis: AstraZeneca (2); Boehringer Ingelheim (2); Bristol Data from the Corrona Psoriatic Myers Squibb (2, 9, Personal fees); Celgene (9, Arthritis/Spondyloarthritis Registry Personal fees); Janssen (2, 9, Personal fees); LEO 0884. Comparison of Disease Control Thresholds (9, Personal fees); Lilly (9, Personal fees); in Psoriatic Arthritis: Results from the Corrona Novartis (9, Personal fees); UCB (2, 9, Personal Psoriatic Arthritis/Spondyloarthritis Registry fees) 0890. Ixekizumab Treatment Improves Fatigue, Spinal Pain, Stiffness, and Sleep in Patients with McKenna, Dr Sean, PhD, BSc, MBA Nonradiographic Axial Spondyloarthritis 0134. The Impact of Exercise on Sleep in People 0905. Probability of Achieving Low Disease with Rheumatoid Arthritis: A Pilot Randomised Activity or Remission with Apremilast Treatment Controlled Trial Among DMARD-Naive Subjects with Active Disclosure: Nothing to disclose Psoriatic Arthritis 0910. Effect of Filgotinib on the Complete Mease, Philip, MD Resolution of Enthesitis in Psoriatic Arthritis 0334. Comparative Efficacy of Guselkumab in (PsA) Patients: 52-week Results from EQUATOR2 Patients with Psoriatic Arthritis: Results from 1343. Early Real-World Experience of Tofacitinib Systematic Literature Review and Network Meta- for Psoriatic Arthritis: Data from a United States Analysis Healthcare Claims Database 0346. Safety Profiles of Ixekizumab versus 1355. Characterization of Remission in Patients Adalimumab: 52-Week Results from a Head-to- with Psoriatic Arthritis Treated with Head Comparison in Patients with Active Upadacitinib: Post-hoc Analysis from Two Phase Psoriatic Arthritis 3 Trials 0359. Clinical Characteristics of Psoriatic Arthritis 1356. Efficacy of Upadacitinib in Patients with Patients with Physician-Identified Spondylitis, Psoriatic Arthritis Stratified by Number of Prior According to HLA-B27 Status: An Analysis from Biologic Disease-modifying Anti-rheumatic Drugs the Corrona Psoriatic Arthritis/Spondyloarthritis 2017. Machine Learning Identifies an Association Registry Between Pre-existing Radiographic Damage and 0366. Symptoms of Peripheral Arthritis Are Long-term Clinical Outcomes with Secukinumab Significantly Improved in Patients with Therapy in Patients with Psoriatic Arthritis Ankylosing Spondylitis Treated with 2025. Efficacy of Guselkumab, a Monoclonal Secukinumab Antibody That Specifically Binds to the p19 0379. Achievement of RAPID3 and cDAPSA Subunit of IL-23, on Axial-Related Endpoints in Treatment Targets Is Associated with Control of Patients with Active PsA with Imaging-Confirmed Articular and Extra-Articular Manifestations of Sacroiliitis: Week-52 Results from Two Phase 3, Active Psoriatic Arthritis in DMARD-Naive Randomized, Double-blind, Plac Patients Treated with Apremilast 2027. Efficacy and Safety of Tildrakizumab, a 0504. Efficacy and Safety of Upadacitinib in High-Affinity Anti–Interleukin-23p19 Monoclonal Patients with Active Psoriatic Arthritis and Antibody, in Patients with Active Psoriatic Inadequate Response to Biologic Disease- Arthritis in a Randomized, Double-Blind, Placebo- Modifying Anti-Rheumatic Drugs: A Double- Controlled, Multiple-Dose, Phase 2b Study Blind, Randomized Controlled Phase 3 Trial Disclosure: AbbVie (2, 5, 8); Amgen (2, 5, 8); 0508. Maintenance or Achievement of Minimal Bristol-Myers Squibb (2, 5); Eli Lilly (2, 5, 8); Disease Activity Following Therapy Optimization Galapagos (5); Gilead (2, 5); GlaxoSmithKline (5); with Adalimumab or Methotrexate in Patients Janssen (2, 5, 8); Novartis (2, 5, 8); Pfizer Inc (2, with Psoriatic Arthritis: Results from Part 2 of a 5, 8); Sun (2, 5); UCB (2, 5

73

Meier, Megan, MD Medina Cintrón, Nicolle, MD 1387. Should Systemic Sclerosis Patients with 0631. Clinical Manifestations and Outcomes in Low Bicarbonate Have Replacement to Prevent DMARD-Naïve Patients with Chronic Renal Dysfunction? Chikungunya Arthritis Disclosure: Nothing to disclose Disclosure: Nothing to disclose Meißner, Yvette, MS Meednu, Nida, PhD 1498. Pregnancy Outcomes in Patients with Axial 0974. Role of NR4A Nuclear Receptor Family in Spondyloarthritis – a First Analysis of a European RA Synovial Ectopic Lymphoid Neogenesis Collaboration of Pregnancy Registries Revealed by Single Cell Profiling Disclosure: Pfizer (8) Disclosure: Nothing to disclose Mendel, Arielle, MD, FRCPC, MSc Mehta, Bella, MS, MBBS 1589. An Initiative to Improve Timely 0005. Geographical Variations in COVID-19 Glucocorticoid Tapering in Vasculitis Perceptions and Patient Management: A Disclosure: Nothing to disclose National Survey of Rheumatologists 1119. Association of Primary Insurance Status on Mendoza-Pinto, Claudia, MD Bilateral Knee Arthroplasty Utilization and 1259. The Impact of Antimalarial Agents on Complications: A United States Nationwide Traditional and Non-traditional Cardiovascular Analysis Markers in Patients with Systemic Lupus 1653. Bilateral vs Unilateral Total Knee Erythematosus: A Systematic Review and Meta- Arthroplasty: Racial Variation in Utilization and analysis In-Hospital Major Complication Rates Disclosure: Nothing to disclose Disclosure: Novartis (5) Merjanah, Sali, MD Mehta, Pankti, MD 1326. Malignancy Risk Among Patients with 1277. Low Cost Composite Markers to Ankylosing Spondylitis in the United States: A Differentiate Infection from Disease Activity in a Population-Based National Study Febrile Patient with Systemic Lupus Disclosure: Nothing to disclose Erythematosus Disclosure: Nothing to disclose Merkel, Peter, MD, MPH 0432. The Effect on Renal Function of the Mehta, Sonya, MD Complement C5a Receptor Inhibitor Avacopan in 1934. What Is the Significance of Periarterial ANCA-Associated Vasculitis Temporal Small Vessel Inflammation (SVI) on Disclosure: AbbVie (5); AstraZeneca (2, 5); Biogen Temporal Artery Biopsy (TAB) in the Diagnosis of (5); Boeringher-Ingelheim (2, 5); Bristol-Myers Vasculitis? A Systematic Review and Meta- Squibb (2, 5); Celgene (2, 5); ChemoCentryx (2, analysis 5); CSL Behring (5); Forbius (2, 5); Disclosure: Nothing to disclose Genentech/Roche (2, 5); Genzyme/Sanofi (2, 5); GlaxoSmithKline (2, 5); InflaRx (2, 5); Insmed (5); Meier, Florian, MD Jannsen (5); Kiniksa (5); Magenta (5); Novartis 0599. Evaluation of Telephone Consultations in (5); Pfizer (5); Sparrow (5); Talaris (5); UpToDate Germany as an Additional Tool in Outpatient (7) Rheumatology Clinics During the COVID-19 Pandemic Merola, Joseph, MD, MSc Disclosure: Nothing to disclose 0328. Healthcare Utilization and Costs Among Patients with Psoriatic Arthritis and Psoriasis in

74

the United States – a Retrospective Study of 0653. Nutrient Content of Gout Flare Trigger Claims Data from 2009 to 2020 Foods 0378. Itch as the Major Mediator of the Effect of 0951. The Comparative Effect of Exposure to Tofacitinib on Health-Related Quality of Life in Various Risk Factors on the Risk of Psoriatic Arthritis: A Mediation Analysis Hyperuricaemia: Diet Has a Weak Causal Effect 1352. Bimekizumab Maintenance of Response in Disclosure: Nothing to disclose Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Meyer, Sara Eileen, BA Open-Label Extension 1753. Substantial Work Limitations in Patients Disclosure: AbbVie (9, Consultant and/or with Rheumatoid Arthritis Despite Optimal investigator); Aclaris (9, Consultant and/or Treat-to-Target (T2) Drug Therapy Intervention investigator); Almirall (9, Consultant and/or Disclosure: Nothing to disclose investigator); Biogen (9, Consultant and/or investigator); Celgene (9, Consultant and/or Miceli-Richard, Corinne investigator); Dermavant (9, Consultant and/or 1893. Predictors of Response in Secukinumab- investigator); Eli Lilly (9, Consultant and/or treated Patients with Ankylosing Spondylitis: investigator); GlaxoSmithKline (9, Consultant Logistic Regression and Machine Learning and/or investigator); Incyte (9, Consultant and/or Analyses investigator); Janssen (9, Consultant and/or Disclosure: Abbott (8); AbbVie (2, 5); Biogen (2); investigator); LEO Pharma (9, Consultant and/or Bristol-Myers Squibb (2, 8); Merck (2, 5, 8); MSD investigator); Merck (9, Consultant and/or (2); Novartis (2, 5); Pfizer (2, 5, 8); Roche (5, 8); investigator); Novartis (9, Consultant and/or Schering-Plough (8); UCB (2, 5); Wyeth (2, 8) investigator); Pfizer (9, Consultant and/or investigator); Regeneron (9, Consultant and/or Michailidou, Despoina, MD investigator); Samumed (9, Consultant and/or 1567. Association of Blood Count Biomarkers investigator); Sanofi (9, Consultant and/or and Clinical Features with Immune Related investigator); Sun Pharmaceutical (9, Consultant Adverse Events (irAEs) in Patients with Cancer and/or investigator); UCB (9, Consultant and/or Treated with Checkpoint Inhibitors (CPI) investigator) Disclosure: Nothing to disclose

Merrill, Joan, MD Michaud, Kaleb, PhD 0849. Herpes Zoster Events with Anifrolumab in 0012. Experiences of Patients with Rheumatic Patients with Active SLE: An Integrated Analysis Diseases in the US During the Early Months of of Phase 2 and Phase 3 Trials the COVID-19 Pandemic 0866. Identifying an SLE Patient Cluster with 0198. A Prospective Cohort Study of Vehicle Greater Treatment Effect: Immune Cell Control as a Measure of Driving Performance in Deconvolution of Gene Expression in Two Patients with Rheumatoid Arthritis Atacicept Phase II Studies Disclosure: Rheumatology Research Foundation 0987. Efficacy and Safety of Iberdomide in (2) Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Michielsens, C.A.J, PhD Randomized, Placebo-Controlled Study 1362. BASDAI Guided Treat-to-target Tapering of Disclosure: AbbVie (5); Amgen (5); AstraZeneca Tumor Necrosis Factor Inhibitors in Axial (5); Aurinia (5); Bristol Myers Squibb (2, 5); EMD Spondyloarthritis: Results of the Retrospective Serono (5); GlaxoSmithKline (2, 5); Janssen (5); TAPAS Study Provention (5); Remegen (5); UCB (5) Disclosure: Nothing to disclose

Merriman, Tony, PhD Mihai, Carina, MD

75

1386. Clinical Correlates and Relevance of the UCLA GIT 2.0 Instrument for Indication for Mirza, Reza, MD Esophagogastroduodenoscopy and Endoscopic 0281. ANCA in SLE: Prevalence and Predictor Esophagitis in Real-life Patients with Systemic Factors Sclerosis Disclosure: Nothing to disclose Disclosure: Boehringer Ingelheim (5); Geneva Romfarm (9, Congress support); Roche (9, Misztal, Melissa Congress support) 1671. Identifying Rare Genetic Variants in Childhood-onset Monogenic Systemic Lupus Mihailova, Anna, MD, PhD Erythematosus 0099. Interleukin 6 Concentration in Synovial Disclosure: Nothing to disclose Fluid of Patients with Different Types of Arthritis Disclosure: Nothing to disclose Mitchell, Jacob, BSc 0171. Interferon Response Gene Expression Miller, Karla, MD Differs in Whole Blood, Peripheral Blood 1977. Delivering Fracture Prevention Through Mononuclear Cells, Monocytes, T Cells, B Cells, Telemedicine: A Process Evaluation and NK Cells in Patients with the Disclosure: Nothing to disclose Autoinflammatory Interferonopathies, CANDLE and SAVI Miller, Rachel, PhD, BS Disclosure: Nothing to disclose 1972. NGF-Responsive Neurons Are Sensitized in Experimental Osteoarthritis Miwa, Yusuke, MD, PhD Disclosure: Nothing to disclose 1748. Effects of Abatacept and Tumor Necrosis Factor Inhibitor on the Normal Glycosylated Milne, Megan Hemoglobin Level in Patients with Rheumatoid 1124. Improving Documentation Rates of Non- Arthritis Pharmacologic Therapies for Knee Osteoarthritis Disclosure: Nothing to disclose Disclosure: Nothing to disclose Moazzami, Mitra, MS Miloslavsky, Eli, MD 1290. A Multitrait-Multimethod Matrix Approach 1706. Advanced Integrated Science Courses: A to the Construct Validity of Patient Reported Novel Approach to Medical Student Science Outcomes Measurement Information System Education Computerized (PROMIS) Adaptive Tests (CAT) in Disclosure: Nothing to disclose Systemic Lupus Erythematous Disclosure: Nothing to disclose Min, Sarah, MD 0577. Qualitative Review of Unsuccessful Pilot Moghadam-Kia, Siamak, MD, MPH Study of Super-Utilizer Systemic Lupus 1088. Recruitment Rates of Virtual Remote Erythematosus (SLE) Patients Enrollment into Research (Tele-Research) in Myositis Team Based Program to Improve Patient Disclosure: Nothing to disclose Outcomes Disclosure: Nothing to disclose Moghaddam, Bahar, MD 1268. Structural Validity of a Comprehensive Minoia, Francesca, MD Neuropsychological Battery for Assessment of 0729. Morbidity of JIA-associated Uveitis: Half of Cognitive Impairment in Systemic Lupus Patients Despite Systemic Treatment Still Show Erythematosus: Exploratory Factor Analysis Ocular Damage During a Long-term Follow-up Confirms Six Cognitive Domains Disclosure: Nothing to disclose Disclosure: Nothing to disclose

76

Moore, Erica, MS Mohameden, Mosaab, MD 0978. Border-associated Macrophages Drive 0079. Analysis of COVID-19 and Rheumatology Recruitment of Immune Cells into the Choroid Twitter Activity During the Pandemic Months Plexus in Mice with Neuropsychiatric Lupus 1800. Association of Air Pollution with Systemic Disclosure: Nothing to disclose Lupus Erythematosus Disease Activity in the Central Valley of California Morand, Eric, MD, PhD Disclosure: Nothing to disclose 0272. Superior Discrimination Between LLDAS and DORIS Remission with Modification of Mok, Chi Chiu, MD Prednisolone Dose Threshold 1442. Denosumab versus Oral Bisphosphonate 1294. Prediction of Damage in SLE Using for Osteoporosis in Long-term Glucocorticoid Unbiased Analysis of Large Datasets Users: A 12-month Randomized Controlled Trial 1828. Comprehensive Efficacy of Anifrolumab Disclosure: Nothing to disclose Across Organ Domains in Patients with Active SLE: Pooled Data from 2 Phase 3 Trials Molina Collada, Juan, MD Disclosure: AbbVie (5); Amgen (5); AstraZeneca 1539. Diagnostic Value of Ultrasound Halo Count (2, 5, 8); Biogen (5); Bristol-Myers Squibb (2, 5); and Halo Score in Giant Cell Arteritis: A Eli Lilly (2, 5); GlaxoSmithKline (2, 5); Janssen (2, Retrospective Study from Routine Care 5); Merck Serono (2, 5); Neovacs (5); Novartis (8); 1552. Ultrasound Doppler Enthesitis Shows Sandoz (5) Sensitivity to Change After Biological Therapy in Spondyloarthritis and Psoriatic Arthritis Patients Moreno McNeill, David, MD Disclosure: Nothing to disclose 1695. Anti-Melanoma Differentiation Associated Protein 5 (MDA5) Positive Juvenile Molto, Anna, MD Dermatomyositis: Focus on the Lung 1444. Cluster-randomized Pragmatic Clinical Trial Disclosure: Nothing to disclose Evaluating the Potential Benefit of a Tight- control and Treat-to-target Strategy in Axial Moriano Morales, Clara, MD Spondyloarthritis: The Results of the TICOSPA 1283. Factors Affecting Mortality of Systemic Trial Lupus Erythematosus Patients in Spain in the Disclosure: ABBVIE (5); BMS (5, 8); GILEAD (5); 21st Century: Data from the RELESSER Registry LILLY (5); NOVARTIS (5, 8); UCB (5) Disclosure: Nothing to disclose

Monahan, Rory, PhD Morlà, Rosa, PhD 0246. Extreme Fatigue in Patients with Systemic 1733. Patients with Rheumatoid Arthritis and Lupus Erythematosus and Neuropsychiatric Comorbid Depression Have High Levels of Symptoms RAPID3 (Routine Assessment of Patient Index 1264. Mortality in Patients with Systemic Lupus Data) and FAST3 (Fibromyalgia Assessment Erythematosus and Neuropsychiatric Symptoms Screening Index) on a Multidimensional Health Disclosure: Nothing to disclose Assessment Questionnaire (MDHAQ) Disclosure: Nothing to disclose Montero, David, MD 0112. Description of Risk Factors at Baseline and Moser, Franklin Need of Bone Agent According to Hadji 1974. Validation of a Deep Learning Based Recommendations in Patients Taking Aromatase Algorithm to Diagnose Vertebral Compression Inhibitors as Breast Cancer Therapy Fractures Disclosure: Nothing to disclose Disclosure: Nothing to disclose

77

Movahedi, Mohammad, MD, PhD Reference Adalimumab in Patients with 0808. Time to Discontinuation of Tofacitinib and Rheumatoid Arthritis, Axial Spondyloarthritis or TNF Inhibitors in Rheumatoid Arthritis Patients Psoriatic Arthritis with and Without Methotrexate: Real World Disclosure: Biogen (8) Results from a Rheumatoid Arthritis Cohort 0830. Discontinuation Rate of Tofacitinib Is Munguía-Realpozo, Pamela Similar When Compared to TNF Inhibitors in 1821. Early Assessment of Left Ventricular Rheumatoid Arthritis Patients: Real World Assessment Using Speckle Tracking Results from a Rheumatoid Arthritis Cohort Echocardiography and It´s Relationship with 0831. Sociodemographic, Disease, and Insulin Resistance in Women with Systemic Medication Profile of RA Patients Under 65 Years Lupus Erythematosus Compared with 65 Years or Older at Registry Disclosure: Nothing to disclose Enrollment: Real World Results from a Rheumatoid Arthritis Cohort Munoz-Grajales, Carolina, MD Disclosure: Nothing to disclose 0296. Investigating the Differences in ANA Specificities Between Asymptomatic and Mruk, Veronica, MD Symptomatic ANA+ Individuals 1778. Improving Teratogenic Medication Disclosure: Nothing to disclose Consent and Sexual Activity Screening in Adolescent and Young Females: A Pediatric Munroe, Melissa, MD, PhD Rheumatology Reproductive Health Initiative 1511. Clinical Features and Select Dysregulated Disclosure: Nothing to disclose Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Mu, Rong Incomplete Lupus or Classified SLE in the Lupus 1141. Reversing Seasonal Decline of T2 Outcome Autoimmunity in Relatives (LAUREL) Follow-up in RA Patients Under Double Hits by Chinese Cohort New Year and COVID-19 Epidemic via Online 1803. Ability of Innate, Adaptive, and TNF- Interaction with SSDM Superfamily Immune Pathways to Characterize Disclosure: Nothing to disclose Disease Activity and Inform a Refined Lupus Disease Activity Immune in a Confirmatory Mueller, Alisa, MD, PhD Cohort of SLE Patients 0626. Early Rise in CRP Is Associated with Disclosure: Progentec Diagnostics, Inc. (2, 9, Progression to Respiratory Failure and Intubation Salary Support) in COVID-19 Patients Disclosure: Nothing to disclose Murdoch, Rachel, MD 0646. “An Apple Pie a Day Does Not Keep the Mukai, Tomoyuki, MD, PhD Doctor Away”. Fictional Depictions of Gout in 0836. SH3BP2 Deficiency Ameliorates Murine Contemporary Film and Television Systemic Lupus Erythematosus Disclosure: Nothing to disclose Disclosure: AYUMI Pharmaceutical Co. (Individual(s) Involved: Self): 2; Chugai Murillo Saich, Jessica, PhD Pharmaceutical Co. (Individual(s) Involved: Self): 0031. Metabolomics Profiling Predicts Outcome 2 of Tocilizumab in Rheumatoid Arthritis Disclosure: Nothing to disclose Müller-Ladner, Ulf, MD 0805. The PROPER Study: Results of the First Murray, Kieran, MD Interim Analysis of a Pan-EU Real-World Study of 0640. Covid-19 and Rheumatic and SB5 Biosimilar Following Transition from Musculoskeletal Disease Patients: Infection

78

Rates, Attitudes and Medication Adherence Arthritis 0765. High Disease Activity at Baseline and Disclosure: Nothing to disclose Seropositivity Are Associated with Treatment Response at One Year Post Synovial Biopsy in RA Nagel, Johanna, MD, PhD Patients 0456. Reduced Risk of Serious Pneumococcal 0810. Long Term Remission Rates from a Biologic Infection up to 10 Years After Immunization with Clinic: 12 Year Real World Data 7-valent Conjugated Pneumococcal Vaccine in 1786. Reproductive Health Outcomes in Women Patients with Inflammatory Arthritis with RA and PsA Disclosure: Nothing to disclose Disclosure: Nothing to disclose Najjar, Rayan, MBChB, MPH Murray, Meredith 1475. Predictors of Thirty-Day Hospital 1460. “Can I Help You with Your RA Today?”: A Readmissions in Systemic Lupus Erythematosus Pilot Study on the User Experience with a Voice- in the US: A Nationwide Study Enabled Smartphone App to Virtually Monitor Disclosure: Nothing to disclose Disease Activity and Collect ePROs in Rheumatoid Arthritis Nalli, Cecilia, MD Disclosure: Nothing to disclose 0938. Low Preconceptional Complement Level Is Related with an Adverse Obstetric Outcome in a Myasoedova, Elena, MD, PhD Multicentric Cohort of Pregnancy in Patients 1190. Sex Differences in Cardiovascular Disease with APS and aPL Positivity Prevention in Patients with Rheumatoid Arthritis: Disclosure: Nothing to disclose World-wide Data from the SURF-RA 1754. The Point of No Return? Functional Nandedkar-Kulkarni, Neha, PhD Disability in Patients with Rheumatoid Arthritis 0992. Impact of Selective Inhibitors of Nuclear versus the General Population: Results from a Export on SLE Plasma Cells Is Modulated by the Population-based Cohort Study BM Microenvironment 2003. Individualized Prediction of Response to Disclosure: Nothing to disclose Methotrexate Treatment in Patients with Rheumatoid Arthritis: A Pharmacogenomics- Naovarat, Benjamin, MD driven Machine Learning Approach 0628. Factors Associated with Knee Disclosure: Nothing to disclose Osteoarthritis in an Outpatient HIV-1 Clinic over a 26 Year Interval Mysler, Eduardo, MD 0637. Clinical and Treatment Features of 0228. Impact of Upadacitinib or Adalimumab as Rheumatoid Arthritis in HIV-Infected Individuals Initial Therapy on the Achievement of 48-Week Followed Longitudinally over Time Treatment Goals in Patients with Rheumatoid 1872. Relative Associations of Arthritis and Inadequate Response to Sociodemographic, Clinical and HLA-B Alleles Methotrexate: Post Hoc Analysis of a Phase 3 with Enthesitis and Peripheral Arthritis in Study Patients with Ankylosing Spondylitis Disclosure: AbbVie (8); Bristol-Myers Squibb (8); Disclosure: Nothing to disclose Eli Lilly (2, 8); Pfizer Inc (2, 8); Roche (2, 8); Sanofi (8) Napier, Ruth, PhD 0740. Card9 Promotes Th17-mediated Arthritis Nagai, Hideto, MD and Spondylitis via Control of Acute Pathogenic 1950. Elevated Serum Gasdermin D N-terminal Neutrophil Responses in SKG Mice Implicates Macrophage Pyroptosis in Adult-onset 1412. A T Cell Intrinsic Role for Nod2 in Still's Disease and Systemic Juvenile Idiopathic Suppression of Th17-Mediated Experimental

79

Arthritis and Uveitis: Implications for Blau 0679. Epidemiology of Intra-Articular Syndrome Mineralization on Knee Dual-Energy Computed Disclosure: Nothing to disclose Tomography: The Multicenter Osteoarthritis Study Naranjo, Antonio, PhD 1111. Intra-Articular Mineralization on Knee CT 0118. Indicators of Effectiveness After 6 Years of Increases Risk of Knee Pain: The Multicenter Follow-up in a Fracture Liaison Service Osteoarthritis Study Disclosure: Nothing to disclose 1115. The Relation of MRI-Based Cartilage Lesions to Knee Replacement and Knee Pain Nash, Peter, MBBS, FRACP Severity in Osteoarthritis: The Multicenter 0214. Sustainability of Response Between Osteoarthritis Study Upadacitinib and Adalimumab Among Patients 1489. Relation of Pain Mechanisms to with Rheumatoid Arthritis and Prior Inadequate Development of Knee Pain in Osteoarthritis: The Response to Methotrexate Multicenter Osteoarthritis Study 1345. Upadacitinib as Monotherapy and in 1642. Observed Efficacy with Subcutaneous Combination with Non-biologic DMARDs for the Tanezumab Is Early and Maintained in Patients Treatment of Psoriatic Arthritis: Subgroup with Osteoarthritis: Results from a 56-Week Analysis from Two Phase 3 Trials Randomized NSAID-Controlled Study 1368. Proportions of Patients Achieving a Disclosure: EMD Merck Serono (5); Lilly (5); Minimal Disease Activity State upon Treatment Novartis (5); Pfizer/Lilly (5); Regeneron (5) with Tildrakizumab in a Psoriatic Arthritis Phase 2b Study Nerviani, Alessandra, MD, PhD Disclosure: AbbVie (2, 5, 8); Bristol Myers Squibb 0787. MerTK Synovial Expression Correlates with (2, 5, 8); Celgene (2, 5, 8); Eli Lilly (2, 5, 8); Disease Activity and Treatment Response in Janssen (2, 5, 8); Novartis (2, 5, 8); Pfizer (2, 5, 8); Rheumatoid Arthritis Patients Roche (2, 5, 8); Sanofi (2, 5, 8); UCB (2, 5, 8) 1373. IL-23 Skin and Joint Profiling in Psoriatic Arthritis: Novel Perspectives in Understanding Nelson, Alexandra Clinical Responses to IL-23 Inhibitors 0606. A Systematic Review Exploring Pre-COVID- Disclosure: Nothing to disclose 19 Telehealthcare Models Used in the Management of Patients with Rheumatological Neto, Agna, MD Disease 1780. Maternal and Fetal Outcomes in Pregnant Disclosure: Nothing to disclose Women with Psoriatic Arthritis: A Systematic Literature Review Nelson, Amanda, MD, MS, RhMSUS Disclosure: Nothing to disclose 1487. Biclustering Reveals Potential Knee Osteoarthritis Phenotypes in Exploratory Neville, Scott, MD Analyses: Data from the Osteoarthritis Initiative 0673. Gout Is an Independent Risk Factor for Disclosure: Nothing to disclose Undergoing an Amputation Procedure Disclosure: Flower Orthopedics (5); Horizon Nelson, Taylor, MD Therapeutics plc (5); Integra Life Sciences (5) 1597. Use of a Clinical Dashboard Improves the Documentation of Disease Severity Scores and Nguyen, Kim, MD May Facilitate the Implementation of Treat to 0161. Validation of Patient-reported Outcomes Target Therapy (PRO) Lung Questionnaires for Systemic Juvenile Disclosure: Nothing to disclose Idiopathic Arthritis (SJIA) Patients at Risk for Lung Disease Neogi, Tuhina, MD, PhD, FRCPC 0162. Identifying Sleep Problems in Systemic

80

Juvenile Idiopathic Arthritis (SJIA) Patients with 0735. Paediatric Sarcoidosis: Phenotype of a Patient-reported Outcomes (PRO) Retrospective Cohort of Biopsy-proven Patients Questionnaires Disclosure: Nothing to disclose Disclosure: Nothing to disclose Nowatzky, Johannes, MD Nguyen, Yann, MD, MS 0511. ERAP1-mediated Immunogenicity and 0524. Determination of Homogenous Subgroups Immune-phenotypes in HLA-B51+ Behçet’s of Antiphospholipid Syndrome: A Cluster Analysis Disease Point to Pathogenic CD8 T Cell Effector Based on 509 Cases Responses Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Nielsen, Morten Aagaard, MD Nowell, William, PhD, MSW 0781. Phenotypic and Functional 0154. Treatment Decision Making Among Axial Characterisation of Synovial Fluid-derived Spondyloarthritis Patients: Real-World Data from Fibroblast-like Synoviocytes in Rheumatoid the ArthritisPower Registry Arthritis 0155. Changes in Patient-Reported Outcome 1402. Galectin-3 Decreases the Activity of 4-1BB (PRO) Scores for Nausea and Fatigue Following by Facilitating Its Decoy Surface Binding in Weekly Methotrexate Dose in a Real-World Rheumatoid Arthritis Sample of RA and PsA Patients in the Disclosure: Nothing to disclose ArthritisPower Registry 1979. Participant Engagement and Adherence in Niemantsverdriet, Ellis an ArthritisPower Real-World Study to Capture 0040. Whole Blood RNA Expression in Clinically Smartwatch and Patient-Reported Outcome Data Suspected Arthralgia Patients Shows a Potential Among Rheumatoid Arthritis Patients Value in Prediction of Inflammatory Arthritis Disclosure: Nothing to disclose Disclosure: Nothing to disclose Nurmohamed, Michael, MD, PhD Norris, Jill, PhD, MPH 1332. Identifying the as Patient at Risk: Is Aortic 0790. Vitamin D Polygenetic Risk Score and the Root Diameter Associated with HLA-B27? Association with RA Autoantibodies Among First- 1333. Ankylosing Spondylitis Patients at Risk of Degree Relatives of RA Subjects Developing Aortic Valve Regurgitation, Need for Disclosure: Nothing to disclose Mandatory Echocardiography? Disclosure: AbbVie (5, 8); BMS (5, 8); Celgene and Northcott, Melissa, MBBS, FRACP Janssen (5, 8); Eli Lilly (5, 8); Merck (5, 8); Pfizer 0297. Towards a Glucocorticoid Exposure (5, 8); Roche (5, 8); UCB (5, 8) Signature in SLE: Effects of Type I Interferon 1805. Longitudinal Analysis of IFN Status and Nuruzzaman, Farzana, MD Disease Characteristics in SLE 1161. Perspectives of Radiologist Physicians in Disclosure: Nothing to disclose the Imaging of Chronic Nonbacterial Osteomyelitis Notarnicola, Antonella, MD Disclosure: Nothing to disclose 1078. Highly Reactive anti-Jo1 Autoantibodies to Distinct HisRS Variants and Domains Associate Nwawka, Ogonna, MD with Lung and Joint Involvement in Patients with 1541. Ultrasound in Knee Osteoarthritis: Reader Myositis Performance, Sonographic Features, and Disclosure: Nothing to disclose Correlation with Radiographic Findings Disclosure: Nothing to disclose Nott, Kerstin, MD, PhD

81

Oatis, Carol, PhD, PT (SUFIA): A Pilot Trial to Test Behavioral 0590. A Web-Based Data Capture System Can Economics Strategy to Increase Physical Activity Successfully Collect Detailed and Quantifiable in Inflammatory Arthritis Physical Therapy Intervention Data Post Total 1031. Real World Treatment Patterns Among Knee Replacement Patients with Psoriatic Arthritis Treated with Disclosure: Nothing to disclose Ixekizumab 1880. Association of Healthcare Utilization and Ocampo, Vanessa, MD Costs with Patient-Reported Outcomes in 1325. Monoclonal Gammopathy in Psoriatic Patients with Ankylosing Spondylitis Arthritis 1964. Engaging Patients in the Development of a Disclosure: Nothing to disclose Quality Measure of Functional Status to Improve Care Among Patients with Rheumatoid Arthritis Oganesyan, Ani, BA Disclosure: abbvie (5); amgen (5); bms (5); 0299. The Minor Protective Allele at rs1876453 Is celgene (5); corona (5); janssen (5); lilly (5); Associated with Increased Age of Onset of novartis (2, 5); novartis (7); pfizer (5) Systemic Lupus Erythematosus Disclosure: Nothing to disclose Oglah, Ahmed, MD 0191. Increased Frequency of Lower Limb Ogdie, Alexis, MD, MSCE Arterial Obstruction in Rheumatoid Arthritis 0148. Perspectives on Treatment Burden for Disclosure: Nothing to disclose Methotrexate and TNF-inhibitors Among Psoriatic Arthritis and Rheumatoid Arthritis Ogura, Takehisa, MD, PhD Patients: A Qualitative Study 1565. Joint Cartilage Damage Evaluated by 0160. Use of PROMIS29 Across Inflammatory Ultrasound in Patients with Systemic Lupus Arthritis: Score Distributions and Impact of Erythematosus Contextual Factors Disclosure: Nothing to disclose 0166. Prevalence and Impact of Unacceptable Symptom State Among Patients with Psoriatic Oldroyd, Alexander, MSc, MBChB, MRCP Arthritis: Results from the National Psoriasis 1057. Earlier Cancer Diagnosis After Idiopathic Foundation’s 2019 Annual Survey Inflammatory Myopathy Onset Is Associated 0170. Utilizing Design Thinking to Develop a with Improved Long Term Survival - Results from Decision Aid for Patients with Psoriasis and Four European Cohorts Psoriatic Arthritis 1061. Daily Myositis Symptom Changes Collected 0306. Characteristics of Patients with Early via a Smartphone-Based App Are Associated with Oligoarticular Psoriatic Arthritis in the Corrona Flare Occurrence - Providing Evidence of Psoriatic Arthritis/Spondyloarthritis Registry Potential Digital Biomarkers 0307. Longitudinal Analysis of the Patient Disclosure: Nothing to disclose Pathways to Diagnosis of Psoriatic Arthritis 0323. Residual Symptoms in Patients with PsA O'Leary, Daire, MBBCH Who Are in Very Low Disease Activity According 0083. Chronic Nonbacterial Osteomyelitis Is to Physician Assessments Associated with HLA-B*27 0329. Healthcare Utilization and Costs Disclosure: Nothing to disclose Associated with Functional Status in Patients with Psoriatic Arthritis Ombrello, Michael, MD 0543. Exercise Among Older Adults Living with 0174. Dense Genotyping of Immunologic Loci Rheumatic Disease: Physical Activity Habits and Identifies CXCR4 as a Novel Susceptibility Locus Patient Reported Outcomes for Systemic Juvenile Idiopathic Arthritis 0546. Stepping up for Inflammatory Arthritis Disclosure: Nothing to disclose

82

Medsystems (9, I am an employee and O'Neil, Liam, MD, MHS shareholder of Exponent, a scientific and 0752. Serum Proteomics Implicates Neutrophil engineering consulting firm. Exponent has been Degranulation in Rheumatoid Arthritis Disease paid fees for my consulting services on behalf of Activity such companies and suppliers); Rex Medical (9, I Disclosure: Nothing to disclose am an employee and shareholder of Exponent, a scientific and engineering consulting firm. O'Neill, Kelly, BA Exponent has been paid fees for my consulting 0158. Relationships Between Disease Patterns in services on behalf of such companies and RA and Rheumatology Treatment suppliers); Sanofi (9, I am an employee and 0159. Patient-Reported Data Show the Impact of shareholder of Exponent, a scientific and Time to Diagnosis in RA engineering consulting firm. Exponent has been Disclosure: Nothing to disclose paid fees for my consulting services on behalf of such companies and suppliers); SI-Technology, Ong, Kevin, PhD LLC (9, I am an employee and shareholder of 0580. Risk of Severe Acute Localized Reactions Exponent, a scientific and engineering consulting for Different Intra-Articular Hyaluronic Acid Knee firm. Exponent has been paid fees for my Injections in a Real World Setting consulting services on behalf of such companies Disclosure: Ethicon (9, I am an employee and and suppliers); Zimmer Biomet (9, I am an shareholder of Exponent, a scientific and employee and shareholder of Exponent, a engineering consulting firm. Exponent has been scientific and engineering consulting firm. paid fees for my consulting services on behalf of Exponent has been paid fees for my consulting such companies and suppliers); Ferring services on behalf of such companies and Pharmaceuticals (9, I am an employee and suppliers) shareholder of Exponent, a scientific and engineering consulting firm. Exponent has been Onkka, Patrick, MD paid fees for my consulting services on behalf of 1627. Phase I Trial of High-dose such companies and suppliers); International Hydroxychloroquine for the Treatment of Society for the Advancement of Spine Surgery (9, Ambulatory Patients with Mild COVID-19: A I am an employee and shareholder of Exponent, Study in the Effects of Shifting Public Opinion on a scientific and engineering consulting firm. Patient Enrollment Exponent has been paid fees for my consulting Disclosure: Nothing to disclose services on behalf of such companies and suppliers); Karl Storz Endoscopy-America (9, I am Orbai, Ana-Maria, MD, MHS an employee and shareholder of Exponent, a 0325. The Impact of PsA Disease Control Status scientific and engineering consulting firm. on Patient Treatment Satisfaction: Real-world Exponent has been paid fees for my consulting Survey in US and Europe services on behalf of such companies and 0370. Guselkumab-Treated Patients Achieved suppliers); Medtronic (9, I am an employee and Clinically Meaningful Improvement in Systemic shareholder of Exponent, a scientific and Symptoms as Measured with PROMIS engineering consulting firm. Exponent has been Instrument: Results from Phase-3 Psoriatic paid fees for my consulting services on behalf of Arthritis Trial DISCOVER 1 such companies and suppliers); Pacira 0381. Efficacy of Tofacitinib on Dactylitis in Pharmaceuticals (9, I am an employee and Individual Digits in Patients with Active Psoriatic shareholder of Exponent, a scientific and Arthritis engineering consulting firm. Exponent has been Disclosure: AbbVie (2); Celgene (2); Eli Lilly (2, 5); paid fees for my consulting services on behalf of Horizon (2); Janssen (2, 5); Novartis (2, 5); Pfizer such companies and suppliers); Relievant Inc (5)

83

; UCB (5) Oztas, Mert, MD 0097. Does Testing for SAA Is More Beneficial Oreská, Sabína, MD Than CRP for the Follow-up of Patients with 1083. Alterations of Lipid Profile in IIM Patients FMF? Are Associated with Disease Activity, Duration, Disclosure: Nothing to disclose and Glucocorticoid Treatment Disclosure: Nothing to disclose Paik, Julie, MD 0933. Advanced Multiparametric Magnetic Ortolan, Augusta, MD Resonance Imaging of Muscle for Detection and 2031. Which Disease Activity Outcome Measure Quantification of Muscle Disease in Systemic Discriminates Best in Axial Spondyloarthritis? A Sclerosis Systematic Literature Review and Meta-analysis 1094. Long Term Open Label Extension of Study Disclosure: Nothing to disclose of Tofacitinib in Refractory Dermatomyositis Disclosure: Nothing to disclose Otalora Rojas, Lilian, MD 0569. Ability and Willingness to Utilize Paine, Ananta Telemedicine Among Rheumatology Patients – a 0967. Absence of Thy1 Associated with Severe Cross Sectional Survey Bone Loss in the TNF-transgenic (TNF-Tg) Mice 1230. Curcumin: Prevalence and Perceived Arthritis Model Efficacy in the Treatment of Rheumatoid and Disclosure: Nothing to disclose Psoriatic Arthritis Disclosure: Nothing to disclose Paknikar, Sujaytha, BS 0755. Exploring the Significance of Anti-Nuclear Overbury, Rebecca, MD, MS Antibody Positivity in the Medical Management 0465. The COVID-19 Pandemic and Its Effect on of Patients with Rheumatoid Arthritis Patients with Chronic Rheumatologic Disease Disclosure: Nothing to disclose Regarding the Value of Vaccination Recommendations Paley, Michael, MD, PhD 0608. Patient and Parent Perspectives in a 0460. Lymphocyte Clonal Expansion Academic Pediatric Rheumatology Transition Distinguishes Different Forms of Uveitis Clinic Disclosure: Nothing to disclose 1142. Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Palomino, Luis, MD Academic Institution 1421. Clinical Features, Disease Activity and 1594. Hydroxychloroquine Prescribing Habits Prognosis of ANCA-Associated Vasculitis in US and Provider Opinion on Dosing Guidelines in the African Americans Rheumatology and Dermatology Practices of an Disclosure: Nothing to disclose Academic Institution Disclosure: Nothing to disclose Pamuk, Omer, MD 1798. IgE Anti-dsDNA Antibodies in Systemic Owada, Takayoshi, MD, PhD Lupus Erythematosus Are Associated with Higher 0754. The Association Between Continuous Disease Activity at the Baseline and in Longterm Decreases in Serum RF Titers and Radiographic Follow-up Remission of Joint Damage in RA Patients Disclosure: Nothing to disclose Treated with Biological or Targeted Synthetic DMARDs Papachristos, Danaë, MBBS, FRACP Disclosure: Nothing to disclose 0983. Outcomes Following Antimalarial Withdrawal in Patients with Quiescent Systemic

84

Lupus Erythematosus 0339. Is Sex-adjusted Treatment in Early-PsA Disclosure: Nothing to disclose Justified? Disclosure: Nothing to disclose Parekh, Akshat, BS 0700. Lipoxin A4 Induces Lipid Class Switching Patel, Akshay, MS and Inflammation Resolution at the Genomic 0843. Rab4A Activation Predisposes to Hepatitis Level in Human Osteoarthritis in Spontaneous and Pristane-Induced Mouse Disclosure: Nothing to disclose Models of Systemic Lupus Erythematosus Disclosure: Nothing to disclose Park, Elizabeth, MD 0431. Hydroxychloroquine Use Was Not Patel, Jay, BS Associated with QTc Length in a Large Cohort of 1404. Investigating the Dermatomyositis Skin SLE and RA Patients Inflammatory Infiltrate Using Image Mass 1184. In a Prospective RA Cohort, Higher Cytometry Baseline Disease Activity Is an Independent 1405. Evaluating the Cellular Composition of Predictor of Decline in Left Ventricular Diastolic Anti-synthetase Syndrome and Dermatomyositis Function Skin Lesions Using Image Mass Cytometry Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Parperis, Konstantinos, MD, FACP, FACR Patel, Jayeshkumar, PhD 0622. Infection-induced MPO-ANCA Associated 1646. Use of Prescription Nonsteroidal Anti- Vasculitis: A Systematic Review of Published Case inflammatory Drugs (NSAIDs) in Adults with Reports Hip/Knee Osteoarthritis (OA) at Increased Risk Disclosure: Nothing to disclose for NSAID-related Adverse Events Disclosure: Regeneron Pharmaceuticals (2) Parra Izquierdo, Leidy Viviana, MD 1855. Elevated Calprotectin Levels Reveal Loss of Patil, Sanjeev, MD Vascular Pattern and Atrophy of Villi in Ileum 1041. Pharmaco-epidemiology of Non-infectious Using Digital Chromo-endoscopy and Ocular Inflammatory Disease in a Tertiary Magnification Colonoscopy in Patients with Academic Center Spondyloarthritis Without Inflammatory Bowel Disclosure: Nothing to disclose Disease Disclosure: Nothing to disclose Patrick, David 0496. A Role of Lipid-Peroxidation in Systemic Pascart, Tristan, MD, PhD Lupus Erythematosus-Associated Cardiovascular 0954. Dual-energy CT Predicts Mortality in Gout Disease Patients: A 3-year Follow-up Cohort Study Disclosure: Nothing to disclose Disclosure: Horizon Therapeutics (2); Novartis (8) Patterson, Sarah, MD Pascart, Tristan, MD, PhD 1267. Perceived Stress During the COVID-19 1550. Change in Tophus Size Measured with Pandemic Independently Associates with Worse Dual-energy CT and Ultrasound: A 1-year Patient-Reported Outcomes in Systemic Lupus Multicenter Follow-up Study Erythematosus (SLE) Disclosure: Horizon Therapeutics (2); Novartis (8) Disclosure: Nothing to disclose

Passia, Evangelia, MD Paudel, Anish, MD 1897. Trends in Hospitalizations for Vertebral Compression Fractures in Ankylosing Spondylitis:

85

Data from the National Inpatient Sample 2001- Perruccio, Anthony, PhD 2014 0562. The Relationship Between Heart Disease Disclosure: Nothing to disclose Risk Profile and Osteoarthritis, Overall and by Multi-/Single-Joint Involvement Pazmino, Sofia, MD Disclosure: Nothing to disclose 1739. Patients with Early Rheumatoid Arthritis Considered to Have a Favourable Risk Profile and Peterson, Madeline Treated According to a Step-up Strategy Have an 0538. Autoimmune Disease Outcomes of Increased Risk of Chronic Analgesic Consumption Women with Breast Implants: A Population- Disclosure: Nothing to disclose Based Study Disclosure: Nothing to disclose Pedersen, Brian, MD 0782. Epigenetic Regulation of Metabolic Peterson, Rosemary, MD Transporters in Rheumatoid Arthritis Fibroblast- 1613. Improving Transition Policy Dissemination Like Synoviocytes and Care Team Communication in Pediatric Disclosure: Nothing to disclose Rheumatology Clinic Through Standardization of Workflow and Electronic Health Record Penumarty, Sravani, MD Documentation 1578. Rituximab in Rheumatic Disclosure: Nothing to disclose and Inflammatory Diseases: Role of Skin Testing Disclosure: Nothing to disclose Petri, Michelle, MD, MPH 0856. Time to Renal Insufficiency Based on Prior Peral Garrido, María Luisa Hydroxychloroquine Blood Levels 0666. Identification of Intracellular Vacuoles in 0857. Agreement of Hydroxychloroquine Blood Synovial Fluid with Calcium Pyrophosphate and Levels Between a University and Commercial Monosodium Urate Crystals Laboratory Disclosure: Nothing to disclose 1261. Antiphospholipid Patterns Predict the Risk of Thrombosis in Systemic Lupus Erythematosus Perez, Paola, PhD 1262. Single LAC Positivity versus Double and 1506. Correction of Sjögren’s Syndrome Fluid Triple Positivity for Thrombosis in SLE Secretion Deficits in Salivary Gland Acinar Cells 1266. Multivariate Risk Model Shows Different by Aquaporin-1 Gene Transfer Risk Factors for Myocardial Infarction and Stroke Disclosure: Nothing to disclose in SLE 1451. Longitudinal Assessment of Anti-beta 2 Perez-Sanchez, Carlos, PhD Glycoprotein in SLE 1450. Integrative Analysis of DNA Methylation 1474. Early Peak of Cardiovascular Events Occurs and Gene Expression in Monocytes from Primary Equally in Caucasians and African-American SLE Antiphospholipid Syndrome Patients Identifies a but Is Attributed to Different Risk Factors Gene Expression Signature Associated with Their 1513. Role of Platelet C4d in Thrombosis and Atherothrombotic Phenotype Lupus Nephritis Disclosure: Nothing to disclose 1770. Lupus Low Disease Activity State Protects Against Pre-Term Birth Perlman, Alan, MD 1789. Time to Renal Insufficiency Based on 0035. Distinct Biological Pathways in Both Blood 25(OH)-Vitamin D Levels and Kidney Further Define Molecular Profiles 1833. Hydroxychloroquine and Vitamin D Both Across Diverse Nephritides Reduce Proteinuria in SLE Disclosure: Nothing to disclose 1837. Clinical Outcomes in Lupus Nephritis by Renal Response Status: A Retrospective Analysis

86

of the Hopkins Lupus Cohort Biomechanics and Strength Impairment in Disclosure: AbbVie Inc. (5); Aleon Pharma Patients with Signs of Inflammation Due to Knee International, Inc (5); Amgen (5); Annenberg Osteoarthritis Center for Health Sciences, (5); Astrazeneca (2, Disclosure: Nothing to disclose 5); Blackrock Pharma (5); Bristol Myers Squibb (5); Decision Resources (5); Eli Lilly and Company Pisaniello, Huai Leng, MBBS, FRACP (2, 5); Exagen (2, 5); GlaxoSmithKline (GSK) (2, 5); 0542. Examining the Long-Term and Short-Term Glenmark Pharmaceuticals (5); INOVA (5); IQVIA Day-To-Day Pain Variability in Inflammatory and (5); Janssen Pharmaceutical (5); Merck EMD Non-Inflammatory Rheumatic and Serono (5); Novartis (5); Sanofi Japan (5); Musculoskeletal Diseases Using Multilevel and Thermofisher (5); UCB (5) Markov Transition Models: Cloudy with a Chance of Pain, a National U.K. Smartphone Study Petrovská, Nora, MD Disclosure: Nothing to disclose 0761. Anti-Peptidylarginine Deaminase Antibodies in the Individuals with Arthralgia at Plasencia-Rodríguez, Chamaida, MD, PhD Risk of Progression to Rheumatoid Arthritis 1229. Blood Lymphocyte Subsets for Early Disclosure: Nothing to disclose Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis Pfeiffenberger, Moritz, MSc Disclosure: Nothing to disclose 0116. The in Vitro 3D Fracture Gap Model: A Tool for Preclinical Testing Plešivčnik Novljan, Martina, MD Disclosure: Nothing to disclose 0923. Criteria for the Diagnosis of Raynaud’s Phenomenon – Do They Recognize the Same Philpott, Holly, MSc Patients? 1110. Osteoarthritis-Related Knee Inflammation Disclosure: Nothing to disclose Measured by Ultrasound Is Associated with Performance-Based Measures of Function Pleyer, Uwe Disclosure: Nothing to disclose 0168. Impact of Adalimumab (Humira) Therapy on Ocular Inflammation, Selected Health Care Pillai, Anjana, MD Resource Utilization, and Patient-Reported 1085. Pain in Myositis Is Associated with the Outcomes in Patients with Active Non-infectious Disease Activity Intermediate, Posterior, or Panuveitis in Routine Disclosure: Nothing to disclose Clinical Practice Disclosure: AbbVie (5); Alcon (5); Allergan (5); Pinto, Ana Dompé (5); Novartis (5); Santen (5); Shire (5); 1242. Transcranial Direct Current Stimulation for Thea (5) Fatigue in Patients with Sjogren’s Syndrome: A Randomized, Double-blind Pilot Study Plotz, Benjamin, MD Disclosure: Nothing to disclose 1100. The Hand Osteoarthritis Registry of New York University: Impacts of Gender and Obesity Pinto, Camila Disclosure: Nothing to disclose 1490. Pain Rating Variability and Response to Treatment in Osteoarthritis Clinical Trials Poddubnyy, Denis, MD, MSc Disclosure: Nothing to disclose 0899. Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Pinto, Ryan, MSc Activity in Patients with Axial Spondyloarthritis: 1649. Effect of Knee Aspiration and Intra- 24-week Results from a Randomized Controlled articular Corticosteroid Injection on Gait Phase 3b Trial

87

0900. Achievement of Low Disease Activity Rheumatoid Arthritis Treated with Sarilumab According to BASDAI with Ixekizumab in Patients 0822. Effectiveness After Transition to SB4 with Axial Spondyloarthritis: 16-Week Results (Brenzys, Etanercept Biosimilar) versus from the COAST Trials Continuation of Etanercept (ETN) Originator 1370. A Delayed Effect of Tumor Necrosis Factor (Enbrel) Among Rheumatoid Arthritis (RA) Inhibitors on Radiographic Spinal Progression in Patients in Low Disease Activity: A Prospective Patients with Axial Spondyloarthritis: Long-term Multinational Multicenter Observational Stud Results from the German Spondyloarthritis Disclosure: Abbott (5); AbbVie (2, 5); Actelion (5); Inception Cohort Amgen (5, 8); AstraZeneca (5); Bayer (5); BMS (2, 1864. How to Diagnose Axial Spondyloarthritis in 5, 8); Boehringer Ingelheim (5); EICOS (5); 2020? A Data-Driven Estimation of the Disease Emerald (5); Gilead Sciences, Inc. (2, 5); Probability in Patients with a priori Different GlaxoSmithKline (5); Janssen (5, 8); Lilly (2, 5, 8); Likelihoods of the Diagnosis Medexus (5); Merck (2, 5, 8); Novartis (5, 8); 1865. Identification of Parameters Associated Pfizer (5, 8); Roche (2, 5, 8); Sandoz (5, 8); Sanofi with a Diagnostic Delay in Axial (5, 8); Seattle Genetics (2); UCB (2, 5, 8) Spondyloarthritis:Results from the European Map of Axial Spondyloarthritis (EMAS) Posas-Mendoza, Therese, MD 2018. Development and Validation of an Artificial 1634. Etiologies and Management of Intelligence Approach for the Detection of Hemophagocytic Lymphohistiocytosis: Is It Time Radiographic Sacroiliitis for an Updated Protocol and Targeted 2030. Treatment with Selective Cyclooxygenase- Treatments? 2 Inhibitors Is Associated with Inhibition of Disclosure: Nothing to disclose Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from Poudel, Dilli, MD the German Spondyloarthritis Inception Cohort 1746. Association of Obesity with Treatment Disclosure: BioCad (5); BMS (8); Eli Lilly and Response to Methotrexate or Tumor Necrosis Company (2, 5, 8); Gilead (5); GSK (5); MSD (2, 5, Factor Inhibitors in Patients with Rheumatoid 8); Novartis (2, 5, 8); Pfizer (2, 5, 8); UCB (5, 8) Arthritis Disclosure: Nothing to disclose Polachek, Ari, MD 0315. The Role of Ultrasound for the Assessment Pouliot, Phil, BA of Psoriatic Arthritis Patients with Fibromyalgia 0019. Lasting COVID-19 Impacts on US 1546. Ultrasound, Magnetic Resonance Imaging Rheumatology Practices and Radiography of the Fingers’ Joints of Disclosure: Nothing to disclose Psoriatic Arthritis Patients Disclosure: Nothing to disclose Prajzlerova, Klara 0763. Plasmatic Proteome in Individuals with Pons-Estel, Guillermo, MD, PhD Arthralgia at Risk of Developing Rheumatoid 1272. Impact of Remission and Low Disease Arthritis Activity Status on Hospitalizations Among SLE Disclosure: Nothing to disclose Patients from the GLADEL Latin American Cohort Disclosure: Nothing to disclose Prak, Roeland, MSc 1243. Self-reported Fatigue in Patients with Pope, Janet, MD, FRCPC, MPH Primary Sjögren’s Syndrome Is Associated with 0392. Prevalence and Survival of Systemic an Objective Decline in Physical Performance and Sclerosis (SSc) and Associated Interstitial Lung Symptoms of Pain and Depression Disease (ILD) in Ontario, Canada over 10 Years Disclosure: Nothing to disclose 0811. Long-term Opioid Use in Patients with

88

Preuss, Pauline, MD (JAMAR) Questionnaire for Improving 0082. Diffuse Sclerosing Osteomyelitis of the Management of JIA Patients Jaw: An Underdiagnosed Disease in Maxillofacial Disclosure: Nothing to disclose Surgery Department Disclosure: Nothing to disclose Quinn, Kaitlin, MD 0428. Enrichment of Clinical Trial Recruitment Prisco, Lauren, BA Using Advanced Molecular Imaging in Takayasu’s 0491. Relationship Between Rheumatoid Arteritis Arthritis and Pulmonary Function in the UK 0514. Feasibility of 18F-fluorodeoxyglucose Biobank Positron Emission Tomography to Monitor the Disclosure: Nothing to disclose Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Pritchett, Quinn Observational Cohort Study 0003. Assessing Cytokine Profiles and COVID 1923. Angiographic Progression of Disease in Serology in Patients on Immunosuppression to Large-Vessel Vasculitis Guide Care Recommendations Disclosure: Nothing to disclose Disclosure: Nothing to disclose Qurie, Ahmad, MD Pryor, Katherine, MD 1053. Efficacy of Rituximab for Connective Tissue 0574. Is Hydroxychloroquine Use a Proxy for Disease (CTD) Associated Interstitial Lung Health Care Access? Predictors of First Disease (ILD) : A Single Center Study of 47 Dispensing Among Medicaid Beneficiaries with Patients- Extension Study Incident Lupus Disclosure: Nothing to disclose Disclosure: Nothing to disclose R, Naveen, MD Putman, Michael, MD, MSc 0727. Hip Involvement Leads to Poor Outcome in 0010. Antirheumatic Disease Therapies in Adulthood in Children with Enthesitis Related Patients with COVID-19: A Systematic Review Arthritis (ERA) Category of Juvenile Idiopathic and Meta-analysis Arthritis (JIA) Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Puyade, Mathieu R, Naveen, MD 0459. Autologous Hematopoietic Stem Cell 1092. NMR-Based Serum Metabolomics, Is It Transplantation for Behçet’s Disease: A Different in Clinico-Serological Clusters of Retrospective Survey of Patients Treated in Idiopathic Inflammatory Myositis? Europe, on the Behalf of the Autoimmune Disclosure: Nothing to disclose Diseases Working Party of the European Society for Blood and Bone Marrow Transplantation Ra, Jennifer, BA Disclosure: Nothing to disclose 0570. The Patient Perspective on Using Digital Resources to Address Unmet Needs in Systemic Qaiser, Iman, MD Lupus Erythematosus 1699. Training Residents to ‘Choose Wisely’ Disclosure: Nothing to disclose When Testing for Antinuclear Antibodies Disclosure: Nothing to disclose Rademacher, Judith, MD 2016. Baseline Serum Biomarker Levels Predict Quesada, Humbert, PhD Spinal Radiographic Progression in Ankylosing 0725. A Data Science Evaluation of the Juvenile Spondylitis Patients on TNF Inhibitor Therapy Arthritis Multidimensional Assessment Report Disclosure: Nothing to disclose

89

Psoriatic Arthritis Mutilans and Understand Its Radtke, Felix Systems Biology 0073. A Cross-Species Map of Neutrophil Disclosure: Nothing to disclose Inflammatory Responses Disclosure: Nothing to disclose Rajendran, Aardra, BSc 1446. Pregnancy Outcomes in Patients with Radwan, Yasser, MD Interstitial Lung Disease 0913. Systemic Sclerosis Portends a Higher Risk 1768. The Importance of Pregnancy Planning in of Conduction and Rhythm Disorders at Lupus Pregnancies Diagnosis and During Disease Course: Results Disclosure: Rheumatology Foundation Medical from a US Population Based Study Student Preceptorship Award (2) 1380. Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Increases the Risk of Digital Ramirez Garcia, Felipe Julio, MD, PhD Ischemic Complications in Systemic Sclerosis: 1756. Comparable Long-Term Outcomes Among Results from a Single Center Referral Cohort DAS28-ESR-based Remission Criteria and (2001-2018) ACR/EULAR Definitions in Patients with Disclosure: Nothing to disclose Established Rheumatoid Arthritis Disclosure: Nothing to disclose Ragesh Panikkath, Deepa, MD 1590. Bone Health in ANCA - Associated Ramirez-Gomez, Andrea, MD Vasculitis Patients 1701. Development and Validity Evidence for a Disclosure: Nothing to disclose Tool to Assess the Performance of Shoulder Injections Rahat, Maya, MD Disclosure: Nothing to disclose 1527. Tofacitinib Inhibits Angiogenesis Through Its Opposite Effects on Pro- and Anti-angiogenic Ramirez-Perez, Sergio, PhD Factors 0741. Constitutive Inhibitor Kappa B (IκB) Kinase Disclosure: Nothing to disclose 2 (IKK2) Activation Induces an Inflammatory State in Fibroblast-Like Synoviocytes Rahman, Proton, MD Disclosure: Nothing to disclose 0347. In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Rampakakis, Emmanouil, PhD Psoriatic Arthritis and Demonstrated 0482. Differential Influence of CDAI Components Independent Treatment Effects on Fatigue After Based on Disease State in Rheumatoid Arthritis Adjustment for Clinical Response (ACR20) Patients: Real World Results from a Rheumatoid Disclosure: Abbott (8); AbbVie (5, 8); Amgen (5, Arthritis Cohort 8); Bristol Myers Squibb (5, 8); Celgene (5, 8); Disclosure: Nothing to disclose Centacor (8); Eli Lilly (5, 8); Janssen (2, 5, 8); Merck (8); Novartis (2, 5, 8); Pfizer (5, 8); Roche Ramsey-Goldman, Rosalind, MD (5); UCB (5, 8) 1797. A Multianalyte Assay Panel (MAP) with Algorithm Containing Cell-Bound Complement Rahmati, Sara, PhD Activation Products (CB-CAPs) Is Superior to Anti- 0502. Integration of Clinical and Protein Markers dsDNA and Low Serum Complement Levels in Through Machine Learning to Distinguish Predicting Transition of Probable Lupus to ACR Patients with Psoriasis Arthritis from Those with Classified Lupus Within 2 Years Psoriasis Without Psoriatic Arthritis Disclosure: Exagen Diagnostics, Inc. () : 2; 1860. An Integrative Approach to Identify ThermoFisher Scientific (Self) : 5 Heritable and De Novo Genomic Variations in

90

Ramu, Anitha, MD 0316. High-sensitivity 18F-FDG PET/CT: A 0261. Predictors of Future Repeat Renal Biopsies Diagnostic Tool for Psoriatic Arthritis in Patients with Lupus Nephritis and Influence of 1854. NGF/TrkA System Regulates Pain and the Repeat Biopsy in Flare Management: A Pannus Formation: Targeting NGF-TrkA in Retrospective Study Psoriatic Arthritis Disclosure: Nothing to disclose 1861. T Cells with IL-17A+ Signature in Psoriatic Arthritis Are of Different Subpopulations and Are Rangaramanujam, Kannan Polyfuntional 0738. Systemic Administration of Novel Hydroxyl Disclosure: Nothing to disclose Dendrimers to Target Inflammation in Arthritic Tissues Rebić, Nevena, BSc, MSc Disclosure: Ashvattha Therapeutics (1); 1774. Making Decisions About Medication Use, Ashvattha Therapeutics (1, 6) Pregnancy, and Having Children Among Women with Rheumatoid Arthritis: A Constructivist Rasheed, Sarah, MD Grounded Theory Study 0372. Tumor Necrosis Factor-α Receptor 2 Disclosure: Nothing to disclose Polymorphisms and Response to TNF Inhibitor Therapy in Patients with Psoriatic Arthritis Rech, Jürgen, MD Disclosure: Nothing to disclose 1747. Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Rat, Anne-Christine Multi-center, Randomized, Double-blind, 0146. Patients’ Perceptions and Expectations Placebo-controlled Trial (PreCePRA) Towards the Role of Rheumatologists in the Disclosure: Abbie, Biogen, BMS, Chugai, Celgene, Recommendations of Physical Activity’s Practice EliLilly, Gilead, GSK, Janssen, MSD, Novartis, - A Cross-sectional Study Involving 308 Patients Roche, Sanofi, Sobi, UCB (5, 8) Living with Rheumatoid Arthritis in France Disclosure: Nothing to disclose Rech, Jürgen, MD 1750. Longitudinal Change in the Central Rathbun, Alan, PhD, MPH Nervous System Pain Response After Treatment 0551. Physical Performance as a Mediator of the with Certolizumab or Placebo. a Post-hoc Association Between Depression and Pain in Analysis from the Pre-CEPRA Trial Knee Osteoarthritis Disclosure: Abbie, Biogen, BMS, Chugai, Celgene, Disclosure: National Institute on Aging (2) EliLilly, Gilead, GSK, Janssen, MSD, Novartis, Roche, Sanofi, Sobi, UCB (5, 8) Ratneswaran, Anusha, PhD 0036. Molecular Phenotyping of Late-Stage Knee Reddy, Soumya, MD Osteoarthritis Synovium Through Total RNA- 0344. Use of the BASDAI in Psoriatic Arthritis Sequencing Patients with and Without Axial Disease Disclosure: Nothing to disclose 0152. Veterans with RA and Gout Identify Their Goals and How They Can Work with Clinicians to Ravishankar, Adarsh Achieve Their Goals 1065. Immunostimulatory Herbal Supplement 1596. Coproduction of Care for Veterans with Use Is More Common Among Patients with RA: Improving Elicitation and Documentation of Dermatomyositis Patient Goals Disclosure: Nothing to disclose Disclosure: Amgen (5); Janssen (5); Novartis (5); Pfizer (5) Raychaudhuri, Siba, MD Rehman, Zahra, MD

91

1625. Pneumocystis Jiroveci Pneumonia in Immunocompromised Patients with Reyes Soto, Mayra Alejandra Rheumatologic Disease in a Single, Tertiary 1182. Increased Prevalence of Carotid Medical Center Atherosclerosis in Postmenopausal Women with Disclosure: Nothing to disclose Rheumatoid Arthritis: A Case Control Study Disclosure: Nothing to disclose Reid, Pankti, MD 1579. Assessing the Effect of Calcineurin Rhee, Rennie, MD, MS Inhibitors for Immune-related Adverse Event 2049. Nasal Bacteria Associated with Disease Management on Tumor Response Activity and ANCA Levels in Granulomatosis with Disclosure: n/a (9, I am co-inventor on a Polyangiitis provisional patent entitled, “Tocilizumab for the Disclosure: Nothing to disclose Treatment of Viral Infections” filed by University of Chicago) Richardson, Carrie, MD, MHS 0399. A Heavy Burden of Calcinosis Reflects Rempenault, Claire, MS Cumulative Disease Damage in Scleroderma 0999. CXCL13 Is a Key Driver for Migration and 1555. 18F-NaF PET/CT Identifies Active Calcium Differentiation of Regulatory B Cells Uptake in Calcinosis Due to Dermatomyositis and Disclosure: Nothing to disclose Scleroderma Disclosure: Nothing to disclose Restrepo, Jose Felix, MD 0194. Depression Symptoms but Not Clinically Richette, Pascal Diagnosed Depression Predict Mortality in 1484. Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis Hand Osteoarthritis: Double Blind, Randomized, Disclosure: Nothing to disclose Placebo Controlled, Multicenter Trial Disclosure: AbbVie Inc. (8); Amgen (8); Biogen Restrepo, Jose Felix, MD (8); BMS (8); Celgene (8); Janssen (8); Lilly (8); 1999. Hydroxychloroquine Is Not Cardiotoxic in Novartis (8); Pfizer (8); Roche (8); Sanofi-Aventis Patients with Rheumatoid Arthritis (8); UCB (8) Disclosure: Nothing to disclose Ridley, Lauren, MD Retuerto, Miriam, MD 0695. Chronic Inflammatory Back Pain Occurring 0818. Efficacy and Safety of Switching Jakinibs in Later in Life: A Neglected Concept Rheumatoid Arthritis 1873. The Changing Profile of Ankylosing Disclosure: Nothing to disclose Spondylitis in the Biologic Era Disclosure: Nothing to disclose Retuerto, Miriam, MD 1393. Systemic Sclerosis: Subclinical Riemekasten, Gabriela, MD Aterosclerosis and Morbimortality 1524. Interstitial Lung Disease, Kidney Disclosure: Nothing to disclose Inflammation and Myositis Are Induced by Transfer of PBMC Derived from Systemic Reveille, John, MD Sclerosis Patients into Rag2-/-/ IL2rg-/- mice 0904. Response to Ixekizumab by C-reactive Disclosure: Nothing to disclose Protein Level in Patients with Radiographic Axial Spondyloarthritis: Results from the COAST-V Rife, Eileen, MD (Biological-Naïve) and COAST-W (TNF Inhibitor- 0109. Glucocorticoid-Induced Osteoporosis: Are Experienced) Trials at 52 Weeks We Practicing Prevention? Disclosure: Eli Lilly (2); Janssen (2); UCB (5) Disclosure: Nothing to disclose

92

2005. Histo-pathological Cellular Markers of Ringsted, Sarah, MD Treatment Response to Rituximab and 1545. An Artificial Intelligence (AI) Assistant Tocilizumab in Matched Pre- and Post-treatment Identifying Spinal Diffuse Idiopathic Skeletal Synovial Biopsies from the R4RA Randomised Hyperostosis on Plain X-rays: A Pilot Deep Clinical Trial in Rheumatoid Arthritis Learning Study Disclosure: Nothing to disclose Disclosure: Nothing to disclose Rivera Teran, Vijaya, MD Rios Rodriguez, Valeria, MD 0821. Gender and Discontinuation of Biologic 0376. Higher Intake of Carbohydrates and Free DMARDs in Patients with Rheumatoid Arthritis: Sugar Are Associated with Higher Disease Data from the Mexican Biologics Registry Activity in Patients with Axial Spondyloarthritis Disclosure: Nothing to disclose 1308. The Presence of Spondyloarthritis Is Associated with Higher Clinical Disease Activity in Roberts, Jordan, MD Patients with Early Crohn’s Disease: Results of a 1615. Assessing Preparation for Care Transition Prospective Cohort Study Among Adolescents with Rheumatologic Disease: 1376. Impact of Body Composition Measures on A Quality Assessment with Patient Survey the Response to Biological Disease-modifying Disclosure: Nothing to disclose Anti-rheumatic Drugs in Patients with Ankylosing Spondylitis Robinson, Cal, MD 2032. Treatment Response to Biological Disease- 0937. Late Cardiovascular Outcomes in Children modifying Anti-rheumatic Drugs Is Associated with Kawasaki Disease: A Population-based with Favorable Changes of the Body Composition Cohort Study in Patients with Ankylosing Spondylitis 1688. Long-term Hearing Loss, Anxiety and Disclosure: Nothing to disclose Neurodevelopmental Outcomes Following Kawasaki Disease: A Population-based Cohort Ritchlin, Christopher, MD, MPH Study 0349. Pooled Safety Results from Two Phase-3 Disclosure: Nothing to disclose Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year Robinson, George, PhD 0888. Guselkumab Efficacy and Safety in TNF- 0472. ApoB:ApoA1 Ratio Could Predict Inhibitor-Experienced and TNF-Inhibitor-Naïve Atherosclerotic Risk in Juvenile-SLE Patients Patients with Active PsA: 1-Year Results of a Associated with Altered Interferon Signalling in Phase 3, Randomized, Controlled Study CD8+ T-cells 0889. Efficacy of Secukinumab Treatment in Disclosure: Nothing to disclose Patients with Early Psoriatic Arthritis: A Pooled Analysis of 4 Phase 3 Studies Robinson, Philip, PhD, FRACP, MBChB 1344. Guselkumab, an IL-23 Inhibitor That 0656. A Sugar Tax Results in Reduced Incident Specifically Binds to the IL23p19-Subunit, for Gout, Quality Adjusted Life Years Lost and Active Psoriatic Arthritis: One Year Results of a Economic Cost from Gout: A Health Economic Phase 3, Randomized, Double-Blind, Placebo- Analysis Controlled Study of Patients Who Were Biologic- Disclosure: Abbvie (5, 8); BMS (9); Eli Lilly (5); Naïve or TNFα Inhibitor-Experien Janssen (2, 5, 8); Novartis (2, 5, 8); Pfizer (5); UCB Disclosure: AbbVie, Amgen, Abbvie,BMS, , (2, 5) Janssen, Lilly, Novartis, Pfizer,UCB () : 5, 2 Robinson, William, MD, PhD Rivellese, Felice, MD, PhD 0743. Higher Baseline Fine-Specificity ACPAs Predict Greater Treatment Response with

93

Abatacept + MTX versus MTX Monotherapy in Rominger, Emily, BA Seropositive RA: A Post Hoc Analysis 0426. T-Cell Receptor (TCR) Sequencing Reveals Disclosure: Nothing to disclose Decreased Diversity and Clonotypic Expansion of T-cells in Relapsing Polychondritis (RP) Robledo, Ileannette, MD Disclosure: Nothing to disclose 1802. Vitamin D Level: Predictor of SLE Disease Activity in AA Cohort with CLE? Romo-Tena, Jorge, MD Disclosure: Nothing to disclose 0290. Role of Protein Tyrosine Phosphatase 1B (PTP1B) in Endothelial-to-Mesenchymal Rodriguez Muguruza, Samantha, MD Transition (EndoMT) Promoted by Inflammation: 1727. Patterns of Fatigue in Early RA over 10 Implications for SLE Years: Results from the ESPOIR Cohort Disclosure: Nothing to disclose Disclosure: Nothing to disclose Rose, Emily, BS Rodriguez-Garcia, Sebastian C, MD 0427. Validation of Physician Global Assessment 1465. The Impact of the Combined Vaccination as an Outcome Measure in Relapsing Scheme Against Streptococcus Pneumoniae on Polychondritis the Incidence of Related Infections in Patients 1129. Discordance in Patient and Physician with Rheumatoid Arthritis Treated with Biologic Assessment of Disease Activity in Relapsing or Targeted Synthetic DMARD: Data from Polychondritis BIOBADASER 3.0 Disclosure: Nothing to disclose Disclosure: Nothing to disclose Rossi, Marianna Nicoletta, PhD Rodriguez-Smith, Jackeline, MD 0172. Early Treatment and IL1RN Single 0731. Comparing S100 Proteins and Cytokine Nucleotide Polymorphisms Affect Response to Levels in Tears Based on Uveitis Activity Anakinra in Systemic Juvenile Idiopathic Arthritis Laterality in Children with JIA-associated Uveitis Disclosure: Nothing to disclose and Non-JIA-U Disclosure: Nothing to disclose Rottmann, Eva, DO 1032. Epidemiology and Geographic Evaluation Rogers, Jennifer, MD of ANCA-associated Vasculitis (AAV) at a Rural 0273. Lupus Nephritis Is Associated with a Academic Health Center Utilizing an Electronic Reduced Prevalence of Fibromyalgia Health Record (EHR) Disclosure: Nothing to disclose 1967. Combating Rheumatologist Burnout: Use of Protocol Driven Medication Refill by Rogier, Cleo, MD Pharmacists 0481. Subclinical Synovitis in Arthralgia: How Disclosure: Nothing to disclose Often Does It Result in Clinical Arthritis? A Longitudinal Study to Reflect on Starting Points Rubbert-Roth, Andrea, MD for DMARD Treatment 1232. Association of Low Hemoglobin with Disclosure: Nothing to disclose Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, Romero-Sanchez, Consuelo, PhD MOBILITY and MONARCH) 0776. The Influence of Adipokine Profile and 1920. Efficacy and Safety of Tocilizumab in Periodontal Infection in Early Stages of Patients with Giant Cell Arteritis and Visual Rheumatoid Arthritis and First-degree Relatives Impairment Disclosure: Nothing to disclose Disclosure: Nothing to disclose

94

Rubio, Jose, MD Servier (5, 8); Sinergie (5, 8); Sobi (2, 5, 8, 9, The 1659. Synergistic Effect of Quadriceps Weakness IRCCS Istituto Giannina Gaslini (IGG), where NR and Obesity in Women at Risk of Knee works as full-time public employee has received Osteoarthritis contributions (> 10.000 USD) from Sobi); Takeda Disclosure: Nothing to disclose (5, 8)

Ruiz-Limon, Patricia, PhD Ruscitti, Piero, MD, PhD 1853. Association of Gut Dysbiosis with 1219. Reaching Remission by IL-1 Inhibition in Radiographic and Enthesis Involvement, Disease Rheumatoid Arthritis Patients with Type 2 Activity and Duration in Axial Spondyloarthritis. Diabetes Improves the Glucose Homeostasis: Data from CASTRO Registry Long-term Findings from TRACK Study, a Disclosure: Nothing to disclose Multicentre, Open-label, Randomised, Controlled Trial Ruperto, Nicolino, MD, MPH Disclosure: BMS (8); Ely Lilly (8); MSD (8); 0715. JIA-ACR50 Response as a Predictor of Novartis (8); Pfizer (2); SOBI (8) Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with Rush, Stephanie, BA SC Abatacept 0196. Objectively-Measured Obstructive Sleep Disclosure: AbbVie (5, 8); Ablynx (5, 8); Apnea Is Frequent Among Individuals with Astrazeneca-Medimmune (5, 8); Biogen (5, 8); Rheumatoid Arthritis Boehringer (5, 8); Bristol Myers Squibb (2, 5, 8, 9, Disclosure: Nothing to disclose The IRCCS Istituto Giannina Gaslini (IGG), where NR works as full-time public employee has Rutstein, Beth, MD received contributions (> 10.000 USD) from 1165. Validation of Healthcare Claims Algorithms Bristol Myers Squibb); Eli Lilly (2, 5, 8, 9, The for Identification of Herpes Zoster Among IRCCS Istituto Giannina Gaslini (IGG), where NR Children with Autoimmune/Autoinflammatory works as full-time public employee has received Disease contributions (> 10.000 USD) from Eli Lilly); EMD Disclosure: Nothing to disclose Serono (5, 8); F Hoffmann-La Roche (2, 5, 8, 9, The IRCCS Istituto Giannina Gaslini (IGG), where Rychkov, Dmitry, PhD NR works as full-time public employee has 0764. Uncovering Novel Biomarkers for received contributions (> 10.000 USD) from F Rheumatoid Arthritis from Feature Selection and Hoffmann-La Roche); GlaxoSmithKline (2, 5, 8, 9, Machine Learning Approaches on Synovium and The IRCCS Istituto Giannina Gaslini (IGG), where Blood Gene Expression Data NR works as full-time public employee has Disclosure: Nothing to disclose received contributions (> 10.000 USD) from GlaxoSmithKline); Janssen (2, 5, 8, 9, The IRCCS Saag, Kenneth, MD, MSc Istituto Giannina Gaslini (IGG), where NR works 0649. A Multicenter, Open-Label, Efficacy and as full-time public employee has received Safety Study of Pegloticase in Patients with contributions (> 10.000 USD) from Janssen); Uncontrolled Gout Who Have Undergone Kidney Merck (5, 8); Novartis (2, 5, 8, 9, The IRCCS Transplantation: Early Data Report Istituto Giannina Gaslini (IGG), where NR works Disclosure: Arthrosi (5); Atom Bioscience (5); as full-time public employee has received Horizon Therapeutics plc (2, 5); LG Pharma (5); contributions (> 10.000 USD) from Novartis); Mallinkrodt (5); Shanton (2); SOBI (2, 5); Takeda Pfizer (2, 5, 8, 9, The IRCCS Istituto Giannina (5) Gaslini (IGG), where NR works as full-time public employee has received contributions (> 10.000 Sabbagh, Sara, DO USD) from Pfizer); R-Pharma (5, 8); Sanofi (5, 8);

95

1059. Anti-mitochondrial Autoantibodies Are Associated with Cardiomyopathy, Dysphagia, and Salliot, Carine, MD, MSc Features of More Severe Disease in Adult-onset 1006. Post-menopausal Rheumatoid Arthritis Is Myositis Inversely Associated with Lifetime High Level of 1694. Risk Factors Associated with Pneumocystis Estrogen Exposure in the French E3N Cohort Jirovecii Pneumonia in Juvenile Myositis in North Disclosure: Nothing to disclose America Disclosure: Nothing to disclose Saltman, Alexandra, MD, FRCPC 0061. Rheumatologists’ Attitudes Toward Sabih, Lena, MD and Medical Assistance in Dying 1017. Racial and Ethnic Disparities in the Risk of Disclosure: Nothing to disclose Preterm Birth Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis Samuels, Jonathan, MD with Varying Reference Groups 1656. Knee OA Outcomes in Patients with Severe Disclosure: Nothing to disclose Obesity Following Bariatric Surgery or Total Knee Arthroplasty Sadun, Rebecca, MD, PhD Disclosure: Nothing to disclose 1273. The Impact of the COVID-19 Pandemic on the Fibromyalgia Symptoms of SLE Patients Sanchez-Bilbao, Lara, MD Disclosure: Nothing to disclose 1043. Ocular Scleral Pathology and Immune- Mediated Inflammatory Diseases. Study of 170 Sagard, Jonas, MD Patients from a Single Universitary Center 1327. Comorbidity Burden in Patients with Non- 1044. Ocular Manifestations in Inflammatory Radiographic Axial Spondyloarthritis at Least as Bowel Disease. Study of 1442 Patients from a High as in Ankylosing Spondylitis Single Referral Center Disclosure: Nothing to disclose 1554. Response to Tocilizumab in Large Vessel Vasculitis According to the Extent of Baseline Saito, Shuntaro, MD, PhD, ARNP 18F-FDG Vascular Uptake 1209. The Strength of IL-6/STAT3 Signal 1626. Long-Term Follow-Up of Renal Inhibition by SAR S.c q2w Showed Significantly Transplantation Due to Lupus Nephritis. Single Higher Level Than That of TCZ S.c q2w but Lower Universitary Center Experience Than TCZ S.c q1w 1921. Ongoing Vascular 18F-FDG Uptake Despite Disclosure: Asahikasei Pharma Corp. (8); Bristol– Clinical Remission in Patients Receiving Myers Squibb (8); Chugai Pharmaceutical Co. Ltd. Tocilizumab for Large Vessel Vasculitis-Giant Cell (8); Eisai Co.,Ltd. (8); Mitsubishi Tanabe Pharma Arteritis: Single Universitary Center Experience Co. (8); Pfizer Japan Inc. (8) of 30 Patients Disclosure: Nothing to disclose Sakai, Ryoko, PhD, MSc, MPH 1729. Associations Between Patient Reported Sanges, Sebastien, MD Outcomes and Impairments of Work and Activity 1522. Biomarkers of Hemodynamic Severity of in Patients with Rheumatoid Arthritis Who Systemic-Sclerosis Associated Pulmonary Arterial Achieved Clinical Remission; Retrospective Hypertension by Serum Proteome Analysis Analysis Using the IORRA Database Disclosure: Nothing to disclose Disclosure: Ayumi Pharmaceutical Co. Ltd. (2); Bristol Meyers Squib (2); Chugai Pharmaceutical Sapart, Emilie, MD Co. Ltd. (2); Mitsubishi Tanabe Pharma Corp. (2); 2008. Should We Use Glucocorticoid in Early Nippon Kayaku Co. Ltd. (2); Taisho Toyama Rheumatoid Arthritis? : Results at 5 Years from Pharmaceutical Co. Ltd. (2)

96

the ERA Louvain Brussels Cohort Sayad, Edouard, MD Disclosure: Nothing to disclose 1430. The Role of Lung Biopsy in Pediatric ANCA- associated Vasculitis Sari, Alper, MD Disclosure: Nothing to disclose 0387. Altered Iron Homeostasis and Pulmonary Haemodynamics in Systemic Sclerosis Associated Saygin, Didem, MD Pulmonary Arterial Hypertension 1084. Consumer-based Activity Trackers in Disclosure: Nothing to disclose Evaluation of Physical Function in Myositis Patients Sarmiento-Monroy, Juan, MD Disclosure: Nothing to disclose 1478. A Multidisciplinary Registry of Patients with Autoinmune and Immune-Mediated Schäfer, Valentin, MD, PhD Diseases with Symptomatic COVID-19 Infection 0420. Prospective Analysis of the Prevalence of from a Single Center Giant Cell Arteritis in Consecutive Newly Disclosure: Nothing to disclose Diagnosed Patients with Polymyalgia Rheumatica 0451. Prevalence, Therapy and Tumor Response Satti, Eman, MD in Patients with Rheumatic Immune-related 1249. The Impact of Anti-Ro Antibodies on the Adverse Events Following Immune Checkpoint Pregnancy Outcome in Relation to Maternal Inhibitor Therapy: A Single-Centre Analysis Disease Presentation: A Descriptive Analysis of 1542. The Role of Dual Energy Computed 231 Pregnancies Tomography (DECT) in the Differentiation of 1772. Vaccinations of Infants Born to Mothers on Gout and Calcium Pyrophosphate Deposition TNF Inhibitors: Safe Administration of Live- Disease vaccines Given Per the National Immunization 1925. Ultrasound Follow-up Examination of Program Intima-Media-Thickness of the Temporal and Disclosure: Nothing to disclose Axillary Artery over Six Months in Patients with Newly Diagnosed Giant Cell Arteritis Sattler, Samantha, BA 1936. Prospective Analysis of Flow Velocity of 0093. Review of Gastrointestinal Manifestations the Central Retinal Artery in Newly Diagnosed of Kohlmeier-Degos Disease Patients with Giant Cell Arteritis with Visual Disclosure: Nothing to disclose Symptoms and Controls 1939. Definitions and Reliability Assessment of Sattui, Sebastian, MD, MS Chronic Ultrasound Lesions of the Axillary Artery 0422. Frailty and Health-Related Quality of Life in in Giant Cell Arteritis: A Study from the Patients with Polymyalgia Rheumatica OMERACT Large Vessel Vasculitis Ultrasound 0488. Incidence of Dementia in Patients with Working Group Rheumatoid Arthritis and Association with 1942. Analysis of Vasculitis Patterns in Patients DMARDs – Analysis of a National Claims with Giant Cell Arteritis Compared to Patients Database with Giant Cell Arteritis and Polymyalgia Disclosure: Nothing to disclose Rheumatica Disclosure: Nothing to disclose Saxena, Amit, MD 1667. Development of Autoimmune Diseases Schanberg, Laura, MD and HLA Associations in Children with Neonatal 1633. A Randomized, Double-Blind, Placebo- Lupus and Their Unaffected Siblings Controlled Study of Anakinra in Pediatric and Disclosure: Bristol Myers Squibb (5); Glaxo Smith Adult Patients with Still’s Disease Kline (5) Disclosure: BMS (2); Sanofi (9, DSMB member); Sobi (2, 5); UCB (9, DSMB Chair)

97

Controlled Clinical Trial Schett, Georg, MD Disclosure: Abbvie (2, 5, 8); Amgen (2, 5, 8); BMS 0011. Patients Receiving Cytokine Inhibitors (2, 5, 8); Eli Lilly (2, 5, 8); Genzyme (2, 5, 8); Have Low Prevalence of SARS-CoV-2 Infection Janssen (2, 5, 8); Novartis (2, 5, 8); Pfizer (2, 5, 8) 0355. Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Schneider, Beth, BA Guselkumab Treatment in a Phase-3 Clinical Trial 0135. Understanding the Rheumatologist-Patient 0880. Ixekizumab Improves Signs and Symptoms Relationship in Treating Rheumatoid Arthritis of Patients with Radiographic and Non- 1125. Patient Reported Impact of Lupus on radiographic Axial Spondyloarthritis and Extra- Quality of Life articular Manifestation of Enthesitis Through 16 Disclosure: Nothing to disclose Weeks Disclosure: Nothing to disclose Schniering, Janine, PhD 2034. Resolving Phenotypic and Prognostic Schieir, Orit, PhD Differences in Interstitial Lung Disease Related to 1715. Longitudinal Patterns of Remission in Real- Systemic Sclerosis by Computed Tomography- World Early Rheumatoid Arthritis Patients: based Radiomics Results from the Canadian Early Arthritis Cohort Disclosure: Nothing to disclose (CATCH) Disclosure: Nothing to disclose Schnitzer, Thomas, MD, PhD 1640. Clinically Important Improvement in Schletzbaum, Maria, BA Osteoarthritis Pain at Week 16 After 0612. Differences in 30-Day Rehospitalization Subcutaneous Administration of Tanezumab: Risk and Predictors by Age Group Among Pooled Analysis from International Studies Patients with Lupus in Medicare 1643. Evaluating Analgesic Response to 1298. Lupus Damage Free-Survival by Age at Subcutaneous Tanezumab in Patients with Diagnosis: A Retrospective Incident Lupus Cohort Inadequate Treatment Response to Other Disclosure: Nothing to disclose Analgesics Based on Daily E-pain Diaries: A Pooled Analysis of 2 Randomized, Placebo- Schmajuk, Gabriela, MD, MS controlled Studies 1961. Decreased Visits in RISE Practices Due to Disclosure: AstraZeneca (5); Lilly (2, 5); Pfizer (2, the SARS-CoV-2 Global Pandemic 5); Regeneron (2) Disclosure: Nothing to disclose Scholz, Helge Schmukler, Juan, MD 1530. Activin a and Follistatin Alter Endothelial 0941. MDHAQ/RAPID3 (multidimensional Health Cell and Rheumatoid Arthritis Synovial Fibroblast Assessment Questionnaire/routine Assessment Adhesion and Interaction of Patient Index Data) Levels Are Elevated in Disclosure: Nothing to disclose Rheumatology Patients Who Meet 2011 Fibromyalgia (FM) or MDHAQ/FAST3 Schulert, Grant, MD, PhD (fibromyalgia Assessment Screening Tool) 0469. IFNγ Is Essential for Alveolar Macrophage Criteria Driven Lung Inflammation in Macrophage Disclosure: Nothing to disclose Activation Syndrome Disclosure: Novartis (5); Sobi (5) Schneeberger, Emilce, MD 1885. Performance of SASDAS (Simplified Axial Schulz, Jenna, BSc Spondyloarthritis Disease Activity Score) versus 1118. Bone Marrow Lesion Scores in Patients ASDAS in a Post Hoc Analysis of a Randomized with Knee Osteoarthritis Undergoing Tibial

98

Osteotomy: Reliability and Concurrent Validity of 1237. Pain and Other Patient-Reported the Knee Inflammation MRI Scoring System Outcomes in Patients with Rheumatoid Arthritis (KIMRISS) Who Did or Did Not Achieve Treatment Disclosure: Nothing to disclose Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials Schutt, Christina, DO Disclosure: Eli Lilly and Company (5, 8) 0175. Identifying Immuno-phenotypes in Juvenile Localized Scleroderma with RNA Seet, Dominic, MBBS, MRCP, MMed Sequencing 1335. Smoking, but Not Use of Complementary Disclosure: Nothing to disclose and Predicts Residual Functional Disability in Patients with Schwartzman, Sergio, MD Inflammatory Arthritis on Biologic Disease 0809. Comparative Effectiveness of Intravenous Modifying Anti-Rheumatic Drugs: Results from Golimumab vs Dose-Escalated Infliximab in a the Singapore National Biologics Register Real World Population of Rheumatoid Arthritis Disclosure: Nothing to disclose Patients: 52-Week Data from the AWARE Study 0892. Long-Term Safety Profile of Ixekizumab Seitz, Luca, MD Treatment in Patients with Axial 1928. Quantitative Ultrasound of Temporal, Spondyloarthritis Axillary and Subclavian Arteries to Monitor Disclosure: Abbvie (5, 8); Amgen (1); Boston Tocilizumab Treatment in Patients with Newly Scientific (1); Genentech (8); Gilead (1, 5); Diagnosed Giant Cell Arteritis: A 24 Week Janssen (5, 8); Lilly (5, 8); Medtronic (1); Myriad Analysis (5); National Psoriasis Foundation (6); Novartis Disclosure: Nothing to disclose (5, 8); Pfizer (1, 8); UCB (5, 8) Sellam, Jérémie, MD, PhD Sciacca, Elisabetta, MSc 1109. Pain in Women with Knee and/or Hip 0973. Novel Network Tool Highlights Key Osteoarthritis Is Related to Systemic Features Associated with Disease Pathotypes Inflammation and to Adipose Tissue Dysfunction and Response to Treatment in Early Rheumatoid and Distribution: A Cross-sectional Metabolic Arthritis Biomarkers Cohort Study Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Scofield, Robert, MD Semalulu, Teresa, MD, MPH 1505. Antibodies Binding Ro/SSA and Muscarinic 1682. Goal-Setting Improves Transition 3 Receptor in Sjogren's Syndrome Readiness in Adolescents with Juvenile Idiopathic Disclosure: Nothing to disclose Arthritis and Systemic Lupus Erythematosus Disclosure: Nothing to disclose Sebastian, Alwin, MD, MSc, MRCP 1919. Efficacy & Safety of Tocilizumab in Giant Sen, Rouhin, MD, MS Cell Arteritis: A Single Centre NHS Experience 1561. Findings Compatible with Axial Using Imaging (Ultrasound and PET CT) as a Spondyloarthritis in Radiologist Reports Diagnostic and Monitoring Tool Disclosure: Nothing to disclose 1927. Ultrasonographic Halo Score as a Marker for Diagnosis and Monitoring of Disease Activity Senkal, Naci in GCA 0279. Pulmonary Involvement in a Single Center Disclosure: Nothing to disclose Cohort of Patients with Systemic Lupus Erythematosus Sebba, Anthony, MD Disclosure: Nothing to disclose

99

in Teaching Internal Medicine Residents Serling-Boyd, Naomi, MD Disclosure: Nothing to disclose 0545. The Use of Tocilizumab and Tofacitinib in Patients with Resolved Hepatitis B Infection: A Sharmeen, Saika, DO Case Series 0081. Prevalence of Systemic Autoimmune 1620. Hepatitis B Screening Practices When Diseases in Polycystic Ovary Syndrome Prescribing Tocilizumab or Tofacitinib in Real Disclosure: Nothing to disclose World Practice 1931. Effect of Cumulative Glucocorticoid Dose Shaver, Dawson, MD and Inflammation on Weight Change During 1197. Biomarkers for Rheumatoid Arthritis- Treatment of Giant Cell Arteritis Associated Interstitial Lung Disease: A Systematic Disclosure: Nothing to disclose Review Disclosure: Nothing to disclose Šestan, Mario, MD 1690. Henoch-Schönlein Purpura Nephritis: Sheikh, Saira, MD Different Histological Classifications, but Which 0854. Mortality and Adverse Events of Special One Is Most Strongly Associated to the Outcome Interest in Adult Patients with Systemic Lupus of the Disease? Pilot Study of the Paediatric Erythematosus Receiving Intravenous Rheumatology European Society Vasculitis Belimumab: A Post Hoc Descriptive Summary of Working Party Serious Psychiatric Events Disclosure: Nothing to disclose Disclosure: GSK (5); Pfizer (2)

Šestan, Mario, MD Shen, Lin, MD, PhD 1691. Applied Geostatistics in Pediatric 1401. Disease Mutation That Weakens ZAP70 Rheumatology – Spatial Clustering of IgA Autoinhibition Enhances Responses to Weak and Vasculitis Self Ligands Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Shadick, Nancy, MD, MPH Shi, Hui, MD, PhD 0756. Increased Risk of Hospitalization in 1448. Single-cell RNA Sequencing of Livedo Patients with RA Who Are ACPA Positive and Reticularis Skin Reveals Endothelial Pathology in Shared Epitope Positive Antiphospholipid Syndrome Disclosure: Amgen (2); Bristol-Myers Squibb Disclosure: Nothing to disclose Company (2, 5); Crescendo Biosciences (2); Lilly (2); Mallinckrodt (2); Sanofi (2) Shi, Xiaojun, RN, BSN 0694. Relationships Among Adherence and Shah, Ankoor, MD Patient Outcomes in a Cognitive Behavioral Plus 1139. Primary Non-adherence in Patients with Physical Activity Intervention for Older Adults Systemic Lupus Erythematosus with Osteoarthritis and Hypertension Disclosure: Affinergy Inc (2); Boehringer- Disclosure: Nothing to disclose Ingleheim (2); Bristol-Myers Squibb (2); Reata Inc. (2) Shiff, Natalie, MD 1983. Trajectories of Disease Activity in Patients Shah, Deepa, MD with Newly Diagnosed Juvenile Idiopathic 1705. In-Person Musculoskeletal Exam Arthritis in the Childhood Arthritis and Demonstration by Rheumatologist More Rheumatology Research Alliance Registry Effective Than Virtual PowerPoint Presentation Disclosure: Nothing to disclose

100

Shimada, Hiromi, MD Erythematosus: What Are the Best-performing 1775. Risk Factors for Adverse Pregnancy SLE Classification Criteria? Outcomes of Women with Positive for Disclosure: Nothing to disclose Antiphospholipid Antibodies Treated with Conventional Therapies Silverman, Gregg, MD Disclosure: Nothing to disclose 1815. Dynamic Changes in Microbiota Representation of a Gut Pathobiont and Clinical Shimizu, Jun, MD Disease Activity in Patients with Lupus Nephritis 1637. Comparison of Nation-wide Epidemical Disclosure: Nothing to disclose Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Silverman, Stuart, MD Rate May Come from Progress of Proficient 1120. A Comparison of Opioid-Related Outcomes Management in Patients with Relapsing Among Commercially-Insured Osteoarthritis Polychondritis in Japan Patients Treated with Tramadol vs. Non- Disclosure: Nothing to disclose Tramadol Opioids Disclosure: Pfizer (5) Shipa, Muhammad, MBBS, MRCP 1240. An Increase in Red Cell Mean Corpuscular Simmons, Daimon, MD, PhD Volume by Methotrexate Is Potentiated by 0949. SLAMF7 Engagement Drives Monocyte Hydroxychloroquine and Predicts Clinical Super-Activation in Acute and Chronic Response in Rheumatoid Arthritis Inflammation Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Shoop-Worrall, Stephanie, PhD Simon, David, MD 1493. Distinct Patient-level Patterns of Response 0501. Structural Entheseal Lesions in Psoriasis to Methotrexate in Juvenile Idiopathic Arthritis Patients Are Associated with an Increased Risk Disclosure: Nothing to disclose Ofprogression to Psoriatic Arthritis - A Prospective Cohort Study Siderius, Mark, BSc, MSc Disclosure: AbbVie (5); Janssen (8); Lilly (5, 8); 1354. The Effect of 8 Years of TNF-α Blocking Novartis (8) Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis Singer, Nora, MD Disclosure: Nothing to disclose 0230. Effect of Dose Escalation of Subcutaneous Tocilizumab on Disease Activity in Patients with Siebert, Stefan, MD, PhD Rheumatoid Arthritis in a Randomized Controlled 0367. Guselkumab Induces Sustained Reduction Trial in Acute Phase Proteins and Th17 Effector Disclosure: Genentech/Roche (Individual(s) Cytokines in Active Psoriatic Arthritis in Two Involved: Self): 2 Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2) Singh, Gurkirpal Disclosure: AbbVie (5, 8); Boehringer-Ingelheim 0657. Gout and Heart Failure in the US (2, 5); Bristol-Myers Squibb (2); Celgene (2, 8); Disclosure: Horizon Therapeutics (2) GlaxoSmithKline (2); Janssen (2, 5, 8); Novartis (2, 5, 8); Pfizer (2, 5); UCB (2, 5) Singh, Jasvinder, MD, MPH 0001. Management of Rheumatic Diseases Signorelli, Flavio Victor, PhD During COVID-19: A National Veterans Affairs 0521. Avoiding Misclassification of Primary Survey of Rheumatologists Antiphospholipid Syndrome as Systemic Lupus 0535. Provider Opinion and Support for Shared

101

Decision-making in Gout Treatment: A Quality Singh, Namrata, MD, MSc Improvement National Survey of Veterans Affairs 1781. Pregnancy After Bariatric Surgery in Rheumatologists Women with Rheumatic Diseases and 0647. Dual-energy CT versus Ultrasound, Alone Association with Adverse Birth Outcomes or in Combination, for the Diagnosis of Gout: A Disclosure: American Heart Association (2); Diagnostic Performance Study Rheumatology Research Foundation (2) 0652. Changes in Serum Urate, in the First 6- months of Initiation or Change of Urate-Lowering Singla, Shikha, MD Therapy, Associate with Immediate Health- 0111. Assessment and Treatment of Related Quality of Life Outcomes in People with Glucocorticoid-Induced Osteoporosis in a Gout Rheumatology Clinic 0689. The Changing Epidemiology of Inpatient Disclosure: Nothing to disclose Gout and Associated Mortality: A 17-year National Study Sinha, Rashmi, PhD 0823. Identifying Physician-Perceived Barriers to 0164. What’s in a Name? Patient and Family a Pragmatic Treatment Trial in Rheumatoid Perspectives on the Naming of Systemic Juvenile Arthritis Idiopathic Arthritis 0914. Serious Infections in People with Systemic Disclosure: Nothing to disclose Sclerosis: A National U.S. Study 0980. Hospitalized Infections in Lupus: A Sirobhushanam, Sirisha, PhD Nationwide Study of Types of Infections, Time- 0300. Exposure to Topical Antimicrobials trends, Healthcare Utilization and In-Hospital Reduces Inflammatory Gene Expression in Mortality Cutaneous Lupus Lesional Skin 1016. Annual Cardiac or Orthopedic Procedure Disclosure: Nothing to disclose Volume in Gout versus Rheumatoid Arthritis: A National Time-trends Study Sirotich, Emily, BSc 1022. Declining In-hospital Mortality Gap in 0007. Antimalarial Drug Shortages During the Lupus Compared to Non-lupus Hospitalizations: COVID-19 Pandemic: Results from the Global A National Study Rheumatology Alliance Patient Experience 1423. Declining In-Hospital Mortality in Survey Vasculitis: A 17-year U.S. National Study 0443. Impact of the COVID-19 Pandemic on 1959. Epidemiology of Hospitalizations and Racial and Ethnic Minority Groups Diagnosed Associated Mortality in Vasculitis: A National with Rheumatic Diseases Study Disclosure: Canadian Arthritis Patient Alliance (9, Disclosure: Amarin pharmaceuticals (1); non-financial support) Clearview healthcare partners (5); Clinical Care options (5); Crealta/Horizon (5); Fidia (5); Focus forward (5); Medisys (5); Medscape (5); Navigant Skaug, Brian, MD, PhD consulting (5); OMERACT (9, JAS is a member of 1907. DNASE1L3 R206C Polymorphism, a the executive of OMERACT, an organization that Systemic Sclerosis Risk Factor, Causes Impaired develops outcome measures in rheumatology Digestion of Genomic DNA in Apoptosis-derived and receives arms-length funding from 12 Extracellular Vesicles companies); Practice Point communications (5); 2033. Large-scale Examination of Longitudinal Putnam associates (5); Spherix (5); the American Skin Gene Expression and Its Associations with College of Rheumatology (5); the National Skin Thickness in Systemic Sclerosis Institutes of Health (5); Trio health (5); UBM LLC Disclosure: Nothing to disclose (5); Viking therapeutics (1); WebMD (5) Skopelja-Gardner, Sladjana, PhD

102

0945. Neutrophils Mediate Kidney Inflammation Following Acute Skin Exposure to UV Light Smitherman, Emily, MD 0946. ENPP1 Regulates UV Light Triggered Type I 1665. Sociodemographic and Clinical Predictors Interferon Response in the Skin of Childhood-Onset SLE Disease Activity in the Disclosure: Nothing to disclose Childhood Arthritis and Rheumatology Research Alliance Registry Skorupa, Tara, MD Disclosure: Nothing to disclose 1593. Adherence to Weight-Based Dosing Guidelines in Patients Receiving Smolen, Josef, MD Hydroxychloroquine for Rheumatoid Arthritis 0209. Upadacitinib as Monotherapy in Patients and Systemic Lupus Erythematosus: Results of a with Rheumatoid Arthritis and Prior Inadequate Quality Improvement Initiative Response to Methotrexate: Results at 84 Weeks Disclosure: Nothing to disclose 0319. Target Outcomes in Psoriatic Arthritis: Simultaneous Achievement of ACR50-Psoriasis Slief, Matt, BS Area and Severity Index 100 and Beyond: Insights 0301. Genetic Associations and Polygenic Risk from Open-Label, Assessor-Blinded Study at Assessment in Incomplete Lupus Erythematosus Week 24 Disclosure: Nothing to disclose 0352. Efficacy and Safety of Ixekizumab versus Adalimumab with and Without Concomitant Slight-Webb, Samantha, PhD Conventional Synthetic Disease-Modifying 0292. Exhausted pSTAT5-IFNα Signaling Antirheumatic Drugs (DMARD) in Biologic Pathways in SLE Patients Are Correlated with DMARD-Naïve Patients with Psoriatic Arthritis: Age-associated B Cells and Disease Activity 52-Week Results 0861. Hydroxychloroquine Use Is Associated with Disclosure: AbbVie (2, 5, 8); AstraZeneca (2, 5, 8); Diminished Type I Interferon-related Pathways in Celgene (5, 8); Celltrion (5, 8); Chugai (5, 8); Eli Systemic Lupus Erythematosus Patients Lilly (2, 5, 8); Gilead (5, 8); ILTOO (5, 8); Janssen Disclosure: Nothing to disclose (5, 8); Kabi (5, 8); Novartis-Sandoz (5, 8); Pfizer Inc (5, 8); Samsung (5, 8); Sanofi (5, 8) Sloan, Elizabeth, MD 1680. Lupus Anticoagulant as a Predictor of Soloman, Nehad, MD Adverse Outcomes in Children with Venous 1628. Management of Gout After Pegloticase; Thromboembolism Observations of US Clinical Practice from Trio Disclosure: Nothing to disclose Health and the American Rheumatology Network (ARN) Slobodkin, Marina, MD 1629. Management of Gout with Pegloticase; 1848. Identification of Native and Citrullinated Real-World Utilization and Outcomes from Trio Autoantibodies to Psoriasis Related-antigen Health and the American Rheumatology Network PsoP27 in Synovial Fluids of Patients with (ARN) Psoriatic Arthritis Disclosure: Abbvie (2, 5, 8); Amgen (2, 8); GSK (2, Disclosure: Nothing to disclose 5, 8); Horizon (5, 8); Jannsen (2, 8); Lilly (2); Novartis (5, 8); Pfizer (8); UCB (2, 5, 8) Smith, Rona, MD 2052. Extended Follow-Up of Patients Recruited Song, Hui, MD to a Randomized, Controlled Trial of Rituximab 1319. Disease Activity and Mental Health of as versus Azathioprine After Induction of Remission Patients: A Cross-section Study with Self- with Rituximab for Patients with ANCA- assessments Based on Smart System of Disease Associated Vasculitis and Relapsing Disease Management (SSDM) Mobile Tools Disclosure: Nothing to disclose Disclosure: Nothing to disclose

103

0489. Prevalence, Incidence, and Cause-Specific Song, Jing, MD, PhD Mortality of Rheumatoid Arthritis-Associated 0775. T and B Cell Responses to Common Interstitial Lung Disease Among Older Patients Tenascin-C Peptides in RA with Rheumatoid Arthritis: A Nationwide Cohort Disclosure: Nothing to disclose Study 0490. Fine Specificity Anti-Citrullinated Protein Song, Zoey Shuang, MPH Antibodies as Biomarkers for Prediction of 0609. Impact of Depressive Symptoms, Anti- Incident Rheumatoid Arthritis-Associated depression Treatment on Direct Medical Costs Interstitial Lung Disease Among Medicare Beneficiaries with Knee Disclosure: Amgen (2); Bristol-Myers Squibb (2, Osteoarthritis (KOA) 5); Gilead (5); Inova (5); Janssen (5); Optum (5) Disclosure: Nothing to disclose Specker, Christof Sood, Akhil, MD 0232. Safety and Effectiveness of Tocilizumab in 0008. COVID-19 Infection Among Patients with Patients with Renal Insufficiency in the Non- Rheumatic Disease on Biologic & Targeted interventional Study ICHIBAN Therapies: A Systematic Review Disclosure: AbbVie (5, 8); Boehringer Ingelheim 0807. Safety of Biologic & Targeted Therapies (2, 5); Chugai (2, 5, 8); GSK (2); Lilly (5, 8); Among Elderly Patients with Rheumatoid Novartis (5); Roche (2, 8); Sobi (5); UCB (5, 8) Arthritis: A Systematic Review and Meta-analysis Disclosure: Nothing to disclose Spitznagle, Jacob, MD 1176. Identifying Targets to Improve the Sophocleous, Eleni, MD Assessment of Psychosocial Risk Factors in 1700. Curricular Implementation of the Adolescent Patients: Perspectives from Pediatric Rheumatic Disease Patient Expert Program: The Rheumatology Fellows in the United States and Students’ Perspective Canada Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Sorensen, Jan, MSc Springer, Jason, MD, MS 0585. Cost-effectiveness of Motivational 0414. Clinical Characteristics of an Internet- Counselling and SMS-reminders on Daily Sitting Based Cohort of Participants with a Self- Time in Patients with Rheumatoid Arthritis Reported Diagnosis of Cryoglobulinemic Disclosure: Nothing to disclose Vasculitis or IgA Vasculitis 1438. Rituximab Immunogenicity in ANCA- Sørensen, Anne Sofie associated Vasculitis (RITUXIMAV) 0450. In Vitro Characterization of Inflammatory Disclosure: InflaRx (2) Arthritis Associated with Immune Check Point Inhibition Stal, Rosalinde, MSc Disclosure: Nothing to disclose 1881. In Radiographic Axial Spondyloarthritis, Bridging Syndesmophytes Increase Risk of Facet Spandorfer, Robert, MD Joint Ankylosis Development on the Same 0078. Retrospective Analysis of Clinical Vertebral Level While Facet Joint Ankylosis Does Characteristics and Classification Criteria Not Increase Risk of Same Level Syndesmophytes Performance in a Single Center Cohort of 114 Development Patients Diagnosed with IgG4-Related Disease Disclosure: Nothing to disclose Disclosure: Nothing to disclose Stamm, Bessie, BA Sparks, Jeffrey, MD, MSc

104

1783. Experience of Pregnant Rheumatology Generations Outpatients from a Tertiary Hospital in New York Disclosure: Nothing to disclose City During the COVID-19 Pandemic Disclosure: Nothing to disclose Stohl, William, MD, PhD 1834. Biomarker Analysis of IFN-I Modulation in Stanford, Stephanie, PhD JNJ-839: First-in-Human Study for Systemic Lupus 0793. Topological Laser Capture Microscopy Erythematosus (LCM)-RNAseq to Map the Rheumatoid Arthritis Disclosure: Gilead Sciences, Inc. (2); (RA) Synovial Transcriptome GlaxoSmithKline (2); Janssen Research & Disclosure: Eli Lilly (2) Development (5)

Starzyk, Kathryn, MSc Stojan, George, MD 1429. An Evaluation of Real World Use of 1019. Outdoor Air Pollution and Systemic Lupus Biologics in Rare Systemic Vasculitides During Erythematosus Routine Clinical Care in the US 1794. Systemic Lupus Erythematosus and Disclosure: Nothing to disclose Geomagnetic Disturbances: A Time Series Analysis Stauder, Sara (Sally), BS 1795. Intracellular Homocysteine and 0648. Dual Energy CT Has Additional Prognostic Homocysteine Metabolites in Systemic Lupus Value over Clinical Measures in Gout Including Erythematosus (SLE) Tophi: Best Evidence Synthesis Disclosure: Nothing to disclose Disclosure: Nothing to disclose Stone, John, MD, MPH Stavre, Zheni, MD, BS 1924. Low Immunogenicity in Patients with Giant 0966. Decoupling Inflammation and Bone Loss in Cell Arteritis Treated with Tocilizumab: 3-Year Rheumatoid Arthritis via Schnurri-3 Results from the Randomized Controlled Portion 1518. The Role for Neutrophils in the Early and the Open-Label Follow-Up of a Phase 3 Trial Phases of Enthesitis in Spondyloarthritis 1926. Efficacy of Adjunctive Methotrexate in Disclosure: Nothing to disclose Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Stein, Anna, MD Subanalysis of a Phase 3 Trial 1618. Frequency and Cost of Repeat HLA-B27 L07. Tocilizumab for COVID-19 Infection: A Testing Within the National Capital Consortium Randomized, Double-Blind, Placebo-Controlled over a Calendar Year Trial Disclosure: Nothing to disclose Disclosure: Genentech/Roche (Self) : 2; Roche () : 5, 2 Stens, Oleg, MD 0553. The US Prevalence of Ulcerative Colitis Štorkánová, Hana, MS Associated Peripheral Arthralgias and Arthritis: 1906. Hsp90 Inhibition Effectively Prevents Data from the National Health & Nutrition Progression of Dermal Fibrosis and Induces Examination Survey (NHANES) Regression of Established Bleomycin-Induced Disclosure: Nothing to disclose Dermal Fibrosis Disclosure: Nothing to disclose Stiburkova, Blanka, PhD 0658. Identification of Two Novel Dysfunctional Strand, Vibeke, MD Variants in a Physiologically Important Urate 1231. Radiographic Outcomes in Patients with Transporter ABCG2 in Paediatric-onset Familial Rheumatoid Arthritis Receiving Upadacitinib as Hyperuricemia and Gout Patients in Three Monotherapy or in Combination with

105

Methotrexate: Results at 2 Years 1341. Improvement in Patient-Reported Suleman, Yasir, MBBS, BSc Outcomes in Patients with Psoriatic Arthritis with 1383. Tocilizumab Shows Potential in Preserving Inadequate Response to Non-Biologic DMARDs Lung Function in Systemic Sclerosis with Positive Treated with Upadacitinib versus Placebo or anti-topoisomerase-1 (Scl-70): A Single Centre Adalimumab: Results from a Phase 3 Study Cohort Study 1363. Efficacy of Secukinumab on Patient- Disclosure: Nothing to disclose Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Sulli, Alberto, MD Necrosis Factor Inhibitor Use: Post Hoc Analysis 0633. Vitamin D Serum Status in a Cohort of from a Phase 3 Trial COVID-19 Patients 1371. Improvement in Patient-Reported 1392. Long-Term Tolerability of Aminaphtone in Outcomes for Upadacitinib versus Placebo Raynaud's Phenomenon Secondary to Systemic Among Patients with Psoriatic Arthritis and an Sclerosis Inadequate Response to Biologic Disease- Disclosure: Nothing to disclose Modifying Anti-Rheumatic Drugs Disclosure: AbbVie (5); Amgen (5); Arena (5); Suman, Saurav, MD AstraZeneca (5); Bayer (5); Boehringer Ingelheim 1265. 2019 Lupus Classification Criteria Score (5); Bristol-Myers Squibb (5); Celltrion (5); Predicting Cost of Future Hospitalizations Galapagos (5); Genentech/Roche (5); Gilead (5); Disclosure: Nothing to disclose GSK (5); Horizon (5); Ichnos (5); Inmedix (5); Janssen (5); Lilly (5); Merck (5); Novartis (5); Sumpter, Nick, MS Pfizer (5); Regeneron (5); Samsung (5); Sandoz 0661. Genomic Regions Jointly Associated with (5); Sanofi (5); Servier (5); Setpoint (5); UCB (5) eGFR and Serum Urate: Implications for Shared Genetic Etiology of Hyperuricemia and Chronic Stubbs, Leigh, MD Kidney Disease 1166. Use of Rituximab to Treat COPA Syndrome: 0663. Analysis of Common Gout Comorbidities in A Multi-Institutional Cohort the UK Biobank Cohort Reveals Sex-Specific Disclosure: Nothing to disclose Effects and Genetic Differentiation Disclosure: Nothing to disclose Stull, Courtney, MD 0324. Comparative Responsiveness of Outcome Sun, Enid, MD, MPH Measures in Psoriatic Arthritis: Preparation for 0049. Disparities in Patient Portal Use Among Pragmatic Trials Patients with Rheumatic and Musculoskeletal Disclosure: Nothing to disclose Diseases in a Large Academic Medical Center Disclosure: Nothing to disclose Subash, Meera, MD 1599. Workflows for Collecting and Using Sun, Kai, MD Patient-reported Outcomes Across 0591. Intervention to Improve SLE Medication Rheumatology Practices Adherence Using Surescripts Refill Disclosure: Nothing to disclose Data Disclosure: Nothing to disclose Sugawara, Masanari, MD 1752. Prediction of Responder and Non- Syngle, Ashit, MD, FRCP responder to JAK Inhibitors in Patients with 1891. Impact of Utilising Smart Phone Rheumatoid Arthritis: A Pilot Study with Application in Ankylosing Spondylitis: SMART- as Integrative Cluster Analysis Study Disclosure: Nothing to disclose Disclosure: Nothing to disclose

106

Lupus Syversen, Silje Watterdal, MD, PhD Disclosure: Nothing to disclose 2029. Therapeutic Drug Monitoring Compared to Standard Treatment of Patients Starting Tamura, Naoto, MD Infliximab: Results from a Multicenter 0206. Fifty-Two Week Outcomes of Biologic- Randomized Controlled Trial of 400 Patients Naïve RA Patients Treated with Subcutaneous Disclosure: Hospira/Pfizer (8); Roche (8); Thermo Abatacept in Japanese Multicenter Fisher (8) Investigational Study (ORIGAMI Study) Disclosure: AbbVie GK. (8); Bristol Myers Squibb Szekanecz, Zoltan, MD, PhD Co.Ltd. (8); Chugai Pharmaceutical Co.Ltd. (8); 0104. Bone Effects of One-year Tofacitinib Eisai Co., Ltd. (8); Eli Lilly Japan K.K. (8); Treatment in Rheumatoid Arthritis GlaxoSmithKline plc (2, 8); Janssen 0105. Use of Peripheral Quantitative Computed Pharmaceutical K.K. (8); Mitsubishi Tanabe Tomography in the Assessment of Bone Mineral Pharma Corporation; Novartis Pharma K.K. (8) Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients Tan, Chou Luan, MBBS, MRCP 1205. Soluble Vascular Biomarkers in 1015. The Prevalence and Risk Factors for Liver Rheumatoid Arthritis and Ankylosing Spondylitis: Fibrosis Among Rheumatoid Arthritis (RA) Effects of One-year Anti-TNF-α Therapy Patients on Disease-Modifying Anti-rheumatic 1206. Associations of Vascular and Bone Status Drugs (DMARDs) in Anti-TNF-treated Rheumatoid Arthritis and Disclosure: Nothing to disclose Ankylosing Spondylitis Patients Disclosure: AbbVie (5, 8); Bristol-Myers Squibb (5, Tan, Hiangkiat, MS 8); Merck Sharp & Dohme (5, 8); Pfizer (5, 8); 1030. Pain Medication Use Among Ankylosing Roche (5, 8) Spondylitis and Psoriatic Arthritis Patients Before and After Initiation of Biologic Therapy Ta, Viviane, MSc Disclosure: Nothing to disclose 0149. How Stable Are Medication Necessity Beliefs and Safety Concerns in the First Year of Tan, York Kiat, MBBS, MRCP, MMed RA? 1533. Ultrasound Joint Inflammation but Not 0151. More Than Half of Newly Diagnosed RA Disease Activity Score at 28 Joints Is Reflective of Patients Are Not Convinced of the Necessity of the Severity of Joint Damage in Patients with RA Medicines: Associations with RA Rheumatoid Arthritis Characteristics, Symptoms, and Function in the 1534. Combined Thermal and Ultrasound Canadian Early Arthritis Cohort (CATCH) Imaging in Rheumatoid Arthritis Is Superior to Disclosure: Nothing to disclose Either Imaging Alone in Terms of Correlation with the 28-joint Disease Activity Score Tabakovic, Dennis, MS Disclosure: Shire (8) 1436. Incidence Rate, Predictors and Outcome of Stroke in Patients with ANCA Associated Tanaka, Yoshiya, MD, PhD Vasculitis - A Population-based Study 0802. Real-World DMARD Experience and Disclosure: Nothing to disclose Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness Taber, Kreager, BA Disclosure: Takeda (8) 0441. Use of an Integrated Care Management Program to Uncover and Address Social Tang, Wei, MD Determinants of Health for Individuals with

107

1553. Optical Tomography Can Accurately Tedeschi, Sara, MD, MPH Diagnose Lupus Arthritis 0670. Risk Factors for Pseudogout: An Electronic Disclosure: Nothing to disclose Medical Record Case-Control Study Disclosure: Nothing to disclose Tarplin, Sarah, MD 1767. Maternal Peripartum Outcomes Are Tejera Segura, Beatriz Similar to the General Population in Rheumatoid 0267. Gastrointestinal Disease in SLE: Does It Arthritis Pregnancies Indicate a Worse Prognosis? Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Taylor, Peter, MD, PhD, MA Teniente-Serra, Aina, PhD 0147. The Interpretation of Patient-reported 0794. Peripheral Blood T and B Lymphocyte Outcomes in Rheumatoid Arthritis: Do Clinical Subsets in Arthritis in the Elderly Trials Adequately Evaluate Meaningful Disclosure: Nothing to disclose Improvements for Patients? 1201. Effect of Filgotinib on Pain in Patients with Teran-Tinedo, Maria Andreina, MD Rheumatoid Arthritis: Results from Phase 3 0730. To Taper or Not to Taper in Juvenile Clinical Trials Idiopathic Arthritis: Is There a Risk of 1212. Whole Blood Transcriptional Changes Development of Uveitis Flares? Following Selective Inhibition of Janus Kinase 1 Disclosure: Nothing to disclose (JAK1) by Filgotinib in MTX-Naïve Adults with Moderately-to-Severely Active Rheumatoid Terkeltaub, Robert, MD Arthritis (RA) 0953. Long-term Xanthine Oxidase Inhibitor 1239. Peripheral Protein Biomarker Changes Treat to Target Urate Lowering Therapy Following Selective Inhibition of Janus Kinase 1 Coordinately Re-wires the Mononuclear (JAK1) by Filgotinib in Methotrexate Naïve Adults Leukocyte Mitochondrial and Inflammatory with Moderately-to-Severely Active Rheumatoid Proteome in Gout Arthritis Disclosure: Astra Zeneca (2); Genentech (5); 2007. Whole Blood Transcriptional Changes Horizon (5); Selecta (5); SOBI (5) Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to- Terrill, Matthew, MBBS, FRACP Severely Active Rheumatoid Arthritis with Prior 1440. The Myeloperoxidase (MPO) Anti- Inadequate Response to Methotrexate Neutrophilic Cytoplasmic Antibody (ANCA) Disclosure: AbbVie (2, 5, 8); Biogen (2, 5, 8); Binding Epitope, MPO447-459 Induces CD4 T-cell Bristol-Myers Squibb (2, 5, 8); Celgene (2, 5, 8); Proliferation in Patients with MPO-ANCA- Celltrion (2, 5, 8); Eli Lilly (2, 5, 8); Fresenius (2, 5, associated Vasculitis 8); Galapagos (2, 5, 8); Gilead (2, 5, 8); Disclosure: Nothing to disclose GlaxoSmithKline (2, 5, 8); Janssen (2, 5, 8); Nordic Pharma (2, 5, 8); Pfizer (2, 5, 8); Roche (2, 5, 8); Terslev, Lene, PhD Sanofi (2, 5, 8); UCB (2, 5, 8) 1538. Doppler Ultrasound Predicts Successful Discontinuation of Biological DMARDs in Tchetina, Elena, PhD, DSc Rheumatoid Arthritis Patients in Sustained 1968. Cathepsin S Gene Expression Measured in Clinical Remission the Peripheral Blood of Osteoarthritic Patients Disclosure: AbbVie (8); Bristol Myers Squibb Prior to Surgery as a Biomarker of Post-operative (BMS) (8); General Electric (GE) (8); Janssen (8); Pain Development MSD (8); Novartis (8); Pfizer (8); Roche (8) Disclosure: Nothing to disclose Teskin, Catherine, DO

108

0125. A Resident-Led Interdisciplinary Quality 0789. Matrix Gla Protein (MGP) Modified with Improvement Initiative to Increase Osteoporosis Malondialdehyde/Acetaldehyde Is Increased in Screening in an Urban Clinic Rheumatoid Arthritis and Cardiovascular Patients Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Theander, Lisa, MD Tillett, William, MD, PhD 0188. The Risk of Fractures in a Community- 0326. Flares Among Patients with Psoriatic based Cohort of Patients with Rheumatoid Arthritis (PsA) - Frequency and Impact on Patient Arthritis Compared with the Background Outcomes: Real-world Survey in the US and Population Europe Disclosure: Nothing to disclose Disclosure: Abbvie (5, 8); Amgen Inc. (5, 8); Celgene (5, 8); Eli Lilly and Company (5, 8); Thietart, Sara Janssen (5, 8); MSD (5, 8); Novartis (5, 8); Pfizer 1417. Risk of Relapse of ANCA-associated (5, 8); UCB Pharma (5, 8) Vasculitis in Patients of 75 Years and Older: A Retrospective Study Tilstra, Jeremy, MD, PhD Disclosure: Nothing to disclose 0976. Kidney-infiltrating T Cells in Murine Lupus Nephritis Exhibit Transcriptional Heterogeneity Thom, Howard, PhD and Oligoclonal Expansion 0581. A Proposed Economic Framework to Disclosure: Nothing to disclose Model the Consequences of Psoriatic Arthritis Disease Domains Tiwari, Arun, MD Disclosure: Amgen Inc. (9, Part of a study 1610. Cutaneous Side Effects of sponsored by Amgen Inc.) Hydroxychloroquine in Rheumatic Diseases – Combination of “Traditional” Multivariate Thoma, Louise, PhD, DPT Analysis for Risk Factors AndClassification Model 0611. Disease Activity and Disability Are Not Development Using Supervised Machine Associated with Rehabilitation Utilization in Learning –Single Centre Retrospective Cohort African Americans with Rheumatoid Arthritis Study in Indi 0698. Baseline Factors Are Not Associated with Disclosure: Nothing to disclose Rehabilitation Dose over Six Months Among Adults with RA Tofighi, Tara, MD Disclosure: Nothing to disclose 0253. Serum Albumin as a Predictor of Proteinuria Recovery in Lupus Nephritis Thomas, Julie, MD Disclosure: Nothing to disclose 1585. Lessons Learned Through Rapid Quality Improvement for Telehealth Implementation in Toprover, Michael, MD an Academic Rheumatology Practice During the 0681. Gout and Serum Urate Levels Are COVID-19 Pandemic Associated with Lumbar Spine Monosodium Disclosure: Nothing to disclose Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study Thomley, Meredith, BSc Disclosure: Nothing to disclose 0096. The Bicipital Stress Test: A Maneuver to More Accurately Diagnose Bicipital Tendinitis Tornero-Marin, Carolina, RhMSUS and Its Referred Pain Patterns 0127. Biochemical Algorithm to Identify Disclosure: Nothing to disclose Individuals with ALPL Variants Between Subjects with Persistent Hypophosphatasaemia Tieliwaerdi, Xiarepati, MD Disclosure: Nothing to disclose

109

Miners Torreggiani, Sofia, MD Disclosure: Nothing to disclose 1158. Clinical Features and Outcomes in STING- Associated Vasculopathy with Onset in Infancy Tse, Karin, MPH (SAVI) 0436. The Addressing Lupus Pillars for Health Disclosure: Nothing to disclose Advancement (ALPHA) Project: Establishing Consensus and Prioritization of Global Torres, Alyssa, BS Community Recommendations to Address Major 0783. Role of Glutamine Metabolism in Challenges in Lupus Diagnosis, Care, Treatment Rheumatoid Arthritis Fibroblast-Like Synoviocyte and Research Aggressive Phenotype Disclosure: Lupus Foundation of America (3) Disclosure: Nothing to disclose Tse, Karin, MPH Touma, Zahi, MD, PhD 1461. Implementation, Feasibility and 0268. Impact of Flares on Healthcare Resource Acceptability of Take Charge, an Email Series to Usage and PROs in Systemic Lupus Increase Knowledge of Lupus Self-Management Erythematosus Patients Skills 1282. The Impact of High Disease Activity as Disclosure: Lupus Foundation of America (3) Measured by SLEDAI and Drug Burden on Healthcare Utilization, Quality of Life and Work Tselios, Konstantinos, MD, PhD Productivity in Systemic Lupus Erythematosus 0852. How Much Prednisone Is Enough for Patients Remission Induction in Lupus Nephritis? A Disclosure: Nothing to disclose Propensity Score Matched Analysis 0853. Gradual Glucocorticoid Withdrawal Is Safe Toussirot, Eric, MD in Clinically Quiescent Systemic Lupus 1336. Bone Mineral Density, Trabecular Bone Erythematosus Score and Proximal Femur 3D-DXA Analysis in Disclosure: Nothing to disclose Psoriatic Diseases 1903. Assessment of Global DNA Methylation in Tsou, Eliza Pei-Suen, PhD Peripheral Blood Cell Subpopulations of Patients 0069. Identification of CD13 as a Potential Cause with Axial Spondyloarthritis : Preliminary Results for SARS-CoV-2-triggered Hyperinflammation Disclosure: Nothing to disclose and Thrombosis Disclosure: Nothing to disclose Trent, Brandon 0996. Bacteria-Derived Indole Drives Tumurkhuu, Gantsetseg, PhD Autoimmune Arthritis by Altering B Cell 0284. Oxidative DNA Damage Accelerates Skin Glycosylation of Autoantibodies Inflammation in Pristane-induced Lupus Model Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Trevisonno, Michael, MD Turesson, Carl, MD 1823. Mycophenolate Mofetil for Systemic Lupus 0419. Survival and Prevalent Comorbidities in Erythematosus: Our 20-year Experience Polymyalgia Rheumatica Disclosure: Nothing to disclose Disclosure: Abbvie (8); Bristol-Myers Squibb (2, 8); Pfizer (8); Roche (5, 8) Trupin, Laura, MPH 1462. Intensity and Duration of Silica Exposure Turnier, Jessica, MD Increase Rheumatoid Arthritis Risk Among Coal

110

1989. NXP2 Autoantibodies Link to Interferon 1390. Outcomes of Systemic Sclerosis Patients Signature in Juvenile Myositis Lesional Skin Who Were Primarily Admitted for Acute Disclosure: Nothing to disclose Myocardial Infarction from 2016 to 2017: Insights from the National Inpatient Sample Ugarte Gil, Manuel Francisco, MD, MSc 1424. Outcomes of Hospitalizations for Acute 0254. LLDAS (Low Lupus Disease Activity State) Myocardial Infarction in Patients with ANCA and Remission Prevent Damage Accrual in Associated Vasculitis from the National Inpatient Systemic Lupus Erythematosus (SLE) Patients in a Sample Primarily Mestizo Cohort Disclosure: Nothing to disclose Disclosure: Janssen (2); Pfizer (2) Valenzuela Vergara, Antonia Maria, MD, MS Ukadike, Kennedy, MD, MS 1080. Sensitivity and Specificity of the 2017 1818. IgG and IgA Autoantibodies Against L1 EULAR/ACR Criteria for Idiopathic Inflammatory ORF1p Expressed in Granulocytes Correlate with Myopathies in a Cohort of Patients from Latin Granulocyte Consumption and Disease Activity in America Pediatric Systemic Lupus Erythematosus Disclosure: Nothing to disclose Disclosure: Nothing to disclose Valerio, Valeria, MD Ulloa Baez, Ana C., MPH 1292. Frequency and Predictors of Influenza 1677. Schizophrenia Genetics and Vaccine Hesitancy in Systemic Autoimmune Neuropsychiatric Features in Childhood-Onset Rheumatic Diseases Systemic Lupus Erythematosus Disclosure: Nothing to disclose Disclosure: Nothing to disclose Valinotti, Vannia, MD Unizony, Sebastian, MD 0084. Clinical Characteristics of Patients with 0513. Mass Spectrometry Identifies Novel Rheumatism of Juvenile Onset and Adult Onset Biomarkers in Giant Cell Arteritis, Useful in in the BIOBADAGUAY Cohort Patients on Interleukin-6 Receptor Blockade Disclosure: Nothing to disclose 0516. Characteristics of Giant Cell Arteritis Flares After Successful Treatment with Tocilizumab: Valle, Ana, MD, MHS Results from the Long-Term Extension of a 1079. Sex Differences in Antibody Profile, Randomized Controlled Phase 3 Trial Phenotype, and Treatment Response in a Racially 1236. Association Between Change in Health Diverse Population with Idiopathic Inflammatory Assessment Questionnaire Disability Index and Myopathies Treatment Response in Patients with Disclosure: Nothing to disclose Rheumatoid Arthritis in Tocilizumab Clinical Trials van Bentum, Rianne, MD Disclosure: Genentech (2); Janssen (2, 5); Kiniksa 0881. Reduction of Anterior Uveitis Flares in (5); Sanofi (5) Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results Useche, Mariana, MD from the C-VIEW Study 1740. Determinants of Influenza Vaccine 1306. High Prevalence of Previously Hesitancy in Rheumatoid Arthritis According to Undiagnosed Axial Spondyloarthritis in Patients the WHO-SAGE Matrix Referred with Anterior Uveitis and Chronic Back Disclosure: Nothing to disclose Pain Disclosure: Nothing to disclose Vafa, Atefeh, MD van Boheemen, Laurette

111

1722. Predicting Rheumatoid Arthritis Using the 2013. Substantial Lifetime Risk of Developing Symptoms in Persons at Risk of Rheumatoid Ankylosing Spondylitis (Axial Spondyloarthritis) Arthritis (SPARRA) Questionnaire for Relatives. Evidence from a 35-Year Follow-up 1742. Patients’ and Rheumatologists’ Family Study of a Swiss Cohort Perceptions on Preventive Intervention in Disclosure: Nothing to disclose Rheumatoid Arthritis and Axial Spondyloarthritis 1744. The STAtins to Prevent Rheumatoid van der Meulen, Coen, MSc Arthritis (STAPRA) Trial: Clinical Results and 1102. Neuropathic Pain in Inflammatory Hand Subsequent Qualitative Study, a Mixed Method Osteoarthritis(OA) Lowers Quality of Life and Evaluation May Require Another Approach Than Anti- Disclosure: Nothing to disclose inflammatory Treatment Disclosure: Nothing to disclose Van den Bosch, Filip, MD, PhD 2028. Predictors of Maintaining Inactive Disease van Gelder, Teun After Etanercept Withdrawal, and Regaining 0862. Voclosporin Does Not Decrease Inactive Disease Status After Flare and Mycophenolic Acid Concentrations in Patients Retreatment, in Adults with Non-radiographic with SLE Axial Spondyloarthritis: Results from RE-EMBARK Disclosure: AstraZeneca (8) Disclosure: AbbVie (5, 8); Celgene (5, 8); Eli Lilly (5, 8); Galapagos (5, 8); Gilead (5); Merck (5, 8); van Leeuwen, Nina, MD Novartis (5, 8); Pfizer (5, 8); UCB (5, 8) 0919. Determinants of Health-related Quality of Life in Systemic Sclerosis van der Heijde, Désirée, MD, PhD 0920. Machine Learning Assisted Prediction of 1235. Radiographic Progression of Structural Progression in Systemic Sclerosis Patients: An Joint Damage over 5 Years of Baricitinib Approach to Concise, Tailored Model Treatment in Patients with Rheumatoid Arthritis: Construction Using Outpatient Clinical Data Results from RA-BEYOND Disclosure: Nothing to disclose Disclosure: AbbVie (5); Amgen Inc. (5); Astellas (5); AstraZeneca (5); Boehringer Ingelheim (5); van Mulligen, Elise, MSc Bristol-Myers Squibb (5); Celgene (5); Cyxone (5); 0572. Two-year Cost-effectiveness Between Two Daiichi-Sankyo (5); Eisai (5); Eli Lilly (5); Gradual Tapering Strategies in Rheumatoid Galapagos NV (5); Gilead Sciences; Arthritis: Cost-utility Analysis of the TARA Trial GlaxoSmithKline (5); Imaging Rheumatology bv 0804. Factors That Influence Biological Survival in (3); Janssen (5); Merck (5); Novartis (5); Pfizer Rheumatoid Arthritis: Results of a Real-world (5); Regeneron (5); Roche (5); Sanofi (5); Takeda Cohort from the Netherlands (5); UCB Pharma (5) Disclosure: Nothing to disclose

Van Der Linden, Sjef, MD Van Vollenhoven, Ronald F, MD, PhD 1305. Is the Occurrence of Acute Anterior Uveitis 0207. Upadacitinib Monotherapy in Linked Primarily to Ankylosing Spondylitis (AS) or Methotrexate-naïve Patients with Rheumatoid to HLA-B27? Results of a 35-Year Follow-Up Arthritis: Results at 72 Weeks Family Study of a Swiss Cohort of Patients with 1826. •Maintenance of Efficacy and Safety and AS Reduction of BILAG Flares with Ustekinumab, an 1863. Clinical History as Tool for Diagnosis and Interleukin-12/23 Inhibitor, in Patients with Classification of Patients with Ankylosing Active Systemic Lupus Erythematosus: 2-Year Spondylitis (Axial Spondyloarthritis): Evidence Results of a Phase 2, Randomized Placebo- from a 35-Year Follow-up Family Study of a Swiss Controlled, Crossover Study Cohort Disclosure: AbbVie, AstraZeneca, Biogen, Biotest,

112

Celgene, GSK, Janssen, Lilly, Pfizer, Servier, UCB 0446. Novel Ultrasound Image Acquisition Pharma: 5, Speaker/Honoraria; BMS, GSK, Lilly, Protocol and Scoring System for the Pediatric Pfizer, UCB Pharma: 2 Ankle Disclosure: Nothing to disclose van Wesemael, Tineke, MSc 0767. Anti-acetylated Protein Antibodies in Venne, Karel, MD Rheumatoid Arthritis (RA): Clues for the Starting 1074. A Novel Autoantibody Recognizing a 65- Point of Autoantibody Responses in RA kDa Protein Is Associated with Scleromyositis Disclosure: Nothing to disclose with Head Drop and/or Bent Spine Disclosure: Nothing to disclose Vanni, Kathleen, BA 2001. Adverse Effects of Low Dose Verhoeven, Maxime Methotrexate: Adjudicated Hematologic 1731. Development of a Disease Activity Index Outcomes in a Large Randomized Double-blind for Rheumatoid Arthritis Patients Using the Placebo-controlled Trial HandScan Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Vargas-Santos, Ana Beatriz, MD, PhD Verstappen, Marloes, MD 0660. Sodium-Glucose Co-Transporter-2 0479. Early DAS Response After DMARD-start Inhibitors and the Risk for Gout – a Comparison Increases Probability of Achieving Sustained Among Canagliflozin, Dapagliflozin and DMARD-free Remission in Rheumatoid Arthritis Empagliflozin Disclosure: Nothing to disclose Disclosure: Abbvie (8) Verstegen, Ruud, MD, PhD Varghese, Timothy, BSc 0716. Variations in Adalimumab and Etanercept 0130. The Prevalence of Osteoporosis in Dosing in Juvenile Idiopathic Arthritis and Their Individuals with Osteoarthritis: A Systematic Effect on Treatment Outcome: A Childhood Review Arthritis and Rheumatology Research Alliance Disclosure: Nothing to disclose (CARRA) Registry Study Disclosure: Nothing to disclose Vasquez Canizares, Natalia, MD 1170. Exploring the Use of Von Willebrand Verweyen, Emely, PhD Factor as a Disease Biomarker in a Cohort of 1154. Distinct Gene Signature Predicts Strong Patients with Juvenile Scleroderma: A Pilot Study Clinical Responses to Canakinumab in Children Disclosure: Nothing to disclose with Systemic Juvenile Idiopathic Arthritis Disclosure: Nothing to disclose Vazzana, Kathleen, DO 1673. Principles of Pediatric Lupus Nephritis in a Vincent, Fabien, MD, PhD Contemporary Multi-Center Cohort 1809. Serum Cytokine Profiling in Systemic Lupus Disclosure: Nothing to disclose Erythematosus, Analysed Using Unsupervised Machine Learning, Reveals Clinically Relevant Vega-Alvarez, Lucia, MD Clusters 0227. Real Life Severe Infections in Patients with Disclosure: Nothing to disclose Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors Vīnkalna, Ilze Disclosure: Nothing to disclose 0872. Usage of Corticosteroids and Hospitalisation Duration in Adult Patients with Vega-Fernandez, Patricia, MD

113

Systemic Lupus Erythematosus (SLE) in Latvia 0917. Drug-Drug Interaction Study of Nintedanib Disclosure: Nothing to disclose (Ofev®) and the Combination of Ethinylestradiol and Levonorgestrel (Microgynon®) in Patients Vital, Edward, PhD, MBChB, MRCP with Systemic Sclerosis-Associated Interstitial 0859. Biomarkers of B-cell Depletion and Lung Disease (SSc-ILD) Response in a Randomized, Controlled Trial of Disclosure: Actelion Pharmaceuticals (2, 5, 8); Obinutuzumab for Proliferative Lupus Nephritis Boehringer Ingelheim (5, 8); Ferrer (2); Disclosure: Roche/Genentech (2, 5) GlaxoSmithKline (5, 8); Roche (5, 8)

Vitone, Gregory, BS Vu, Khiem, MD 0018. PROMIS-29 and Health Related Quality of 0115. Improving Osteoporosis Screening in Men Life in Rheumatology Outpatients During the at a Resident-run Primary Care Clinic: A Quality COVID-19 Pandemic in New York City Improvement Project Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Vo, Caroline, MD Vukelic, Milena, MD 1064. Anti-SMN Autoantibodies Are Associated 0838. T Cell–Specific CaMKIV Deficiency Protects with Systemic Sclerosis Small Bowel Involvement Mice from Imiquimod-induced in anti-U1RNP Positive Autoimmune Myositis Glomerulonephritis Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Voinier, Dana, MS, DPT Vuppala, Anusha, MD 0557. The Joint Association of Steps/day and 1042. Building LSU Uveitis Registry ( BLUR ) Study Typical Sedentary Bout Length with Worsening – a Review of an Academic Rheumatology Knee Cartilage Damage over Two Years: The Center’s Experience and Approach to Uveitis MOST Study Disclosure: Nothing to disclose Disclosure: Nothing to disclose Wade, Stefanie, MD Volkmann, Elizabeth, MD 0474. Assessment of Teaching Behavior and 0383. Sex Differences in Severity and Progression Knowledge Among Faculty to Inform an Active of Interstitial Lung Disease in Systemic Sclerosis: Teaching Intervention Within a Rheumatology What We Have Learned from Clinical Trials Fellowship Curriculum Disclosure: Boehringer Ingelheim (2, 5); Corbus Disclosure: Nothing to disclose (2); Forbius (2, 5) Wakabayashi, Kuninobu, MD, PhD Volkmann, Elizabeth, MD 0780. Subsets of Synovial Fluid Derived 1523. Pulmonary Cytokine, Chemokine and Fibroblast-like Synoviocytes in Rheumatoid Growth Factor Profiles of Distinct Radiographic Arthritis Patterns of Interstitial Lung Disease in Systemic Disclosure: Nothing to disclose Sclerosis 2041. Disease Features of Systemic Sclerosis Are Wakefield, Emily, PhD Associated with Alterations in Gastrointestinal 0737. “It’ll Go Away. There’s Nothing Wrong Microbial Composition in Two Independent with you:” the Experience of Pain-Related Stigma Cohorts Among Adolescents with Pain Amplification Disclosure: Boehringer Ingelheim (2, 5); Corbus Syndrome (2); Forbius (2, 5) Disclosure: Nothing to disclose

Vonk, Madelon, MD, PhD Walker, David, MD

114

1215. Filgotinib Provided Rapid and Sustained 1988. Skin Disease More Recalcitrant to Relief of Pain and Fatigue and Improved Health- Intervention Than Muscle Disease: A Long-Term Related Quality of Life in Patients with Prospective Study of 184 Children with Juvenile Rheumatoid Arthritis and Inadequate Response Dermatomyositis to Biologic DMARDs Disclosure: Nothing to disclose Disclosure: Eli Lilly (5, 8); Gilead Sciences, Inc. (5, 8); Novartis (5, 8); Pfizer (5, 8) Wang, Qiang, PhD 0039. Identification of a Regulatory Pathway Wallace, Beth, MD, MS Governing Expression of TRAF1 via a JIA- 1958. Patterns and Impact of Long-term associated Non-coding Variant Glucocorticoid Use on RA Patients at Risk for 1955. High-throughput Identification of Major Adverse Cardiac Events Functional Regulatory SNPs Associated with Disclosure: Nothing to disclose Systemic Lupus Erythematosus Disclosure: Nothing to disclose Wallace, Daniel, MD 0865. Efficacy and Safety of Evobrutinib (M2951) Wang, Runci, MD, PhD in Adult Patients with Systemic Lupus 0977. Expanded T Peripheral Helper Cells and Erythematosus Who Received Standard of Care Increased Pathologic B Cell Lung Infiltration in Therapy: A Phase II, Randomized, Double-blind, Pristane-induced Murine Lupus in the Absence of Placebo-controlled Dose Ranging Study BCL6+ Tfh Cells Disclosure: Nothing to disclose 1443. High-dimensional Analyses of Checkpoint- inhibitor Related Arthritis Synovial Fluid Cells Wallace, Zachary, MD, MSc Reveal a Unique, Proliferating CD38hi Cytotoxic 1422. Healthcare Utilization Among Patients CD8 T Cell Population Induced by Type I IFN Diagnosed with ANCA-Associated Vasculitis Disclosure: Nothing to disclose Between 2007 and 2014 in a Multi-Center Cohort Linked to Medicare Claims Data Wang, Runsheng, MD, MHS 1425. Reduced Risk of Cardiovascular Diseases 1029. Clinical Characteristics of Patients with Events with Renal Transplantation in Axial Spondyloarthritis in China: Results from the Granulomatosis with Polyangiitis in the United ChinaAS Registry States: Data from the US Renal Data System 1346. Predicting Major Treatment Response to Disclosure: Bristol-Myers Squibb (2) Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis Walsh, Jessica, MD Disclosure: Eli Lilly (5); Novartis (8) 0327. Skin Involvement in Psoriatic Arthritis (PsA) - The Incremental Impact of Psoriasis on Wang, Shudan, MD Quality of Life, Disability and Work Productivity: 1791. Renal Tubular Complement C9 Deposition Real-world Survey in US and Europe Is Associated with Renal Tubular Damage and 0500. Genomic, Phenomic, Proteomic Predictors Fibrosis in Lupus Nephritis of Psoriatic Arthritis 1814. The Association of Urinary Membrane 1314. Fatigue in Psoriatic Arthritis (PsA): Attack Complex (C5b-9) with Proteinuria and Prevalence in Patients from the US and Europe, Glomerular Activity in Lupus Nephritis and Impact on Quality of Life and Work Disclosure: Nothing to disclose Productivity Disclosure: AbbVie (2, 5); Amgen (5); Eli Lilly (5); Wang, Xinghao, BSc Janssen (5); Novartis (5); Pfizer (2); UCB (5) 0975. Gasdermin D Modulates Murine Lupus and Its Associated Organ Damage Wang, Andi, BA Disclosure: Nothing to disclose

115

Psoriasis, Iritis, and Colitis Cohort Wang, Yongfu, MD Disclosure: Nothing to disclose 1295. Disease Activity and Mental Health in SLE Patients: A Cross-section Study with Self- Webster, Dan, PhD Assessments Based on Smart System of Disease 0322. Development and Preliminary Validation Management (SSDM) Mobile Tools of Smartphone Sensor-based Measurement Disclosure: Nothing to disclose Tools for Psoriatic Arthritis Disclosure: Otsuka Pharmaceutical (8) Wareing, Nancy 0384. Serum Neutrophil Count Predicts Weeding, Emma, MD Progression of Interstitial Lung Disease and 0029. Urine Proteomic Classifiers Predict Renal Mortality in Patients with Systemic Sclerosis Histological Activity and Chronicity Indices and Related Interstitial Lung Disease May Predict Treatment Response in Lupus Disclosure: Nothing to disclose Nephritis Disclosure: Nothing to disclose Warner, Blake, PhD, MPH, DDS 0449. Cytotoxic T Cells with a Chronic Antigen Wehr, Pascale, BSc Exposure Phenotype Drive Immune Checkpoint 0972. Mapping Oligoclonally Expanded T Cells Inhibitor Sicca Within the Peripheral and Synovial Immune Disclosure: Nothing to disclose Landscape of Untreated ACPA+ Rheumatoid Arthritis Patients at the Single Cell Level Watrous, Daniel, MD Disclosure: Nothing to disclose 0017. Impact of COVID19 on Missed/Cancelled Rheumatology Office Visits and Parenteral Wei, Kevin, MD, PhD Immunosuppressive Medications 0971. Single-cell Profiling of Synovial Stromal Disclosure: Nothing to disclose Cells Reveals an Angiocrine Endothelium in Rheumatoid Arthritis Waytz, Josh, MD Disclosure: Gilead (5) 1965. Reducing Delays for Biologic Medication Approval in Outpatient Rheumatology Weinblatt, Michael, MD Disclosure: Nothing to disclose 0683. Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Webber, Declan, BSc, MPH Uncontrolled Gout Receiving Pegloticase and Co- 0982. Genetics of Avascular Necrosis in Children treatment of Methotrexate and Adults with Systemic Lupus Erythematosus Disclosure: AbbVie (5); Amgen (2); Amgen (2, 5); Disclosure: Nothing to disclose Arena (5); Bristol Myers Squibb (2, 5); Bristol Myers Squibb (2); Canfite (1); Canfite (1, 5); Weber, Brittany, MD, PhD Corrona (5); Crescendo (2, 5); Crescendo 1191. Specificity for Inflammatory Pathways Bioscience (2); Gilead (9); GlaxoSmithKline (5); Associated with Coronary Microvascular Horizon (9); Inmedix (1); Johnson and Johnson Dysfunction in Rheumatoid Arthritis (9); Lilly (2, 9); Lilly (2); Lycera (1); Pfizer (9); Disclosure: Nothing to disclose Roche (9); Sanofi (2); Scipher (1, 9); Set Point (9); Vorso (1) Weber, Ulrich, MD 1303. Performance of Three Referral Algorithms Weiner, Julia for Diagnosing Axial Spondyloarthritis: Results 0526. Patient-Reported Outcomes in from the Screening in Axial Spondyloarthritis for Antiphospholipid Syndrome Disclosure: Nothing to disclose

116

Weiss, Pamela, MD, MSCE Westhovens, Rene, MD, PhD 1870. Development of Candidate Criteria for 0217. Efficacy and Safety of Filgotinib in Axial Disease in Juvenile Spondyloarthritis: An Methotrexate-Naïve Patients with Rheumatoid International Collaboration Arthritis: 52-Week Results Disclosure: Lilly (5); Pfizer (5) 0236. Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre- Wells, Alvin, MD, PhD filled Syringe (PFS) in Patients with Active 0224. Efficacy of Long-term Treatment with Rheumatoid Arthritis (RA): Patient-reported Baricitinib 2 Mg in Patients with Active Experience from a Multicenter, Randomized Rheumatoid Arthritis Controlled Pivotal Trial 1762. Benefit and Risk Profiles of Janus Kinase 1208. Utility of Measuring the Immunogenicity Inhibitors Approved in the US for the Treatment to CT-P13 for Subcutaneous Use in Patients with of RA Active Rheumatoid Arthritis: 1-Year Results from Disclosure: Abbvie (2, 5); Eli Lilly & Co. (2, 5) a Multicenter, Randomized Controlled Pivotal Trial Wells, Kristina, BS Disclosure: Celltrion, Inc. (2, 5); Galapagos NV (2, 0424. Anti-Collagen II Antibodies in Patients with 5); Gilead Sciences, Inc. (2, 5) Relapsing Polychondritis Disclosure: Nothing to disclose Wheeler, Austin, MD 1196. Associations of Biological Sex with Wendling, Daniel, MD, PhD Interstitial Lung Disease in Patients with 1304. Uveitis Occurrence in Early Inflammatory Rheumatoid Arthritis Are Independent of Other Back Pain: Five Years Data from a Prospective Known Risk Factors French Nationwide Cohort Disclosure: Nothing to disclose Disclosure: Nothing to disclose White, Matthew, DO Werth, Victoria, MD 0123. Aromatase Inhibitor-Associated Bone Loss: 0985. Early and Sustained Reduction in Severity Screening and Prevention of Skin Disease with Anifrolumab Treatment in Disclosure: Nothing to disclose Patients with Active SLE Measured by the Cutaneous Lupus Erythematosus Disease Area Whitney, Raeann, MD and Severity Index (CLASI): Pooled Data from 2 0276. Type 2 SLE Symptoms Persist Despite Type Phase 3 Studies 2 Medication Polypharmacy 0986. BIIB059, a Humanized Monoclonal Disclosure: Nothing to disclose Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose- Whittall-Garcia, Laura Related Efficacy in a Phase 2 Study in Participants 0270. The New EULAR/ ACR 2019 SLE with Active Cutaneous Lupus Erythematosus Classification Criteria: Defining Ominosity in SLE 1639. Preliminary Baseline Subject Disclosure: Nothing to disclose Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Widener, Benjamin, MD Lenabasum in Dermatomyositis (DETERMINE) 0475. To Attend or Not to Attend; The Medical L10. Targeting Plasmacytoid Dendritic Cells Student's Dilemma Improves Cutaneous Lupus Erythematosus Skin Disclosure: Nothing to disclose Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734 Wiemer, Nicholas, DO Disclosure: Biogen (2, 5)

117

0177. Association of Hydroxychloroquine Use High-Risk Patients with Lupus with Development of Non-Alcoholic Fatty Liver Disclosure: Nothing to disclose Disease in Rheumatoid Arthritis Disclosure: Nothing to disclose Willis, Rohan, MD 0519. Thrombotic and Obstetric Associations of Wiens, Dana, BSc Non-Criteria Antiphospholipid Immunoassays 0758. Anti-citrullinated Protein Antibodies Are That Detect Antibodies to Neutral and Associated with Functional Disability in Negatively-Charged Phospholipid Unaffected First-degree Relatives of Rheumatoid 1447. Vitamin D Deficiency Enhances Arthritis Patients Antiphospholipid Antibody-Mediated Disclosure: Nothing to disclose Thrombosis in a Passive Immunization Mouse Model Wilding, Anna, MD Disclosure: Louisville APL Diagnostics Inc (5); 1433. Thyroid Disease in ANCA-associated Pfizer (2) Vasculitis. a Population-based Study Disclosure: Nothing to disclose Wilson, Timothy, MD 1200. Serum Anti-PAD4 and Anti-PAD3/4XR Wilfong, Erin, MD, PhD Antibodies in Rheumatoid Arthritis Associated- 1055. Myositis and Systemic Sclerosis Spectrum Interstitial Lung Disease Are Associated with IPAF Patients Are More Likely to Respond Better Lung Function Favorably to Immunosuppression Disclosure: Nothing to disclose Disclosure: Nothing to disclose Wincup, Chris, MBChB, MRCP Williams, Christopher, MD 0294. Tired T-Cells and Monocytes with Malaise: 1086. The Diagnostic Value and Clinical Investigating the Links Between Cellular Iron Significance of Myositis-Specific Antibodies in Deficiency and Mitochondrial Dysfunction in Patients Suspected to Have Autoimmune Systemic Lupus Erythematosus Myopathies and/or Autoimmune Rheumatic Disclosure: Nothing to disclose Diseases Disclosure: Nothing to disclose Winter, Deborah, PhD 1969. The Dynamics of Macrophage Sub- Williams, Edith, PhD Populations in the Inflammatory Phase Following 0616. Correlation Between Disease Activity and Joint Trauma Perceived Economic Barriers to Care in a Disclosure: Nothing to disclose Population of African American Women with Systemic Lupus Erythematosus Winthrop, Kevin, MD, MPH 0617. Support Methodologies for African 0202. Safety Profile of Baricitinib for the American Women with Lupus – Comparing Two Treatment of Rheumatoid Arthritis up to 8.4 Study’s Effects on Patient Activation Years: An Updated Integrated Safety Analysis 0618. The Effect of Travel Burden on Depression 0229. Integrated Safety of Filgotinib in Patients and Anxiety in African American Women Living with Moderately or Severely Active Rheumatoid with Systemic Lupus Arthritis Receiving Treatment for up to 5.5 Years Disclosure: Nothing to disclose 0234. Characterization of Serious Infections with Upadacitinib in Patients with Rheumatoid Williams, Jessica, MD, MPH Arthritis 0575. The Impact of an Integrated Care 1996. Evaluation of Response to Pneumococcal Management Program on Acute Care Utilization Vaccination in Patients with Rheumatoid and Outpatient Appointment Attendance Among Arthritis Receiving Upadacitinib: Results from a

118

Phase 2 Open-Label Extension Study Longitudinal Serological Study 2002. Incidence and Risk Factors for Herpes Disclosure: Nothing to disclose Zoster in Rheumatoid Arthritis Patients Receiving Upadacitinib Wright, Grace, MD, PhD, FACR Disclosure: Abbvie (2, 5); Bristol-Myers Squibb (2, 0507. Comparison of Secukinumab versus 5); Eli Lilly (2, 5); Galapagos (2, 5); Gilead (2, 5); Adalimumab Efficacy by Sex in Psoriatic Arthritis GlaxoSmithKline (5); Pfizer (2, 5); Roche (2, 5); from a Phase 3b, Double-blinded, Randomized, UCB (2, 5) Active-controlled Study 1214. Association Between Changes in C-reactive Wipfler, Kristin, PhD Protein at Week 12 and Patient-Reported 0034. Gene Expression Signatures in C-Reactive Outcomes at Week 24 with Sarilumab Therapy Protein High and Low Rheumatoid Arthritis Across Three Pivotal Phase 3 Studies 1962. Utilization of Telehealth Among Patients Disclosure: AbbVie (5, 8); Amgen (5, 8); Bristol- with Rheumatic Diseases in the Early Months of Myers Squibb (5, 8); Eli Lilly and Company (5, 8); the COVID-19 Pandemic Exagen (5, 8); Myriad Autoimmune (5, 8); Disclosure: Nothing to disclose Novartis (5, 8); Pfizer (5, 8); Regeneron Pharmaceuticals, Inc. (5, 8); Sanofi Genzyme (5, Wojcik, Sophie, MD 8) 0455. HLA-B27 and Host Immune Response: Lessons from Wright, Matthew, MS Disclosure: Nothing to disclose 0033. Pre-pregnancy Long Non-coding RNA Expression Signatures Among Women with Wolfe, Frederick, MD Rheumatoid Arthritis Who Improve or Worsen 0943. Reliability and Validity Issues in During Pregnancy Fibromyalgia Diagnosis Disclosure: Nothing to disclose Disclosure: Nothing to disclose Wu, Lijun, MD Wolfe, Madison, BS 1018. Seasonal Variation in the Treat-to-Target 0965. Repetitive Inhalant Lipopolysaccharide Rate of Rheumatoid Arthritis (RA) and Systemic Exposure in the Setting of Arthritis Induction Lupus Erythematosus (SLE): A Cohort Study on Potentiates Pro-Fibrotic Inflammatory Lung Self-reported Data from Smart System of Disease Disease in Mice Management (SSDM) Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Wollenhaupt, Jurgen Wu, Qiong, PhD 0345. Effectiveness and Safety of Apremilast in 0746. HDL-bound yRNA-derived Small RNAs Are Biologic-Naive versus Biologic-Experienced Altered in Patients with Rheumatoid Arthritis Patients with Psoriatic Arthritis in Real-World Disclosure: Nothing to disclose Clinical Practice Settings in Germany: Interim Analysis of an Ongoing, Multicenter, Prospective, Wyman, Brandon, BS Non-interventional Study 0844. Rab4A Regulates Glomerulonephritis and Disclosure: Abbott, Bristol-Myers Squibb, Merck Tryptophan Metabolism in Sle1.2.3. Lupus-prone Sharp & Dohme, Pfizer, UCB (2, 5) Mice via Recycling of CD98 Disclosure: Nothing to disclose Wouters, Fenne, MSc 0769. Does the Autoantibody-Response Mature Wysham, Katherine, MD Between Presentation with Arthralgia and 1134. Prevalence of Frailty and Associated Development of Rheumatoid Arthritis? – a Factors in a National Observational Cohort of

119

Rheumatic Diseases 0674. Disease Control of Hyperuricemia Newly 1976. High Disease Activity Is Associated with Detected by Medical Check-up: A Retrospective Incident Osteoporotic Fractures Among Veterans Cohort Study of Health Insurance Claims Data in with Rheumatoid Arthritis Japan Disclosure: Nothing to disclose 0829. International Comparison of Japanese and US Cross Country Utilization of RA Medications Xu, Chang, MS Disclosure: AbbVie Japan Co. Ltd (2); Astellas 1023. Epidemiology and Sociodemographic Pharma Inc. (2, 8); Ayumi Pharmaceutical Co. Ltd. Distribution of Upper Gastrointestinal Bleeding (2); Boehringer Ingelheim (2); Bristol-Meyers Among Medicaid Beneficiaries with Systemic Squibb (2, 8); Chugai Pharmaceutical Co. Ltd. (2, Lupus Erythematosus 8); Daiichi-Sankyo Co. Ltd (2, 8); Eisai Co., Ltd (2); Disclosure: Nothing to disclose Kaken Pharmaceutical Co., Ltd. (2); Mitsubishi- Tanabe Pharma Corp. (2, 8); Nippon-Shinyaku Xu, Jinhua (2); Novartis Pharma K. K. (2); Ono 0874. A Multi-Center, Randomized, Double- Pharmaceutical Co., Ltd (2); Pfizer Japan Inc (2, blind, Placebo-controlled Dose-ranging Study 8); Taisho Toyama Pharmaceutical Co., Ltd. (2); Evaluating Efficacy and Safety of SHR-1314 in Takeda Pharmaceutical Co. Ltd. (2, 8); Teijin Subjects with Moderate-to-Severe Plaque Pharma Ltd. (2, 8); Torii Pharmaceutical Co., Ltd Psoriasis (2); UCB Japan Co. Ltd (2); YLbio (2, 8) Disclosure: Nothing to disclose Yamaoka, Kunihiro, MD, PhD Xue, Jimeng, DO 0200. Predictors of Durable Clinical Response to 0784. Upregulation of Tyro3TK on CD14+CD16- Tofacitinib 11 Mg Once Daily with or Without Monocytes Promotes Osteoclast Formation in Methotrexate in Patients with Rheumatoid Rheumatoid Arthritis Arthritis: Post Hoc Analysis of Data from a Phase Disclosure: Nothing to disclose 3b/4 Methotrexate Withdrawal Study Disclosure: AbbVie (2, 5, 8); Actelion (5, 8); Xue, Jing, MD Actelion Pharmaceuticals Japan (8); Asahikasei 1892. Pattern and Influential Factors in Pharma Corp (5, 8); Astellas (2, 5, 8); AYUMI Promoting Treat-to-Target (T2) for F Ankylosing Pharma Co. (8); Boehringer Ingelheim Japan (8); Spondylitis (AS) Patients with the App of Smart Bristol-Myers Squibb (8); Chugai (2, 5, 8); Daiichi System of Disease Management (SSDM): A Sankyo (2, 8); Eisai (2, 5, 8); Eli Lilly (2, 5, 8); Eli Cohort Study from China Lilly Japan K. K. (5); Gilead G. K. (5, 8); Disclosure: Nothing to disclose GlaxoSmithKline (5, 8); Hisamitsu Pharma Co. (8); Janssen (5, 8); Japan Tobacco Inc. (5); Merck Yamada, Hirotaka, MD Sharp & Dohme (2, 8); Mitsubishi Tanabe (2, 5, 1407. Resolvin D5 Modulates Th17/Treg Cell 8); Nippon Kayaku (2, 8); Nippon Shinyaku (5, 8); Differentiation and Suppresses Ono Pharma (8); Otsuka Pharma (8); Pfizer Inc (2, Osteoclastogenesis 5, 8); Sanofi (8); Shionogi (2); Takeda (5, 8); Disclosure: Nothing to disclose Takeda Industrial Pharma (2, 8); Teijin Pharma (2) Yamamoto, Yuzuru, MD 1905. Soluble Guanylate Cyclase Reduced the Yang, Jing, MD Gastrointestinal Fibrosis in Bleomycin-induced 1738. Promote Treat-to-Target for RA via Mouse Model of Systemic Sclerosis Empowering Patients: A Cohort Study from China Disclosure: Nothing to disclose by Smart System of Disease Management (SSDM) Yamanaka, Hisashi, MD Disclosure: Nothing to disclose

120

Yaseen, Kinanah, MD Yoshida, Kazuki, ScD 1437. Measuring Disease Activity and Functional 0678. Patient Characteristics and Patterns of Status in Patients with Granulomatosis with Urate-lowering Treatments in Older Patients Polyangiitis (Wegener's) (GPA) with Incident Gout Disclosure: Nothing to disclose 1000. Passive Smoking Throughout the Life Course and the Risk of Incident Rheumatoid Yasin, Shima, MD, MSc Arthritis in Adulthood Among Women 1152. IL-18: A Biomarker That Reflects Disease Disclosure: Corrona (2); OM1 (5) Activity, Could It Be the Next Disease Activity Measure in Systemic Juvenile Idiopathic Yoshida, Takeshi, MD Arthritis? 1537. Usefulness of Ultrasound Assessment of 0288. Targeted Sequencing Revealed Novel Sarcopenia in Patients with Rheumatoid Arthritis Candidate Genetic Contributions to Lupus Disclosure: Nothing to disclose Nephritis in a Cohort of Swedish Patients with Systemic Lupus Erythematosus Yoshida, Tsuneyasu, MD Disclosure: Nothing to disclose 0089. The Risk Factors of Recurrence in Relapsing Polychondritis; A Study of 41 Cases Yedimenko, Juliette, MD Disclosure: Menarini (2, 8) 0169. Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Yoshimoto, Keiko, PhD Psoriatic Arthritis 1951. Possible Involvement of Disclosure: Nothing to disclose Fractalkine/CX3CR1 Axis in Peripheral CD14++CD16+ Monocytes in Disease Yeh, Li-Tain, PhD Development of Patients with Systemic Lupus 0675. AR882, a Potent and Selective Uricosuric Erythematosus Agent, Significantly Reduced Serum Urate Levels Disclosure: Nothing to disclose Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers Yoshimura, Masaru, MD 0690. AR882, a Potent and Selective Uricosuric 1760. The Association Between the Risk of Agent, Significantly Reduced Serum Urate in Venous Thromboembolism and Disease Activity Patients with Gout in a Phase 2a Study in Patients with Rheumatoid Arthritis: A Disclosure: Nothing to disclose Retrospective Observational Study Disclosure: Nothing to disclose Yokose, Chio, MD 0552. Fast Food Habits and Serum Urate Change Youm, Bruce, BS, BA, MPH in Young Adults: 15-Year Prospective Cohort 1137. Access to Digital Health in an Urban Analysis Rheumatology Population Disclosure: Nothing to disclose Disclosure: Nothing to disclose

Yoo, DaeHyun, MD, PhD Young-Glazer, Jennifer, MD 1207. Impact of Body Mass Index on Clinical 0995. Jo-1-Binding B Cells Undergo Limited Class- Responses of Novel Subcutaneous Infliximab (CT- Switching but Are Biased Towards Autoreactive- P13 SC) in Patients with Active Rheumatoid Prone and Memory B Cell Subsets in Anti- Arthritis: 1-Year Results from a Part 2 of Phase histidyl-tRNA Synthetase Syndrome I/III Randomized Controlled Trial Disclosure: Nothing to disclose Disclosure: Celltrion Healthcare, Inc (8); Celltrion, Inc. (2, 5) Younossi, Zobair, MD

121

0141. Filgotinib Improved Work Productivity and 0550. Mapping Multimorbidity Using Drug Activity Impairment in Patients with Rheumatoid Concept Unique Identifiers (RxCUIs) via the Rx- Arthritis and Inadequate Response to Risk Comorbidity Index Methotrexate: Results from FINCH-1 Study 0555. Utilization and Adherence Among 0142. Filgotinib Improved Work Productivity and Infliximab Biosimilar Initiators in a U.S. National Activity Impairment in Patients with Rheumatoid Commercial Insurance Database Arthritis and Inadequate Response to Biologic 0819. The Adherence Patterns Among Patients DMARDs: Results from the FINCH 2 Study Using Infliximab Bio-originator and Biosimilar 0143. Filgotinib Improved Work Productivity and Disclosure: Pfizer (2) Activity Impairment in Patients with Rheumatoid Arthritis Who Are Methotrexate-naïve: Results Zahn, Carleigh, DO from the FINCH-3 Study 0053. ¿Comprende? Assessing the Readability of Disclosure: Abbvie (5); BMS (5); Gilead (5); Freely Available Spanish-Language Online Patient Intercept (5); Merck (5); Novartis (5); Novo Education Materials for Rheumatologic Diseases Nordisk (5); Shionogi (5); Siemens (5); Terns (5); Disclosure: Nothing to disclose Viking (5) Zanotti Cavazzoni, Magali, MD Yu, Jeong Min, MD 0186. The Number of Associated Comorbidities 0282. Expression of the cGAMP Transporter Can Impact Disease Activity Scores SLC19A1 Is Altered in Systemic Lupus Independently from Objective Measures of Erythematosus Inflammation in Patients with Rheumatoid Disclosure: Nothing to disclose Arthritis Disclosure: Nothing to disclose Yu, KyungSang, MD 0204. Pharmacokinetics and Safety of CT-P17, a Zeng, Xiaofeng Proposed High Concentration (100 mg/mL) 0201. A Multicenter, Randomized, Placebo- Adalimumab Biosimilar, in Comparison with EU- controlled, Double-blind Phase 2 Study of Approved Adalimumab and US-Licensed SHR0302 versus Placebo in Chinese Subjects with Adalimumab; Results of a Phase 1, Randomized, Moderate to Severe Active Rheumatoid Arthritis Double-blind, Three-arm, Single-dose Study in H (RA) Disclosure: Nothing to disclose 0211. Efficacy and Safety of Upadacitinib in Patients from China, Brazil, and South Korea with Yu, Shuilian, MD Rheumatoid Arthritis Who Have Had Inadequate 0497. Interleukin-23 Acts Directly on Podocytes Response to Conventional Synthetic Disease- and Contributes to the Development of modifying Antirheumatic Drugs Glomerulonephritis Disclosure: Jiangsu Hengrui Medicine Co., Ltd (2) Disclosure: Nothing to disclose Zhang, Michael, MD, PhD Yuen, Kimberley, BSc 1151. Implementation and Initial Experience 1276. Using Classification and Regression Tree with a Screening Protocol for Inflammatory Analysis to Assess the Construct Validity of the Hyperferritinemia Automated Neuropsychological Assessment Disclosure: Nothing to disclose Metrics in the Assessment of Cognitive Impairment in SLE Compared to the ACR Zhang, Phillip, MD Neuropsychological Battery 1603. P4 Index Correlates with RAPID3 and Disclosure: Nothing to disclose Disease-Specific Indices in Rheumatoid Arthritis (RA) and Axial Spondyloarthritis (axSpA) Yun, Huifeng, MD, PhD Disclosure: Nothing to disclose

122

Rheumatology Practice: A Study in 15 Arab Zhang, Ying, PhD Countries 0068. Single Cell RNA-seq to Characterize Disclosure: Nothing to disclose Monocyte Subtypes in the Autoinflammatory Interferonopathy, SAVI and the Zobbe, Kristian, MD Inflammasomopathy, NOMID 0655. Weight Loss as Treatment for Gout in Disclosure: Nothing to disclose Patients with Concomitant Obesity: A Proof-of- Concept Randomized Controlled Trial Zhao, Yan, MD Disclosure: Nothing to disclose 1723. RA Flare Prediction via Machine Learning and Algorithm Based on SSDM Big Data Zuo, Yu, MD Disclosure: Nothing to disclose 0429. Prothrombotic Antiphospholipid Antibodies in COVID-19 Zhao, Yongdong, MD, PhD Disclosure: Nothing to disclose 1162. Comparison of Clinicopathologic and Imaging Features Between Chronic Nonbacterial Osteomyelitis and Its Mimickers: A Multi- national 450 Case-Control Study Disclosure: Novartis (5)

Zheng, Boyang, MD 0393. Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Disclosure: Nothing to disclose

Zheng, Jiayi, MD 1937. Aortic Aneurysm in Giant Cell Arteritis: A Nationwide Analysis Disclosure: Nothing to disclose

Zhu, Jane, BA 2038. Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis Disclosure: Nothing to disclose

Zhu, Lisa, MD 0864. Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression in Patients with Systemic Lupus Erythematosus Disclosure: Nothing to disclose

Ziade, Nelly, MD, PhD 0004. The Impact of the COVID-19 Pandemic on Patients with Chronic Rheumatic Diseases: A Study in 15 Arab Countries 1604. The Impact of the COVID-19 Pandemic on

123